
<html lang="en"     class="pb-page"  data-request-id="d4657ed0-f41a-4d63-abf4-95da3c55ec4b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2016.59.issue-19;article:article:10.1021/acs.jmedchem.6b01088"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers" /></meta><meta name="dc.Creator" content="Scott H.  Watterson" /></meta><meta name="dc.Creator" content="George V.  De Lucca" /></meta><meta name="dc.Creator" content="Qing  Shi" /></meta><meta name="dc.Creator" content="Charles M.  Langevine" /></meta><meta name="dc.Creator" content="Qingjie  Liu" /></meta><meta name="dc.Creator" content="Douglas G.  Batt" /></meta><meta name="dc.Creator" content="Myra  Beaudoin Bertrand" /></meta><meta name="dc.Creator" content="Hua  Gong" /></meta><meta name="dc.Creator" content="Jun  Dai" /></meta><meta name="dc.Creator" content="Shiuhang  Yip" /></meta><meta name="dc.Creator" content="Peng  Li" /></meta><meta name="dc.Creator" content="Dawn  Sun" /></meta><meta name="dc.Creator" content="Dauh-Rurng  Wu" /></meta><meta name="dc.Creator" content="Chunlei  Wang" /></meta><meta name="dc.Creator" content="Yingru  Zhang" /></meta><meta name="dc.Creator" content="Sarah C.  Traeger" /></meta><meta name="dc.Creator" content="Mark A.  Pattoli" /></meta><meta name="dc.Creator" content="Stacey  Skala" /></meta><meta name="dc.Creator" content="Lihong  Cheng" /></meta><meta name="dc.Creator" content="Mary T.  Obermeier" /></meta><meta name="dc.Creator" content="Rodney  Vickery" /></meta><meta name="dc.Creator" content="Lorell N.  Discenza" /></meta><meta name="dc.Creator" content="Celia J.  D’Arienzo" /></meta><meta name="dc.Creator" content="Yifan  Zhang" /></meta><meta name="dc.Creator" content="Elizabeth  Heimrich" /></meta><meta name="dc.Creator" content="Kathleen M.  Gillooly" /></meta><meta name="dc.Creator" content="Tracy L.  Taylor" /></meta><meta name="dc.Creator" content="Claudine  Pulicicchio" /></meta><meta name="dc.Creator" content="Kim W.  McIntyre" /></meta><meta name="dc.Creator" content="Michael A.  Galella" /></meta><meta name="dc.Creator" content="Andy J.  Tebben" /></meta><meta name="dc.Creator" content="Jodi K.  Muckelbauer" /></meta><meta name="dc.Creator" content="ChiehYing  Chang" /></meta><meta name="dc.Creator" content="Richard  Rampulla" /></meta><meta name="dc.Creator" content="Arvind  Mathur" /></meta><meta name="dc.Creator" content="Luisa  Salter-Cid" /></meta><meta name="dc.Creator" content="Joel C.  Barrish" /></meta><meta name="dc.Creator" content="Percy H.  Carter" /></meta><meta name="dc.Creator" content="Aberra  Fura" /></meta><meta name="dc.Creator" content="James R.  Burke" /></meta><meta name="dc.Creator" content="Joseph A.  Tino" /></meta><meta name="dc.Description" content="Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases. BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ recep..." /></meta><meta name="Description" content="Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases. BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ recep..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 19, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01088" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01088" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01088" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01088" /></link>
        
    
    

<title>Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01088" /></meta><meta property="og:title" content="Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0031.jpeg" /></meta><meta property="og:description" content="Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases. BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiology of autoimmune disease. As a result, inhibition of BTK is anticipated to provide an effective strategy for the clinical treatment of autoimmune diseases such as lupus and rheumatoid arthritis. This article details the structure–activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK. Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a reduction in safety liabilities. With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clinical studies." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases. BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiology of autoimmune disease. As a result, inhibition of BTK is anticipated to provide an effective strategy for the clinical treatment of autoimmune diseases such as lupus and rheumatoid arthritis. This article details the structure–activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK. Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a reduction in safety liabilities. With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clinical studies." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0031.jpeg" /></meta><meta name="twitter:title" content="Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01088"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01088">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01088&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01088&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01088&amp;href=/doi/10.1021/acs.jmedchem.6b01088" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 9173-9200</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01071" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01126" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 6-Fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott+H.++Watterson">Scott H. Watterson</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=George+V.++De+Lucca">George V. De Lucca</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qing++Shi">Qing Shi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Charles+M.++Langevine">Charles M. Langevine</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qingjie++Liu">Qingjie Liu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+G.++Batt">Douglas G. Batt</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Myra++Beaudoin+Bertrand">Myra Beaudoin Bertrand</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hua++Gong">Hua Gong</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Dai">Jun Dai</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shiuhang++Yip">Shiuhang Yip</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peng++Li">Peng Li</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dawn++Sun">Dawn Sun</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dauh-Rurng++Wu">Dauh-Rurng Wu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chunlei++Wang">Chunlei Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yingru++Zhang">Yingru Zhang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+C.++Traeger">Sarah C. Traeger</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+A.++Pattoli">Mark A. Pattoli</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stacey++Skala">Stacey Skala</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lihong++Cheng">Lihong Cheng</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary+T.++Obermeier">Mary T. Obermeier</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rodney++Vickery">Rodney Vickery</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lorell+N.++Discenza">Lorell N. Discenza</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Celia+J.++D%E2%80%99Arienzo">Celia J. D’Arienzo</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yifan++Zhang">Yifan Zhang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth++Heimrich">Elizabeth Heimrich</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen+M.++Gillooly">Kathleen M. Gillooly</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tracy+L.++Taylor">Tracy L. Taylor</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Claudine++Pulicicchio">Claudine Pulicicchio</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kim+W.++McIntyre">Kim W. McIntyre</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+A.++Galella">Michael A. Galella</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andy+J.++Tebben">Andy J. Tebben</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jodi+K.++Muckelbauer">Jodi K. Muckelbauer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=ChiehYing++Chang">ChiehYing Chang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Rampulla">Richard Rampulla</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arvind++Mathur">Arvind Mathur</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luisa++Salter-Cid">Luisa Salter-Cid</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joel+C.++Barrish">Joel C. Barrish</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Percy+H.++Carter">Percy H. Carter</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aberra++Fura">Aberra Fura</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+R.++Burke">James R. Burke</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+A.++Tino">Joseph A. Tino</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 609-252-6778. E-mail: <a href="/cdn-cgi/l/email-protection#d9aabab6adadf7aeb8adadbcabaab6b799bbb4aaf7bab6b4"><span class="__cf_email__" data-cfemail="d9aabab6adadf7aeb8adadbcabaab6b799bbb4aaf7bab6b4">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01088&amp;href=/doi/10.1021%2Facs.jmedchem.6b01088" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 9173–9200</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 1, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 July 2016</li><li><span class="item_label"><b>Published</b> online</span>19 September 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 October 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01088" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01088</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9173%26pageCount%3D28%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DScott%2BH.%2BWatterson%252C%2BGeorge%2BV.%2BDe%2BLucca%252C%2BQing%2BShi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D19%26contentID%3Dacs.jmedchem.6b01088%26title%3DDiscovery%2Bof%2B6-Fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2B%2528BMS-986142%2529%253A%2BA%2BReversible%2BInhibitor%2Bof%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2B%2528BTK%2529%2BConformationally%2BConstrained%2Bby%2BTwo%2BLocked%2BAtropisomers%26numPages%3D28%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9200%26publicationDate%3DOctober%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01088"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3992</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">64</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01088" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;H. Watterson&quot;},{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;V. De Lucca&quot;},{&quot;first_name&quot;:&quot;Qing&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;M. Langevine&quot;},{&quot;first_name&quot;:&quot;Qingjie&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;G. Batt&quot;},{&quot;first_name&quot;:&quot;Myra&quot;,&quot;last_name&quot;:&quot;Beaudoin Bertrand&quot;},{&quot;first_name&quot;:&quot;Hua&quot;,&quot;last_name&quot;:&quot;Gong&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Dai&quot;},{&quot;first_name&quot;:&quot;Shiuhang&quot;,&quot;last_name&quot;:&quot;Yip&quot;},{&quot;first_name&quot;:&quot;Peng&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Dawn&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Dauh-Rurng&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Chunlei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yingru&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;C. Traeger&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;A. Pattoli&quot;},{&quot;first_name&quot;:&quot;Stacey&quot;,&quot;last_name&quot;:&quot;Skala&quot;},{&quot;first_name&quot;:&quot;Lihong&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;T. Obermeier&quot;},{&quot;first_name&quot;:&quot;Rodney&quot;,&quot;last_name&quot;:&quot;Vickery&quot;},{&quot;first_name&quot;:&quot;Lorell&quot;,&quot;last_name&quot;:&quot;N. Discenza&quot;},{&quot;first_name&quot;:&quot;Celia&quot;,&quot;last_name&quot;:&quot;J. D’Arienzo&quot;},{&quot;first_name&quot;:&quot;Yifan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;Heimrich&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;M. Gillooly&quot;},{&quot;first_name&quot;:&quot;Tracy&quot;,&quot;last_name&quot;:&quot;L. Taylor&quot;},{&quot;first_name&quot;:&quot;Claudine&quot;,&quot;last_name&quot;:&quot;Pulicicchio&quot;},{&quot;first_name&quot;:&quot;Kim&quot;,&quot;last_name&quot;:&quot;W. McIntyre&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;A. Galella&quot;},{&quot;first_name&quot;:&quot;Andy&quot;,&quot;last_name&quot;:&quot;J. Tebben&quot;},{&quot;first_name&quot;:&quot;Jodi&quot;,&quot;last_name&quot;:&quot;K. Muckelbauer&quot;},{&quot;first_name&quot;:&quot;ChiehYing&quot;,&quot;last_name&quot;:&quot;Chang&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Rampulla&quot;},{&quot;first_name&quot;:&quot;Arvind&quot;,&quot;last_name&quot;:&quot;Mathur&quot;},{&quot;first_name&quot;:&quot;Luisa&quot;,&quot;last_name&quot;:&quot;Salter-Cid&quot;},{&quot;first_name&quot;:&quot;Joel&quot;,&quot;last_name&quot;:&quot;C. Barrish&quot;},{&quot;first_name&quot;:&quot;Percy&quot;,&quot;last_name&quot;:&quot;H. Carter&quot;},{&quot;first_name&quot;:&quot;Aberra&quot;,&quot;last_name&quot;:&quot;Fura&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;R. Burke&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;A. Tino&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;9173-9200&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01088&quot;},&quot;abstract&quot;:&quot;Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases. BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiology of autoimmune disease. As a result, inhibition of BTK is anticipated to provide an effective strategy for the clinical treatment of autoimmune diseases such as lupus and rheumatoid arthritis. This article details the structure–activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK. Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a reduction in safety liabilities. With significantly enhanced potency and selectivity, excellent in vivo properties and ef&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01088&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01088" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01088&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01088" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01088&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01088" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01088&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01088&amp;href=/doi/10.1021/acs.jmedchem.6b01088" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01088" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01088" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26pmid%3D27583770%26genre%3Darticle%26aulast%3DWatterson%26date%3D2016%26atitle%3DDiscovery%2Bof%2B6-Fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2B%2528BMS-986142%2529%253A%2BA%2BReversible%2BInhibitor%2Bof%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2B%2528BTK%2529%2BConformationally%2BConstrained%2Bby%2BTwo%2BLocked%2BAtropisomers%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D19%26spage%3D9173%26epage%3D9200%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/19" title="Go to Volume 59, Issue 19"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/jmcmar.2016.59.issue-19/20161013/jmcmar.2016.59.issue-19.largecover.jpg" alt="Go to Volume 59, Issue 19"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases. BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiology of autoimmune disease. As a result, inhibition of BTK is anticipated to provide an effective strategy for the clinical treatment of autoimmune diseases such as lupus and rheumatoid arthritis. This article details the structure–activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK. Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a reduction in safety liabilities. With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, <b>14f</b> (BMS-986142) was advanced into clinical studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73365" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73365" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bruton’s tyrosine kinase (BTK) is a nonreceptor tyrosine kinase expressed in all hematopoietic cells with the exception of T cells and differentiated plasma cells. BTK is a member of the Tec family of kinases which includes TEC, BTK, ITK, TXK, and BMX. In B cells, BTK plays an essential role in B cell receptor (BCR)-mediated activation and proliferation, as well as T cell costimulation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Specifically, when an antigen binds to the B cell receptor, BTK is recruited to a macro-molecular complex where it is phosphorylated on two key tyrosine residues.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Upon activation, BTK subsequently phosphorylates PLCγ.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Further downstream signaling leads to the activation of both the NFAT and NFκB pathways,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> resulting in cell proliferation, antibody and cytokine production, and costimulatory molecule expression (e.g., CD80, CD86, and CD69). In addition to its role in BCR signaling, BTK is involved in myeloid cell functions where it has been shown to be a crucial component in low affinity activating Fcγ receptor signaling (e.g., FcγRIIa and FcγRIIIa) in monocytes and FcεRI signaling in mast cells and basophils.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> When BTK is activated through the Fcγ and Fcε receptors, downstream signaling results in the expression of pro-inflammatory cytokines, chemokines, and cell adhesion molecules.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Finally, BTK-dependent signaling is required for RANK-L controlled osteoclastogenesis in monocytic precursors.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Rituximab, an anti-CD20 B cell depleting antibody approved for the clinical treatment of rheumatoid arthritis, clearly demonstrates the fundamental role that B cells play in the pathogenesis of autoimmune diseases such as rheumatoid arthritis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> With BCR-mediated effects on proliferation, production of cytokines and costimulatory molecules, and autoantibody production, inhibition of BTK is expected to provide an effective strategy for the clinical treatment of autoimmune diseases such as lupus and rheumatoid arthritis, without depleting B cells. In support of this, transgenic mice expressing catalytically inactive BTK (“kinase-dead”) showed that the enzyme is essential for BCR signaling in mature B cells.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Although both <i>xid</i> mice, which have a mutation in the pleckstrin homology domain of BTK, and BTK knockout mice have B cell developmental defects characterized by the lack of mature antibody producing B cells, these studies have shown that the defects result from the loss of adaptor functions of BTK (i.e., scaffolding) rather than the loss of kinase activity.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The human immunodeficiency condition known as X-linked agammaglobulinemia (XLA) results from a similar mutation which also likely impacts the adaptor functions of BTK.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> As a consequence, it is anticipated that inhibiting the kinase activity of BTK with a small molecule drug will attenuate antigen-induced BCR signaling and subsequent functions without depleting B cells through effects on pre-B cells. Adding further support, transgenic mice expressing a low level of BTK had normal numbers of mature B cells, but antibody responses and BCR-induced proliferation remained significantly impaired.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Pharmacologically, BTK-deficient mice and BTK inhibitor treated rodents exhibited reduced disease progression in animal models of human rheumatoid arthritis and lupus.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> Overall, the inhibition of BTK, with its impact on both BCR signaling and Fcγ and Fcε receptor signaling, is expected to provide an effective strategy for the clinical treatment of autoimmune diseases such as lupus and rheumatoid arthritis.</div><div class="NLM_p">As a result of strong preclinical and clinical validation, there has been an intense effort to identify orally active small molecule inhibitors of BTK, both irreversible and reversible, as clinical therapeutic agents. With an appropriately positioned noncatalytic cysteine residue (Cys481) in the kinase domain,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> there has been particular interest in identifying inhibitors that covalently bind to Cys481 as potential agents for both oncological and autoimmune diseases. One such drug, ibrutinib, was approved for the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Several additional covalent inhibitors have advanced into clinical trials for the treatment of rheumatoid arthritis.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In addition to covalent inhibitors, there has been significant interest in developing reversible inhibitors of BTK,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> including our own efforts.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14-16)</a></div><div class="NLM_p">As part of our effort to identify reversible inhibitors of BTK, we previously disclosed the discovery of a novel carbazole series of inhibitors, providing <b>1</b> as an initial lead.<a onclick="showRef(event, 'cit15a'); return false;" href="javascript:void(0);" class="ref cit15a">(15a)</a> Recently, we disclosed the structure–activity relationships (SAR) to further optimize this series leading to carbazole <b>2</b>.<a onclick="showRef(event, 'cit15b'); return false;" href="javascript:void(0);" class="ref cit15b">(15b)</a> Compound <b>2</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) provided potent inhibition of BTK with an IC<sub>50</sub> of 3 nM and a reasonable human whole blood IC<sub>50</sub> of 550 nM. With a desirable pharmacokinetic profile, <b>2</b> was further evaluated in vivo for both efficacy and tolerability. In animal models of human rheumatoid arthritis, a mouse collagen-induced arthritis (CIA) model and a Fcγ dependent, B cell independent mouse collagen antibody-induced arthritis (CAIA) model, <b>2</b> demonstrated significant efficacy at oral doses of 20 and 30 mg/kg q.d.<a onclick="showRef(event, 'cit15b'); return false;" href="javascript:void(0);" class="ref cit15b">(15b)</a> Unfortunately, in tolerability studies, <b>2</b> provided a less than desirable therapeutic margin (<20-fold) in multiple species.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0002.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Identification of lead BMS-935177 (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As we considered a path forward for the carbazoles, not fully understanding the source of the observed toxicity, we reasoned that improving the whole blood potency and the kinase selectivity could potentially increase our safety margins. In addition, it was noted that compound <b>2</b> consists of four interconverting atropisomers derived from the ortho-methyl substituent on the phenyl linker (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). This results in hindered rotation at both the carbazole C4-linker bond and the quinazolinone-linker bond. The atropisomers were separated by chiral chromatography, but racemized at room temperature. A kinetic stability study in methanol at 37 °C revealed that the carbazole C4 bond had a kinetic <i>t</i><sub>1/2</sub> of 38 min. The quinazolinone bond had a much more rapid rate of interconversion, prohibiting kinetic evaluation by chiral HPLC. An effort to reduce observable atropisomerism by removing the methyl substituent on the phenyl linker (<b>3</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) was successful but resulted in a significant loss in activity relative to <b>2</b>. In this article, we outline our strategy to improve the intrinsic potency of the carbazole series and to overcome safety concerns through the identification of highly potent and selective inhibitors of BTK as single, stable atropisomers, ultimately leading to clinical compound <b>14f</b>, 6-fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142)<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0003.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>2</b> has four interconverting atropisomers which were separated by chiral SFC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Potency of Linker Modifications vs <b>2</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0026.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">BTK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Ramos IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">hWB IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">2.6 ± 0.9</td><td class="colsep0 rowsep0" align="left">30 ± 15</td><td class="colsep0 rowsep0" align="left">550 ± 100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">44 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">410 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">5.1 ± 1.9</td><td class="colsep0 rowsep0" align="left">30 ± 2</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are shown as mean values of at least three determinations unless specified otherwise.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">ND = not determined.</p></div></div></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0004.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>14f</b> as a single, stable atropisomer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58661" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58661" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthetic pathways utilized in the preparation of the compounds presented in this article are provided in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Analogues <b>6</b> and <b>7</b> were prepared as outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Carbazole core <b>16</b> was coupled with the racemic boronic ester <b>17</b> under Suzuki conditions<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> to provide <b>6</b> in good yield. Subsequent separation of the atropisomers by chiral SFC provided <b>7a</b> and <b>7b</b> as mixtures of interconverting atropisomers at carbazole C4 but rotationally locked at the quinazolinedione-linker bond. The absolute stereochemical configuration of the quinazolinedione atropisomer was determined to be (S) by single crystal X-ray analysis of <b>7a</b> (CCDC # 1501158; see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for additional details). Analogues <b>8</b>, <b>9</b>, and <b>12</b> were prepared as single, stable atropisomers in a similar fashion from carbazoles <b>18</b> and the chirally pure (<i>S</i>)-boronic acid <b>19</b>, as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Des-methyl analogs <b>10</b> and <b>13</b> and analog <b>11</b> were prepared from chiral boronic esters <b>33</b> and <b>34</b>, respectively, in a similar manner as depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Tetrahydrocarbazole derivatives <b>14</b> and <b>15</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) were prepared in good yield as single, stable atropisomers, as outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> depicts the optimized route to <b>14f</b>. Of particular interest is the chiral induction observed during the Suzuki coupling,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> resulting from the chiral carbinol, providing a 3:1 mixture of the C5 atropisomers favoring the formation of <b>14f</b> over <b>14g</b>. The absolute stereochemistry of final compounds <b>7a</b> (CCDC # 1501158), <b>9a</b> (CCDC # 1501159), <b>14b</b> (CCDC # 1501160), <b>14d</b> (CCDC # 1501161), and <b>14f</b> (CCDC # 1501162) were determined by single crystal X-ray structure analysis (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for more detail).</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0016.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Carbazoles <b>6</b> and <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (PPh<sub>3</sub>)<sub>4</sub>Pd, 2 M aqueous K<sub>3</sub>PO<sub>4</sub>, toluene, EtOH, 74%; (b) SFC chiral separation.</p></p></figure><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0017.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Carbazoles <b>8</b>, <b>9</b>, and <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Dichloro 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)–CH<sub>2</sub>Cl<sub>2</sub> adduct, Cs<sub>2</sub>CO<sub>3</sub>, THF, water, 50–60 °C, 32–84%; (b) 1,1′-bis(di<i>tert</i>-butylphosphino)ferrocene palladium dichloride, 2 M aqueous K<sub>3</sub>PO<sub>4</sub>, THF, RT, 55–60%. (c) SFC chiral separation at carbazole C4.</p></p></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0018.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Tetrahydrocarbazoles <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) a) Dichloro 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)–CH<sub>2</sub>Cl<sub>2</sub> adduct, Cs<sub>2</sub>CO<sub>3</sub>, THF, water, 50 °C, 50%; (b) 1,1′-bis(di<i>tert</i>-butylphosphino)ferrocene palladium dichloride, 2 M aqueous K<sub>3</sub>PO<sub>4</sub>, THF, RT, 93%. (c) SFC chiral separation at carbazole C5.</p></p></figure><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0019.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Optimized Preparation of <b>14f</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The carbazole core intermediates <b>18</b> in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> were prepared as outlined in <a class="ref internalNav" href="#sch5" aria-label="Schemes 5">Schemes 5</a>–<a class="ref internalNav" href="#sch7" aria-label="7">7</a>. Both the C3 chloro and the C3 nitrile substituted carbazole cores utilized in the preparation of analogues <b>9</b>, <b>10</b>, <b>11</b>, and <b>12b</b> were prepared through a regioselective substitution on the C3 position of carbazole core <b>16</b>,<a onclick="showRef(event, 'cit15c'); return false;" href="javascript:void(0);" class="ref cit15c">(15c)</a> as shown in <a class="ref internalNav" href="#sch5" aria-label="Schemes 5">Schemes 5</a> and <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. The C3 methyl and C3 fluoro carbazole cores (<b>18c</b> and <b>18d</b>) used in the preparation of analogues <b>12a</b> and <b>12c</b> were prepared as described in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. A Fischer indole cyclization between hydrazines <b>25</b> and ethyl 3-oxocyclohexanecarboxylate in the presence of acetic acid gave tetrahydrocarbazoles <b>26</b> in good yield. Aromatization with DDQ provided the carbazole carboxylic acids <b>27</b> in ∼90% yield. These acids (<b>27</b>) were then activated with EDCI and HOBt and treated with ammonium hydroxide to afford carbazole amides <b>28</b>. The carbazole C7 ester was methylated with methyl lithium to give <b>18c</b> in good yield. The hydrazine intermediates <b>25</b> were either prepared from commercially available aniline <b>24</b> or from the aniline prepared as shown in <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>.</div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0020.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of the Carbazole C3 Cl Core<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NCS, NMP, CCl<sub>4</sub>, 45 °C, 92%.</p></p></figure><figure id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0021.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Preparation of the Carbazole C3 CN Core<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NIS, pyridine, DMF, 60 °C, 23%; (b) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 90 °C, 83%.</p></p></figure><figure id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0022.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Preparation of the Carbazole C3 Me, Cl, and F Cores<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaNO<sub>2</sub>, SnCl<sub>2</sub>, HCl, H<sub>2</sub>O, 50–61%%; (b) ethyl 3-oxocyclohexanecarboxylate, AcOH, toluene, 55–62%; (c) DDQ, THF, 85–90%; (d) NH<sub>4</sub>OH, EDCI, HOBt, THF, CH<sub>2</sub>Cl<sub>2</sub>, 91–95%; (e) MeLi, THF, 50–85%.</p></p></figure><figure id="sch8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0023.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Preparation of the Tetrahydrocarbazole Cores <b>20</b> and <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeLi, THF, 95%; (b) SFC chiral separation.</p></p></figure><figure id="sch9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0024.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Preparation of Boronic Ester Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Δ, xylene, 90%; (b) CDI, THF, 90%; (c) bis(pinacolato)diboron, dichloro 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)–CH<sub>2</sub>Cl<sub>2</sub> adduct, KOAc, toluene, 90%; (d) SFC chiral separation; (e) MeI, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90%.</p></p></figure><figure id="sch10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0025.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Preparation of Aniline <b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) pyr<sub>2</sub>IBF<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 63%; (b) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 83%; (c) NaOH, EtOH/H<sub>2</sub>O, 91%.</p></p></figure><div class="NLM_p">The tetrahydrocarbazole cores <b>20</b> and <b>21</b>, utilized in the preparation of analogues <b>14</b> and <b>15</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), were prepared as shown in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>. Intermediate <b>26</b> was methylated with methyl lithium to give the desired dimethyl carbinol in a yield of ∼95%. Subsequent SFC chiral separation of the enantiomers provided both (<i>S</i>)-<b>20</b> and (<i>R</i>)-<b>21</b>. The absolute stereochemistry of each was determine through single crystal X-ray analysis of final analogues <b>14b</b>, <b>14d</b>, and <b>14f</b>, as described above.</div><div class="NLM_p">The boronic ester intermediates described in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a> were prepared as depicted in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>. A mixture of 3-bromo-2-methylaniline and 8-fluoro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazine-2,4-dione was heated at reflux in xylene to give amide <b>30</b> in 90% yield. Subsequent cyclization with 1,1′-carbonyldiimidazole provided quinazolinedione <b>31</b> in 90% yield. Intermediate <b>31</b> was then converted to the boronic ester <b>32</b>, and the two locked atropisomers were separated by chiral SFC to give the (<i>S</i>)-quinazolinedione <b>33</b> and the (<i>R</i>)-quinazolinedione <b>34</b>. Methylation of intermediate <b>32</b> afforded <b>17</b> in good yield. Alternatively, methylation of <b>31</b> followed by conversion to the boronic ester provided <b>17</b>. The two locked atropisomers of <b>17</b> were separated by chiral SFC to give (<i>S</i>)-quinazolinedione <b>19</b> and (<i>R</i>)-quinazolinedione <b>35</b>. The absolute stereochemistry of <b>19</b> as (<i>S</i>) and <b>35</b> as (<i>R</i>) was confirmed by single crystal X-ray analysis of <b>7a</b> (CCDC # 1501158). The des-methyl intermediate <b>33</b> could be methylated to give <b>19</b>, thus confirming the stereochemistry of <b>33</b> as (<i>S</i>).</div><div class="NLM_p last">The carbazole and tetrahydrocarbazole compounds presented in this article were evaluated in a human recombinant BTK enzyme assay to determine their intrinsic activity against BTK. A BCR stimulated calcium flux assay in Ramos B cells was used to establish activity in a cellular environment. Analogues with adequate potency were then evaluated in a human whole blood assay (hWB) measuring BCR stimulated CD69 expression on B cells. In parallel with the in vitro potency assays, in vitro liability profiling data were assessed to prioritize compounds. Selected compounds were evaluated in multispecies pharmacokinetic (PK) studies and ultimately rodent efficacy models of lupus and rheumatoid arthritis.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02418" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02418" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As we previously reported,<a onclick="showRef(event, 'cit15b'); return false;" href="javascript:void(0);" class="ref cit15b">(15b)</a> the X-ray cocrystal structure of compound <b>4</b>, a close analogue of <b>2</b>, bound to the kinase domain of BTK (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS">5JRS</a>)<a onclick="showRef(event, 'cit15b'); return false;" href="javascript:void(0);" class="ref cit15b">(15b)</a> revealed that the carbazole NH and the primary amide bind to the hinge region of the kinase domain, forming critical hydrogen bonding interactions with Met477 and Glu475. In addition, the primary amide forms a third hydrogen bonding interaction with a water molecule in the gatekeeper region of the active site, which is incorporated into an extensive water network within the pocket. The cocrystal structure also revealed that the fluoro-phenyl linker is orthogonal to the carbazole, in the (<i>S</i>)-atropisomeric configuration, with the fluoro substituent filling a small hydrophobic pocket formed by Leu528, at the base of the ATP pocket, and Cys481. As expected, the quinazolinone ring is clearly orthogonal to the fluoro-phenyl linker with the carbonyl forming a hydrogen bonding interaction with conserved water. The carbazole C7 dimethylcarbinol is projected toward the solvent in the extended hinge region and appears to contribute only to the stabilization of the pocket’s water network.</div><figure id="fig4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0005.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Co-crystal structure (1.9 Å) of compound <b>4</b> bound to the kinase domain of BTK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS">5JRS</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an effort to continue to evolve the carbazole chemotype, a second carbonyl was incorporated into the quinazolinone to form a quinazolinedione (<b>5</b> and <b>6</b>, <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Although <b>5</b> and <b>6</b> did not improve the overall intrinsic potency, it was discovered that the addition of the second carbonyl resulted in two rotationally locked atropisomers, which could be separated by chiral SFC. Both atropisomers were found to be completely stable for 3 days when heated in methanol at 37 °C. Ultimately, the fluoro substituted derivatives had better pharmacokinetic (PK) properties and will be the focus of the remainder of the discussion. As shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>, both isolated, locked quinazolinedione atropisomers <b>7a</b> and <b>7b</b> consisted of a mixture of two interconverting atropisomers at carbazole C4 (kinetic <i>t</i><sub>1/2</sub> = 69 min; methanol; 37 °C) with <b>7a</b> providing enhanced human whole blood potency with an IC<sub>50</sub> of 190 nM relative to <b>2</b> with an IC<sub>50</sub> of 550 nM (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). It is worth noting that <b>6</b>, <b>7a</b>, and <b>7b</b> are all highly protein bound in human serum (>99%). The absolute stereochemistry of <b>7a</b> was established by single crystal X-ray analysis to be the (<i>S</i>)-quinazolinedione atropisomer, but with a mixture of atropisomers at carbazole C4, as seen in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>. The addition of the second carbonyl would allow for the bicyclic dione to orient in either of two possible conformations and still retain the interaction with the conserved water, but interestingly, the more potent (<i>S</i>)-configuration <b>7a</b> would be expected to bind in the same orientation as that observed in the X-ray cocrystal structure of <b>4</b>. With the enhanced whole blood potency of <b>7a</b>, it is reasonable to anticipate that the additional carbonyl might be engaged in a hydrogen bonding interaction with another conserved water in the kinase domain.</div><figure id="fig5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0006.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Quinazoline-diones <b>5</b> and <b>6</b>, a route to locking one of the atropisomeric centers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Potency of Carbazoles <b>9a</b> and <b>12</b> vs Carbazoles <b>2</b> and <b>7a</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0027.gif" alt="" id="fx7" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">in vitro activity</th><th class="rowsep1 colsep0" colspan="3" align="center">mouse PK (10 mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">BTK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">JAK2/BTK selectivity</th><th class="colsep0 rowsep0" align="center">Ramos IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">hWB IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CMax (μM)</th><th class="colsep0 rowsep0" align="center">AUC (μM·h)</th><th class="colsep0 rowsep0" align="center">% formation of <b>13</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">3.0 ± 0.10</td><td class="colsep0 rowsep0" align="left">94×</td><td class="colsep0 rowsep0" align="left">26 ± 15</td><td class="colsep0 rowsep0" align="left">550 ± 100</td><td class="colsep0 rowsep0" align="left">8.9</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2.3 ± 1.2</td><td class="colsep0 rowsep0" align="left">510×</td><td class="colsep0 rowsep0" align="left">19 ± 9</td><td class="colsep0 rowsep0" align="left">190 ± 30</td><td class="colsep0 rowsep0" align="left">2.2<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">25<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">4<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.5</td><td class="colsep0 rowsep0" align="left">1,900×</td><td class="colsep0 rowsep0" align="left">11 ± 5</td><td class="colsep0 rowsep0" align="left">90 ± 41</td><td class="colsep0 rowsep0" align="left">4.7</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">66 (<b>10</b>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">0.65 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">1,200×</td><td class="colsep0 rowsep0" align="left">17 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">240 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">6.3</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">0.27 ± 0.04</td><td class="colsep0 rowsep0" align="left">7,100×</td><td class="colsep0 rowsep0" align="left">6.0 ± 0.4</td><td class="colsep0 rowsep0" align="left">120 (<i>n</i> = 1)</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.31</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">0.45 ± 0.12</td><td class="colsep0 rowsep0" align="left">4,400×</td><td class="colsep0 rowsep0" align="left">11 ± 9</td><td class="colsep0 rowsep0" align="left">90 ± 60</td><td class="colsep0 rowsep0" align="left">5.5</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">15</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are shown as mean values of at least three determinations unless specified otherwise.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Mouse PK at 5 mg/kg; NA = not applicable; ND = not determined.</p></div></div></div><figure id="fig6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0007.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray crystal structures of <b>7a</b> with the locked (<i>S</i>)-quinazolinedione atropisomer revealing a mixture of two interconverting C4 atropisomers (CCDC # 1501158).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to gain a better understanding of the atropisomeric dynamics of <b>7a</b>, we initiated in vitro plasma stability studies in human (male and female), cynomolgus monkey, dog, rat, and mouse plasma. In this study, <b>7a</b>, a fully racemic mixture of interconverting atropisomers at carbazole C4 but locked in the (<i>S</i>)-configuration at the quinazolinedione-linker bond, was heated at 37 °C for 4 h with chiral analysis at the 0, 1, and 4 h time points, as presented in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>. As was previously shown in the cocrystal structure of <b>4</b> bound to the kinase domain of BTK, the preferred conformation at carbazole C4 is derived from the (<i>S</i>)-atropisomer configuration with the methyl group pointing down, as seen in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>. This study revealed that the stereoisomeric distribution of the carbazole C4 atropisomer of <b>7a</b> in plasma is variable with a bias toward the less target relevant (<i>R</i>)-atropisomer. Specifically, in dog and mouse, a 1:1 ratio of the C4 (<i>S</i>)-atropisomer and the C4 (<i>R</i>)-atropisomer remained after 4 h. In rats, within 1 h, the mixture showed a 67% preference for the undesired (<i>R</i>)-atropisomer. Interestingly, in human and cyno plasma at 4 h, ∼90% of the mixture corresponded to the undesired C4 (<i>R</i>)-atropisomer. During this study, racemization of the (<i>S</i>)-quinazolinedione atropisomer was not observed. Additionally, chiral HPLC analysis of plasma samples collected at 24 h during in vivo PK studies confirmed that racemization of the quinazolinedione atropisomer had not occurred (data not shown).</div><figure id="fig7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0008.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Distribution of carbazole C4 atropisomers (<b>7a</b>) in multispecies plasma studies at 37 °C over 4 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Encouraged by the enhanced human whole blood potency resulting from locking the quinazolinedione atropisomer but concerned with the possible impact that the less target relevant atropisomer might have on kinase selectivity and off-target toxicity, our strategy evolved into identifying a single, stable atropisomer through rotationally locking the carbazole C4 atropisomer in the desired bioactive conformation for optimal binding to the kinase domain by addition of small substituents at carbazole C3, as depicted in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>. We rationalized that this strategy would provide improvements in activity, particularly human whole blood potency. Additionally, we anticipated that a locked, predefined conformation could potentially enhance both the selectivity profile and the overall tolerability profile of the series by eliminating any off-target liabilities associated with the less target relevant atropisomer, as recently supported in the literature.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In further support of this, there are well established instances where the desired pharmacological activity of a chiral drug is associated with one enantiomer while off-target liabilities are linked to the other enantiomer.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Since a single, stable atropisomer should behave more like a traditional chiral center, this strategy was expected to also minimize the complications associated with progressing a mixture of interconverting atropisomers.<a onclick="showRef(event, 'cit18d'); return false;" href="javascript:void(0);" class="ref cit18d">(18d)</a></div><figure id="fig8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0009.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Medicinal chemistry strategy: Lock the C4 atropisomer into the preferred conformation for optimal binding to BTK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Fully racemic compound <b>8</b> (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>, mixture of 4 atropisomers) with a chloro substituent at carbazole C3 was prepared and was found to have similar activity against BTK as both <b>2</b> and <b>7a</b> (IC<sub>50</sub> = 4 nM). When prepared with the (<i>S</i>)-quinazolinedione atropisomer, the resulting mixture of carbazole C4 atropisomers was separated by chiral SFC to give <b>9a</b> and <b>9b</b> as single, stable atropisomers. It is worth noting that the chiral prioritization changed with the addition of the chloro at carbazole C3, with the bioactive conformation now derived from the (<i>R</i>)-atropisomer. As expected, <b>9a</b> (<i>R</i>-isomer with the linker methyl oriented down) was substantially more potent than <b>9b</b> (<i>S</i>-isomer, linker methyl up), as seen in <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a> (BTK IC<sub>50</sub> = 1.0 nM vs 130 nM, respectively). Computational modeling of both isomers <b>9a</b> and <b>9b</b> based on the cocrystal structure of <b>4</b> bound in the kinase domain of BTK suggested that the less active isomer <b>9b</b> orients the quinazolinedione moiety into solvent, thus minimizing van der Waal interactions that may be favorable for binding (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>). Additionally, the linker methyl group is projected up into the P-loop of the kinase domain. These combined effects apparently disrupt the hydrogen bond interactions with Met477 in the hinge region of the pocket, likely contributing to the observed loss in potency.</div><figure id="fig9" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0010.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>9a</b>, a single, stable atropisomer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0011.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Computational model of atropisomer <b>9a</b> and (B) computational model of atropisomer <b>9b</b>, based on the X-ray cocrystal structure of <b>4</b> bound to the kinase domain of BTK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS">5JRS</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As predicted, locking the carbazole C4 atropisomer, providing a single, stable atropisomer (<b>9a</b>), resulted in a 6-fold improvement in the human whole blood activity relative to <b>2</b> (IC<sub>50</sub> = 90 nM vs 550 nm) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Although the benefits of the locked, predefined conformation on whole blood potency are reasonably clear, it is less clear as to what role the C3 chloro may play in modulating the electronic nature of the core through inductive effects. Interestingly, compound <b>9a</b> was 1,900-fold selective for BTK over JAK2 (Janus kinase 2), demonstrating significantly improved selectivity relative to both <b>2</b> (JAK2/BTK: 94×) and <b>7a</b> (JAK2/BTK: 550×). In stability studies in methanol and plasma at 37 °C, both locked atropisomers <b>9a</b> and <b>9b</b> were stable for greater than 5 days. With a significantly improved human whole blood potency and an overall improved selectivity profile (data not shown) relative to <b>2</b>, compound <b>9a</b> was advanced into multispecies PK studies. Unfortunately, substantial demethylation of the quinazolinedione was observed in mouse (66%) and rat (80%) to give metabolite <b>10</b> (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>). However, very little formation of <b>10</b> was seen in dogs (<1%). Metabolite <b>10</b> was less active than <b>9a</b> (hWB IC<sub>50</sub> = 260 vs 90, respectively), but interestingly, the (<i>R</i>)-quinazolinedione analogue <b>11</b> was substantially more potent in the human whole blood assay with an IC<sub>50</sub> of 20 nM. Unfortunately, both <b>10</b> and <b>11</b> suffered from high clearance and poor exposure in vivo in rodent PK studies.</div><figure id="fig11" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0012.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Metabolite formation in PK studies with <b>9a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the enhanced human whole blood potency and selectivity observed with a single atropisomer (<b>9a</b>), we continued to explore carbazole C3 substitution, as outlined in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Interestingly, replacement of the chloro with a more neutral methyl (<b>12a</b>) maintained activity against BTK as well as the improved selectivity observed for <b>9a</b>. Surprisingly, <b>12a</b> was less potent in the human whole blood assay with an IC<sub>50</sub> of 240 nM, consistent with the human whole blood potency observed for <b>7a</b>. This could be attributed to the similarity in the electronic nature of the cores. In a mouse PK study, <b>12a</b> showed similar if not better exposure when compared to <b>9a</b>, but with less than 1% formation of the quinazolinedione des-methyl metabolite <b>13a</b>. Substitution with an electronically withdrawing nitrile group (<b>12b</b>) significantly improved the BTK binding with an IC<sub>50</sub> of 0.27 nM (9-fold over <b>7a</b>), suggesting that the hydrogen bonding interactions of the carbazole NH and perhaps the carboxamide to the hinge are likely strengthened with an electron withdrawing group at carbazole C3. Additionally, the selectivity of <b>12b</b> for BTK over JAK2 was significantly improved (7,100×) relative to <b>9a</b>. Unfortunately, <b>12b</b> demonstrated poor exposure in a mouse PK study. Since the metabolite <b>13b</b> was not available at the time, it is not clear whether the poor PK properties are a result of the compound’s intrinsic physicochemical characteristics (solubility or absorption) or a result of significant demethylation of the quinazolinedione. As seen with <b>12c</b>, fluoro substitution at carbazole C3 provided an ideal combination of highly potent activity (BTK IC<sub>50</sub> = 0.45 nM and hWB IC<sub>50</sub> = 90 nM) and good PK in a mouse study showing exposure similar to that of <b>9a</b> but with only ∼15% formation of metabolite <b>13c</b>. Stability studies in methanol at 37 °C confirmed that even the relatively small C3 fluoro substituent was enough to hinder rotation at carbazole C4 with a kinetic <i>t</i><sub>1/2</sub> of at least 24 days. The changes observed in the N-demethylation metabolic profiles of compounds <b>9a</b>, <b>12a</b>, and <b>12c</b> are likely the result of indirect, subtle effects on overall metabolism mediated by the changes in C3 substitution.</div><div class="NLM_p">In an effort to expand and diversify the carbazole chemotype during SAR development, we explored tetrahydrocarbazoles, as shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Our interest was derived from both a selectivity and a physicochemical perspective. As was previously stated, the carbazole C7 dimethylcarbinol projects toward the solvent in the extended hinge region and does not appear to contribute to binding in the kinase domain, but we have previously established that changes to this region of the molecule can influence kinase selectivity.<a onclick="showRef(event, 'cit15b'); return false;" href="javascript:void(0);" class="ref cit15b">(15b)</a> As a result, we anticipated that replacing the nonbinding critical aromatic ring with a saturated ring, along with the addition of chirality at the dimethylcarbinol point of attachment, would not negatively impact the overall potency, but could positively impact both potency and kinase selectivity. From a physicochemical persspective, reducing the aromatic ring count from five to four might improve the overall PK parameters of the series.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Additionally, one of the concerns with the carbazole C7 dimethylcarbinol was the potential for elimination of water to form the α-methylstyrene derivative under acidic conditions, although this was not something that we had observed in vivo. The saturated ring of the tetrahydrocarbazole core would be expected to significantly reduce any electronic incentive for elimination.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Potency of Tetrahydrocarbazoles <b>14</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0028.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0029.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are shown as mean values of at least three determinations unless specified otherwise; ND = not determined.</p></div></div><div></div></div><div class="NLM_p">The SAR for tetrahydrocarbazoles <b>14a</b>–<b>g</b> are outlined in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. With the addition of chirality at the carbinol point of attachment, both enantiomers were explored to determine which was more favorable. Overall, the (<i>S</i>)-enantiomer trended toward improved potency, selectivity, and liability profiling. Consistent with the results for the carbazoles (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), rotationally locking both atropisomeric centers produced similar improvements in potency relative to <b>2</b> when compared to that of carbazoles <b>7a</b>, <b>9a</b>, and <b>12a</b>–<b>c</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) but provided better overall selectivity, including significant improvement with respect to selectivity against JAK2. In a mouse in vivo PK study at a dose of 10 mg/kg, the tetrahydrocarbazoles <b>14b</b>, <b>14d</b>, and <b>14f</b> had a very similar profile when compared with those of carbazoles <b>7a</b>, <b>9a</b>, and <b>12c</b> but with significantly less formation of the des-methylquinazoline dione metabolite (<b>14d</b> Cl: 15%; <b>14f</b> F: < 4%). As was the case in the carbazole series, the fluoro substituted analogue <b>14f</b> ultimately provided the most desirable activity and selectivity profile (BTK IC<sub>50</sub> = 0.50 nM, Ramos IC<sub>50</sub> = 9 nM, and hWB IC<sub>50</sub> = 90 nM), along with an acceptable initial PK profile in mice and a clean liability profile (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). As a result, compound <b>14f</b> was selected as a lead for further evaluation.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Partial in Vitro Cell Activity Data and Whole Blood Data for <b>14f</b> Compared with <b>2</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0030.gif" alt="" id="fx10" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">receptor/stimulation</th><th class="colsep0 rowsep0" align="center"><b>14f</b> IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><b>2</b> IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">Cellular Assays</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">calcium flux in Ramos B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM</td><td class="colsep0 rowsep0" align="left">0.009 ± 0.005</td><td class="colsep0 rowsep0" align="left">0.026 ± 0.015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">proliferation of human peripheral B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM/IgG</td><td class="colsep0 rowsep0" align="left">0.003 ± 0.001</td><td class="colsep0 rowsep0" align="left">0.008<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CD86 surface expression in peripheral B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM/IgG</td><td class="colsep0 rowsep0" align="left">0.004 ± 0.003</td><td class="colsep0 rowsep0" align="left">0.040 ± 0.030</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CD69 surface expression in peripheral B cells</td><td class="colsep0 rowsep0" align="left">CD40/CD40L</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TNFα from human PBMC cells</td><td class="colsep0 rowsep0" align="left">FCλR/immune complex</td><td class="colsep0 rowsep0" align="left">0.003 ± 0.0.003</td><td class="colsep0 rowsep0" rowspan="3" align="left">0.014<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ITK catalyzed phosphorylation of PLCγ1 (human peripheral T cells)</td><td class="colsep0 rowsep0" align="left">TCR/anti-CD3</td><td class="colsep0 rowsep0" align="left">0.41<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">proliferation of human peripheral T cells</td><td class="colsep0 rowsep0" align="left">TCR/anti-CD3</td><td class="colsep0 rowsep0" align="left">3.8<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center">Human Whole Blood Assays</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human whole blood CD69 surface expression in peripheral B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM</td><td class="colsep0 rowsep0" align="left">0.090 ± 0.040</td><td class="colsep0 rowsep0" align="left">0.550 ± 0.100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse whole blood CD69 surface expression in peripheral B cells</td><td class="colsep0 rowsep0" align="left">BCR/Anti-IgM/IgG</td><td class="colsep0 rowsep0" align="left">0.14 ± 0.08</td><td class="colsep0 rowsep0" align="left">2.1 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human whole blood CD63 surface expression in basophils</td><td class="colsep0 rowsep0" align="left">FceRI/anti-IgE</td><td class="colsep0 rowsep0" align="left">0.089 ± 0.046</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are shown as mean values of at least three determinations unless specified otherwise.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">IC<sub>50</sub> values as single determinations; PBMC = peripheral blood mononuclear cells; ND = not determined.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Partial in Vitro Profiling Data for <b>14f</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">result</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="5" align="left">protein binding (bound)</td><td class="colsep0 rowsep0" align="left">99.1% human</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">98.5% mouse</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">98.3% rat</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">99.1% dog</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">98.8% monkey</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mutagenicity</td><td class="colsep0 rowsep0" align="left">Ames negative</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG (patch clamp)</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 5.5 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Na<sup>+</sup> (patch clamp)</td><td class="colsep0 rowsep0" align="left">10/13% @ 10 μM (1 and 4 Hz)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ca<sup>+</sup> (patch clamp)</td><td class="colsep0 rowsep0" align="left">40% @ 10 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="5" align="left">CYP<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> inhibition (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">>40 μM 1A2, 2B6, 2D6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2.6 μM 2C8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">17.1 μM 2C9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">32.2 μM 2C19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8.5 μM 3A4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PAMPA permeability</td><td class="colsep0 rowsep0" align="left">673/725 nm/s (pH 5.5/7.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco2 permeability:</td><td class="colsep0 rowsep0" align="left">ND due to insufficient recovery</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility</td><td class="colsep0 rowsep0" align="left"><0.004 mg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FaSSIF<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a> solubility</td><td class="colsep0 rowsep0" align="left">18 μg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FeSSIF<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a> solubility</td><td class="colsep0 rowsep0" align="left">368 μg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log D at pH 7.0 (HPLC)</td><td class="colsep0 rowsep0" align="left">4.06</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">CYP = cytochrome P450.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">FaSSIF = fasted state simulated intestinal fluid.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">FeSSIF = fed state simulated intestinal fluid; ND = not determined.</p></div></div></div><div class="NLM_p">The X-ray cocrystal structure of <b>14f</b> bound to the kinase domain of BTK (1.5 Å, <a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>; PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18">5T18</a>) revealed that the tetrahydrocarbazole NH and the carboxamide carbonyl are engaged in a hydrogen bonding interaction with Met477 in the hinge region of the active site. The NH<sub>2</sub> of the carboxamide forms a hydrogen bonding interaction not only with Glu475 but also with a conserved water, providing a bridging interaction with the gatekeeper Leu408 residue. The cocrystal structure confirmed the (<i>R</i>)-configuration of the C5 phenyl linker atropisomer, projecting the methyl group down into a hydrophobic pocket. As was the case with <b>2</b> and <b>4</b>, the orthogonal nature of the linker projects the (<i>S</i>)-quinazolinedione, also orthogonal to the phenyl linker, into a region of the active site allowing for further stabilization through two hydrogen bonding interactions with conserved water molecules. Consistent with the X-ray cocrystal structure of <b>4</b>, one of the carbonyls is interacting with a water molecule that allows for a bridging interaction with Cys481. The other carbonyl provides additional stabilization through a hydrogen bonding relationship with a network of water molecules associated with both Lys430 and Gly414. The X-ray cocrystal structure also revealed that the C2 carbinol is directed toward the solvent and does not appear to form any interaction. One of our primary strategies in this effort was to improve the potency of the carbazole series, both against BTK and in human whole blood, by locking the atropisomers into the preferred bioactive conformation to minimize the overall entropy in the binding process. As shown in <a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>, the overlay of the single crystal X-ray structure with the cocrystal structure of <b>14f</b> bound with BTK clearly highlights the benefit of this approach.</div><figure id="fig12" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0013.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. X-ray crystal structure of <b>14f</b> bound to the kinase domain of BTK (1.5 Å structure) (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18">5T18</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig13" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0014.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Overlay of the single crystal X-ray structure (pink) with the X-ray crystal structure of <b>14f</b> bound to the active site of BTK (gold).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A more expanded view of the in vitro activity profile of 1<b>4f</b> is outlined in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. In B cells stimulated through the B cell receptor (BCR), <b>14f</b> potently inhibited signaling and functional end points, including calcium flux (IC<sub>50</sub> = 9 nM), production of cytokines, proliferation, and surface expression of the costimulatory molecule CD86 (IC<sub>50</sub> = 3–4 nM). As expected, CD69 expression in peripheral B cells, when stimulated through CD40, was not impacted by <b>14f</b> since this pathway is not dependent on the kinase activity of BTK to mediate downstream signaling, thus demonstrating the functional selectivity of <b>14f</b>. When evaluated against the IgG-containing immune complex low affinity activating Fcγ (FcγRIIa and FcγRIII) receptor end points in peripheral blood mononuclear cells (PBMC), <b>14f</b> was very effective in inhibiting TNFα production with equivalent potency to those measured for the BCR-dependent end points in B cells (IC<sub>50</sub> = 3 nM). In T cells, ITK-catalyzed phosphorylation of PLCγ1 stimulated through the T cell receptor (TCR) was at least 45-fold less potently inhibited by <b>14f</b> than BTK-dependent signaling end points in B cells, as expected based on the 30-fold selectivity for BTK over ITK in the enzymatic assays. TCR-dependent proliferation of T cells, which is sensitive to LCK inhibition, was also evaluated, and <b>14f</b> was shown to be ∼1,200-fold less potent when compared to the BCR-dependent B cell proliferation results. As has been previously stated, 1<b>4f</b> potently inhibited BCR-stimulated expression of CD69 on B cells in human whole blood with an IC<sub>50</sub> of 90 nM. When evaluated against FcεRI-driven CD63 surface expression on basophils in human whole blood, <b>14f</b> provided equally potent inhibition with an IC<sub>50</sub> of 89 nM. Compared to our previous lead <b>2</b> (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), it is apparent that <b>14f</b> has significantly enhanced cellular and whole blood potencies.</div><div class="NLM_p">In order to gain an understanding of general kinase selectivity, <b>14f</b> was evaluated against 384 kinases. A partial list of kinase selectivity data is summarized in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. Eleven kinases showed less than 15% control binding at a 10 μM concentration, and only five kinases were inhibited with less than 100-fold selectivity for BTK. Out of those, four were Tec family kinases, with only TEC (20×) having less than 30-fold selectivity for BTK.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Partial in Vitro Selectivity Data for <b>14f</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">biochemical IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">kinase/BTK fold selectivity</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK (Tec family)</td><td class="colsep0 rowsep0" align="left">0.50</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TEC (Tec family)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">20×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ITK (Tec family)</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">30×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BLK</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">30×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TXK (Tec family)</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">56×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMX (Tec family)</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">64×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LCK</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">142×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="left">1,100</td><td class="colsep0 rowsep0" align="left">2,000×</td></tr></tbody></table></div></div><div class="NLM_p">With a highly desirable activity and selectivity profile, a clean liability profile (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>), and good preliminary PK results, <b>14f</b> was further evaluated in vivo. In multispecies pharmacokinetic studies (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>), the absolute oral bioavailability of <b>14f</b> was 93% in mice, 67% in rats, 33% in cynomolgus monkeys, and 100% in dogs. The total body plasma clearance of <b>14f</b> was low in all species. The large steady-state volume of distribution observed was indicative of extravascular distribution, in spite of the high protein binding (free fraction, 0.9–1.7%; <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>); however, brain penetration was very low in rats (<5% of plasma concentration). Of particular interest, no significant in vivo isomerization of <b>14f</b> at either atropisomeric center was observed (<2%) in plasma samples collected at 24 h post-oral dosing. On the basis of its highly desirable PK profile, <b>14f</b> was advanced into animal models of human autoimmune disease.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Parameters for <b>14f</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">mouse<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">rat<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">monkey<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">dog<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μM), PO</td><td class="colsep0 rowsep0" align="left">4.9</td><td class="colsep0 rowsep0" align="left">2.3 ± 0.3</td><td class="colsep0 rowsep0" align="left">0.85 ± 0.68</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (μM), PO</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">3.0 ± 1.2</td><td class="colsep0 rowsep0" align="left">3.7 ± 2.3</td><td class="colsep0 rowsep0" align="left">3.0 ± 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (μM·h), PO</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">23 ± 4.9</td><td class="colsep0 rowsep0" align="left">5.0 ± 2.8</td><td class="colsep0 rowsep0" align="left">16 ± 1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h), iv</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">3.6 ± 0.7</td><td class="colsep0 rowsep0" align="left">5.1 ± 1.4</td><td class="colsep0 rowsep0" align="left">13 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT (h), iv</td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">5.1 ± 0.9</td><td class="colsep0 rowsep0" align="left">4.7 ± 1.1</td><td class="colsep0 rowsep0" align="left">18 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg),iv</td><td class="colsep0 rowsep0" align="left">4.1</td><td class="colsep0 rowsep0" align="left">4.2 ± 0.9</td><td class="colsep0 rowsep0" align="left">10 ± 7.9</td><td class="colsep0 rowsep0" align="left">3.2 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg), iv</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.3</td><td class="colsep0 rowsep0" align="left">3.0 ± 2.2</td><td class="colsep0 rowsep0" align="left">3.4 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i><sub>po</sub> (%)</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">67 ± 15</td><td class="colsep0 rowsep0" align="left">33 ± 21</td><td class="colsep0 rowsep0" align="left">100 ± 34</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Average of three animals.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Cynomolgus monkey.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">Average of two animals; vehicle, 10% EtOH, 70–80% PEG300 or PEG400, 10–20% water.</p></div></div></div><div class="NLM_p">Compound <b>14f</b> was evaluated in vivo in a female NZB/W lupus-prone mouse model in which the mice develop a disease closely resembling human systemic lupus erythematosus and lupus nephritis. Mice were dosed by oral gavage, q.d., for 16 weeks with <b>14f</b> (30 mg/kg), prednisolone (10 mg/kg), or vehicle (80:20 PEG400/water). In this study, <b>14f</b> was shown to block the increase in severe proteinuria (<a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>A), a measure of the underlying nephritis. Treatment with <b>14f</b> also provided protection from disease-related death over the course of the treatment (<a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>B). Histological evaluation of the kidneys at the end of the study demonstrated that treatment with <b>14f</b> provided robust protection against tubulo-interstitial and glomerular nephritis, as well as inflammatory infiltration, at levels equivalent to those seen with prednisolone (<a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>C). IgG immune complex deposition, critical in driving disease pathobiology in both this murine model and human lupus nephritis, was prominent in the capillaries of the glomeruli of vehicle control mice. As seen in <a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>D, histological evaluation revealed that <b>14f</b> reduced the level of immune complex deposits as effectively as prednisolone.</div><figure id="fig14" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0015.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Efficacy of <b>14f</b> in a NZB/W lupus-prone mice model vs prednisolone and vehicle. Mice dosed daily starting at 24 weeks of age (<i>n</i> = 12 per group). (A) Percentage of mice with severe proteinuria (≥300 mg/dL) over the 14 week course of treatment. (B) Anti-dsDNA titers in serum at the end of the study, mean ± SEM. (C) Total nephritis histology scores (tubulointerstitial and glomerular nephritis) of kidneys at the end of the study, mean ± SEM. (D) Mononuclear infiltration in kidneys at the end of the study, mean ± SEM. (E) Representative sections from each group. *<i>P</i> < 0.05, **<i>P</i> < 0.01 versus the vehicle control group. Vehicle: 80:20 PEG400/water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Additionally, <b>14f</b> was evaluated in vivo in a mouse anticollagen antibody-induced arthritis study, a preclinical model of human rheumatoid arthritis that is dependent on Fcγ receptor driven mechanisms. Female BALB/c mice were injected intraperitoneally (IP) with a mixture of four monoclonal antimouse type II collagen antibodies. Daily oral dosing q.d. was immediately initiated with <b>14f</b>. On day 3, the mice were injected IP with LPS. The mice were then monitored and clinically scored out to day 11. Administration of <b>14f</b> reduced both the severity and incidence of clinically evident paw swelling, with an oral dose of 5 mg/kg q.d. resulting in a 72% reduction in clinical scores relative to the vehicle group and an oral dose of 20 mg/kg q.d. providing essentially complete suppression of clinical symptoms. Histological evaluation of the right hind paws, evaluating bone resorption and inflammation, was consistent with the clinical scores. Results from additional efficacy studies with <b>14f</b> in animal models of rheumatoid arthritis will be communicated in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, a novel third generation series of carbazole based, reversible inhibitors of BTK has been identified, providing significant improvements in potency and selectivity relative to the previous lead <b>2</b>, which consisted of a mixture of four interconverting, observable atropisomers. This was accomplished by locking two atropisomeric centers into the preferred conformation for optimal binding to BTK with substitution of small groups at carbazole C3 to rotationally lock the carbazole C4 atropisomeric center and with the addition of a second carbonyl to form a rotationally locked quinazolinedione atropisomeric center. Incorporation of electron inductive substituents at C3 may be contributing to the improved potency through enhanced hydrogen bonding interactions with the hinge region of the kinase domain. The additional structural diversification of a tetrahydrocarbazole core, with a third chiral center, provided enhanced selectivity and PK properties relative to the carbazoles. On the basis of its in vitro potency and selectivity profile, liability profile, and in vivo PK and efficacy profiles, tetrahydrocarbazole <b>14f</b>, 6-fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide, was selected as our lead drug candidate. With a very desirable tolerability and safety profile in multiple species, <b>14f</b> was advanced into clinical studies. The significant improvements observed in the tolerability studies (data not shown) relative to those of <b>2</b>, highlight the potential benefits of preparing a single, stable atropisomeric compound to both enhance intrinsic potency and to remove the less target relevant atropisomer, which could contribute to off-target toxicity. With favorable Phase I results, <b>14f</b> has entered Phase II clinical studies for the treatment of rheumatoid arthritis. Clinical results will be published in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08646" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08646" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Proton magnetic resonance (<sup>1</sup>H) spectra were recorded on a Bruker Avance 400 (400 MHz), a Bruker Avance III 500 (500 MHz), or a JEOL Eclipse 500 (500 MHz) spectrometer and are reported in ppm relative to the reference solvent of the sample in which they were run. HPLC and LCMS analyses were conducted using a Shimadzu SCL-10A liquid chromatograph and a SPD UV–vis detector at 220 or 254 nm with the MS detection performed on a Waters Micromass ZQ spectrometer or a Waters Acquity UPLC with MS detection performed on a Waters SQ spectrometer. Preparative reverse-phase HPLC purifications were performed using the following conditions: columns, Waters SunFire C<sub>18</sub>, Phenomenex Axia C<sub>18</sub>, or YMC S5 ODS with a binary solvent system where solvent A = 10% methanol or acetonitrile, 90% water, and 0.1% trifluoroacetic acid, and solvent B = 90% methanol or acetonitrile, 10% water, and 0.5 or 0.1% trifluoroacetic acid and eluting with a gradient of increasing concentration of methanol or acetonitrile suitable to the column size and separation to be achieved. Fractions containing the product were immediately neutralized with an aqueous solution of sodium bicarbonate and concentrated under reduced pressure. The residue was dissolved in an organic solvent, washed with water, dried over anhydrous sodium sulfate or magnesium sulfate, and concentrated under reduced pressure. All flash column chromatography was performed on EM Science silica gel 60 (particle size of 40–60 μm) or with an ISCO column. All reagents were purchased from commercial sources and used without further purification unless otherwise noted. All reactions were performed under an inert atmosphere.</div><div class="NLM_p">HPLC analyses were performed using the following conditions. All final compounds had an HPLC purity of ≥95%.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Method A</h3><div class="NLM_p last">A linear gradient using 5% acetonitrile, 95% water, and 0.05% trifluoroacetic acid (Solvent A) and 95% acetonitrile, 5% water, and 0.05% trifluoroacetic acid (Solvent B), <i>t</i> = 0 min, and 10% B, <i>t</i> = 12 min, 100% B (15 min) was employed on a SunFire C18 3.5u 3.0 × 150 mm column. The flow rate was 1.0 mL/min, and UV detection was set to 220/254 nm. The LC column was maintained at ambient temperature.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Method B</h3><div class="NLM_p last">A linear gradient using 5% acetonitrile, 95% water, and 0.05% trifluoroacetic (Solvent A) and 95% acetonitrile, 5% water, and 0.05% trifluoroacetic (Solvent B), <i>t</i> = 0 min, 10% B, and <i>t</i> = 12 min, 100% B (15 min) was employed on a XBridge Ph 3.5u 3.5 × 150 mm column. The flow rate was 1.0 mL/min, and UV detection was set to 220/254 nm. The LC column was maintained at ambient temperature.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Method C</h3><div class="NLM_p last">A linear gradient using 10% methanol, 90% water, and 0.2% phosphoric acid (Solvent A) and 90% methanol, 10% water, and 0.2% phosphoric acid (Solvent B), <i>t</i> = 0 min, 0% B, and <i>t</i> = 4 min, 100% B (5 min) was employed on a Chromolith SpeedROD 4.6 × 50 mm column. The flow rate was 4.0 mL/min, and UV detection was set to 220 nm. The LC column was maintained at ambient temperature.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Method D</h3><div class="NLM_p">A linear gradient using 10% methanol, 90% water, and 0.2% phosphoric acid (Solvent A) and 90% methanol, 10% water, and 0.2% phosphoric acid (Solvent B), <i>t</i> = 0 min, 0% B, and <i>t</i> = 4 min, 100% B (5 min) was employed on a YMC S5 CombiScreen 4.6 × 50 mm column. The flow rate was 4.0 mL/min, and UV detection was set to 220 or 254 nm. The LC column was maintained at ambient temperature.</div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 7-(2-Hydroxypropan-2-yl)-4-(2-methyl-3-(1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)phenyl)-9<i>H</i>-carbazole-1-carboxamide (<b>5</b>)</h4><div class="NLM_p last">Compound <b>5</b> can be prepared in a manner similar to that described for the preparation of compound <b>6</b> using 4-bromo-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide<a onclick="showRef(event, 'cit15b cit15c'); return false;" href="javascript:void(0);" class="ref cit15b cit15c">(15b, 15c)</a> and 1-methyl-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione<a onclick="showRef(event, 'cit16b'); return false;" href="javascript:void(0);" class="ref cit16b">(16b)</a> to afford <b>5</b> as a white solid. HPLC purity: 98.0%; <i>t</i><sub>r</sub> = 8.07 min (Method A); 97.7%; <i>t</i><sub>r</sub> = 8.08 min (Method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>28</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 533.2. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 515.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.54 (s, 1H), 8.32 (ddd, <i>J</i> = 9.8, 8.1, 1.4 Hz, 1H), 7.76 (ddt, <i>J</i> = 8.4, 7.2, 1.5 Hz, 1H), 7.69–7.66 (m, 1H), 7.63 (dd, <i>J</i> = 7.8, 1.7 Hz, 1H), 7.52–7.46 (m, 1H), 7.43–7.39 (m, 1H), 7.35 (m, 2H), 7.33–7.29 (m, 2H), 7.28 (m, 2H), 7.25–7.23 (m, 1H), 7.12 (dd, <i>J</i> = 7.8, 4.1 Hz, 1H), 4.13 (q, <i>J</i> = 7.0 Hz, 1H), 3.69 (d, <i>J</i> = 2.4 Hz, 3H), 1.89 (s, 3H), and 1.65 (d, <i>J</i> = 2.4 Hz, 6H).</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4-(3-(8-Fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>6</b>).<a onclick="showRef(event, 'cit16b'); return false;" href="javascript:void(0);" class="ref cit16b">(16b)</a></h4><div class="NLM_p last">A mixture of 4-bromo-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide<a onclick="showRef(event, 'cit15b cit15c'); return false;" href="javascript:void(0);" class="ref cit15b cit15c">(15b, 15c)</a> (827 mg, 2.38 mmol,), 8-fluoro-1-methyl-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>32</b>, 850 mg, 2.07 mmol), 2 M aqueous tripotassium phosphate (3.11 mL, 6.22 mmol), and tetrakis(triphenylphosphine)palladium (120 mg, 0.104 mmol) in a mixture of toluene (27 mL) and ethanol (9 mL) was heated at reflux under nitrogen overnight. The mixture was cooled to room temperature, diluted with ethyl acetate, washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was subjected to column chromatography on silica gel, eluting with a mixture of dichloromethane, methanol, and ammonium hydroxide (90:9:1 to 97:2.7:0.3), to give <b>6</b> (860 mg, 1.56 mmol, 76% yield). HPLC purity: 98.1%; <i>t</i><sub>r</sub> = 8.63 min (Method A); 98.6%; <i>t</i><sub>r</sub> = 9.07 min (Method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>27</sub>FN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 551.2. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 533.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.40 (s, 1H), 8.17 (br. s., 1H), 8.04–7.93 (m, 2H), 7.84 (d, <i>J</i> = 1.1 Hz, 1H), 7.74 (ddd, <i>J</i> = 14.4, 8.0, 1.3 Hz, 1H), 7.54–7.42 (m, 3H), 7.38–7.30 (m, 2H), 7.12–7.05 (m, 1H), 7.04–6.99 (m, 2H), 4.99 (d, <i>J</i> = 1.3 Hz, 1H), 3.75 (t, <i>J</i> = 8.4 Hz, 3H), 1.76 (s, 3H), and 1.50–1.45 (m, 6H).</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4-(3-(<i>S</i>)-(8-Fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>7a</b>)<a onclick="showRef(event, 'cit16b'); return false;" href="javascript:void(0);" class="ref cit16b">(16b)</a></h4><div class="NLM_p">A sample of 4-(3-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (mixture of four atropisomers) (<b>6</b>, 0.532 g, 0.966 mmol) was separated by chiral SFC as follows: column, Lux Cel-4 (3 × 25 cm, 5 μm); mobile phase, CO<sub>2</sub>-MeOH (60:40) at 85 mL/min; sample preparation, 6.7 mg/mL in MeOH–acetone (9:1); injection, 3 mL. Peaks three and four eluting from the column were combined to provide <b>7a</b> (0.230 g, 0.418 mmol, 43% yield) as a light yellow solid and as a mixture of two interconverting atropisomers. HPLC purity: 98.9%; <i>t</i><sub>r</sub> = 8.65 min (Method A); 99.5%; <i>t</i><sub>r</sub> = 8.99 min (Method B). Chiral purity: > 99% ie; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>27</sub>FN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 551.2. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 533.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.39 (s, 1H), 8.16 (br. s., 1H), 8.03–7.92 (m, 2H), 7.83 (s, 1H), 7.72 (dd, <i>J</i> = 14.1, 8.0 Hz, 1H), 7.53–7.41 (m, 3H), 7.38–7.29 (m, 2H), 7.11–6.96 (m, 3H), 4.98 (br. s., 1H), 3.74 (dd, <i>J</i> = 10.8, 8.3 Hz, 3H), 1.75 (s, 3H), and 1.46 (d, <i>J</i> = 5.5 Hz, 6H).</div><div class="NLM_p last">The absolute stereochemistry of the (<i>S</i>)-quinazoline dione was confirmed by single crystal X-ray analysis (CCDC # 1501158). The analysis also confirmed that <b>7a</b> consists of a mixture of (<i>R</i>)- and (<i>S</i>)-carbazole C4 atropisomers.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0032.gif" alt="" id="fx1" /></img></div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 4-(3-(<i>R</i>)-(8-Fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>7b</b>)<a onclick="showRef(event, 'cit16b'); return false;" href="javascript:void(0);" class="ref cit16b">(16b)</a></h4><div class="NLM_p last">A sample of 4-(3-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (mixture of four atropisomers) (<b>6</b>, 0.532 g, 0.966 mmol) was separated by chiral SFC chromatography as follows: column, Lux Cel-4 (3 × 25 cm, 5 μm); mobile phase, CO<sub>2</sub>–MeOH (60:40) at 85 mL/min; sample preparation, 6.7 mg/mL in MeOH–acetone (9:1); injection, 3 mL. Peaks one and two eluting from the column were collected together to provide <b>7b</b> (0.230 g, 0.418 mmol, 43% yield) as a light yellow solid and as a mixture of two interconverting atropisomers. HPLC purity, 99.4%; <i>t</i><sub>r</sub> = 8.65 min (Method A); 100%; <i>t</i><sub>r</sub> = 8.99 min (Method B). Chiral purity: >99% ie; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>27</sub>FN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 551.2. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 533.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.39 (s, 1H), 8.15 (br. s., 1H), 8.02–7.93 (m, 2H), 7.83 (s, 1H), 7.72 (dd, <i>J</i> = 14.4, 8.3 Hz, 1H), 7.52–7.41 (m, 3H), 7.37–7.30 (m, 2H), 7.10–7.03 (m, 1H), 7.03–6.97 (m, 2H), 4.98 (d, <i>J</i> = 1.1 Hz, 1H), 3.74 (t, <i>J</i> = 8.4 Hz, 3H), 1.74 (s, 3H), and 1.46 (d, <i>J</i> = 4.4 Hz, 6H).</div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-Chloro-4-(3-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>8</b>)<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a></h4><div class="NLM_p last">A mixture of ethyl 5-bromo-8-carbamoyl-9<i>H</i>-carbazole-2-carboxylate (<b>16</b>, 0.100 g, 0.277 mmol) and <i>N</i>-chlorosuccinimide (recrystallized from toluene; 0.037 g, 0.277 mmol) in carbon tetrachloride (10 mL) and dimethylformamide (2 mL) was stirred at room temperature for 112 h. The mixture was filtered, and the collected precipitate was washed with carbon tetrachloride and dried overnight under reduced pressure. The residue was purified by column chromatography on silica gel (40 g), eluting with hexanes followed by a mixture of ethyl acetate and hexanes (30%, then 50%), to give ethyl 5-bromo-8-carbamoyl-6-chloro-9<i>H</i>-carbazole-2-carboxylate as a fluffy white solid (<b>18a</b>, 0.071g, 0.187 mmol, 67% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>12</sub>BrClN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 395.0. Found: 395.0 and 397.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.13 (s, 1H), 8.77 (d, <i>J</i> = 8.6 Hz, 1H), 8.53 (d, <i>J</i> = 1.1 Hz, 1H), 8.36 (br. s., 1H), 8.29 (s, 1H), 7.89 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 7.74 (br. s., 1H), 4.38 (q, <i>J</i> = 7.0 Hz, 2H), and 1.38 (t, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec5_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Alternative Procedure</h4><div class="NLM_p">To a mixture of ethyl 5-bromo-8-carbamoyl-9<i>H</i>-carbazole-2-carboxylate (90 g, 249 mmol), carbon tetrachloride (2.9 L) and <i>N</i>-methyl-2-pyrrolidone (0.60 L) was added <i>N</i>-chlorosuccinimide (36.1 g, 271 mmol). The reaction mixture was stirred at 45 °C for 2 h. After cooling to room temperature, the solid was collected by vacuum filtration. The solid was stirred in methanol (1.0 L) at 60 °C for 2 h and then cooled to room temperature. The solid was collected and dried to give ethyl 5-bromo-8-carbamoyl-6-chloro-9<i>H</i>-carbazole-2-carboxylate (<b>18a</b>, 70 g, 167 mmol, 67% yield) (95% purity). The filtrate was concentrated under reduced pressure to remove carbon tetrachloride. To the <i>N</i>-methyl-2-pyrrolidone residue was added water (2.0 L). The resulting precipitate was collected and dried to give an additional 14 g of product (25% yield, 75% purity).</div><div class="NLM_p">A solution of ethyl 5-bromo-8-carbamoyl-6-chloro-9<i>H</i>-carbazole-2-carboxylate (4.14 g, 10.5 mmol) in tetrahydrofuran (200 mL), cooled in a dry ice–acetone bath, was treated portionwise over 30 min with 1.6 M methyllithium in hexanes (45.8 mL, 73.2 mmol). The mixture was stirred at −78 °C for 60 min and then was treated portionwise with a saturated aqueous solution of ammonium chloride. Water was added, and the mixture was extracted with ethyl acetate (2×). The combined organic layers were washed with water (2×), and the aqueous phases were combined and extracted with dichloromethane. The combined organic layers were dried over anhydrous sodium sulfate and concentrated. The residue was crystallized from ethyl acetate, the precipitate was collected by vacuum filtration, and the filtrate was concentrated under reduced pressure and purified by silica gel chromatography, eluting with a mixture of ethyl acetate and hexanes (0–100%), to give an additional solid. The two solids were combined to give 4-bromo-3-chloro-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide as a light yellow solid (3.13 g, 8.20 mmol, 78% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>14</sub>BrClN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 381.0. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 363.0 and 365.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.71 (s, 1H), 8.56 (d, <i>J</i> = 8.6 Hz, 1H), 8.29 (br. s., 1H), 8.17 (s, 1H), 7.97 (d, <i>J</i> = 1.3 Hz, 1H), 7.66 (br. s., 1H), 7.42 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 5.10 (s, 1H), and 1.52 (s, 6H).</div><div class="NLM_p last">A mixture of 4-bromo-3-chloro-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>18a</b>, 100 mg, 0.262 mmol), 8-fluoro-1-methyl-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>32</b>, 161 mg, 0.393 mmol), tetrakis(triphenylphosphine)palladium (15 mg, 0.013 mmol), and 2 M aqueous solution of tripotassium phosphate (0.26 mL, 0.524 mmol) in tetrahydrofuran (2 mL) in a pressure reaction vial was heated at 90 °C for 2.5 h. The cooled mixture was concentrated, and the residue was purified by silica gel chromatography, eluting with a mixture of dichloromethane, methanol, and ammonium hydroxide (90:9:1–97:2.7:0.3). The resulting impure product was again purified by silica gel chromatography, eluting with a mixture of ethyl acetate and hexanes (50–100%), to give <b>8</b> (110 mg, 0.188 mmol, 68% yield) as a white solid and as a mixture of four atropisomers. HPLC purity: 95.4%; <i>t</i><sub>r</sub> = 9.12 min (Method A); 96.1%; <i>t</i><sub>r</sub> = 9.60 min (Method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>26</sub>ClFN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 585.2. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 567.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.45 (s, 1H), 8.15–8.09 (m, 1H), 7.74 (s, 1H), 7.67 (d, <i>J</i> = 1.1 Hz, 1H), 7.57–7.51 (m, 1H), 7.47 (ddt, <i>J</i> = 13.9, 8.1, 1.8 Hz, 1H), 7.37 (dd, <i>J</i> = 12.4, 7.8 Hz, 2H), 7.26–7.18 (m, 2H), 6.98–6.92 (m, 1H), 5.31 (s, 1H), 3.89 (dd, <i>J</i> = 9.2, 8.1 Hz, 3H), 1.86 (d, <i>J</i> = 1.8 Hz, 3H), 1.65 (s, 3H), and 1.65 (s, 3H).</div></div><div id="sec5_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-Chloro-4-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>9a</b>)<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a></h4><div class="NLM_p">A mixture of 4-bromo-3-chloro-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>18a</b>, 4 g, 10.5 mmol), 8-fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19</b>, 4.73 g, 11.5 mmol), 1,1′-bis(diphenylphosphino)ferrocenepalladium(II) dichloride-dichloromethane adduct (21.4 mg, 0.026 mmol) and cesium carbonate (512 mg, 1.57 mmol) in tetrahydrofuran (60 mL) and water (20 mL) was heated at 60 °C overnight. The aqueous layer was separated and extracted with ethyl acetate (2×). The organic layers were combined and concentrated, and the residue was purified by flash silica gel chromatography using ethyl acetate and hexane to give 3-chloro-4-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (5.16 g, 8.83 mmol, 84% yield) as a yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>26</sub>ClFN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 585.2. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 567.3.</div><div class="NLM_p">A sample of 3-chloro-4-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (mixture of 2 atropisomers) was separated by chiral SFC to give two single, stable atropisomers as follows: column, AS-H 3 × 25 cm; 5 μm; BPR pressure, 100 bar; temperature, 40 °C; flow rate, 140 mL/min; mobile phase, CO<sub>2</sub>/MeOH (60/40); detector wavelength, 280 nm; injection, 1.15 mL; and sample preparation, 3.56 mg/25 mL MeOH/DMSO (5:1), 30 mg/mL. The first peak eluting from the column provided <b>9a</b> as a single, stable atropisomer and as a white solid. HPLC purity: 99.6%; <i>t</i><sub>r</sub> = 9.12 min (Method A); 99.8%; <i>t</i><sub>r</sub> = 9.61 min (Method B). Chiral purity: >99.5%; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>26</sub>ClFN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 585.2. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 567.0. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.46 (s, 1H), 8.13 (d, <i>J</i> = 7.3 Hz, 1H), 7.75 (s, 1H), 7.69 (d, <i>J</i> = 1.3 Hz, 1H), 7.59–7.53 (m, 1H), 7.48 (ddd, <i>J</i> = 13.9, 8.0, 1.7 Hz, 1H), 7.39 (dd, <i>J</i> = 11.1, 7.8 Hz, 2H), 7.27–7.21 (m, 2H), 6.99 (d, <i>J</i> = 8.4 Hz, 1H), 3.91 (d, <i>J</i> = 7.9 Hz, 3H), 1.88 (s, 3H), 1.66 (s, 6H).</div><div class="NLM_p last">The absolute configuration of <b>9a</b> was confirmed by single crystal X-ray analysis (CCDC # 1501159).<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0033.gif" alt="" id="fx2" /></img></div></div><div id="sec5_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-Chloro-4-(<i>S</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>9b</b>)</h4><div class="NLM_p last">A sample of 3-chloro-4-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (see procedure for <b>9a</b>; mixture of 2 atropisomers) was separated by chiral SFC chromatography to give two single, stable atropisomers as follows: column, AS-H 3 × 25 cm; 5 μm; BPR pressure, 100 bar; temperature, 40 °C; flow rate, 140 mL/min; mobile phase, CO<sub>2</sub>/MeOH (60/40); detector wavelength, 280 nm; injection, 1.15 mL; sample preparation, 3.56 mg/25 mL MeOH/DMSO (5:1), 30 mg/mL. The second peak eluting from the column provided <b>9a</b> as a single, stable atropisomer and as a white solid. HPLC purity: 98.8%; <i>t</i><sub>r</sub> = 9.13 min (Method A); 98.3%; <i>t</i><sub>r</sub> = 9.62 min (Method B). Chiral purity: >99.2%; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>26</sub>ClFN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 585.2. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 567.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.44 (s, 1H), 8.11 (d, <i>J</i> = 7.9 Hz, 1H), 7.73 (s, 1H), 7.67 (d, <i>J</i> = 1.1 Hz, 1H), 7.57–7.52 (m, 1H), 7.46 (ddd, <i>J</i> = 13.9, 8.1, 1.5 Hz, 1H), 7.41–7.37 (m, 1H), 7.36 (d, <i>J</i> = 7.5 Hz, 1H), 7.25–7.23 (m, 1H), 7.23–7.21 (m, 1H), 6.97 (d, <i>J</i> = 8.4 Hz, 1H), 3.90 (d, <i>J</i> = 8.1 Hz, 3H), 3.50 (d, <i>J</i> = 5.7 Hz, 3H), 1.86 (s, 3H), and 1.64 (s, 6H).</div></div><div id="sec5_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 3-Chloro-4-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>10</b>)</h4><div class="NLM_p">A mixture of 4-bromo-3-chloro-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>18a</b>, 1.00 g, 2.62 mmol), 8-fluoro-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>33</b>, 1.25 g, 3.14 mmol), tripotassium phosphate (2 M in water) (3.93 mL, 7.86 mmol), and tetrahydrofuran (12 mL) was degassed (3×). 1,1′-Bis(di-<i>tert</i>-butylphosphino)ferrocene palladium dichloride (0.085 g, 0.131 mmol) was added, and the reaction mixture was degassed (2×). The reaction mixture was stirred at room temperature overnight. Analysis confirmed that the reaction was ∼50% complete. Additional catalyst was added, and the reaction mixture was degassed and stirred at 50 °C for 7 h and then at room temperature over the weekend. The reaction mixture was diluted with ethyl acetate, washed with water, washed with brine, and dried over anhydrous sodium sulfate. Concentration under reduce pressure followed by purification by flash silica gel chromatography using a mixture of ethyl acetate and hexane (50%–62%–75%–85%) afforded 3-chloro-4-(3-(<i>S</i>)-(8-fluoro-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (1.20 g, 2.10 mmol, 80% yield) as an off-white solid. HPLC <i>t</i><sub>r</sub> = 2.63 min (Method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>3</sub>1H<sub>24</sub>ClFN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 571.2. Found: (M + H – H<sub>2</sub>O) 553.2.</div><div class="NLM_p last">A sample of 3-chloro-4-(3-(<i>S</i>)-(8-fluoro-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (mixture of 2 atropisomers) was separated by chiral SFC to give two single, stable atropisomers using the following conditions: column, OJ-H 3 × 25 cm; 5 μm; BPR pressure, 100 bar; temperature, 40 °C; flow rate, 150 mL/min; mobile phase, CO<sub>2</sub>/MeOH (60/40); detector wavelength, 220 nm; injection, 1.2 mL; sample preparation, 1.19 mg/25 mL MeOH/DCM (2:1), 48 mg/mL. The second peak eluting from the column provided <b>10</b> as a single, stable atropisomer and as an off-white solid. HPLC purity: 99.5%; <i>t</i><sub>r</sub> = 9.67 min (Method A); 99.0%; <i>t</i><sub>r</sub> = 9.47 min (Method B). Chiral purity: >99.5%; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>24</sub>ClFN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 571.2. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 553.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.77 (br. s., 1H), 11.50 (s, 1H), 8.28 (br. s., 1H), 8.14 (s, 1H), 7.87–7.80 (m, 2H), 7.65 (ddd, <i>J</i> = 10.0, 8.8, 1.0 Hz, 1H), 7.59 (br. s., 1H), 7.55–7.49 (m, 3H), 7.28 (dd, <i>J</i> = 6.4, 2.6 Hz, 1H), 7.23 (td, <i>J</i> = 8.0, 4.6 Hz, 1H), 7.05 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 6.70 (d, <i>J</i> = 8.6 Hz, 1H), 5.00 (s, 1H), 1.72 (s, 3H), and 1.45 (d, <i>J</i> = 2.9 Hz, 6H).</div></div><div id="sec5_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 3-Chloro-4-(<i>R</i>)-(3-(<i>R</i>)-(8-fluoro-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>11</b>)<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a></h4><div class="NLM_p">A mixture of 4-bromo-3-chloro-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>18a</b>, 0.360 g, 0.943 mmol), 8-fluoro-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>34</b>,0.392 g, 0.990 mmol), 1,1′-bis(diphenylphosphino)ferrocenepalladium(II) dichloride–dichloromethane adduct (0.039 g, 0.047 mmol) and cesium carbonate (0.615 g, 1.89 mmol) in dioxane (10 mL) and water (2.5 mL) was heated at 100 °C overnight. The cooled mixture was diluted with ethyl acetate, washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate and hexanes (0–50%–70%, containing 1% methanol) to provide 3-chloro-4-(3-(8-fluoro-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (mixture of four atropisomers) as a white solid (0.361 g, 0.632 mmol, 67% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>24</sub>ClFN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 571.2. Found: (M + H – H<sub>2</sub>O) 553.3. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.09 (d, <i>J</i> = 1.1 Hz, 1H), 7.95 (d, <i>J</i> = 8.0 Hz, 1H), 7.81–7.69 (m, 1H), 7.64–7.54 (m, 2H), 7.48 (dd, <i>J</i> = 7.8, 1.1 Hz, 1H), 7.43–7.29 (m, 1H), 7.31–7.24 (m, 1H), 7.18 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 7.16–7.07 (m, 1H), 6.92 (dd, <i>J</i> = 8.6, 5.3 Hz, 1H), 1.94–1.71 (m, 3H), 1.65–1.50 (m, 6H).</div><div class="NLM_p last">A sample of the mixture of four atropisomers of 3-chloro-4-(3-(8-fluoro-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (0.250 g, 0.438 mmol) was separated by chiral SFC as follows: column, Chiralpak AD-H (5 × 25 cm, 5 μm); mobile phase, CO<sub>2</sub>–IPA (60:40) at 220 mL/min, 35 °C, 100 bar; sample preparation, 21 mg/mL in MeOH; injection, 3.0 mL. The third peak eluting from the column provided <b>11</b> as a single, stable atropisomer (0.024 g, 0.042 mmol, 10% yield). HPLC purity: 96%; <i>t</i><sub>r</sub> = 3.39 min (Method D). Chiral purity: >98%; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>24</sub>ClFN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 571.2. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 553.2. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.09 (s, 1H), 7.95 (d, <i>J</i> = 7.9 Hz, 1H), 7.74 (d, <i>J</i> = 1.1 Hz, 1H), 7.60–7.54 (m, 2H), 7.54–7.43 (m, 1H), 7.37 (d, <i>J</i> = 7.5 Hz, 1H), 7.28 (d, <i>J</i> = 4.6 Hz, 1H), 7.11 (dd, <i>J</i> = 8.6, 1.5 Hz, 1H), 6.91 (d, <i>J</i> = 8.6 Hz, 1H), 2.00–1.76 (m, 3H), 1.69–1.52 (m, 6H)</div></div><div id="sec5_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 4-(<i>R</i>)-(3-(<i>S</i>)-(8-Fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-3-methyl-9<i>H</i>-carbazole-1-carboxamide (<b>12a</b>)<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a></h4><div class="NLM_p">A dark, homogeneous solution of 3-bromo-4-methylaniline (<b>36</b>, 5.00 g, 26.9 mmol) and <i>N</i>-iodosuccinimide (4.53 g, 20.16 mmol) and bis(pyridine)iodonium tetraborofluorate (2.70g, 7.26 mmol) in dichloromethane (100 mL) was stirred at room temperature overnight. The reaction mixture was diluted with dichloromethane, washed with a saturated aqueous solution of sodium bisulfite, washed with water, and dried over anhydrous sodium sulfate. Concentration under reduced pressure followed by purification by flash silica gel chromatography using a mixture of ethyl acetate in hexane (1%–2%–3%) afforded 5-bromo-2-iodo-4-methylaniline (<b>37</b>, 5.27 g, 16.9 mmol, 63% yield) as a yellow solid. HPLC <i>t</i><sub>r</sub> = 2.03 min (Method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>7</sub>H<sub>7</sub>BrIN [M + H]<sup>+</sup> 212.0. Found: mass spectrum <i>m</i>/<i>z</i> (M + H)<sup>+</sup> = 212.0 and 214.0. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.49 (d, <i>J</i> = 0.6 Hz, 1H), 6.94 (s, 1H), 4.17–3.91 (br.s, 2H), and 2.25 (s, 3H).</div><div class="NLM_p">A mixture of 5-bromo-2-iodo-4-methylaniline (<b>37</b>, 5.25 g, 16.8 mmol) and zinc cyanide (0.988 g, 8.41 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (80 mL) was degassed well with vacuum and nitrogen (3×). To the mixture was added tetrakis(triphenylphosphine)palladium (0) (0.972 g, 0.841 mmol) with degassing, and the yellow, homogeneous solution was immersed in an oil bath at 90 °C and stirred overnight. The reaction mixture was diluted with ethyl acetate, washed with a 10% lithium chloride solution (2×), and washed with brine. The organic layer was collected, and the aqueous layers were sequentially extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate and concentrated to give the crude product as a brown solid which was purified by flash silica gel chromatography using a mixture of ethyl acetate and hexane (1%–2.5%–5%–50%) to give a brown solid. The compound was further purified by trituration with methanol to give 2-amino-4-bromo-5-methylbenzonitrile (3 crops) (<b>38</b>, 2.68 g, 12.7 mmol, 75% yield) as a tan solid. HPLC <i>t</i><sub>r</sub> = 1.70 min (Method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>8</sub>H<sub>7</sub>BrN<sub>2</sub> [M + H]<sup>+</sup> 211.0. Found: 211.1 and 213.1. The filtrate was purified by flash silica gel chromatography using a mixture of ethyl acetate in hexane (5%–10%) to give additional 2-amino-4-bromo-5-methylbenzonitrile (0.272 g, 1.29 mmol, 8% yield) as a tan solid. Total: 2.95 g (83% yield).</div><div class="NLM_p">A heterogeneous mixture of 2-amino-4-bromo-5-methylbenzonitrile (<b>38</b>, 2.95 g, 14.0 mmol) in a mixture of ethanol (21 mL) and sodium hydroxide (2 M in water) (34.9 mL, 69.9 mmol) was heated at reflux overnight. Within 10 min, the solution became homogeneous. The solvent was removed under reduced pressure, and the aqueous residue was diluted with water, the pH was adjusted to ∼5 with concentrated hydrochloric acid, and stirred for 30 min to ensure pH stability. The solid was collected by vacuum filtration, washed well with water, and dried to give the product as a pale yellow solid. The wet solid was dissolved in ethyl acetate, washed with brine, and dried over anhydrous sodium sulfate. Concentration under reduced pressure afforded 2-amino-4-bromo-5-methylbenzoic acid (<b>39</b>, 2.92 g, 12.7 mmol, 91% yield) as a pale yellow solid. HPLC <i>t</i><sub>r</sub> = 1.52 min (Method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>8</sub>H<sub>8</sub>BrNO<sub>2</sub> [M + H]<sup>+</sup> 230.0. Found: 230.1 and 232.1.</div><div class="NLM_p">To a suspension of 2-amino-4-bromo-5-methylbenzoic acid (<b>39</b>, 2.92 g, 12.7 mmol) in a mixture of 37% hydrochloric acid (12.7 mL) and water (4.3 mL) cooled with a salt–ice bath was added a 3 M solution of sodium nitrite (0.963 g, 14.0 mmol) in water (4.5 mL) dropwise slowly via syringe. After the addition was complete, the creamy solution was stirred for 45 min (ice-salt bath). A 7 M solution of tin(II) chloride dihydrate (8.59 g, 38.1 mmol) in hydrochloric acid (37%, 8.2 mL) was added dropwise slowly via syringe. The ice-bath was removed, and the reaction mixture was stirred at room temperature for 60 min. The thick, off-white colored reaction mixture was filtered under reduced pressure, and the solid was washed well with water and dried overnight. The solid was transferred to a round-bottomed flask and dispersed in methanol with sonication. The suspension was concentrated under reduced pressure, and the solid was triturated with dichloromethane with sonication. The solid was collected by vacuum filtration and washed with dichloromethane to give 4-bromo-2-hydrazinyl-5-methylbenzoic acid hydrochloride (2.17 g, 7.71 mmol, 61% yield) as a white solid. HPLC <i>t</i><sub>r</sub> = 0.798 min (Method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>8</sub>H<sub>9</sub>BrN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 245.0. Found: 245.1 and 247.1.</div><div class="NLM_p">A mixture of 4-bromo-2-hydrazinyl-5-methylbenzoic acid, hydrochloride (2.17 g, 7.71 mmol), ethyl 3-oxocyclohexanecarboxylate (1.44 g, 8.48 mmol), and acetic acid (1.32 mL, 23.1 mmol) in toluene (40 mL) was heated in an oil bath at 117 °C for 5 h. The solvent was removed under reduced pressure, and the residue (dried well) was diluted with toluene (18 mL) and trifluoroacetic acid (4.5 mL). The reaction mixture was stirred in an oil bath at 90 °C overnight. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (with sonication), and the precipitate was collected by vacuum filtration and washed with ethyl acetate to give a yellow solid. The filtrate was concentrated under reduced pressure, and the residue was suspended in ethyl acetate with sonication. The solid was collected to give additional product which was combined with the previous batch to give 5-bromo-2-(ethoxycarbonyl)-6-methyl-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxylic acid (2.04 g, 4.77 mmol, 62% yield) as a yellow solid. The solid was triturated with methanol to give 5-bromo-2-(ethoxycarbonyl)-6-methyl-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxylic acid (1.60 g, 4.21 mmol, 55% yield) as a pale yellow solid. HPLC <i>t</i><sub>r</sub> = 3.22 min (Method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>18</sub>BrNO<sub>4</sub> [M + H]<sup>+</sup> 380.1. Found: 380.2 and 382.2.</div><div class="NLM_p">A solution of 5-bromo-2-(ethoxycarbonyl)-6-methyl-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxylic acid (1.60 g, 4.21 mmol) and DDQ (2.10 g, 9.26 mmol) in tetrahydrofuran (45 mL) was heated at 60 °C for 60 min. After cooling to room temperature, the mixture was diluted with ethyl acetate (∼70 mL), stirred for 15 min, and filtered under reduced pressure. The solid was washed with ethyl acetate and dried. The filtrate was concentrated, triturated with methanol, filtered under reduced pressure, and washed with methanol. The solids were combined to give 4-bromo-7-(ethoxycarbonyl)-3-methyl-9<i>H</i>-carbazole-1-carboxylic acid (1.40 g, 3.72 mmol, 88% yield) as a pale yellow solid. HPLC <i>t</i><sub>r</sub> = 3.39 min (Method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>14</sub>BrNO<sub>4</sub> [M + H]<sup>+</sup> 376.0. Found: 376.2 and 378.2.</div><div class="NLM_p">A heterogeneous mixture of 4-bromo-7-(ethoxycarbonyl)-3-methyl-9<i>H</i>-carbazole-1-carboxylic acid (1.40 g, 3.72 mmol), 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide, hydrochloride (1.070 g, 5.58 mmol), and 1<i>H</i>-benzo[d][1,2,3]triazol-1-ol, monohydrate (0.855 g, 5.58 mmol) in a mixture of tetrahydrofuran (30 mL) and dichloromethane (5 mL) was stirred at room temperature for 60 min. Ammonium hydroxide (0.217 mL, 5.58 mmol) was added, and the heterogeneous reaction mixture was stirred at room temperature overnight. The mixture was diluted with ethyl acetate and washed with a saturated aqueous solution of sodium bicarbonate. Unfortunately, the mixture remained heterogeneous, resulting in a difficult separation. Consequently, the mixture was filtered, and the cake was washed with water followed by ethyl acetate, resulting in an off-white solid which was determined to be the product. The solid was triturated with methanol and dried to give ethyl 5-bromo-8-carbamoyl-6-methyl-9<i>H</i>-carbazole-2-carboxylate (0.908 g, 2.42 mmol, 65% yield) as an off-white solid HPLC <i>t</i><sub>r</sub> = 3.15 min (Method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>15</sub>BrN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 375.0. Found: 375.1 and 377.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.88 (s, 1H), 8.77 (d, <i>J</i> = 8.6 Hz, 1H), 8.48 (d, <i>J</i> = 0.9 Hz, 1H), 8.20 (br. s., 1H), 7.84 (dd, <i>J</i> = 8.5, 1.4 Hz, 1H), 7.59 (br. s., 1H), 4.37 (q, <i>J</i> = 7.0 Hz, 2H), 2.55 (s, 3H), and 1.37 (t, <i>J</i> = 7.0 Hz, 3H). The ethyl acetate/water filtrated was separated, and the organic layer was washed with brine. The organic layer was collected and dried over anhydrous sodium sulfate. Concentration under reduced pressure followed by trituration with methanol with sonication afforded additional ethyl 5-bromo-8-carbamoyl-6-methyl-9<i>H</i>-carbazole-2-carboxylate (0.366 g, 0.975 mmol, 26% yield) as a yellow solid. Total product: 1.27 g (91%).</div><div class="NLM_p">To a solution of ethyl 5-bromo-8-carbamoyl-6-methyl-9<i>H</i>-carbazole-2-carboxylate (0.500 g, 1.33 mmol) in tetrahydrofuran (12 mL) at −78 °C was added methyllithium (1.6 M in ether) (3.0 equiv; 2.50 mL, 4.00 mmol) dropwise over 10 min. The reaction mixture was stirred at −78 °C for 30 min. Additional methyllithium (2.0 equiv; 1.6 M in ether) (1.67 mL, 2.67 mmol) was added, and the heterogeneous reaction mixture was stirred at −78 °C for 30 min. HPLC analysis indicated that there was still starting material remaining. An additional 2.0 equiv of methyllithium was added, and the reaction was stirred for 45 min. The reaction mixture was quenched at −78 °C with a saturated aqueous solution of ammonium chloride. After warming to room temperature, the mixture was diluted with ethyl acetate, washed with water, and washed with brine. The organic layer was collected, the aqueous layers were sequentially extracted with ethyl acetate, and the combined organic layers were dried over anhydrous sodium sulfate. Concentration under reduce pressure afforded a quantitative yield of the product as an off-white solid. The solid was triturated with methanol with sonication and filtered to give 4-bromo-7-(2-hydroxypropan-2-yl)-3-methyl-9<i>H</i>-carbazole-1-carboxamide (0.336 g, 0.930 mmol, 70% yield) as a tan solid. HPLC <i>t</i><sub>r</sub> = 2.77 min (Method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>17</sub>BrN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 361.1. Found: (M + H – H<sub>2</sub>O) 343.2 and 345.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.42 (s, 1H), 8.56 (d, <i>J</i> = 8.6 Hz, 1H), 8.12 (br. s., 1H), 7.91–7.89 (m, 2H), 7.48 (br. s., 1H), 7.36 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 5.06 (s, 1H), 2.53 (s, 3H), and 1.51 (s, 6H). The filtrate was purified by reverse-phase preparative HPLC, and the desired fractions were immediately neutralized with a saturated aqueous solution of sodium bicarbonate and concentrated under reduced pressure. The residue was dissolved in ethyl acetate and water, and the organic layer was collected and washed with brine. The aqueous layers were sequentially extracted with ethyl acetate, and the organic layers were combined and dried over anhydrous sodium sulfate. Concentration under reduced pressure afforded additional 4-bromo-7-(2-hydroxypropan-2-yl)-3-methyl-9<i>H</i>-carbazole-1-carboxamide (0.073 g, 0.202 mmol, 15% yield) as a pale yellow solid. Total product: 0.409 g (85% yield).</div><div class="NLM_p">A mixture of 4-bromo-7-(2-hydroxypropan-2-yl)-3-methyl-9<i>H</i>-carbazole-1-carboxamide (0.091 g, 0.252 mmol), 8-fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19</b>, 0.134 g, 0.327 mmol), tripotassium phosphate (2 M in water) (0.378 mL, 0.756 mmol), and tetrahydrofuran (2.0 mL) was degassed with vacuum and nitrogen (3×). 1,1′-Bis(di<i>tert</i>-butylphosphino)ferrocene palladium dichloride (8.21 mg, 0.013 mmol) was added, and the reaction mixture was degassed (2×). The reaction mixture was stirred at room temperature overnight. The dark reaction mixture was diluted with ethyl acetate, washed with water, washed with brine, and dried over anhydrous sodium sulfate. Concentration under reduce pressure followed by purification by flash silica gel chromatography using a mixture of ethyl acetate and hexane (50%–62%–75%–85%) afforded 4-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-3-methyl-9<i>H</i>-carbazole-1-carboxamide (mixture of 2 atropisomers at carbazole C4, 0.087 g, 0.149 mmol, 59% yield) as a pale yellow solid. HPLC purity: 97.0%; <i>t</i><sub>r</sub> = 10.69 min (Method A); 97.3%; <i>t</i><sub>r</sub> = 10.45 min (Method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>33</sub>H<sub>29</sub>FN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 565.2. Found: (M + H – H<sub>2</sub>O) 547.4. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.20 (s, 1H), 8.10 (br. s., 1H), 7.97 (ddd, <i>J</i> = 7.9, 7.2, 1.0 Hz, 1H), 7.90 (s, 1H), 7.78 (s, 1H), 7.76–7.68 (m, 1H), 7.53–7.48 (m, 1H), 7.44 (dd, <i>J</i> = 7.9, 1.2 Hz, 1H), 7.40 (br. s., 1H), 7.36–7.30 (m, 1H), 7.23 (dd, <i>J</i> = 7.4, 1.2 Hz, 1H), 6.98 (ddd, <i>J</i> = 12.0, 8.4, 1.5 Hz, 1H), 6.68 (t, <i>J</i> = 7.9 Hz, 1H), 4.94 (d, <i>J</i> = 3.1 Hz, 1H), 3.73 (dd, <i>J</i> = 8.2, 3.5 Hz, 3H), 2.17 (s, 3H), 1.66 (s, 3H), and 1.48–1.41 (m, 6H).</div><div class="NLM_p last">A sample of 4-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-3-methyl-9<i>H</i>-carbazole-1-carboxamide (mixture of 2 atropisomers) was separated by SFC chromatography as follows: column, ChiralPak AD-H 25 × 3.0 cm; 5 μm; temperature, 40 °C; flow rate, 150 mL/min; mobile phase, CO<sub>2</sub>/MeOH (65/35); detector wavelength, 220 nm. The second peak eluting from the column provided <b>12a</b> as single, stable atropisomer and as a white solid. HPLC purity: 100%; <i>t</i><sub>r</sub> = 10.75 min (Method A); 99.8%; <i>t</i><sub>r</sub> = 10.49 min (Method B). Chiral Purity: >99.5% ie; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>33</sub>H<sub>29</sub>FN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 565.2. Found: (M + H – H<sub>2</sub>O) 547.4. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.19 (s, 1H), 8.10 (br. s., 1H), 7.96 (d, <i>J</i> = 8.0 Hz, 1H), 7.90 (s, 1H), 7.78 (s, 1H), 7.76–7.68 (m, 1H), 7.53–7.48 (m, 1H), 7.44 (d, <i>J</i> = 7.8 Hz, 1H), 7.40 (br. s., 1H), 7.34 (td, <i>J</i> = 8.0, 4.0 Hz, 1H), 7.23 (d, <i>J</i> = 7.5 Hz, 1H), 6.96 (dd, <i>J</i> = 8.5, 1.2 Hz, 1H), 6.68 (d, <i>J</i> = 8.3 Hz, 1H), 4.93 (s, 1H), 3.73 (d, <i>J</i> = 8.0 Hz, 3H), 2.18 (s, 3H), 1.66 (s, 3H), and 1.44 (d, <i>J</i> = 5.5 Hz, 6H).</div></div><div id="sec5_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 3-Cyano-4-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>12b</b>)<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a></h4><div class="NLM_p">A mixture of 4-bromo-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>16</b>, 2.00 g, 5.76 mmol),<a onclick="showRef(event, 'cit15b cit15c'); return false;" href="javascript:void(0);" class="ref cit15b cit15c">(15b, 15c)</a><i>N</i>-iodosuccinimide (1.69 g, 7.49 mmol), and pyridine (1.86 mL, 23.0 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (20 mL) was heated in an oil bath at 65 °C for 2 days. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, washed with a 10% aqueous solution of lithium chloride (2×), and washed with brine. The organic layer was collected, and the aqueous layers were sequentially extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate. Concentration followed by purification by flash silica gel chromatography using a mixture of ethyl acetate in hexane (50%–65%) afforded 4-bromo-7-(2-hydroxypropan-2-yl)-3-iodo-9<i>H</i>-carbazole-1-carboxamide (<b>23</b>, 0.609 g, 1.29 mmol, 23% yield) as a yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>14</sub>BrIN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 472.9. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> = 456.9. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.66 (s, 1H), 8.49 (d, <i>J</i> = 8.6 Hz, 1H), 8.38 (s, 1H), 8.26 (br. s., 1H), 7.94 (d, <i>J</i> = 1.1 Hz, 1H), 7.58 (br. s., 1H), 7.40 (dd, <i>J</i> = 8.6, 1.4 Hz, 1H), 5.09 (s, 1H), and 1.51 (s, 6H).</div><div class="NLM_p">A mixture of 4-bromo-7-(2-hydroxypropan-2-yl)-3-iodo-9<i>H</i>-carbazole-1-carboxamide (<b>23</b>, 0.609 g, 1.29 mmol) and zinc cyanide (0.076 g, 0.644 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (7 mL) was degassed well with vacuum and nitrogen (3×). To the mixture was added tetrakis(triphenylphosphine)palladium(0) (0.074 g, 0.064 mmol) with degassing, and the yellow, homogeneous solution was immersed in an oil bath at 95 °C and stirred overnight. The reaction mixture was diluted with ethyl acetate, washed with a 10% lithium chloride solution (2×), and washed with brine. The organic layer was collected, and the aqueous layers were sequentially extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate and concentrated to give the crude product as a yellow solid. The solid was triturated with dichloromethane with sonication to give 4-bromo-3-cyano-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>18b</b>, 0.400 g, 1.08 mmol, 83% yield) as a pale yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>14</sub>BrN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 372.0. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> = 356.0. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.12 (s, 1H), 8.55 (d, <i>J</i> = 8.6 Hz, 1H), 8.38 (s, 1H), 8.31 (br. s., 1H), 8.03 (s, 1H), 7.74 (br. s., 1H), 7.49 (dd, <i>J</i> = 8.6, 1.1 Hz, 1H), 5.15 (s, 1H), and 1.52 (s, 6H).</div><div class="NLM_p">A mixture of 4-bromo-3-cyano-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>18b</b>, 0.400 g, 1.08 mmol), 8-fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19</b>, 0.573 g, 1.40 mmol), cesium carbonate (0.700 g, 2.15 mmol), and dioxane (5 mL) was degassed with vacuum and nitrogen (3×). 1,1′-Bis(diphenylphosphino)ferrocenepalladium(II) dichloride–dichloromethane adduct (0.053 g, 0.064 mmol) was added, and the reaction mixture was degassed (2×). The reaction mixture was immersed in an oil bath at 88 °C and stirred for 2 days. The mixture was diluted with ethyl acetate, washed with water, washed with brine, and dried over anhydrous sodium sulfate. Concentration under reduce pressure followed by purification by flash silica gel chromatography using a mixture of ethyl acetate in hexane (50%–75%–85%–100%) afforded the product (0.350 g, 0.608 mmol, 57% yield) as a pale yellow solid. The compound was further purified by reverse phase preparative HPLC to give 3-cyano-4-(3-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (0.200 g, 0.347 mmol, 32% yield) as a white sold. HPLC purity: 98.2%; <i>t</i><sub>r</sub> = 9.01 min (Method A); 98.2%; <i>t</i><sub>r</sub> = 8.81 min (Method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>33</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup> 576.2. Found: 576.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.96 (s, 1H), 8.45 (s, 1H), 8.35 (br. s., 1H), 8.00–7.94 (m, 1H), 7.92 (s, 1H), 7.77–7.68 (m, 2H), 7.60–7.52 (m, 2H), 7.41 (dd, <i>J</i> = 6.6, 2.2 Hz, 1H), 7.38–7.29 (m, 1H), 7.13 (t, <i>J</i> = 10.1 Hz, 1H), 6.85 (t, <i>J</i> = 8.1 Hz, 1H), 5.05 (d, <i>J</i> = 2.0 Hz, 1H), 3.74 (dd, <i>J</i> = 8.1, 2.6 Hz, 3H), 1.73 (s, 3H), and 1.48–1.43 (m, 6H).</div><div class="NLM_p last">A sample of 3-cyano-4-(3-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (mixture of 4 atropisomers) was separated by chiral SFC chromatography using the following preparative conditions to give four single, stable atropisomers: column, ChiralPak AD-H 25 × 3.0 cm; 5 μm; temperature, 45 °C; flow rate, 150 mL/min; mobile phase, CO<sub>2</sub>/ iPA (65/35); detector wavelength, 220 nm. The forth peak eluting from the column provided <b>12b</b> as a single, stable atropisomer and as a pale yellow solid. HPLC purity: 99.9%; <i>t</i><sub>r</sub> = 9.08 min (Method A); 99.7%; <i>t</i><sub>r</sub> = 8.82 min (Method B). Chiral Purity: 98.9% ie. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>33</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup> 576.2. Found: 576.1.</div></div><div id="sec5_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 3-Fluoro-4-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>12c</b>)<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a></h4><div class="NLM_p">To a suspension of 2-amino-4-bromo-5-fluorobenzoic acid (10.0 g, 42.7 mmol) in a mixture of hydrochloric acid (37%, 42.7 mL) and water (14.3 mL) cooled with a salt-ice bath was added a 3 M solution of sodium nitrite (3.24 g, 47.0 mmol) in water (15.7 mL) dropwise slowly via syringe. After the addition was complete, the creamy solution was stirred for 30 min (ice-salt bath). A 7 M solution of tin(II) chloride dihydrate (28.9 g, 128 mmol) in hydrochloric acid, 37% (27.5 mL), was added dropwise slowly via syringe. The ice-bath was removed, and the reaction mixture was stirred at room temperature for 45 min. The thick, cream colored reaction mixture was filtered under reduced pressure, and the solid was washed well with water and dried overnight under reduced pressure. The solid was transferred to a round-bottomed flask and triturated with methanol with sonication. The suspension was filtered under reduced pressure, and the solid was washed with methanol and dried. Since a significant amount of the product was in the filtrate, the solution was concentrated, and the residue was triturated with dichloromethane. The product was collected by vacuum filtration and dried well. The solids were combined to give 4-bromo-5-fluoro-2-hydrazinylbenzoic acid hydrochloride (5.37 g, 18.6 mmol, 44% yield) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>7</sub>H<sub>6</sub>BrFN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 249.0. Found: 249.1 and 251.1.</div><div class="NLM_p">A heterogeneous mixture of 4-bromo-5-fluoro-2-hydrazinylbenzoic acid hydrochloride (5.37 g, 18.8 mmol), ethyl 3-oxocyclohexanecarboxylate (3.52 g, 20.7 mmol), and acetic acid (3.23 mL, 56.4 mmol) in toluene (90 mL) was heated in an oil bath at 110 °C for 20 h. The solvent was removed under reduced pressure, and the residue was diluted with toluene (43 mL) and trifluoroacetic acid (11 mL). The homogeneous reaction mixture was stirred overnight in an oil bath heated to 90–94 °C. The reaction mixture was diluted with ethyl acetate, sonicated, and filtered under reduced pressure to give the product. The filtrate was concentrated and resuspended in ethyl acetate with sonication. The solid was collected and washed with ethyl acetate. The combined solids contained a significant amount of 5-bromo-6-fluoro-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-2,8-dicarboxylic acid. The solid was triturated with methanol to give 3.22 g of the product (HPLC purity: 79%). The solid was retriturated with methanol to give 5-bromo-2-(ethoxycarbonyl)-6-fluoro-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxylic acid (2.87 g, 7.47 mmol, 40% yield) as a pale yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>15</sub>BrFNO<sub>4</sub> [M + H]<sup>+</sup> 284.0. Found: 384.1 and 386.1. The methanol filtrates were combined and concentrated. Trituration with methanol and filtration provided additional 5-bromo-2-(ethoxycarbonyl)-6-fluoro-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxylic acid (0.513 g, 1.34 mmol) as a light tan solid.</div><div class="NLM_p">A solution of 5-bromo-2-(ethoxycarbonyl)-6-fluoro-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxylic acid (2.87 g, 7.47 mmol) and DDQ (3.73 g, 16.4 mmol) in tetrahydrofuran (45 mL) was heated at 60 °C for 90 min. After cooling to room temperature, the homogeneous mixture was diluted with ethyl acetate (∼50 mL) and stirred for 60 min. The resulting precipitate was collected by vacuum filtration, and the solid was washed with ethyl acetate and dried. The filtrate was concentrated, triturated with methanol with sonication, filtered, and washed with methanol. The solids were combined to give 4-bromo-7-(ethoxycarbonyl)-3-fluoro-9<i>H</i>-carbazole-1-carboxylic acid (2.39 g, 6.29 mmol, 84% yield) as a pale yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>11</sub>BrFNO<sub>4</sub> [M + H]<sup>+</sup> 380.0. Found: 380.0 and 382.0.</div><div class="NLM_p">A heterogeneous mixture of 4-bromo-7-(ethoxycarbonyl)-3-fluoro-9<i>H</i>-carbazole-1-carboxylic acid (2.39 g, 6.29 mmol), 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride (1.81 g, 9.43 mmol), and 1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-ol, monohydrate (1.44 g, 9.43 mmol) in a mixture of tetrahydrofuran (30 mL) and dichloromethane (5 mL) was stirred at room temperature for 20 min. Ammonium hydroxide (0.367 mL, 9.43 mmol) was added, and the heterogeneous reaction mixture was stirred at room temperature for 4 h. The mixture was diluted with ethyl acetate, washed with a saturated aqueous solution of sodium bicarbonate (2×), and washed with brine. The organic layer was collected, and the aqueous layers were sequentially extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate. Concentration under reduced pressure followed by trituration with methanol with sonication afforded ethyl 5-bromo-8-carbamoyl-6-fluoro-9<i>H</i>-carbazole-2-carboxylate (2.26 g, 5.96 mmol, 95% yield) as a pale yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>12</sub>BrFN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 279.0. Found: 379.1 and 381.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.02 (s, 1H), 8.70 (d, <i>J</i> = 8.3 Hz, 1H), 8.51 (d, <i>J</i> = 1.1 Hz, 1H), 8.29 (br. S., 1H), 8.10 (d, <i>J</i> = 10.3 Hz, 1H), 7.87 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H), 7.74 (br. S., 1H), 4.37 (q, <i>J</i> = 6.9 Hz, 2H), and 1.37 (t, <i>J</i> = 7.1 Hz, 3H).</div><div class="NLM_p">To a solution of ethyl 5-bromo-8-carbamoyl-6-fluoro-9<i>H</i>-carbazole-2-carboxylate (0.500 g, 1.32 mmol) in tetrahydrofuran (9.0 mL) at −78 °C was added methyllithium (1.6 M in ether) (3.0 equiv; 2.47 mL, 3.96 mmol) dropwise over 10 min. The reaction mixture was stirred at −78 °C for 30 min. Additional methyllithium (2.0 equiv; 1.6 M in ether) (1.65 mL, 2.64 mmol) was added, and the reaction mixture was stirred at −78 °C for 45 min. The homogeneous reaction was quenched at −78 °C with a saturated aqueous solution of ammonium chloride. After warming to room temperature, the mixture was diluted with ethyl acetate, washed with water, and washed with brine. The organic layer was collected, and the aqueous layers were sequentially extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate. Concentration under reduce pressure afforded a pale yellow solid which was purified by reverse phase preparative HPLC. The desired fractions were immediately neutralized with a saturated aqueous solution of sodium bicarbonate and concentrated under reduced pressure. The residue was dissolved in a mixture of ethyl acetate and water, and the organic layer was collected and washed with brine. The aqueous layers were sequentially extracted with ethyl acetate, and the combined organic layers were dried over anhydrous sodium sulfate. Concentration under reduced pressure afforded 4-bromo-3-fluoro-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (0.240 g, 0.657 mmol, 50% yield) as a pale yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>14</sub>BrFN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 365.0. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 347.1 and 349.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.58 (s, 1H), 8.50 (d, <i>J</i> = 8.6 Hz, 1H), 8.22 (br. S., 1H), 7.96 (d, <i>J</i> = 10.3 Hz, 1H), 7.94 (d, <i>J</i> = 1.1 Hz, 1H), 7.65 (br. S., 1H), 7.39 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H), 5.09 (s, 1H), and 1.51 (s, 6H).</div><div class="NLM_p">A mixture of 4-bromo-3-fluoro-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (0.100 g, 0.274 mmol), 8-fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19</b>, 0.146 g, 0.356 mmol), tripotassium phosphate (2 M in water) (0.411 mL, 0.821 mmol), and tetrahydrofuran (2.0 mL) was degassed with vacuum and nitrogen (3×). 1,1′-Bis(di<i>tert</i>-butylphosphino)ferrocene palladium dichloride (8.92 mg, 0.014 mmol) was added, and the reaction mixture was degassed (2×). The reaction mixture was stirred at room temperature overnight. The dark reaction mixture was diluted with ethyl acetate, washed with water, washed with brine, and dried over anhydrous sodium sulfate. Concentration under reduce pressure followed by purification by flash silica gel chromatography using a mixture of ethyl acetate and hexane (50%–62%–75%–85%) provided 3-fluoro-4-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (0.084 g, 0.146 mmol, 53% yield) as an off-white solid. HPLC purity: 98.3%; <i>t</i><sub>r</sub> = 10.87 min (Method A); 98.0%; <i>t</i><sub>r</sub> = 10.64 min (Method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>26</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 569.2. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 551.4. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.39 (s, 1H), 8.21 (br. s., 1H), 7.99–7.92 (m, 2H), 7.84 (s, 1H), 7.73 (ddt, <i>J</i> = 14.4, 8.0, 1.4 Hz, 1H), 7.59 (br. s., 1H), 7.54–7.47 (m, 2H), 7.40 (dd, <i>J</i> = 7.2, 1.7 Hz, 1H), 7.34 (tt, <i>J</i> = 7.9, 4.0 Hz, 1H), 7.04 (ddd, <i>J</i> = 11.5, 8.6, 1.5 Hz, 1H), 6.88 (t, <i>J</i> = 8.0 Hz, 1H), 4.99 (d, <i>J</i> = 2.2 Hz, 1H), 3.74 (dd, <i>J</i> = 8.2, 1.0 Hz, 3H), 1.77 (s, 3H), and 1.49–1.42 (m, 6H).</div><div class="NLM_p last">A sample of 3-fluoro-4-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (mixture of 2 atropisomers) was separated by chiral SFC to give two single, stable atropisomers using the following conditions: column, AS-H 3 × 25 cm; 5 μm; BPR pressure, 100 bar; temperature, 40 °C; flow rate, 120 mL/min; mobile phase, CO<sub>2</sub>/ MeOH (70/30); detector wavelength, 220 nm; injection, 2 mL; sample preparation, 18 mg/5 mL MeOH, ∼3.6 mg/mL. The first peak eluting from the column provided <b>12c</b> as a single, stable atropisomer and as a white solid. HPLC purity: 99.3%; <i>t</i><sub>r</sub> = 10.70 min (Method A); 99.4%; <i>t</i><sub>r</sub> = 10.45 min (Method B). Chiral purity: >99.4% ie; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>26</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 569.2. Found: (M + H – H<sub>2</sub>O)<sup>+</sup> 551.3.0. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.39 (s, 1H), 8.21 (br. s., 1H), 8.00–7.92 (m, 2H), 7.84 (s, 1H), 7.73 (ddd, <i>J</i> = 14.4, 8.0, 1.4 Hz, 1H), 7.59 (br. s., 1H), 7.55–7.47 (m, 2H), 7.40 (dd, <i>J</i> = 7.2, 1.4 Hz, 1H), 7.33 (td, <i>J</i> = 8.0, 4.0 Hz, 1H), 7.05 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 4.99 (s, 1H), 3.74 (d, <i>J</i> = 8.0 Hz, 3H), 3.17 (d, <i>J</i> = 5.3 Hz, 3H), 1.77 (s, 3H), and 1.46 (d, <i>J</i> = 4.2 Hz, 6H).</div></div><div id="sec5_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 5-(3-(<i>S</i>)-(8-Fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>R</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (<b>14a</b>)</h4><div class="NLM_p">A sample of 5-bromo-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide<a onclick="showRef(event, 'cit16b'); return false;" href="javascript:void(0);" class="ref cit16b">(16b)</a> (320 mg, 0.914 mmol) was separated by chiral SFC using the following conditions: column, Chiral OD-H 3 × 25 cm; 5 μm; flow rate, 85 mL/min; mobile phase, CO<sub>2</sub>/MeOH (65/35); injection, 3 mL; sample preparation, 320 mg/50 mL MeOH/MeCN (1:1). The second peak eluting from the column provided (<i>R</i>)-5-bromo-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide as a white solid (165 mg, 0.471 mmol, 50% yield). Chiral purity: >99.5% ie; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>BrN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 351.1. Found: 351.0 and 353.0. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 7.38 (d, <i>J</i> = 8.14 Hz, 1H), 7.16 (d, <i>J</i> = 8.14 Hz, 1H), 3.37–3.45 (m, 1H), 2.90–2.97 (m, 1H), 2.79–2.89 (m, 1H), 2.54–2.64 (m, 1H), 2.20–2.28 (m, 1H), 1.80–1.90 (m, <i>J</i> = 11.94, 11.94, 4.95, 2.20 Hz, 1H), 1.41–1.53 (m, <i>J</i> = 12.43, 12.43, 12.32, 5.28 Hz, 1H), and 1.30 (s, 6H).</div><div class="NLM_p last">A mixture of 8-fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19</b>, 49.2 mg, 0.120 mmol), 5-(<i>R</i>)-bromo-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (40 mg, 0.114 mmol), cesium carbonate (74.4 mg, 0.228 mmol), and 1,1′-bis(diphenylphosphino)ferrocenepalladium(II) dichloride–dichloromethane adduct (4.66 mg, 5.71 μmol) in tetrahydrofuran (2 mL) and water (0.50 mL) was heated at 40 °C for 3 h. The reaction mixture was diluted with dichloromethane, washed with water, and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO, 20–100% ethyl acetate/hexane, 40 g silica gel column) to give <b>14a</b> as a white solid. HPLC purity: 97.2%; <i>t</i><sub>r</sub> = 8.56 min (Method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>31</sub>FN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 555.2. Found: 555.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.04 (s, 1H), 8.13 (dd, <i>J</i> = 7.2, 3.9 Hz, 1H), 7.52–7.34 (m, 4H), 7.28–7.21 (m, 2H), 6.97 (dd, <i>J</i> = 7.7, 6.2 Hz, 1H), 3.89 (d, <i>J</i> = 7.7 Hz, 3H), 2.92 (d, <i>J</i> = 16.5 Hz, 1H), 2.71–2.58 (m, 1H), 2.27–2.19 (m, 1H), 2.17–2.09 (m, 1H), 2.03 (d, <i>J</i> = 12.3 Hz, 1H), 1.93–1.76 (m, 4H), and 1.29 (s, 6H).</div></div><div id="sec5_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 5-(3-(<i>S</i>)-(8-Fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (<b>14b</b>)</h4><div class="NLM_p">A sample of 5-bromo-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide<a onclick="showRef(event, 'cit16b'); return false;" href="javascript:void(0);" class="ref cit16b">(16b)</a> (320 mg, 0.914 mmol) was separated by chiral SFC using the following conditions: column, Chiral OD-H 3 × 25 cm; 5 μm; flow rate, 85 mL/min; mobile phase, CO<sub>2</sub>/MeOH (65/35); injection, 3 mL; sample preparation, 320 mg/50 mL MeOH/MeCN (1:1). The first peak eluting from the column provided 5-bromo-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide as a single, stable atropisomer as a white solid (164 mg, 0.468 mmol, 50% yield). Chiral purity: >99.5% ie; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>19</sub>BrN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 351.1. Found: 351.0 and 353.0. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm 7.38 (d, <i>J</i> = 8.14 Hz, 1H), 7.16 (d, <i>J</i> = 8.14 Hz, 1H), 3.37–3.45 (m, 1H), 2.90–2.97 (m, 1H), 2.79–2.89 (m, 1H), 2.54–2.64 (m, 1H), 2.20–2.28 (m, 1H), 1.80–1.90 (m, <i>J</i> = 11.94, 11.94, 4.95, 2.20 Hz, 1H), 1.41–1.53 (m, <i>J</i> = 12.43, 12.43, 12.32, 5.28 Hz, 1H), and 1.30 (s, 6H).</div><div class="NLM_p">A mixture of 8-fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19</b>, 49.2 mg, 0.120 mmol), 5-bromo-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (40 mg, 0.114 mmol), cesium carbonate (74.4 mg, 0.228 mmol), and 1,1′-bis(diphenylphosphino)ferrocenepalladium(II) dichloride–dichloromethane adduct (9.33 mg, 0.011 mmol) in tetrahydrofuran (2 mL) and water (0.500 mL) was heated at 40 °C for 3 h. The reaction mixture was diluted with dichloromethane, washed with water, and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using a mixture of ethyl acetate and hexane (20%–100%) to give <b>14b</b> (0.038 g, 0.066 mmol, 58% yield) as a pale yellow solid. HPLC purity: 95.9%; <i>t</i><sub>r</sub> = 8.54 min (Method A); 98.0%; <i>t</i><sub>r</sub> = 8.92 min (Method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>31</sub>FN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 555.2. Found: 555.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.04 (s, 1H), 8.12 (d, <i>J</i> = 7.7 Hz, 1H), 7.51–7.45 (m, 1H), 7.43–7.34 (m, 3H), 7.26–7.21 (m, 2H), 6.97 (dd, <i>J</i> = 7.6, 3.9 Hz, 1H), 3.92–3.87 (m, 3H), 2.92 (d, <i>J</i> = 12.1 Hz, 1H), 2.70–2.57 (m, 1H), 2.29–2.18 (m, 1H), 2.13 (d, <i>J</i> = 14.3 Hz, 1H), 2.03 (br. s., 1H), 1.92–1.77 (m, 4H), and 1.28 (d, <i>J</i> = 2.4 Hz, 6H).</div><div class="NLM_p last">The absolute stereochemistry of <b>14b</b> was determined by single crystal X-ray analysis (CCDC # 1501160).<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0034.gif" alt="" id="fx3" /></img></div></div><div id="sec5_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 6-Chloro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>R</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (<b>14c</b>)<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a></h4><div class="NLM_p">A solution of sodium nitrite (3.03 g, 43.9 mmol) in water (14.8 mL) was added dropwise to a cooled (−10 °C, sodium chloride–ice bath) suspension of 2-amino-4-bromo-5-chlorobenzoic acid (10.0 g, 39.9 mmol) in hydrochloric acid (37%, 39.9 mL) and water (13.3 mL) at such a rate that the temperature did not exceed 0 °C. The resulting suspension was stirred at 0 °C for 15 min and was then treated with a solution of tin(II) chloride hydrate (22.7 g, 120 mmol) in hydrochloric acid (37%, 17 mL). The resulting mixture was warmed to room temperature and stirred for 60 min. The precipitate was collected by vacuum filtration, washed with water, and air-dried overnight to give 4-bromo-5-chloro-2-hydrazinylbenzoic acid hydrochloride as an off-white solid (12.9 g, 37.5 mmol, 96% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>7</sub>H<sub>6</sub>BrClN<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 264.9. Found: 265.0 and 267.0. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.05 (br. s., 1H), 7.95 (s, 1H), and 7.55 (s, 1H).</div><div class="NLM_p">A suspension of 4-bromo-5-chloro-2-hydrazinylbenzoic acid hydrochloride (12.9 g, 37.6 mmol), ethyl 3-oxocyclohexanecarboxylate (7.03 g, 41.3 mmol), and acetic acid (6.45 mL, 113 mmol) in toluene (188 mL) was heated at 105 °C overnight. After 16 h, additional acetic acid (6 mL) and ethyl 3-oxocyclohexanecarboxylate (2.00 g) were added, and the reaction mixture was heated at 110 °C for 4.5 h. The mixture was concentrated, and the residue was diluted with toluene (100 mL) and trifluoroacetic acid (20 mL), and the suspension was heated at 90 °C overnight. The cooled mixture was concentrated, and the residue was suspended in ethyl acetate. The resulting solid was collected by vacuum filtration, washed with ethyl acetate, and air-dried to give 5-bromo-6-chloro-2-(ethoxycarbonyl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxylic acid as a yellow solid (11.0 g, 27.6 mmol, 73% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>15</sub>BrClNO<sub>4</sub> [M + H]<sup>+</sup> 400.0. Found: 400.2 and 402.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.44 (br. s., 1H), 11.24 (s, 1H), 7.69 (s, 1H), 4.12 (qd, <i>J</i> = 7.1, 2.3 Hz, 2H), 3.23–2.81 (m, 5H), 2.23–2.09 (m, 1H), 1.91–1.75 (m, 1H), and 1.22 (t, <i>J</i> = 7.0 Hz, 3H).</div><div class="NLM_p">Following the procedure used to prepare <b>14e</b>, 5-bromo-6-chloro-2-(ethoxycarbonyl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxylic acid was converted into ethyl 5-bromo-8-carbamoyl-6-chloro-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-2-carboxylate (light brown solid, 8.54 g, 78% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>16</sub>BrClN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 399.0. Found: 399.1 and 401.1.</div><div class="NLM_p">A solution of ethyl 5-bromo-8-carbamoyl-6-chloro-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-2-carboxylate (7.03 g, 17.6 mmol) in tetrahydrofuran (200 mL) was cooled in a dry ice–acetone bath and treated portionwise over 40 min with 1.6 M methyllithium in tetrahydrofuran (66.0 mL, 106 mmol). After 60 min, the mixture was treated slowly at −78 °C with a saturated aqueous solution of ammonium chloride and stirred for 10 min while warming to room temperature. The mixture was extracted with dichloromethane (3×), and the combined organic phases were washed sequentially with water and brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with a mixture of ethyl acetate and hexanes (0–100%) to give 5-bromo-6-chloro-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide as a yellow solid (4.66 g, 15.2 mmol, 86% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>18</sub>BrClN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 385.0. Found: 385.2 and 387.2.</div><div class="NLM_p">A sample of racemic 5-bromo-6-chloro-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (2.35 g, 6.09 mmol) was separated by chiral SFC as follows: column, Chiralpak IA (3 × 25 cm, 5 μm); mobile phase, CO<sub>2</sub>/MeOH (50:50) at 124 mL/min, 100 bar, 45 °C; sample preparation, 39 mg/mL in MeOH/DMSO (4:1); injection, 2.33 mL. The first peak eluting from the column provided the (<i>R</i>)-isomer, 5-bromo-6-chloro-2-(<i>R</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide as a yellow solid (1.15 g, 2.98 mmol, 49% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>18</sub>BrClN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 385.0. Found: 385.2 and 387.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.07 (s, 1H), 8.12 (br. s., 1H), 7.75 (s, 1H), 7.57–7.45 (m, 1H), 4.23 (s, 1H), 3.27 (d, <i>J</i> = 4.7 Hz, 1H), 2.93 (dd, <i>J</i> = 17.2, 4.7 Hz, 1H), 2.78–2.67 (m, 1H), 2.48–2.39 (m, 1H), 2.16–2.08 (m, 1H), 1.69–1.59 (m, 1H), 1.37–1.26 (m, 1H), 1.14 (s, 6H).</div><div class="NLM_p">A mixture of 8-fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19</b>, 134 mg, 0.327 mmol), 5-bromo-6-chloro-2-(<i>R</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (120 mg, 0.311 mmol), cesium carbonate (203 mg, 0.622 mmol), and 1,1′-bis(diphenylphosphino)ferrocenepalladium(II) dichloride–dichloromethane adduct (20.3 mg, 0.025 mmol) in tetrahydrofuran (5 mL) and water (1.3 mL) was heated at 50 °C overnight. The reaction mixture was diluted with ethyl acetate, washed with water, washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using a mixture of ethyl acetate in hexanes (50–70–80%) to give 136 mg of the product. The compound was further purified by reverse-phase, preparative HPLC to give 6-chloro-5-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>R</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (0.088 g, 0.149 mmol, 48% yield) as a solid and as a mixture of two atropisomers. HPLC purity: 99%; <i>t</i><sub>r</sub> = 1.77 min (Method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>30</sub>ClFN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 589.2. Found: 589.4. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.90 (s, 1H), 8.14 (br. s., 1H), 7.99–7.93 (m, 1H), 7.77–7.68 (m, 2H), 7.46 (br. s., 1H), 7.41–7.29 (m, 3H), 7.22–7.17 (m, 1H), 4.25–4.11 (m, 1H), 3.77–3.66 (m, 3H), 2.95–2.83 (m, 1H), 2.47–2.34 (m, 1H), 1.97–1.72 (m, 3H), 1.70–1.63 (m, 3H), 1.54 (dd, <i>J</i> = 11.4, 3.5 Hz, 1H), 1.17–0.98 (m, 7H).</div><div class="NLM_p last">A sample of 6-chloro-5-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>R</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (mixture of two atropisomers, 0.085 g, 0.144 mmol) was separated by chiral SFC to give two single stable atropisomers as follows: column, OD-H (3 × 25 cm, 5 μm); mobile phase, CO<sub>2</sub>–MeOH (70:30) at 180 mL/min, 35 °C, 100 bar; injection, 3 mL (430 s cycle time); sample preparation, 0.071 mg/mL in MeOH/CH<sub>2</sub>Cl<sub>2</sub> (4:1), ∼8.4 mg/mL. The second peak eluting from the column provided <b>14c</b> (0.049, 0.082 mmol, 57% yield) as single, stable atropisomer and as an off-white solid. HPLC purity: 97.8%; <i>t</i><sub>r</sub> = 9.08 min (Method A); 98.9%; <i>t</i><sub>r</sub> = 9.72 min (Method B). Chiral purity: >99.5% ie; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>30</sub>ClFN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 589.2. Found: 589.4. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.86 (s, 1H), 8.12 (br. s., 1H), 7.98–7.93 (m, 1H), 7.76–7.66 (m, 2H), 7.49–7.35 (m, 2H), 7.34–7.28 (m, 2H), 7.20 (d, <i>J</i> = 6.2 Hz, 1H), 4.17 (br. s., 1H), 3.72 (d, <i>J</i> = 7.9 Hz, 3H), 2.88 (d, <i>J</i> = 12.8 Hz, 1H), 2.44–2.34 (m, 1H), 1.99–1.71 (m, 3H), 1.64 (s, 3H), 1.60–1.48 (m, 1H), and 1.08 (d, <i>J</i> = 7.3 Hz, 7H).</div></div><div id="sec5_4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 6-Chloro-5-(<i>R</i>)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (<b>14d</b>)<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a></h4><div class="NLM_p">A sample of racemic 5-bromo-6-chloro-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (2.35 g, 6.09 mmol) was separated by chiral SFC as follows: column, Chiralpak IA (3 × 25 cm, 5 μm); mobile phase, CO<sub>2</sub>/MeOH (50:50) at 124 mL/min, 100 bar, 45 °C; sample preparation, 39 mg/mL in MeOH/DMSO (4:1); injection, 2.33 mL. The second peak eluting from the column provided the (<i>S</i>) isomer, 5-bromo-6-chloro-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide, as an off-white solid (0.923 g, 2.39 mmol, 39% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>18</sub>BrClN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 385.0. Found: 385.2 and 387.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.06 (s, 1H), 8.12 (br. s., 1H), 7.74 (s, 1H), 7.49 (br. s., 1H), 4.23 (s, 1H), 3.27 (d, <i>J</i> = 5.0 Hz, 1H), 2.93 (dd, <i>J</i> = 17.1, 4.6 Hz, 1H), 2.72 (t, <i>J</i> = 11.8 Hz, 1H), 2.48–2.37 (m, 1H), 2.12 (d, <i>J</i> = 9.2 Hz, 1H), 1.69–1.59 (m, 1H), 1.38–1.24 (m, 1H), and 1.14 (s, 6H).</div><div class="NLM_p">A mixture of 5-bromo-6-chloro-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (100 mg, 0.259 mmol), 8-fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19</b>, 112 mg, 0.272 mmol), cesium carbonate (169 mg, 0.519 mmol), and 1,1′-bis(diphenylphosphino)ferrocenepalladium(II) dichloride–dichloromethane adduct (16.9 mg, 0.021 mmol) in tetrahydrofuran (4.3 mL) and water (1.1 mL) was heated at 50 °C overnight. The reaction mixture was diluted with ethyl acetate, washed with water, washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography using a mixture of ethyl acetate and hexane (50–80%), followed further purification by reverse-phase, preparative HPLC to afford 6-chloro-5-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (0.059 g, 0.129 mmol, 50% yield) as a pale yellow solid and as a mixture of two atropisomers. HPLC purity: 97.8%; <i>t</i><sub>r</sub> = 9.08 min (Method A); 98.9%; <i>t</i><sub>r</sub> = 9.72 min (Method B). Chiral purity: >99.5% ie; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>30</sub>ClFN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 589.2. Found: 589.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.89 (s, 1H), 8.13 (br. s., 1H), 7.94 (d, <i>J</i> = 7.9 Hz, 1H), 7.76–7.68 (m, 2H), 7.46 (br. s., 1H), 7.40–7.28 (m, 3H), 7.22–7.16 (m, 1H), 4.21–4.13 (m, 1H), 3.77–3.64 (m, 3H), 2.95–2.82 (m, 1H), 2.40 (d, <i>J</i> = 16.3 Hz, 1H), 1.94–1.70 (m, 3H), 1.70–1.61 (m, 3H), 1.58–1.48 (m, 1H), and 1.16–1.02 (m, 7H).</div><div class="NLM_p">A sample of 6-chloro-5-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (mixture of two atropisomers, 0.071 g, 0.121 mmol) was separated by chiral SFC to give two single, stable atropisomers as follows: column, OD-H (3 × 25 cm, 5 μm); mobile phase, CO<sub>2</sub>–MeOH (70:30) at 180 mL/min, 35 °C, 100 bar; injection, 3 mL (430 s cycle time); sample preparation, 0.071 mg/mL in MeOH/CH<sub>2</sub>Cl<sub>2</sub> (4:1), ∼8.4 mg/mL. The first peak eluting from the column provided <b>14d</b> (0.034, 0.056 mmol, 47% yield) as a single, stable atropisomer and as a white solid. HPLC purity: 95.2%; <i>t</i><sub>r</sub> = 9.09 min (Method A); 96.1%; <i>t</i><sub>r</sub> = 9.73 min (Method B). Chiral purity: >99.5% ie; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>30</sub>ClFN<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 589.2. Found: 589.4. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.06–7.99 (m, 1H), 7.69 (s, 1H), 7.60 (ddd, <i>J</i> = 14.3, 8.1, 1.4 Hz, 1H), 7.40 (d, <i>J</i> = 7.5 Hz, 1H), 7.34–7.27 (m, 2H), 7.24 (dd, <i>J</i> = 7.5, 1.1 Hz, 1H), 3.85 (d, <i>J</i> = 7.9 Hz, 3H), 2.90 (dd, <i>J</i> = 16.5, 5.1 Hz, 1H), 2.56 (dd, <i>J</i> = 16.4, 12.0 Hz, 1H), 2.10–2.02 (m, 1H), 2.00–1.84 (m, 2H), 1.77 (s, 3H), 1.75–1.68 (m, 1H), 1.28 (d, <i>J</i> = 3.1 Hz, 1H), and 1.22 (d, <i>J</i> = 2.2 Hz, 6H).</div><div class="NLM_p last">The absolute stereochemistry of <b>14d</b> was determined by single crystal X-ray analysis (CCDC # 1501161).<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0035.gif" alt="" id="fx4" /></img></div></div><div id="sec5_4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 6-Fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>R</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (<b>14e</b>)<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a></h4><div class="NLM_p">A heterogeneous mixture of 5-bromo-2-(ethoxycarbonyl)-6-fluoro-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxylic acid (0.513 g, 1.34 mmol), 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride (0.384 g, 2.00 mmol), and 1<i>H</i>-benzo[<i>d</i>][1,2,3]triazol-1-ol, monohydrate (0.307 g, 2.00 mmol) in a mixture of tetrahydrofuran (10 mL) and dichloromethane (1.65 mL) was stirred at room temperature for 20 min. Ammonium hydroxide (0.078 mL, 2.00 mmol) was added, and the heterogeneous reaction mixture was stirred at room temperature for 60 min (homogeneous). The mixture was diluted with ethyl acetate, washed with a saturated aqueous solution of sodium bicarbonate (2×), and washed with brine. The organic layer was collected, and the aqueous layers were sequentially extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate. Concentration followed by trituration with methanol with sonication afforded ethyl 5-bromo-8-carbamoyl-6-fluoro-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-2-carboxylate (0.432 g, 1.12 mmol, 84% yield) as a pale yellow solid. HPLC purity: >99%; <i>t</i><sub>r</sub> = 2.89 min (Method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>16</sub>BrFN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 383.0. Found: 383.1 and 385.1.</div><div class="NLM_p">To a solution of ethyl 5-bromo-8-carbamoyl-6-fluoro-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-2-carboxylate (10.0 g, 26.1 mmol) in tetrahydrofuran (200 mL) at −78 °C was added methyllithium (1.6 M in ether) (3 equiv; 49 mL, 78 mmol) dropwise over 30 min The reaction mixture was stirred at −78 °C for 45 min. An additional 2 equiv of methyllithium (33 mL) was added over 25 min, and the reaction mixture was stirred at −78 °C for an additional 1.5 h. The reaction was quenched at −78 °C with a saturated aqueous solution of ammonium chloride was warmed to room temperature. The mixture was diluted with ethyl acetate, washed with water, and washed with brine. The organic layer was collected, and the aqueous layers were sequentially extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was dissolved in ∼100 mL of ethyl acetate and filtered through a pad of Celite topped with a pad of silica gel in a 600 mL fritted funnel using ethyl acetate (∼1 L). Concentration under reduced pressure afforded 5-bromo-6-fluoro-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (9.24 g, 25.03 mmol, 96% yield) as a pale yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>18</sub>BrFN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 369.1. Found: 369.2 and 371.2.</div><div class="NLM_p">A sample of racemic 5-bromo-6-fluoro-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide was separated by chiral SFC as follows: column, Chiralpak AD-H (3 × 25 cm, 5 μm); temperature, 45 °C; flow rate, 120 mL/min; mobile phase, CO<sub>2</sub>/MeOH (50:50); detector wavelength, 220 nm; injection, 1 mL (20 μg/mL). The first peak eluting from the column provided the (<i>R</i>)-isomer, 5-bromo-6-fluoro-2-(<i>R</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide, as a white solid. HPLC purity: >99%; <i>t</i><sub>r</sub> = 2.73 min (Method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>18</sub>BrFN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 369.1. Found: 369.2 and 371.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.96 (s, 1H), 8.07 (br. s., 1H), 7.55 (d, <i>J</i> = 10.3 Hz, 1H), 7.50 (br. s., 1H), 4.24 (s, 1H), 3.26 (dd, <i>J</i> = 15.8, 4.4 Hz, 1H), 2.93 (dd, <i>J</i> = 17.1, 4.6 Hz, 1H), 2.72 (t, <i>J</i> = 11.7 Hz, 1H), 2.48–2.40 (m, 1H), 2.12 (d, <i>J</i> = 9.2 Hz, 1H), 1.70–1.62 (m, 1H), 1.32 (qd, <i>J</i> = 12.4, 5.3 Hz, 1H), and 1.14 (s, 6H).</div><div class="NLM_p">A mixture of 5-bromo-6-fluoro-2-(<i>R</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (0.052 g, 0.141 mmol), 8-fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19</b>, 0.075 g, 0.183 mmol), cesium carbonate (0.092 g, 0.282 mmol), and dioxane (0.8 mL) was degassed with a vacuum and nitrogen (3×). 1,1′-Bis(diphenylphosphino)ferrocenepalladium(II) dichloride–dichloromethane adduct (6.90 mg, 8.45 μmol) was added, and the reaction mixture was degassed (2×). The mixture was immersed in an oil bath at 52 °C and stirred overnight. The reaction mixture was diluted with ethyl acetate, washed with water, washed with brine, and dried over anhydrous sodium sulfate. Concentration under reduce pressure afforded the crude product mixture which was purified by flash silica gel chromatography using a mixture of ethyl acetate and hexane (50%–62%–75%) to afford 6-fluoro-5-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>R</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (0.050 g, 0.086 mmol, 61% yield) as a white solid. HPLC purity: 99.2%; <i>t</i><sub>r</sub> = 10.67 min (Method A); 98.9%; <i>t</i><sub>r</sub> = 10.35 min (Method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>30</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 573.2. Found: 573.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.79–10.74 (m, 1H), 8.05 (br. s., 1H), 7.98–7.93 (m, 1H), 7.76–7.69 (m, 1H), 7.57–7.51 (m, 1H), 7.43 (br. s., 1H), 7.40–7.26 (m, 4H), 4.19–4.13 (m, 1H), 3.74–3.68 (m, 3H), 2.94–2.84 (m, 1H), 2.49–2.35 (m, 2H), 1.92–1.80 (m, 3H), 1.76–1.68 (m, 3H), 1.62–1.52 (m, 1H), and 1.12–1.06 (m, 6H).</div><div class="NLM_p last">A sample of 6-fluoro-5-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>R</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (mixture of 2 atropisomers) was separated by chiral SFC to give two single, stable atropisomers using the following conditions: column, AS-H 3 × 25 cm; 5 μm; BPR pressure, 100 bar; temperature, 35 °C; flow rate, 120 mL/min; mobile phase, CO<sub>2</sub>/MeOH (70/30); detector wavelength, 220 nm; injection, 1.7 mL; sample preparation, 45 mg/5 mL MeOH and ∼9 mg/mL. The first peak eluting from the column provided <b>14e</b> as a single, stable atropisomer and as a white solid. HPLC purity: 98.2%; <i>t</i><sub>r</sub> = 10.66 min (Method A); 98.6%; <i>t</i><sub>r</sub> = 10.33 min (Method B). Chiral purity: >99.5% ie; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>30</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 573.2. Found: 573.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.79–10.74 (m, 1H), 8.05 (br. s., 1H), 7.98–7.93 (m, 1H), 7.76–7.69 (m, 1H), 7.57–7.51 (m, 1H), 7.43 (br. s., 1H), 7.40–7.26 (m, 4H), 4.19–4.13 (m, 1H), 3.74–3.68 (m, 3H), 2.94–2.84 (m, 1H), 2.49–2.35 (m, 2H), 1.92–1.80 (m, 3H), 1.76–1.68 (m, 3H), 1.62–1.52 (m, 1H), and 1.12–1.06 (m, 6H).</div></div><div id="sec5_4_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 6-Fluoro-5-(<i>R</i>)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (<b>14f</b>)<a onclick="showRef(event, 'cit16a'); return false;" href="javascript:void(0);" class="ref cit16a">(16a)</a></h4><div class="NLM_p">A sample of 5-bromo-6-fluoro-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (97 g, 264 mmol, see procedure for <b>14e</b>) was separated by chiral SFC as follows: column, Chiralpak OD-H (3 × 25 cm, 5 μm); BPR pressure, 100 bar; temperature, 40 °C; flow rate, 150 mL/min; mobile phase, CO<sub>2</sub>/MeOH (70:30); detector wavelength, 240 nm; injection, 1.33 mL (3.5 min cycle time); sample preparation, 97 g/2590 mL MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1:1), ∼38 mg/mL. The first peak eluting from the column provided, after a methanol trituration, 5-bromo-6-fluoro-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (37 g, 102 mmol, 71% yield) as an off-white solid. HPLC purity: >99%; <i>t</i><sub>r</sub> = 2.67 min (Method C). Chiral purity: 99.5% ie; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>18</sub>BrFN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 369.1. Found: 369.1 and 371.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.96 (s, 1H), 8.07 (br. s., 1H), 7.55 (d, <i>J</i> = 10.3 Hz, 1H), 7.50 (br. s., 1H), 4.24 (s, 1H), 3.26 (dd, <i>J</i> = 15.8, 4.4 Hz, 1H), 2.93 (dd, <i>J</i> = 17.1, 4.6 Hz, 1H), 2.72 (t, <i>J</i> = 11.7 Hz, 1H), 2.48–2.40 (m, 1H), 2.12 (d, <i>J</i> = 9.2 Hz, 1H), 1.70–1.62 (m, 1H), 1.32 (qd, <i>J</i> = 12.4, 5.3 Hz, 1H), and 1.14 (s, 6H).</div><div class="NLM_p">A mixture of 5-bromo-6-fluoro-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (6.00 g, 16.25 mmol), 8-fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19</b>, 8.00 g, 19.50 mmol), tripotassium phosphate (2 M in water) (24.4 mL, 48.8 mmol), and tetrahydrofuran (72 mL) was degassed with vacuum and nitrogen (3×). 1,1′-Bis(di-<i>tert</i>-butylphosphino)ferrocene palladium dichloride (0.530 g, 0.813 mmol) was added, and the reaction mixture was degassed (2×). The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate, washed with water, washed with brine, and dried over anhydrous sodium sulfate. Concentration under reduce pressure followed by purification by flash silica gel chromatography using a mixture of ethyl acetate and hexane (50%–62%–75%–85%) afforded 6-fluoro-5-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (8.7 g, 15.19 mmol, 93% yield) as an off-white solid. HPLC purity: 99%; <i>t</i><sub>r</sub> = 2.80 min (Method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>30</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 573.2. Found: 573.2.</div><div class="NLM_p">A sample of 6-fluoro-5-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (23.7 g, 41.3 mmol) was separated by chiral SFC to give two single, stable atropisomers as follows: column, AS-H (3 × 25 cm, 5 μm); BPR pressure, 100 bar; temperature, 40 °C; flow rate, 150 mL/min; mobile phase, CO<sub>2</sub>/MeOH (70:30); detector wavelength, 220 nm; injection, 1.8 mL (4.6 min cycle time); sample preparation, MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1:1). The first peak eluting from the column provided 6-fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (12.7 g, 22.2 mmol, 54% yield) as a single, stable atropisomer and as an off-white solid. The compound was suspended in methanol with sonication, and the solid was collected by vacuum filtration, washed with methanol, and dried well to give <b>14f</b> (11.2 g, 19.5 mmol, 88% yield) as a white solid.</div><div class="NLM_p">HPLC purity: 99.9%; <i>t</i><sub>r</sub> = 11.05 min (Method A); 99.9%; <i>t</i><sub>r</sub> = 10.72 min (Method B). Chiral purity: 99.8% ie; Optical rotation: [α]<sub><i>D</i></sub><sup>20</sup> (c = 2.10, CHCl<sub>3</sub>) = +63.8°; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>30</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 573.2. Found: 573.5. Anal. calcd for C<sub>32</sub>H<sub>30</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub>, 0.72% H<sub>2</sub>O: C 65.56, H 5.42, N 9.55. Found: C 65.69, H 5.40, N 9.52. <sup>1</sup>H NMR (500 MHz, DMSO-d6) δ 10.78 (s, 1H), 8.07 (br. s., 1H), 7.95 (d, <i>J</i> = 7.8 Hz, 1H), 7.72 (dd, <i>J</i> = 14.2, 8.0 Hz, 1H), 7.56 (d, <i>J</i> = 10.8 Hz, 1H), 7.45 (br. s., 1H), 7.42–7.36 (m, 1H), 7.34 (d, <i>J</i> = 6.9 Hz, 1H), 7.34–7.31 (m, 1H), 7.29 (dd, <i>J</i> = 7.5, 1.3 Hz, 1H), 4.17 (s, 1H), 3.73 (d, <i>J</i> = 8.0 Hz, 3H), 2.91 (dd, <i>J</i> = 16.8, 4.4 Hz, 1H), 2.48–2.37 (m, 1H), 1.98–1.89 (m, 2H), 1.87 (d, <i>J</i> = 11.0 Hz, 1H), 1.76 (s, 3H), 1.59 (td, <i>J</i> = 11.5, 4.1 Hz, 1H), 1.20–1.12 (m, 1H), and 1.11 (s, 6H). <sup>13</sup>C NMR (126 MHz, DMSO-d6) δ 168.2 (d, <i>J</i> = 1.8 Hz, 1C), 160.1 (d, <i>J</i> = 3.6 Hz, 1C), 151.9 (d, <i>J</i> = 228.9 Hz, 1C), 150.5 (d, <i>J</i> = 41.8 Hz, 1C), 148.7 (d, <i>J</i> = 205.3 Hz, 1C), 139.2, 135.1, 135.0, 134.8, 131.4, 130.6, 130.0 (d, <i>J</i> = 7.3 Hz, 1C), 128.5, 127.1 (d, <i>J</i> = 4.5 Hz, 1C), 125.7, 124.3 (d, <i>J</i> = 2.7 Hz, 1C), 123.6 (d, <i>J</i> = 8.2 Hz, 1C), 123.0 (d, <i>J</i> = 23.6 Hz, 1C), 120.8 (d, <i>J</i> = 20.0 Hz, 1C), 118.4, 115.3 (d, <i>J</i> = 7.3 Hz, 1C), 108.8 (d, <i>J</i> = 5.4 Hz, 1C), 106.7 (d, <i>J</i> = 28.2 Hz, 1C), 70.4, 45.4, 34.3 (d, <i>J</i> = 14.5 Hz, 1C), 27.1, 26.8, 24.8, 24.7, 22.1, and 14.5. <sup>19</sup>F-NMR (470 MHz, DMSO-d6) δ −121.49 (dt, <i>J</i> = 22.9, 11.4 Hz, 1F), and −129.56 (d, <i>J</i> = 11.4 Hz, 1F).</div><div class="NLM_p">The absolute configuration of <b>14f</b> was confirmed by single crystal X-ray analysis (CCDC # 1501162).</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0036.gif" alt="" id="fx5" /></img></div><div id="sec5_4_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 6-Fluoro-5-(<i>S</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (<b>14g</b>)</h4><div class="NLM_p last">A sample of 6-fluoro-5-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (23.7 g, 41.3 mmol) was separated by chiral SFC to give two single, stable atropisomers as follows: column, AS-H (3 × 25 cm, 5 μm); BPR pressure, 100 bar; temperature, 40 °C; flow rate, 150 mL/min; mobile phase, CO<sub>2</sub>/MeOH (70:30); detector wavelength, 220 nm; injection, 1.8 mL (4.6 min cycle time); sample preparation, MeOH/CH<sub>2</sub>Cl<sub>2</sub> (1:1). The second peak eluting from the column provided <b>14g</b> as a single, stable atropisomer and as a white solid. HPLC purity: 99.9%; <i>t</i><sub>r</sub> = 10.62 min (Method A); 99.9%; <i>t</i><sub>r</sub> = 10.28 min (Method B). Chiral purity: 97.7% ie; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>30</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 573.2. Found: 573.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) d 10.77 (s, 1H), 8.05 (br. s., 1H), 7.94 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.72 (ddd, <i>J</i> = 14.4, 8.0, 1.4 Hz, 1H), 7.55 (d, <i>J</i> = 10.5 Hz, 1H), 7.43 (br. s., 1H), 7.40–7.35 (m, 1H), 7.34–7.28 (m, 3H), 4.17 (s, 1H), 3.72 (d, <i>J</i> = 8.0 Hz, 3H), 2.90 (d, <i>J</i> = 4.7 Hz, 1H), 2.87 (d, <i>J</i> = 4.7 Hz, 1H), 2.45–2.35 (m, 1H), 2.00–1.91 (m, 1H), 1.86 (dd, <i>J</i> = 15.3, 5.5 Hz, 2H), 1.71 (s, 3H), 1.57 (td, <i>J</i> = 11.9, 3.3 Hz, 1H), 1.10 (s, 3H), and 1.08 (s, 3H).</div></div><div id="sec5_4_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 8-Fluoro-1-methyl-3-(<i>R</i>,<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>17</b>)</h4><div class="NLM_p">A solution of 3-(3-bromo-2-methylphenyl)-8-fluoroquinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (4.80 g, 13.8 mmol) in dimethylformamide (25 mL) was treated with cesium carbonate (13.4 g, 41.2 mmol). The suspension was stirred at room temperature and treated dropwise, but quickly, with iodomethane (4.30 mL, 68.7 mmol) and then stirred rapidly at room temperature for 1 h. The mixture was diluted with ethyl acetate and water (200 mL). The organic phase was separated and washed sequentially with water and brine and then was dried and concentrated to provide 3-(3-bromo-2-methylphenyl)-8-fluoro-1-methylquinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione as a tan solid (4.80 g, 13.3 mmol, 96% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>12</sub>BrFN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 363.0. Found: 363.0 and 365.0.</div><div class="NLM_p last">A mixture of 3-(3-bromo-2-methylphenyl)-8-fluoro-1-methylquinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (4.80 g, 13.2 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (4.36 g, 17.2 mmol), potassium acetate (3.89 g, 39.6 mmol), and 1,1′-bis(diphenylphosphino)ferrocenepalladium(II) dichloride–dichloromethane adduct (0.540 g, 0.661 mmol) in dioxane (65 mL) was heated at reflux for 2 h. After cooling to room temperature, the mixture was filtered through Celite, and the solids were rinsed with ethyl acetate. The filtrate was diluted with ethyl acetate, washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was subjected to column chromatography on silica gel (80 g), eluting with ethyl acetate and hexanes (20–50%), to provide <b>17</b> (4.61 g, 11.2 mmol, 85% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>24</sub>BFN<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 411.2. Found: 411. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.14–8.08 (m, 1H), 7.93 (dd, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.48 (ddd, <i>J</i> = 14.0, 8.0, 1.5 Hz, 1H), 7.34 (t, <i>J</i> = 7.6 Hz, 1H), 7.27–7.20 (m, 2H), 3.88 (d, <i>J</i> = 7.9 Hz, 3H), 2.36 (s, 3H), and 1.36 (s, 12H).</div></div><div id="sec5_4_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 8-Fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (19) and 8-Fluoro-1-methyl-3-(<i>R</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>35</b>)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></h4><div class="NLM_p">A sample of racemic 8-fluoro-1-methyl-3-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>17</b>) was separated by chiral SFC as follows: column, (R,R)-Whelk-O1 (3 × 25 cm, 5 μm); mobile phase, CO<sub>2</sub>–MeOH (70:30) at 200 mL/min, 100 bar, 30 °C; sample preparation, 97.3 mg/mL in MeOH/DCM (1:1); injection, 4 mL. The first peak eluting from the column provided the (<i>S</i>)-isomer, 8-fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>19</b>), as a single, stable atropisomer and as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>24</sub>BFN<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 411.2. Found: 411. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.14–8.08 (m, 1H), 7.93 (dd, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.48 (ddd, <i>J</i> = 14.0, 8.0, 1.5 Hz, 1H), 7.34 (t, <i>J</i> = 7.6 Hz, 1H), 7.27–7.20 (m, 2H), 3.88 (d, <i>J</i> = 7.9 Hz, 3H), 2.36 (s, 3H), and 1.36 (s, 12H). The absolute stereochemistry of <b>19</b> as (<i>S</i>) was determined by single crystal X-ray analysis of carbazole <b>7a</b>.</div><div class="NLM_p last">The second peak eluting from the column provided the (<i>R</i>)-isomer, 8-fluoro-1-methyl-3-(<i>R</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>35</b>), as a white solid and a single, stable atropisomer. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>24</sub>BFN<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 411.2. Found: 411. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.13–8.08 (m, 1H), 7.93 (dd, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.48 (ddd, <i>J</i> = 13.9, 8.1, 1.5 Hz, 1H), 7.37–7.31 (m, 1H), 7.27–7.20 (m, 2H), 3.88 (d, <i>J</i> = 7.9 Hz, 3H), 2.36 (s, 3H), and 1.36 (s, 12H).</div></div><div id="sec5_4_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Alternative Preparation of <b>19</b></h4><div class="NLM_p last">A solution of 8-fluoro-3-(2-methyl-3-(<i>S</i>)-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>33</b>, 40 g, 101 mmol) in tetrahydrofuran (400 mL) was treated with cesium carbonate (99 g, 303 mmol) and iodomethane (12.6 mL, 202 mmol). The resulting cloudy solution was stirred at room temperature overnight. Water (300 mL) was added, and the reaction mixture was extracted with ethyl acetate (3 × 150 mL). The combined organic phases were washed sequentially with brine and water, and dried and concentrated. The residue was purified by recrystallization from ethyl acetate to provide 8-fluoro-1-methyl-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione as a white solid (<b>19</b>, 38 g, 92.6 mmol, 92% yield).</div></div><div id="sec5_4_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 3-(3-Bromo-2-methylphenyl)-8-fluoroquinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>31</b>)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></h4><div class="NLM_p">A suspension of 8-fluoro-1<i>H</i>-benzo[<i>d</i>][1,3]oxazine-2,4-dione (3.00 g, 16.6 mmol) in xylenes (50 mL) was treated with 3-bromo-2-methylaniline (3.08 g, 16.6 mmol) and heated to reflux. After 6 h, the mixture was allowed to cool to room temperature overnight. The resulting suspension was diluted with hexanes, and the precipitate was collected by filtration, rinsed with hexanes, and air-dried to provide 2-amino-<i>N</i>-(3-bromo-2-methylphenyl)-3-fluorobenzamide as a white solid (<b>30</b>, 4.50 g, 84% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>12</sub>BrFN<sub>2</sub>O [M + H]<sup>+</sup> 323.0. Found: 323.0 and 325.0. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.69 (d, <i>J</i> = 7.9 Hz, 1H), 7.65 (br. s., 1H), 7.50–7.46 (m, 1H), 7.32 (d, <i>J</i> = 8.1 Hz, 1H), 7.19–7.11 (m, 2H), 6.73–6.64 (m, 1H), 5.69 (br. s., 2H), and 2.44 (s, 3H).</div><div class="NLM_p last">A solution of 2-amino-<i>N</i>-(3-bromo-2-methylphenyl)-3-fluorobenzamide (<b>30</b>, 5.70 g, 17.6 mmol) in tetrahydrofuran (100 mL) was treated with bis(trichloromethyl)carbonate (triphosgene) (6.28 g, 21.2 mmol) at room temperature and stirred for 15 min. The mixture was diluted with ethyl acetate, carefully treated with a saturated aqueous solution of sodium bicarbonate, and stirred at room temperature until gas evolution stopped. The separated organic phase was washed sequentially with a saturated aqueous solution of sodium bicarbonate, water, and brine. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was triturated with ether to provide 3-(3-bromo-2-methylphenyl)-8-fluoroquinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>31</b>, 6.00 g, 17.2 mmol, 97% yield) as an off white solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>10</sub>BrFN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> 349.0. Found: 349.0 and 351.0. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.59 (d, <i>J</i> = 17.6 Hz, 1H), 7.99 (d, <i>J</i> = 8.1 Hz, 1H), 7.70 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 7.54–7.43 (m, 1H), 7.28–7.21 (m, 2H), 7.21–7.17 (m, 1H), and 2.28 (s, 3H).</div></div><div id="sec5_4_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 8-Fluoro-3-(<i>R</i>,<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>32</b>)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></h4><div class="NLM_p last">A stirred mixture of 3-(3-bromo-2-methylphenyl)-8-fluoroquinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (0.349 g, 1.00 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (0.305 g, 1.20 mmol), 1,1′-bis(diphenylphosphino)ferrocenepalladium(II) dichloride–dichloromethane adduct (0.041 g, 0.050 mmol), and potassium acetate (0.245 g, 2.50 mmol) in dioxane (20 mL) and dimethyl sulfoxide (4 mL) was bubbled with nitrogen for 5 min, then heated at 90 °C overnight. The cooled mixture was partitioned between ethyl acetate and water. The organic phase was washed sequentially with a saturated aqueous solution of sodium bicarbonate, washed with water, washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with a mixture of ethyl acetate and hexanes (20:80) to give <b>32</b> (0.326 g, 82% yield) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>22</sub>BFN<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup> 397.2. Found: 397.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.78 (s, 1H), 7.80 (d, <i>J</i> = 7.2 Hz, 1H), 7.72 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.71–7.56 (m, 1H), 7.45–7.35 (m, 1H), 7.35–7.29 (m, 1H), 7.29–7.16 (m, 1H), 2.22 (s, 3H), and 1.33 (s, 12H).</div></div><div id="sec5_4_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 8-Fluoro-3-(<i>R</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (34) and 8-Fluoro-3-(<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>33</b>)</h4><div class="NLM_p last">A sample of 8-fluoro-3-(<i>R</i>,<i>S</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>32</b>) was separated by chiral SFC to give two single, stable atropisomers as follows: column, Chiralcel OD-H (5 × 25 cm, 5 μm); mobile phase, CO<sub>2</sub>-MeOH (70:30) at 300 mL/min, 100 bar, 40 °C; sample preparation, 103 mg/mL in DCM–MeOH (44:56); injection, 5.0 mL. The first peak eluting from the column provided the (<i>R</i>)-atropisomer, 8-fluoro-3-(<i>R</i>)-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)quinazoline-2,4(1<i>H</i>,3<i>H</i>)-dione (<b>34</b>), as a white solid. The second peak eluting from the column provided the (<i>S</i>)-enantiomer <b>34</b> as a white solid. The mass spectrum and <sup>1</sup>H NMR for each enantiomeric atropisomer were the same as those for intermediate <b>32</b>.</div></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Human Recombinant BTK Enzyme Assay</h3><div class="NLM_p last">To V-bottom 384-well plates were added test compounds, human recombinant BTK (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES at pH 7.4, 10 mM MgCl<sub>2</sub>, 0.015% Brij 35 surfactant, and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LabChip 3000 (Caliper, Hopkinton, MA) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to control reactions with no enzyme (for 100% inhibition) and controls with no inhibitor (for 0% inhibition). Dose–response curves were generated to determine the concentration required for inhibiting 50% of BTK activity (IC<sub>50</sub>). Compounds were dissolved at 10 mM in DMSO and evaluated at 11 concentrations.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> BCR-Stimulated Calcium Flux in Ramos B Cells</h3><div class="NLM_p last">Human Ramos (RA1) B cells (ATCC CRL-1596) at a density of 2 × 106 cells/mL in RPMI minus phenol red (Invitrogen 11835-030) and 50 mM HEPES (Invitrogen 15630-130) containing 0.1% BSA (Sigma A8577) were added to one-half volume of calcium loading buffer (BD bulk kit for probenecid sensitive assays, # 640177) and incubated at room temperature in the dark for 1 h. Dye-loaded cells were pelleted (Beckmann GS-CKR, 1200 rpm, room temperature, 5 min) and resuspended at room temperature in RPMI minus phenol red with 50 mM HEPES and 10% FBS to a density of 1 × 106 cells/mL. 150 μL aliquots (150,000 cells/well) were plated into 96 well poly-<span class="smallcaps smallerCapital">d</span>-lysine coated assay plates (BD 35 4640) and briefly centrifuged (Beckmann GS-CKR 800 rpm, 5 min, without brake). Next, 50 μL compound dilutions in 0.4% DMSO/RPMI minus phenol red +50 mM HEPES + 10% FBS were added to the wells, and the plate was incubated at room temperature in the dark for 1 h. The assay plate was briefly centrifuged as above prior to measuring calcium levels. Using the FLIPR1 (Molecular Devices), cells were stimulated by adding goat antihuman IgM (Invitrogen AHI0601) to 2.5 μg/mL. Changes in intracellular calcium concentrations were measured for 180 s, and percent inhibition was determined relative to peak calcium levels seen in the presence of stimulation only.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Whole Blood Assays of BCR-Stimulated CD69 Expression on B Cells</h3><div class="NLM_p last">To measure BCR-stimulated B cells, heparanized human whole blood was added with various concentrations of test compound and stimulated with 30 μg/mL AffiniPure F(ab′)2 fragment goat anti human IgM (Jackson 109-006-1299-endotoxin cleared) and 10 ng/mL human IL-4 (Peprotech 200-04) for 18 h at 37 °C with agitation. The cells were stained with FITC-conjugated mouse antihuman CD20 (BD Pharmingen 555622) and PE-conjugated mouse antihuman CD69 monoclonal antibody (BD Pharmingen 555531), lysed and fixed, then washed. The amount of CD69 expression was quantitated by the mean fluorescence intensity (MFI) after gating on the CD20-positive B cell population as measured by FACS analysis. B cells in mouse whole blood were stimulated in an similar way, using AffinPure F(ab′)2 Fragment goat anti mouse IgG + IgM (Jackson Cat#115-006-068) at 100 μg/mL to stimulate and staining with allophycocyanin (APC) rat antimouse CD19 antibody (BD Biosciences 550992) to identify the B cells and CD69 quantitation with FITC-conjugated antimouse CD69 monoclonal antibody (BD Biosciences 553236).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> JAK2 Tyrosine Kinase Assay</h3><div class="NLM_p last">The assays were performed in V-bottomed 384-well plates. The final assay volume was 30 μL prepared from 15 μL additions of enzyme and substrates (fluoresceinated peptide and ATP) and test compounds in assay buffer (100 mM HEPES at pH 7.4, 10 mM MgCl<sub>2</sub>, 25 mM beta-glycerolphosphate, 0.015% Brij 35 surfactant, and 4 mM DTT). The reaction was initiated by the combination of Jak2 tyrosine kinase with substrates and test compounds. The reaction mixture was incubated at room temperature for 60 min and terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to no enzyme control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentration of reagents in the assays is ATP, 30 μM; Jak2 fluorescent peptide, 1.5 μM; Jak2, 1 nM; and DMSO, 1.6%. Dose–response curves were generated to determine the concentration required inhibiting 50% of kinase activity (IC<sub>50</sub>). Compounds were dissolved at 10 mM in DMSO and evaluated at 11 concentrations, each in duplicate. IC<sub>50</sub> values were derived by nonlinear regression analysis.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> NZB/W Lupus-Prone Mice</h3><div class="NLM_p last">Baseline body weight, proteinuria, and serum dsDNA titers were determined for female NZB/WF1 mice (Jackson Laboratories) at 24 weeks of age prior to their randomization into treatment groups, each with <i>n</i> = 12. Mice were dosed by oral gavage, QD, for 16 weeks and included the following treatment groups: <b>14f</b> at 30 mg/kg in vehicle (80:20 PEG400/water) and prednisolone (Sigma P6004) at 10 mg/kg. Mice were routinely monitored for overall health, and body weight, proteinuria, and dsDNA titers were measured every 3 weeks. Proteinuria was measured using a colorimetric assay for albumin (Siemens Albustix Reagent Strips for Urinalysis). Anti-dsDNA antibody titers were measured by applying serial dilutions of serum samples to DNA-coated ELISA plates. Bound antibody was detected with HRP-conjugated polyclonal goat-antimouse IgG. The individual titers were expressed as relative to that of a pooled serum standard. At the end of the study, final body weight and proteinuria were measured. Terminal blood samples were drawn for PK and anti-dsDNA titers. The amount of BTK inactivation in blood from these mice, 24 h after their last dose, was determined as described above. At the end of the study, kidneys (<i>n</i> = 5–6 per group) were collected in 10% Neutral Buffered Formalin for histological evaluation. Fixed kidney tissues were routinely processed and paraffin embedded. Kidney sections were stained with periodic acid Schiff and hematoxylin (PASH) and hematoxylin and eosin (H&E) for the evaluation of nephritis severity. Blinded to treatment group, severity of nephritis was evaluated using the following criteria. For glomerular damage: 1, mesangial matrix thickening and/or mesangial cell proliferation; 2, crescent formation, cellular deposits/casts in Bowman’s space; 3, cellular infiltration, composed of mononuclear cells in glomerular tufts; and 4, fibrosis of Bowman’s capsule. For tubular damage: 1, infiltration of mononuclear cells; 2, severity of tubular epithelial cell damage; and 3, protein casts. For tubule-interstitial damage: 1, fibrosis; and 2, infiltration of mononuclear cells. Each subcategory was assigned a score from 0 to 4. The total score for each mouse was the sum of the above nine subcategories with the highest possible score of 36. To evaluate IC deposition in the glomeruli, immunohistochemistry was performed using biotinylated goat antimouse IgG, (Vector Laboratories, Burlingame, CA) with 45 μg/mL normal goat serum (Jackson Immunoresearch Laboratories, Inc.) as the negative control. Sections were conjugated to horse radish peroxidase using Vectastain ABC ELITE reagent (Vector Laboratories) and developed with Deep Space Black chromogen (Biocare Medical) for visualization of IgG. IC deposition was evaluated under 100× magnification by dividing the kidney into three sections and randomly selecting 10 glomeruli from each section. Each glomerulus was subdivided into four quadrants, and each quadrant was assigned a score from 0 to 4 based on the severity of IgG deposition, defined as 0, unremarkable; 1, minimal linear deposition and/or focal lesion; 2, mild linear deposition or multifocal lesions; 3, moderate/segmental lesions; 4, marked/global or diffuse deposition. The total score of each glomerulus was calculated, as was the total score of each kidney, and the group average score was determined. Statistical analysis was performed using a one-way ANOVA model after a square root transformation of the data to establish significant overall difference in the mean score of treatment groups with <i>P</i> < 0.0001. One-sided Dunnett’s test was used to determine significance of inhibition of each treatment group compared to the vehicle control group.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Collagen Antibody-Induced Arthritis in Mice</h3><div class="NLM_p last">Female BALB/c mice (8–10 weeks of age; Harlan) were injected IP with a mixture of four monoclonal antimouse type II collagen antibodies (1 mg of each). Daily oral dosing was immediately started with vehicle (EtOH/TPGS/PEG300; 5:5:90), compound <b>6</b> (10 or 30 mg/kg) or dexamethasone (1 mg/kg). Three days later, the mice were injected IP with 1.25 mg/kg LPS (<i>E. coli</i> O111:B4; Sigma). Thereafter, mice were monitored 3×/week for the development and severity of paw inflammation. Each paw was visually scored by the following scheme: +0 = normal; +1 = one (or more) joints inflamed on digits; +2 = mild-moderate inflammation of plantar surface of paw and paw thickness modestly increased; +3 = moderate-severe inflammation of plantar surface of paw and paw thickness significantly increased; +4 = ankylosis of ankle joint (significantly reduced hock joint motion on flexion/extension). Clinical paw scores for all four paws were summed for each mouse, and mean ± SEM was calculated for each treatment group.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Single Crystal X-ray Diffraction Data Collection</h3><div class="NLM_p last">Single crystal X-ray diffraction data were collected on a Bruker-AXS APEX2 CCD system using Cu Kα radiation (λ = 1.5418 Å). Indexing and processing of the measured intensity data were carried out with the APEX2 software package/program suite.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> When indicated, crystals were cooled in the cold stream of an Oxford Cryosystem<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> during data collection. The structures were solved by direct methods and refined on the basis of observed reflections using the crystallographic package SHELXTL.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The derived atomic parameters (coordinates and temperature factors) were refined through full matrix least-squares. The function minimized in the refinements was Σ<sub>w</sub>(|<i>F</i><sub>o</sub>| – |<i>F</i><sub>c</sub>|).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a><i>R</i> is defined as Σ∥<i>F</i><sub>o</sub>| – |<i>F</i><sub>c</sub>∥/Σ|<i>F</i><sub>o</sub>|, while <i>R</i><sub>w</sub> = [Σ<sub>w</sub>(|<i>F</i><sub>o</sub>| – |<i>F</i><sub>c</sub>|)<sup>2</sup>/Σ<sub>w</sub>|<i>F</i><sub>o</sub>|<sup>2</sup>]<sup>1/2</sup> where <i>w</i> is an appropriate weighting function based on errors in the observed intensities. Difference maps were examined at all stages of refinement. Hydrogens were introduced in idealized positions with isotropic temperature factors, but no hydrogen parameters were varied.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> X-ray Crystallography of <b>14f</b> Bound to the Kinase Domain of BTK</h3><div class="NLM_p last">A baculovirus construct of His-TEV-hBTK (E396-S659) was used to generate protein for X-ray crystallography as previously reported.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> For protein/compound complex formation, 2 μL of compound <b>14f</b> (50 mM DMSO stock) was added to 1.3 mL of hBTK at 0.38 mg/mL and incubated at room temperature for 3 h and then concentrated to 9.1 mg/mL prior to set up drops. Crystals were grown at room temperature using the hanging drop vapor diffusion method. The drop consisted of 1.5 μL protein solution and 1 μL reservoir solution containing 3% (w/v) methyl ether PEG 5000, 25% (w/v) PEG 8000 and 0.2 M Tris-HCl, pH 7.0. Macroseeding was performed to initiate crystal growth. The crystals appeared within a few days and continued to grow for 2–3 weeks. Crystals were flash-cooled in liquid nitrogen for data collection with 25% glycerol and 75% reservoir solution as cryoprotectant. Diffraction data were collected by Shamrock Structures, Inc. at Canadian Light Source, beamline 08ID. hBTK/compound <b>14f</b> cocrystals belonged to the space group p2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>: <i>a</i> = 46.6 Å, <i>b</i> = 69.8 Å, <i>c</i> = 89.0 Å, α = β = γ = 90.0°. The 1.50 Å resolution structure was determined by molecular replacement using a previously determined in-house BTK structure (unpublished results). The structure of hBTK + compound <b>14f</b> has been deposited to RCSB with PDB ID: 5T18.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01088">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01088" class="ext-link">10.1021/acs.jmedchem.6b01088</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Single crystal X-ray experimental details for <b>7a</b>, <b>9a</b>, <b>14b</b>, <b>14d</b>, and <b>14f</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01088/suppl_file/jm6b01088_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">PDB coordinates for the computational models of <b>9a</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01088/suppl_file/jm6b01088_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">PDB coordinates for the computational models of <b>9b</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01088/suppl_file/jm6b01088_si_003.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01088/suppl_file/jm6b01088_si_001.pdf">jm6b01088_si_001.pdf (343.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01088/suppl_file/jm6b01088_si_002.pdb">jm6b01088_si_002.pdb (170.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01088/suppl_file/jm6b01088_si_003.pdb">jm6b01088_si_003.pdb (172.03 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID code for <b>14f</b>: 5T18.</p><div class="testing" data-doi="10.1021/acs.jmedchem.6b01088" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott H. Watterson</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1665757962623861776262736465797856747b653875797b"><span class="__cf_email__" data-cfemail="780b1b170c0c560f190c0c1d0a0b1716381a150b561b1715">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George V. De Lucca</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qing Shi</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles M. Langevine</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingjie Liu</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas G. Batt</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Myra Beaudoin Bertrand</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hua Gong</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Dai</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shiuhang Yip</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peng Li</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dawn Sun</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dauh-Rurng Wu</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunlei Wang</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingru Zhang</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah C. Traeger</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark A. Pattoli</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stacey Skala</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lihong Cheng</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary T. Obermeier</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rodney Vickery</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lorell N. Discenza</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Celia J. D’Arienzo</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yifan Zhang</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth Heimrich</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen M. Gillooly</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tracy L. Taylor</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudine Pulicicchio</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kim W. McIntyre</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael A. Galella</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andy J. Tebben</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jodi K. Muckelbauer</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">ChiehYing Chang</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Rampulla</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arvind Mathur</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luisa Salter-Cid</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joel C. Barrish</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Percy H. Carter</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aberra Fura</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James R. Burke</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph A. Tino</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers
Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i63" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i63"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i64" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i64"> Abbreviations Used</h2><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">NFAT</td><td class="NLM_def"><p class="first last">nuclear factor of activated T cells</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor kappa-light chain enhancer of activated B cells</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">super critical fluid chromatography</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43760" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43760" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 22 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bäckesjö, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faryal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aints, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglöf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I. E.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00741.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1111%2Fj.1600-065X.2008.00741.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=19290921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=58-73&author=A.+J.+Mohamedauthor=L.+Yuauthor=C.-M.+B%C3%A4ckesj%C3%B6author=L.+Vargasauthor=R.+Faryalauthor=A.+Aintsauthor=B.+Christenssonauthor=A.+Bergl%C3%B6fauthor=M.+Vihinenauthor=B.+F.+Noreauthor=C.+I.+E.+Smith&title=Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29%3A+function%2C+regulation%2C+and+transformation+with+special+emphasis+on+the+PH+domain&doi=10.1111%2Fj.1600-065X.2008.00741.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span></div><div class="casAuthors">Mohamed, Abdalla J.; Yu, Liang; Backesjo, Carl-Magnus; Vargas, Leonardo; Faryal, Rani; Aints, Alar; Christensson, Birger; Berglof, Anna; Vihinen, Mauno; Nore, Beston F.; Smith, C. I. Edvard</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-73</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase important in B-lymphocyte development, differentiation, and signaling.  Btk is a member of the Tec family of kinases.  Mutations in the Elk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice.  Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT).  In B cells, NF-κB was shown to bind to the Btk promoter and induce transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional Btk.  Moreover, Btk activation is tightly regulated by a plethora of other signaling proteins including protein kinase C (PKC), Sab/SH3BP5, and caveolin-1.  For example, the prolyl isomerase Pin1 neg. regulates Btk by decreasing tyrosine phosphorylation and steady state levels of Btk.  It is intriguing that PKC and Pin1, both of which are neg. regulators, bind to the pleckstrin homol. domain of Btk.  To this end, we describe here novel mutations in the pleckstrin homol. domain investigated for their transforming capacity.  In particular, we show that the mutant D43R behaves similar to E41K, already known to possess such activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1L-Ch4HjNLVg90H21EOLACvtfcHk0lh2FQp5w_9jPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO&md5=7a84f2b3604d67bcc1490fadcbfea234</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00741.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00741.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DB%25C3%25A4ckesj%25C3%25B6%26aufirst%3DC.-M.%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DFaryal%26aufirst%3DR.%26aulast%3DAints%26aufirst%3DA.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DBergl%25C3%25B6f%26aufirst%3DA.%26aulast%3DVihinen%26aufirst%3DM.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%253A%2520function%252C%2520regulation%252C%2520and%2520transformation%2520with%2520special%2520emphasis%2520on%2520the%2520PH%2520domain%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D58%26epage%3D73%26doi%3D10.1111%2Fj.1600-065X.2008.00741.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I. E.</span><span> </span><span class="NLM_article-title">Signaling of Bruton’s tyrosine kinase, Btk</span> <span class="citation_source-journal">Scand. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1046/j.1365-3083.1999.00504.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1046%2Fj.1365-3083.1999.00504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10075013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1999&pages=113-118&author=A.+J.+Mohamedauthor=B.+F.+Noreauthor=B.+Christenssonauthor=C.+I.+E.+Smith&title=Signaling+of+Bruton%E2%80%99s+tyrosine+kinase%2C+Btk&doi=10.1046%2Fj.1365-3083.1999.00504.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling of Bruton's tyrosine kinase, Btk</span></div><div class="casAuthors">Mohamed, A. J.; Nore, B. F.; Christensson, B.; Smith, C. I. E.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-118</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review with 63 refs.  Bruton's tyrosine kinase, which is encoded by the BTK gene, is a cytoplasmic protein tyrosine kinase (PTK) crucial for B-cell development and differentiation.  It belongs to the Tec family of PTKs contg. several domains that are characteristic of signalling mols.  In humans, mutations that disrupt the function of this gene lead to the classical XLA syndrome (X-linked agammaglobulinemia), a primary immunodeficiency mainly characterized by lack of mature B cells as well as low levels of Igs.  In contrast, animal models of this disease such as the xid mice display profoundly milder XLA phenotype.  BTK phosphorylation and activation in response to engagement of the B-cell receptor (BCR) by antigen is a dynamic process whereby a variety of proteins interact with each other and recruit signalling mols. resulting in a physiol. response such as B-cell proliferation and antibody prodn.  The main players, however, that participate in the intracellular downstream cascade have not yet been identified and are therefore under intense scrutiny in several labs.  This review discusses certain aspects of BTK activation following receptor stimulation by agonists and how this event is translated into the biochem. signals within the cell that eventually lead to nuclear responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphmZBDkpS1ubVg90H21EOLACvtfcHk0lgwA0xHIWQlpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D&md5=a3842c00d3cd4e45458c050941026476</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-3083.1999.00504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-3083.1999.00504.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DSignaling%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520Btk%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D1999%26volume%3D49%26spage%3D113%26epage%3D118%26doi%3D10.1046%2Fj.1365-3083.1999.00504.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Takata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurosaki, T.</span><span> </span><span class="NLM_article-title">A role for Bruton’s tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-γ2</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1084/jem.184.1.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1084%2Fjem.184.1.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=8691147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1ajs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=1996&pages=31-40&author=M.+Takataauthor=T.+Kurosaki&title=A+role+for+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+antigen+receptor-mediated+activation+of+phospholipase+C-%CE%B32&doi=10.1084%2Fjem.184.1.31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-γ2</span></div><div class="casAuthors">Takata, Minoru; Kurosaki, Tomohiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Defects in the gene encoding Bruton's tyrosine kinase (Btk) result in a disease called X-linked agammaglobulinemia, in which there is a profound decrease of mature B cells due to a block in B cell development.  Recent studies have shown that Btk is tyrosine phosphorylated and activated upon B cell antigen receptor (BCR) stimulation.  To elucidate the functions of this kinase, we examd. BCR signaling of DT40 B cells deficient in Btk.  Tyrosine phosphorylation of phospholipase C (PLC)-γ2 upon receptor stimulation was significantly reduced in the mutant cells, leading to the loss of both BCR-coupled phosphatidylinositol hydrolysis and calcium mobilization.  Pleckstrin homol. and Src-homol. 2 domains of Btk were required for PLC-γ2 activation.  Since Syk is also required for the BCR-induced PLC-γ2 activation, our findings indicate that PLC-γ2 activation is regulated by Btk and Syk through their concerted actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrvJR6GCfI7rVg90H21EOLACvtfcHk0lgwA0xHIWQlpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1ajs74%253D&md5=7244a36ac8298ccde274e05016ec68ba</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1084%2Fjem.184.1.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.184.1.31%26sid%3Dliteratum%253Aachs%26aulast%3DTakata%26aufirst%3DM.%26aulast%3DKurosaki%26aufirst%3DT.%26atitle%3DA%2520role%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520antigen%2520receptor-mediated%2520activation%2520of%2520phospholipase%2520C-%25CE%25B32%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1996%26volume%3D184%26spage%3D31%26epage%3D40%26doi%3D10.1084%2Fjem.184.1.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jongstra-Bilen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puig Cano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasija, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cybulsky, M. I.</span><span> </span><span class="NLM_article-title">Dual functions of Bruton’s tyrosine kinase and Tec kinase during Fcγ receptor-induced signaling and phagocytosis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span><span class="refDoi"> DOI: 10.4049/jimmunol.181.1.288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.4049%2Fjimmunol.181.1.288" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2008&pages=288-298&author=J.+Jongstra-Bilenauthor=A.+Puig+Canoauthor=M.+Hasijaauthor=H.+Xiaoauthor=C.+I.+Smithauthor=M.+I.+Cybulsky&title=Dual+functions+of+Bruton%E2%80%99s+tyrosine+kinase+and+Tec+kinase+during+Fc%CE%B3+receptor-induced+signaling+and+phagocytosis&doi=10.4049%2Fjimmunol.181.1.288"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.181.1.288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.181.1.288%26sid%3Dliteratum%253Aachs%26aulast%3DJongstra-Bilen%26aufirst%3DJ.%26aulast%3DPuig%2BCano%26aufirst%3DA.%26aulast%3DHasija%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DCybulsky%26aufirst%3DM.%2BI.%26atitle%3DDual%2520functions%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520and%2520Tec%2520kinase%2520during%2520Fc%25CE%25B3%2520receptor-induced%2520signaling%2520and%2520phagocytosis%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D181%26spage%3D288%26epage%3D298%26doi%3D10.4049%2Fjimmunol.181.1.288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kuehn, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaven, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilfillan, A. M.</span><span> </span><span class="NLM_article-title">Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">2576</span><span class="NLM_x">–</span> <span class="NLM_lpage">2585</span><span class="refDoi"> DOI: 10.1242/jcs.071043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1242%2Fjcs.071043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=20587594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2mtL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2010&pages=2576-2585&author=H.+S.+Kuehnauthor=M.+Radingerauthor=J.+M.+Brownauthor=K.+Aliauthor=B.+Vanhaesebroeckauthor=M.+A.+Beavenauthor=D.+D.+Metcalfeauthor=A.+M.+Gilfillan&title=Btk-dependent+Rac+activation+and+actin+rearrangement+following+Fc%CE%B5RI+aggregation+promotes+enhanced+chemotactic+responses+of+mast+cells&doi=10.1242%2Fjcs.071043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells</span></div><div class="casAuthors">Kuehn, Hye Sun; Radinger, Madeleine; Brown, Jared M.; Ali, Khaled; Vanhaesebroeck, Bart; Beaven, Michael A.; Metcalfe, Dean D.; Gilfillan, Alasdair M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2576-2585</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Mast cells infiltrate the sites of inflammation assocd. with chronic atopic disease and during helminth and bacterial infection.  This process requires receptor-mediated cell chemotaxis across a concn. gradient of their chemotactic ligands.  In vivo, mast cells are likely to be exposed to several such agents, which can cooperate in a synergistic manner to regulate mast cell homing.  Here, we report that chemotaxis of mouse bone-marrow-derived mast cells (BMMCs) in response to the chemoattractants stem-cell factor (SCF) and prostaglandin (PG)E2, is substantially enhanced following antigen-dependent ligation of the high-affinity receptor for IgE (FcεRI).  These responses were assocd. with enhanced activation of phosphoinositide 3-kinase (PI3K), and downstream activation of the tyrosine protein kinase Btk, with subsequent enhanced phospholipase (PL)Cγ-mediated Ca2+ mobilization, Rac activation and F-actin rearrangement.  Antigen-induced chemotaxis, and the ability of antigen to amplify responses mediated by SCF, adenosine and PGE2 were suppressed following inhibition of PI3K, and were impaired in BMMCs derived from Btk-/- mice.  There were corresponding decreases in the PLCγ-mediated Ca2+ signal, Rac activation and F-actin rearrangement, which, as they are essential for BMMC chemotaxis, accounts for the impaired migration of Btk-deficient cells.  Taken together, these data demonstrate that, by regulating signaling pathways that control F-actin rearrangement, Btk is crucial for the ability of antigen to amplify mast-cell chemotactic responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx05z-3Sv-D7Vg90H21EOLACvtfcHk0lgwA0xHIWQlpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2mtL7O&md5=2a02fc66a2b3994eb6c983a8c3b91f63</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1242%2Fjcs.071043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.071043%26sid%3Dliteratum%253Aachs%26aulast%3DKuehn%26aufirst%3DH.%2BS.%26aulast%3DRadinger%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DAli%26aufirst%3DK.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DBeaven%26aufirst%3DM.%2BA.%26aulast%3DMetcalfe%26aufirst%3DD.%2BD.%26aulast%3DGilfillan%26aufirst%3DA.%2BM.%26atitle%3DBtk-dependent%2520Rac%2520activation%2520and%2520actin%2520rearrangement%2520following%2520Fc%25CE%25B5RI%2520aggregation%2520promotes%2520enhanced%2520chemotactic%2520responses%2520of%2520mast%2520cells%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2010%26volume%3D123%26spage%3D2576%26epage%3D2585%26doi%3D10.1242%2Fjcs.071043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tsukada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlings, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span> </span><span class="NLM_article-title">Role of Bruton’s tyrosine kinase in immunodeficiency</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span><span class="refDoi"> DOI: 10.1016/0952-7915(94)90151-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2F0952-7915%2894%2990151-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=7946052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1994&pages=623-630&author=S.+Tsukadaauthor=D.+J.+Rawlingsauthor=O.+N.+Witte&title=Role+of+Bruton%E2%80%99s+tyrosine+kinase+in+immunodeficiency&doi=10.1016%2F0952-7915%2894%2990151-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in immunodeficiency</span></div><div class="casAuthors">Tsukada, Satoshi; Rawlings, David J.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-30</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    </div><div class="casAbstract">A review, with 71 refs.  The genetic defect assocd. with human X-linked agammaglobulinemia and murine X-linked immunodeficiency was recently shown to result from lack of function of a new cytoplasmic tyrosine kinase, called Bruton's tyrosine kinase (Btk).  The phenotypes assocd. with these immunodeficiencies indicate that Btk plays a crit. role in B lymphocyte development.  The distinctive protein structure of Btk and preliminary functional studies suggest that Btk may act in a novel manner in a variety of signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAyW0bZjSS3rVg90H21EOLACvtfcHk0ljKngLngIbRCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D&md5=d9932cf5d56f7a77723a46cae519cbeb</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1016%2F0952-7915%2894%2990151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0952-7915%252894%252990151-1%26sid%3Dliteratum%253Aachs%26aulast%3DTsukada%26aufirst%3DS.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520immunodeficiency%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D1994%26volume%3D6%26spage%3D623%26epage%3D630%26doi%3D10.1016%2F0952-7915%2894%2990151-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y.</span><span> </span><span class="NLM_article-title">The Tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">11526</span><span class="NLM_x">–</span> <span class="NLM_lpage">11534</span><span class="refDoi"> DOI: 10.1074/jbc.M708935200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1074%2Fjbc.M708935200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11526-11534&author=S.+H.+Leeauthor=T.+Kimauthor=D.+Jeongauthor=N.+Kimauthor=Y.+Choi&title=The+Tec+family+tyrosine+kinase+Btk+regulates+RANKL-induced+osteoclast+maturation&doi=10.1074%2Fjbc.M708935200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708935200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708935200%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DJeong%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DChoi%26aufirst%3DY.%26atitle%3DThe%2520Tec%2520family%2520tyrosine%2520kinase%2520Btk%2520regulates%2520RANKL-induced%2520osteoclast%2520maturation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D11526%26epage%3D11534%26doi%3D10.1074%2Fjbc.M708935200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Mease, P. J.</span><span> </span><span class="NLM_article-title">B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1245</span><span class="NLM_x">–</span> <span class="NLM_lpage">1255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=18609733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslajtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2008&pages=1245-1255&author=P.+J.+Mease&title=B+cell-targeted+therapy+in+autoimmune+disease%3A+rationale%2C+mechanisms%2C+and+clinical+application"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application</span></div><div class="casAuthors">Mease, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1245-1255</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">A review.  B cells play a crit. role in the pathogenesis of rheumatoid arthritis (RA) and other autoimmune diseases.  Recently, a no. of biol. agents that target B cells have been tested as therapies for these conditions.  These agents either deplete B cells, by targeting cell-surface antigens such as CD20, or block B cell function, for example by inhibiting the activity of B cell survival factors such as BLyS.  Of this group of agents, the first in clin. use has been rituximab, a chimeric monoclonal antibody that depletes B cells by binding to the CD20 cell-surface antigen.  Initially introduced as a treatment for non-Hodgkin's lymphoma, rituximab is now approved for the treatment of RA.  In this review we explore the rationale behind B cell-targeted therapy, highlight the results of clin. trials with rituximab in RA and other autoimmune diseases, and describe other emerging therapies directed at B cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpprn0Fq_lLVg90H21EOLACvtfcHk0ljKngLngIbRCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslajtro%253D&md5=1e31bd50b6afae7e8273a1da7a06f828</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DP.%2BJ.%26atitle%3DB%2520cell-targeted%2520therapy%2520in%2520autoimmune%2520disease%253A%2520rationale%252C%2520mechanisms%252C%2520and%2520clinical%2520application%26jtitle%3DJ.%2520Rheumatol.%26date%3D2008%26volume%3D35%26spage%3D1245%26epage%3D1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Middendorp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingjan, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlenborg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendriks, R. W.</span><span> </span><span class="NLM_article-title">Function of Bruton’s tyrosine kinase during B cell development is partially independent of its catalytic activity</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">5988</span><span class="NLM_x">–</span> <span class="NLM_lpage">5996</span><span class="refDoi"> DOI: 10.4049/jimmunol.171.11.5988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.4049%2Fjimmunol.171.11.5988" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2003&pages=5988-5996&author=S.+Middendorpauthor=G.+M.+Dingjanauthor=A.+Maasauthor=K.+Dahlenborgauthor=R.+W.+Hendriks&title=Function+of+Bruton%E2%80%99s+tyrosine+kinase+during+B+cell+development+is+partially+independent+of+its+catalytic+activity&doi=10.4049%2Fjimmunol.171.11.5988"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.171.11.5988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.171.11.5988%26sid%3Dliteratum%253Aachs%26aulast%3DMiddendorp%26aufirst%3DS.%26aulast%3DDingjan%26aufirst%3DG.%2BM.%26aulast%3DMaas%26aufirst%3DA.%26aulast%3DDahlenborg%26aufirst%3DK.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DFunction%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520during%2520B%2520cell%2520development%2520is%2520partially%2520independent%2520of%2520its%2520catalytic%2520activity%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D171%26spage%3D5988%26epage%3D5996%26doi%3D10.4049%2Fjimmunol.171.11.5988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Petro, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, S. M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, W. N.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">1745</span><span class="NLM_x">–</span> <span class="NLM_lpage">1753</span><span class="refDoi"> DOI: 10.1084/jem.191.10.1745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1084%2Fjem.191.10.1745" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2000&pages=1745-1753&author=J.+B.+Petroauthor=S.+M.+J.+Rahmanauthor=D.+W.+Ballardauthor=W.+N.+Khan&title=Bruton%E2%80%99s+tyrosine+kinase+is+required+for+activation+of+I%CE%BAB+kinase+and+nuclear+factor+%CE%BAB+in+response+to+B+cell+receptor+engagement&doi=10.1084%2Fjem.191.10.1745"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1084%2Fjem.191.10.1745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.191.10.1745%26sid%3Dliteratum%253Aachs%26aulast%3DPetro%26aufirst%3DJ.%2BB.%26aulast%3DRahman%26aufirst%3DS.%2BM.%2BJ.%26aulast%3DBallard%26aufirst%3DD.%2BW.%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520is%2520required%2520for%2520activation%2520of%2520I%25CE%25BAB%2520kinase%2520and%2520nuclear%2520factor%2520%25CE%25BAB%2520in%2520response%2520to%2520B%2520cell%2520receptor%2520engagement%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D191%26spage%3D1745%26epage%3D1753%26doi%3D10.1084%2Fjem.191.10.1745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Puck, J. M.</span><span> </span><span class="NLM_article-title">Molecular and genetic basis of X-linked immunodeficiency disorders</span> <span class="citation_source-journal">J. Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span><span class="refDoi"> DOI: 10.1007/BF01541340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1007%2FBF01541340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=8195317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaK2cXksFGht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1994&pages=81-89&author=J.+M.+Puck&title=Molecular+and+genetic+basis+of+X-linked+immunodeficiency+disorders&doi=10.1007%2FBF01541340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and genetic basis of X-linked immunodeficiency disorders</span></div><div class="casAuthors">Puck, Jennifer M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-9</span>CODEN:
                <span class="NLM_cas:coden">JCIMDO</span>;
        ISSN:<span class="NLM_cas:issn">0271-9142</span>.
    </div><div class="casAbstract">A review with 51 refs.  Topics discussed include X-linked hyper-IgM syndrome, X-linked agammaglobulinemia, X-linked severe combined immunodeficiency, and immunodeficiency genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0dSBJ76uLHLVg90H21EOLACvtfcHk0lhC3Mk--bI8Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksFGht7s%253D&md5=c9c2d448576c949acc62b4926389b46b</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1007%2FBF01541340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01541340%26sid%3Dliteratum%253Aachs%26aulast%3DPuck%26aufirst%3DJ.%2BM.%26atitle%3DMolecular%2520and%2520genetic%2520basis%2520of%2520X-linked%2520immunodeficiency%2520disorders%26jtitle%3DJ.%2520Clin.%2520Immunol.%26date%3D1994%26volume%3D14%26spage%3D81%26epage%3D89%26doi%3D10.1007%2FBF01541340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hendriks, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredius, R. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike-Overzet, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staal, F. J. T.</span><span> </span><span class="NLM_article-title">Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1003</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1517/14728222.2011.585971</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1517%2F14728222.2011.585971" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=21635151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Gkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=1003-1021&author=R.+W.+Hendriksauthor=R.+G.+M.+Brediusauthor=K.+Pike-Overzetauthor=F.+J.+T.+Staal&title=Biology+and+novel+treatment+options+for+XLA%2C+the+most+common+monogenetic+immunodeficiency+in+man&doi=10.1517%2F14728222.2011.585971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man</span></div><div class="casAuthors">Hendriks, Rudi W.; Bredius, Robbert G. M.; Pike-Overzet, Karin; Staal, Frank J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1003-1021</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: X-linked agammaglobulinemia (XLA) is the most common primary immunodeficiency in man, and is caused by a single genetic defect.  Inactivating mutations in the Bruton's tyrosine kinase (BTK) gene are invariably the cause of XLA,.  XLA is characterized by a differentiation arrest at the pre-B cell stage, the absence of Igs and recurrent bacterial infections, making it an insidious disease that gradually disables the patient, and can result in death due to chronic lung disease.  Current treatment involves prophylactic antibiotics and Ig infusions, which are non-curative.  This disease is a good candidate for curative hematopoietic stem cell (HSC)-based gene therapy, which could correct the B cell and myeloid deficiencies.  Areas covered: This paper reviews the basic biol. of BTK in B cell development, the clin. features of XLA, and the possibilities of gene therapy for XLA, covering the literature from 1995 to 2010.  Expert opinion: Work from various labs. demonstrates the feasibility of using gene-cor. HSCs to complement the immune defects of Btk-deficiency in mice.  We propose that it is timely to start clin. programs to develop stem cell based therapy for XLA, using gene-cor. autologous HSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeANh_LlclL7Vg90H21EOLACvtfcHk0lhC3Mk--bI8Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Gkt74%253D&md5=24f073dee412df4b5ec3beb5dc982b0e</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.585971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.585971%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26aulast%3DBredius%26aufirst%3DR.%2BG.%2BM.%26aulast%3DPike-Overzet%26aufirst%3DK.%26aulast%3DStaal%26aufirst%3DF.%2BJ.%2BT.%26atitle%3DBiology%2520and%2520novel%2520treatment%2520options%2520for%2520XLA%252C%2520the%2520most%2520common%2520monogenetic%2520immunodeficiency%2520in%2520man%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2011%26volume%3D15%26spage%3D1003%26epage%3D1021%26doi%3D10.1517%2F14728222.2011.585971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lederman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkelstein, J. A.</span><span> </span><span class="NLM_article-title">X-linked agammaglobulinemia: an analysis of 96 patients</span> <span class="citation_source-journal">Medicine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1097/00005792-198505000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1097%2F00005792-198505000-00001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1985&pages=145-156&author=H.+M.+Ledermanauthor=J.+A.+Winkelstein&title=X-linked+agammaglobulinemia%3A+an+analysis+of+96+patients&doi=10.1097%2F00005792-198505000-00001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1097%2F00005792-198505000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005792-198505000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DLederman%26aufirst%3DH.%2BM.%26aulast%3DWinkelstein%26aufirst%3DJ.%2BA.%26atitle%3DX-linked%2520agammaglobulinemia%253A%2520an%2520analysis%2520of%252096%2520patients%26jtitle%3DMedicine%26date%3D1985%26volume%3D64%26spage%3D145%26epage%3D156%26doi%3D10.1097%2F00005792-198505000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Whyburn, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halcomb, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contreras, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satterthwaite, A. B.</span><span> </span><span class="NLM_article-title">Haploinsufficiency of B cell linker protein enhanced B cell signaling defects in mice expressing a limiting dosage of Bruton’s tyrosine kinase</span> <span class="citation_source-journal">Int. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span><span class="refDoi"> DOI: 10.1093/intimm/dxg034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1093%2Fintimm%2Fdxg034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=12618482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFKlsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2003&pages=383-392&author=L.+R.+Whyburnauthor=K.+E.+Halcombauthor=C.+M.+Contrerasauthor=R.+Pappuauthor=O.+N.+Witteauthor=A.+C.+Chanauthor=A.+B.+Satterthwaite&title=Haploinsufficiency+of+B+cell+linker+protein+enhanced+B+cell+signaling+defects+in+mice+expressing+a+limiting+dosage+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1093%2Fintimm%2Fdxg034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Haploinsufficiency of B cell linker protein enhances B cell signaling defects in mice expressing a limiting dosage of Bruton's tyrosine kinase</span></div><div class="casAuthors">Whyburn, Lindsey R.; Halcomb, Kristina E.; Contreras, Cristina M.; Pappu, Rajita; Witte, Owen N.; Chan, Andrew C.; Satterthwaite, Anne B.</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-392</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Current models of lymphocyte activation suggest that formation of a signaling complex, or signalosome', composed of Syk, Bruton's tyrosine kinase (Btk), phospholipase γ2 and the adaptor protein B cell linker protein (BLNK) is crit. for transmission of signals from the BCR.  However, impaired B cell development in mice lacking each individual signalosome component has made it difficult to study the functional consequences of the formation of this complex in mature B cells.  Sensitized genetic systems, commonly used in Drosophila, define signaling pathways by combining partial loss of function mutations in the components of interest.  This allows genetic interactions to be obsd. in the absence of pleiotropic or lethal effects of complete deficiency of either gene.  We used this approach to demonstrate that Btk and BLNK are limiting components of a common signaling pathway that mediates the mitogenic response of mature B cells to antigen.  B cells from transgenic mice expressing a limiting dosage of Btk (Btklo) have normal nos. of mature B cells that have reduced, but measurable, responses to BCR crosslinking.  Haploinsufficiency of BLNK did not affect the development of Btklo B cells.  However, it exacerbated their defects in BCR-induced Ca2+ flux, IκB degrdn., and up-regulation of cyclin D2, bcl-xL and A1 leading to dramatic impairment of B cell mitogenic responses.  In contrast, no effect of reduced Btk and BLNK dosage was obsd. on extracellular signal-regulated kinase activation.  These results suggest that the signals regulating the maintenance and activation of mature B cells are differentially sensitive to the strength of the signal emanating from the signalosome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrowqlQ3xDitLVg90H21EOLACvtfcHk0lhC3Mk--bI8Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFKlsL4%253D&md5=8d56f66c8b68159d61a86322e174c81f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxg034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxg034%26sid%3Dliteratum%253Aachs%26aulast%3DWhyburn%26aufirst%3DL.%2BR.%26aulast%3DHalcomb%26aufirst%3DK.%2BE.%26aulast%3DContreras%26aufirst%3DC.%2BM.%26aulast%3DPappu%26aufirst%3DR.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DChan%26aufirst%3DA.%2BC.%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26atitle%3DHaploinsufficiency%2520of%2520B%2520cell%2520linker%2520protein%2520enhanced%2520B%2520cell%2520signaling%2520defects%2520in%2520mice%2520expressing%2520a%2520limiting%2520dosage%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DInt.%2520Immunol.%26date%3D2003%26volume%3D15%26spage%3D383%26epage%3D392%26doi%3D10.1093%2Fintimm%2Fdxg034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jansson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmdahl, R.</span><span> </span><span class="NLM_article-title">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span> <span class="citation_source-journal">Clin. Exp. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span><span class="refDoi"> DOI: 10.1111/j.1365-2249.1993.tb08218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1111%2Fj.1365-2249.1993.tb08218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=8252807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1993&pages=459-465&author=L.+Janssonauthor=R.+Holmdahl&title=Genes+on+the+X+chromosome+affect+development+of+collagen-induced+arthritis+in+mice&doi=10.1111%2Fj.1365-2249.1993.tb08218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span></div><div class="casAuthors">Jansson, Liselotte; Holmdahl, R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-65</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">Susceptibility to collagen-induced arthritis (CIA) in mice is assocd. with a class II gene in MHC (Aq) but also with unknown genes outside MHC.  Investigated here is the influence of genes on the X chromosome as well as the role of the X-linked immunodeficiency (xid) mutation.  Reciprocal male F1 hybrids, bred to be heterozygous or homozygous for Aq, showed a genetic influence in their susceptibility to develop CIA.  Crosses were made between B10.G, B10.Q, DBA/1, SWR/J, C3H.Q and CBA/Ca, and all F1 mice were castrated to avoid sex hormone modulation of the susceptibility.  A differential timing of arthritis onset and severity were seen in the reciprocal F1 males.  An exception was the reciprocal F1 male offspring from SWR/J and DBA/1 crosses which differed only in disease severity late in the course of the disease.  The female F1 crosses did not show the same pattern of differential susceptibility to CIA as the F1 males.  To exclude the possible influence of the Y chromosome, F1 males of reciprocal crosses were back-crossed to the parental strains creating offspring with equal X chromosomes but divergent Y chromosomes.  No difference in development of arthritis was obsd. in these.  The influence of the xid mutation was investigated next.  The xid loci from the CBA/N mouse was bred into DBA/1 strain which is highly susceptible to CIA.  The resulting congenic DBA/1-xid strain was resistant to induction of CIA and did not develop an antibody response to type II collagen.  The authors concluded that polymorphic genes on the X chromosome modulate susceptibility to CIA.  The results from the expts. with mice carrying xid mutations confirm that such immune modulating genes exist on the sex chromosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuu6ocKN6h7Vg90H21EOLACvtfcHk0lhC3Mk--bI8Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D&md5=77777b6215fb6c1e839b5a68d555df3c</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.1993.tb08218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.1993.tb08218.x%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DL.%26aulast%3DHolmdahl%26aufirst%3DR.%26atitle%3DGenes%2520on%2520the%2520X%2520chromosome%2520affect%2520development%2520of%2520collagen-induced%2520arthritis%2520in%2520mice%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1993%26volume%3D94%26spage%3D459%26epage%3D465%26doi%3D10.1111%2Fj.1365-2249.1993.tb08218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Steinberg, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smathers, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederiksen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, A. D.</span><span> </span><span class="NLM_article-title">Ability of the <i>xid</i> gene to prevent autoimmunity in (NZBXNZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">597</span><span class="refDoi"> DOI: 10.1172/JCI110651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1172%2FJCI110651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=6980900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1982&pages=587-597&author=B.+J.+Steinbergauthor=P.+A.+Smathersauthor=K.+Frederiksenauthor=A.+D.+Steinberg&title=Ability+of+the+xid+gene+to+prevent+autoimmunity+in+%28NZBXNZW%29F1+mice+during+the+course+of+their+natural+history%2C+after+polyclonal+stimulation%2C+or+following+immunization+with+DNA&doi=10.1172%2FJCI110651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span></div><div class="casAuthors">Steinberg B J; Smathers P A; Frederiksen K; Steinberg A D</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-97</span>
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">F1 hybrid offspring of New Zealand Black mothers and New Zealand White fathers [(NZB X NZW)F1] female mice develop antibodies to single-stranded (ss) and native DNA, immune complex glomerulonephritis, massive proteinuria, and premature death with renal failure.  By a series of matings, congenic (NZB X NZW)F1 . xid/xid mice were prepared.  These mice were different from (NZB X NZW)F1 mice in having the X chromosome-linked immune deficiency gene, xid, in homozygous form.  Such congenic (NZB X NZW)F1 . xid/xid females failed to develop antibodies to single-stranded or native DNA.  They also failed to develop fatal renal disease as measured by proteinuria, glomerular histology, glomerular immunofluorescence, and survival.  To control for unknown genetic factors, studies were performed with littermates that were derived by mating NZB . xid/+ females with NZW . xid/Y males such that the resulting offspring were either (NZB X NZW)F1 . xid/xid (and therefore "defective") or (NZB X NZW)F1 . xid/+ [phenotypically like (NZB X NZW)F1].  In these and in additional studies, mice were housed in the same cages and identified by ear tagging so as to avoid possible environmental variations from cage to cage.  In these studies, xid/xid mice failed to develop the characteristic signs of autoimmunity, whereas the controls did.  Similar results were also obtained with (NZW X NZB)F1 xid/xid mice compared with (NZW X NZB)F1 xid/+ mice.  The effect of xid/xid upon (NZB X NZW)F1 mice was further investigated by assessing responses to immunization and polyclonal B cell activation in vivo.  The xid/xid mice failed to produce anti-ssDNA following immunization with ssDNA complexed to a protein carrier in fluid form or even emulsified in adjuvant.  Finally, the xid/xid mice failed to produce antiDNA in response to multiple injections of the polyclonal activator, bacterial lipopolysaccharide (LPS), or the polyclonal activator, polyribose inosinic acid . polyribose cytidylic acid.  However, the xid/xid mice were neither generally hyporesponsive nor unable to recognize LPS because they made normal antibody responses following immunization with LPS to which multiple trinitrophenyl groups were chemically attached.  We conclude from these studies that xid/xid, which is known to cause the deletion of a B cell subset, has a profound affect upon (NZB X NZW)F1 mice, rendering them insusceptible to the naturally occurring autoimmune disease characteristic of (NZB X NZW)F1 mice, and preventing them from producing antibodies to DNA despite purposeful immunization and polyclonal B cell activation.  These results force a reevaluation of previous concepts regarding the mechanisms by which xid/xid might interfere with the development of autoimmunity, and a consideration of therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThDLn7032pYRBrI9DTGjC0fW6udTcc2ear4IeeMvrLYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D&md5=8608a4617f65a1c46ef46a6e5388f7a6</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1172%2FJCI110651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI110651%26sid%3Dliteratum%253Aachs%26aulast%3DSteinberg%26aufirst%3DB.%2BJ.%26aulast%3DSmathers%26aufirst%3DP.%2BA.%26aulast%3DFrederiksen%26aufirst%3DK.%26aulast%3DSteinberg%26aufirst%3DA.%2BD.%26atitle%3DAbility%2520of%2520the%2520xid%2520gene%2520to%2520prevent%2520autoimmunity%2520in%2520%2528NZBXNZW%2529F1%2520mice%2520during%2520the%2520course%2520of%2520their%2520natural%2520history%252C%2520after%2520polyclonal%2520stimulation%252C%2520or%2520following%2520immunization%2520with%2520DNA%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1982%26volume%3D70%26spage%3D587%26epage%3D597%26doi%3D10.1172%2FJCI110651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postelnek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, D.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pashine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivassan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J. S.</span><span> </span><span class="NLM_article-title">RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1124/jpet.111.187740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.-Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivassanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+abrogates+immune+hypersensitivity+responses+and+arthritis+in+rodents&doi=10.1124%2Fjpet.111.187740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span></div><div class="casAuthors">Xu, Daigen; Kim, Yong; Postelnek, Jennifer; Vu, Minh Diem; Hu, Dong-Qing; Liao, Cheng; Bradshaw, Mike; Hsu, Jonathan; Zhang, Jun; Pashine, Achal; Srinivasan, Dinesh; Woods, John; Levin, Anita; O'Mahony, Alison; Owens, Timothy D.; Lou, Yan; Hill, Ronald J.; Narula, Satwant; DeMartino, Julie; Fine, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic mutation and pharmacol. inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor crosslinking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α prodn. in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-mol. disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBTQENfl5RbVg90H21EOLACvtfcHk0liMjRbc0MKyLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D&md5=06be56a47afd2eb09e0871710c1d2b47</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivassan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520abrogates%2520immune%2520hypersensitivity%2520responses%2520and%2520arthritis%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103%26doi%3D10.1124%2Fjpet.111.187740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Di Paolo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barck, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carano, R. A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeForge, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrando, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannetti, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymowitz, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staker, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell and myeloid cell-mediated arthritis</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span><span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lhlAAxKF1N40g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%2BP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rankin, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreyeva, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmonds, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathialagan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benoit, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeva, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homer, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunussi-Joannopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.,  III.</span><span> </span><span class="NLM_article-title">Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">4540</span><span class="NLM_x">–</span> <span class="NLM_lpage">4550</span><span class="refDoi"> DOI: 10.4049/jimmunol.1301553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.4049%2Fjimmunol.1301553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=24068666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=4540-4550&author=A.+L.+Rankinauthor=N.+Sethauthor=S.+Keeganauthor=T.+Andreyevaauthor=T.+A.+Cookauthor=J.+Edmondsauthor=N.+Mathialaganauthor=M.+J.+Bensonauthor=J.+Syedauthor=Y.+Zhanauthor=S.+E.+Benoitauthor=J.+S.+Miyashiroauthor=N.+Woodauthor=S.+Mohanauthor=E.+Peevaauthor=S.+K.+Ramaiahauthor=D.+Messingauthor=B.+L.+Homerauthor=K.+Dunussi-Joannopoulosauthor=C.+L.+Nickerson-Nutterauthor=M.+E.+Schnuteauthor=J.+Douhan&title=Selective+inhibition+of+BTK+prevents+murine+lupus+and+antibody-mediated+glomerulonephritis&doi=10.4049%2Fjimmunol.1301553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span></div><div class="casAuthors">Rankin, Andrew L.; Seth, Nilufer; Keegan, Sean; Andreyeva, Tatyana; Cook, Tim A.; Edmonds, Jason; Mathialagan, Nagappan; Benson, Micah J.; Syed, Jameel; Zhan, Yutian; Benoit, Stephen E.; Miyashiro, Joy S.; Wood, Nancy; Mohan, Shashi; Peeva, Elena; Ramaiah, Shashi K.; Messing, Dean; Homer, Bruce L.; Dunussi-Joannopoulos, Kyri; Nickerson-Nutter, Cheryl L.; Schnute, Mark E.; Douhan, John, III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4540-4550</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Autoantibody prodn. and immune complex deposition within the kidney promote renal disease in patients with lupus nephritis.  Thus, therapeutics that inhibit these pathways may be efficacious in the treatment of systemic lupus erythematosus.  Bruton's tyrosine kinase (BTK) is a crit. signaling component of both BCR and FcR signaling.  We sought to assess the efficacy of inhibiting BTK in the development of lupus-like disease, and in this article describe (R)-5-amino-1-(1-cyanopiperidin-3-yl)-3-(4-[2,4-difluorophenoxy]phenyl)-1H-pyrazole-4-carboxamide (PF-06250112), a novel highly selective and potent BTK inhibitor.  We demonstrate in vitro that PF-06250112 inhibits both BCR-mediated signaling and proliferation, as well as FcR-mediated activation.  To assess the therapeutic impact of BTK inhibition, we treated aged NZBxWF1 mice with PF-06250112 and demonstrate that PF-06250112 significantly limits the spontaneous accumulation of splenic germinal center B cells and plasma cells.  Correspondingly, anti-dsDNA and autoantibody levels were reduced in a dose-dependent manner.  Moreover, administration of PF-06250112 prevented the development of proteinuria and improved glomerular pathol. scores in all treatment groups.  Strikingly, this therapeutic effect could occur with only a modest redn. obsd. in anti-dsDNA titers, implying a crit. role for BTK signaling in disease pathogenesis beyond inhibition of autoantibody prodn.  We subsequently demonstrate that PF-06250112 prevents proteinuria in an FcR-dependent, Ab-mediated model of glomerulonephritis.  Importantly, these results highlight that BTK inhibition potently limits the development of glomerulonephritis by impacting both cell- and effector mol.-mediated pathways.  These data provide support for evaluating the efficacy of BTK inhibition in systemic lupus erythematosus patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBldekay4INLVg90H21EOLACvtfcHk0lhlAAxKF1N40g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE&md5=7abfb074bf422aa3fb63aa0bc3d8cf58</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301553%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DA.%2BL.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DAndreyeva%26aufirst%3DT.%26aulast%3DCook%26aufirst%3DT.%2BA.%26aulast%3DEdmonds%26aufirst%3DJ.%26aulast%3DMathialagan%26aufirst%3DN.%26aulast%3DBenson%26aufirst%3DM.%2BJ.%26aulast%3DSyed%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBenoit%26aufirst%3DS.%2BE.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BS.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPeeva%26aufirst%3DE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DHomer%26aufirst%3DB.%2BL.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DDouhan%26aufirst%3DJ.%26atitle%3DSelective%2520inhibition%2520of%2520BTK%2520prevents%2520murine%2520lupus%2520and%2520antibody-mediated%2520glomerulonephritis%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D4540%26epage%3D4550%26doi%3D10.4049%2Fjimmunol.1301553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Structural bioinformatics-based design of selective, irreversible kinase inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">1318</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span><span class="refDoi"> DOI: 10.1126/science1108367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1126%2Fscience1108367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=15919995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=1318-1321&author=M.+S.+Cohenauthor=C.+Zhangauthor=K.+M.+Shokatauthor=J.+Taunton&title=Structural+bioinformatics-based+design+of+selective%2C+irreversible+kinase+inhibitors&doi=10.1126%2Fscience1108367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Cohen, Michael S.; Zhang, Chao; Shokat, Kevan M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5726</span>),
    <span class="NLM_cas:pages">1318-1321</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge.  We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK).  A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells.  Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter.  Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovfUrzVFth_bVg90H21EOLACvtfcHk0lhlAAxKF1N40g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D&md5=1364444dada4d1d46510aa0212428952</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1126%2Fscience1108367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience1108367%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DStructural%2520bioinformatics-based%2520design%2520of%2520selective%252C%2520irreversible%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D1318%26epage%3D1321%26doi%3D10.1126%2Fscience1108367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Leproult, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moras, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurtz, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span><span class="refDoi"> DOI: 10.1021/jm101396q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.-M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformationally+distinct+kinase+nucleotide+binding+sites%3A+application+to+the+design+of+selective+covalent+inhibitors&doi=10.1021%2Fjm101396q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span></div><div class="casAuthors">Leproult, Emeline; Barluenga, Sofia; Moras, Dino; Wurtz, Jean-Marie; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1347-1355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases have emerged as one of the most prolific therapeutic targets.  An important criterion in the therapeutic success of inhibitors targeting the nucleotide binding pocket of kinases is the inhibitor residence time.  Recently, covalent kinase inhibitors have attracted attention since they confer terminal inhibition and should thus be more effective than reversible inhibitors with transient inhibition.  The most robust approach to design irreversible inhibitors is to capitalize on the nucleophilicity of a cysteine thiol group present in the target protein.  Herein, the authors report a systematic anal. of cysteine residues present in the nucleotide binding site of kinases, which could be harnessed for irreversible inhibition, taking into consideration the different kinase conformations.  The authors demonstrate the predictive power of this anal. with the design and validation of an irreversible inhibitor of KIT/PDGFR kinases.  This is the first example of a covalent kinase inhibitor that combines a pharmacophore addressing the DFG-out conformation with a covalent trap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzqt0gMrz3rVg90H21EOLACvtfcHk0liDLF62gvRRQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D&md5=329ae5eaa6102b6dd34a0d1274631247</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.-M.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformationally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1347%26epage%3D1355%26doi%3D10.1021%2Fjm101396q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Burger, J. A.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (BTK) inhibitors in clinical trials</span> <span class="citation_source-journal">Curr. Hematol. Malig. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">49</span><span class="refDoi"> DOI: 10.1007/s11899-013-0188-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1007%2Fs11899-013-0188-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=24357428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A280%3ADC%252BC2c3nvV2rsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=44-49&author=J.+A.+Burger&title=Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+in+clinical+trials&doi=10.1007%2Fs11899-013-0188-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (BTK) inhibitors in clinical trials</span></div><div class="casAuthors">Burger Jan A</div><div class="citationInfo"><span class="NLM_cas:title">Current hematologic malignancy reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the B-cell receptor (BCR) and tissue homing receptors.  Genetic BTK deletion causes B-cell immunodeficiency in humans and mice, making this kinase an attractive therapeutic target for B-cell disorders.  The BTK inhibitor ibrutinib (PCI-32765, brand name: Imbruvica) demonstrated high clinical activity in B-cell malignancies, especially in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom's macroglobulinemia (WM).  Therefore, ibrutinib was granted a 'breakthrough therapy' designation for these indications and was recently approved for the treatment of relapsed MCL by the U.S.  Food and Drug Administration.  Other BTK inhibitors in earlier clinical development include CC-292 (AVL-292), and ONO-4059.  In CLL and MCL, ibrutinib characteristically induces redistribution of malignant B cells from tissue sites into the peripheral blood, along with rapid resolution of enlarged lymph nodes and a surge in lymphocytosis.  With continuous ibrutinib therapy, growth- and survival-inhibitory activities of ibrutinib result in the normalization of lymphocyte counts and remissions in a majority of patients.  This review discusses the clinical advances with BTK inhibitor therapy, as well as its pathophysiological basis, and outlines perspectives for future use of BTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqhvp3dQ4UIub6AVA-44PTfW6udTcc2eYRkm141WAoQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3nvV2rsg%253D%253D&md5=2e6e9639a96e00f2669027ab74f8c7c4</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1007%2Fs11899-013-0188-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11899-013-0188-8%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520in%2520clinical%2520trials%26jtitle%3DCurr.%2520Hematol.%2520Malig.%2520Rep.%26date%3D2014%26volume%3D9%26spage%3D44%26epage%3D49%26doi%3D10.1007%2Fs11899-013-0188-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Akinleye, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span> </span><span class="NLM_article-title">Ibrutinib and novel BTK inhibitors in clinical development</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1186/1756-8722-6-59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1186%2F1756-8722-6-59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=23958373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=59-67&author=A.+Akinleyeauthor=Y.+Chenauthor=N.+Mukhiauthor=Y.+Songauthor=D.+Liu&title=Ibrutinib+and+novel+BTK+inhibitors+in+clinical+development&doi=10.1186%2F1756-8722-6-59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib and novel BTK inhibitors in clinical development</span></div><div class="casAuthors">Akinleye, Akintunde; Chen, Yamei; Mukhi, Nikhil; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Small mol. inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clin. outcomes in cancer patients.  Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders.  Ibrutinib, a novel first-in-human BTK inhibitor, has demonstrated clin. effectiveness and tolerability in early clin. trials and has progressed into phase III trials.  However, addnl. research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition.  This review summarizes preclin. and clin. development of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292 and ONO-4059, CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-fz7_rhCHvbVg90H21EOLACvtfcHk0liDLF62gvRRQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI&md5=e5067b998c61818e2efbb62da935b490</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-6-59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-6-59%26sid%3Dliteratum%253Aachs%26aulast%3DAkinleye%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMukhi%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DIbrutinib%2520and%2520novel%2520BTK%2520inhibitors%2520in%2520clinical%2520development%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D6%26spage%3D59%26epage%3D67%26doi%3D10.1186%2F1756-8722-6-59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Whang, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B. Y.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1200</span><span class="NLM_x">–</span> <span class="NLM_lpage">1204</span><span class="refDoi"> DOI: 10.1016/j.drudis.2014.03.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.drudis.2014.03.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=24721226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvV2ntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1200-1204&author=J.+A.+Whangauthor=B.+Y.+Chang&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1016%2Fj.drudis.2014.03.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Whang, Jennifer A.; Chang, Betty Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1200-1204</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The function and role of Bruton's tyrosine kinase (BTK) in human B cell development was demonstrated by its assocn. with X-linked agammaglobulinemia (XLA) manifested by a substantial redn. in Igs and B cells.  BTK has a crucial role in pre-B cell receptor (BCR) and BCR signaling during normal B cell development and activation.  Aberrant BCR signaling is assocd. with autoimmune diseases, such as rheumatoid arthritis (RA).  In addn., BTK is also expressed in myeloid cell populations, including monocytes, macrophages, neutrophils and mast cells.  These innate cells infiltrate the synovial cavity and produce inflammatory cytokines, aggravating arthritic symptoms.  In myeloid cell populations, BTK functions downstream of the Fcγ receptors (FcγR) and Fcε receptors (FcεR) [1,2].  In the absence of BTK, FcR-mediated functions, such as cytokine prodn., are impaired.  In addn., Xid mice, which have a mutation in BTK, have decreased susceptibility to developing collagen-induced arthritis (CIA) [3].  Given that BTK is involved in multiple signaling pathways downstream of the BCR and FcR, it is an attractive therapeutic target for RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrfM0cjYRpt7Vg90H21EOLACvtfcHk0ljMZ7d86Jn_mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvV2ntLw%253D&md5=59de1ccd677bb64001719daf5e83952e</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.03.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.03.028%26sid%3Dliteratum%253Aachs%26aulast%3DWhang%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DB.%2BY.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1200%26epage%3D1204%26doi%3D10.1016%2Fj.drudis.2014.03.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thamm, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">13075</span><span class="NLM_x">–</span> <span class="NLM_lpage">13080</span><span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11dR"><div class="casContent"><span class="casTitleNuber">11d</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0ljMZ7d86Jn_mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bradshaw, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paavilainen, V. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisconte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughhead, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunn, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karr, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerritsen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">525</span><span class="NLM_x">–</span> <span class="NLM_lpage">531</span><span class="refDoi"> DOI: 10.1038/nchembio.1817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1038%2Fnchembio.1817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=26006010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=525-531&author=J.+M.+Bradshawauthor=J.+M.+McFarlandauthor=V.+O.+Paavilainenauthor=A.+Bisconteauthor=D.+Tamauthor=V.+T.+Phanauthor=S.+Romanovauthor=D.+Finkleauthor=J.+Shuauthor=V.+Patelauthor=T.+Tonauthor=X.+Liauthor=D.+G.+Loughheadauthor=P.+A.+Nunnauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=J.+O.+Funkauthor=T.+D.+Owensauthor=E.+Vernerauthor=K.+A.+Brameldauthor=R.+J.+Hillauthor=D.+M.+Goldsteinauthor=J.+Taunton&title=Prolonged+and+tunable+residence+time+using+reversible+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span></div><div class="casAuthors">Bradshaw, J. Michael; McFarland, Jesse M.; Paavilainen, Ville O.; Bisconte, Angelina; Tam, Danny; Phan, Vernon T.; Romanov, Sergei; Finkle, David; Shu, Jin; Patel, Vaishali; Ton, Tony; Li, Xiaoyan; Loughhead, David G.; Nunn, Philip A.; Karr, Dane E.; Gerritsen, Mary E.; Funk, Jens Oliver; Owens, Timothy D.; Verner, Erik; Brameld, Ken A.; Hill, Ronald J.; Goldstein, David M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.  Here the authors made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors.  Using an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, the authors identified potent and selective BTK inhibitors that demonstrated biochem. residence times spanning from minutes to 7 d.  An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK for more than 18 h after clearance from the circulation.  The inverted cyanoacrylamide strategy was further used to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating the generalizability of the approach.  Targeting of noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates 'residence time by design', the ability to modulate and improve the duration of target engagement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCpNprhn6kLVg90H21EOLACvtfcHk0ljMZ7d86Jn_mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE&md5=85a73d9ecd62695d03166f7009c68dd8</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1817%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DPaavilainen%26aufirst%3DV.%2BO.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DFinkle%26aufirst%3DD.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DProlonged%2520and%2520tunable%2520residence%2520time%2520using%2520reversible%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fnchembio.1817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Park, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byun, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suh, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span> </span><span class="NLM_article-title">HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: A potential drug for rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.1186/s13075-016-0988-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1186%2Fs13075-016-0988-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=26732314" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=1-9&author=J.+K.+Parkauthor=J.-Y.+Byunauthor=J.+A.+Parkauthor=Y.-Y.+Kimauthor=Y.+J.+Leeauthor=J.+I.+Ohauthor=S.+Y.+Jangauthor=Y.+H.+Kimauthor=Y.+W.+Songauthor=J.+Sonauthor=K.+H.+Suhauthor=Y.-M.+Leeauthor=E.+B.+Lee&title=HM71224%2C+a+novel+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+suppresses+B+cell+and+monocyte+activation+and+ameliorates+arthritis+in+a+mouse+model%3A+A+potential+drug+for+rheumatoid+arthritis&doi=10.1186%2Fs13075-016-0988-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1186%2Fs13075-016-0988-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-016-0988-z%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DByun%26aufirst%3DJ.-Y.%26aulast%3DPark%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DY.-Y.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DOh%26aufirst%3DJ.%2BI.%26aulast%3DJang%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DSong%26aufirst%3DY.%2BW.%26aulast%3DSon%26aufirst%3DJ.%26aulast%3DSuh%26aufirst%3DK.%2BH.%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DLee%26aufirst%3DE.%2BB.%26atitle%3DHM71224%252C%2520a%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520suppresses%2520B%2520cell%2520and%2520monocyte%2520activation%2520and%2520ameliorates%2520arthritis%2520in%2520a%2520mouse%2520model%253A%2520A%2520potential%2520drug%2520for%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2016%26volume%3D18%26spage%3D1%26epage%3D9%26doi%3D10.1186%2Fs13075-016-0988-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Park, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suh, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span> </span><span class="NLM_article-title">HM71224, a novel oral BTK inhibitor, inhibits human immune cell activation: New drug candidate to treat B-cell associated autoimmune diseases</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span><span class="refDoi"> DOI: 10.1136/annrheumdis-2014-eular.2783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1136%2Fannrheumdis-2014-eular.2783" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=355-356&author=J.+K.+Parkauthor=J.+A.+Parkauthor=Y.+J.+Leeauthor=J.+Songauthor=J.+I.+Ohauthor=Y.-M.+Leeauthor=K.+H.+Suhauthor=J.+Sonauthor=E.+B.+Lee&title=HM71224%2C+a+novel+oral+BTK+inhibitor%2C+inhibits+human+immune+cell+activation%3A+New+drug+candidate+to+treat+B-cell+associated+autoimmune+diseases&doi=10.1136%2Fannrheumdis-2014-eular.2783"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2014-eular.2783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2014-eular.2783%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DOh%26aufirst%3DJ.%2BI.%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DSuh%26aufirst%3DK.%2BH.%26aulast%3DSon%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26atitle%3DHM71224%252C%2520a%2520novel%2520oral%2520BTK%2520inhibitor%252C%2520inhibits%2520human%2520immune%2520cell%2520activation%253A%2520New%2520drug%2520candidate%2520to%2520treat%2520B-cell%2520associated%2520autoimmune%2520diseases%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2014%26volume%3D73%26spage%3D355%26epage%3D356%26doi%3D10.1136%2Fannrheumdis-2014-eular.2783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Evans, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aslanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witowski, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lounsbury, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazdiyasni, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freed, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span> </span><span class="NLM_article-title">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">228</span><span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+Btk+with+CC-292+provides+early+pharmacodynamic+assessment+of+activity+in+mice+and+humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0lhGe-Pk_Eyhgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520Btk%2520with%2520CC-292%2520provides%2520early%2520pharmacodynamic%2520assessment%2520of%2520activity%2520in%2520mice%2520and%2520humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiadeen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krikorian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boga, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alhassan, A.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaccaro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Man, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raaijmakers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu-Pham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Presland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manusueto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leccese, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang-Hoover, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knemeyer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlisi, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bays, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stivers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandish, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Discovery of 8-amino-imidazo[1,5-a]pyrazines as reversible selective BTK inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=198-203&author=J.+Liuauthor=D.+Guiadeenauthor=A.+Krikorianauthor=X.+Gaoauthor=J.+Wangauthor=S.+B.+Bogaauthor=A.-B.+Alhassanauthor=Y.+Yuauthor=H.+Vaccaroauthor=S.+Liuauthor=C.+Yangauthor=H.+Wuauthor=A.+Cooperauthor=A.+De+Manauthor=A.+Kapteinauthor=K.+Maloneyauthor=V.+Hornakauthor=Y.-D.+Gaoauthor=T.+O.+Fischmannauthor=H.+Raaijmakersauthor=D.+Vu-Phamauthor=J.+Preslandauthor=M.+Manusuetoauthor=Z.+Xuauthor=E.+Lecceseauthor=J.+Zhang-Hooverauthor=I.+Knemeyerauthor=C.+G.+Garlisiauthor=N.+Baysauthor=P.+Stiversauthor=P.+E.+Brandishauthor=A.+Hicksauthor=R.+Kimauthor=J.+A.+Kozlowski&title=Discovery+of+8-amino-imidazo%5B1%2C5-a%5Dpyrazines+as+reversible+selective+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Facsmedchemlett.5b00463"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00463%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGuiadeen%26aufirst%3DD.%26aulast%3DKrikorian%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBoga%26aufirst%3DS.%2BB.%26aulast%3DAlhassan%26aufirst%3DA.-B.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DVaccaro%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DDe%2BMan%26aufirst%3DA.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DMaloney%26aufirst%3DK.%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DGao%26aufirst%3DY.-D.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DRaaijmakers%26aufirst%3DH.%26aulast%3DVu-Pham%26aufirst%3DD.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DManusueto%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLeccese%26aufirst%3DE.%26aulast%3DZhang-Hoover%26aufirst%3DJ.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DBays%26aufirst%3DN.%26aulast%3DStivers%26aufirst%3DP.%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DR.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25208-amino-imidazo%255B1%252C5-a%255Dpyrazines%2520as%2520reversible%2520selective%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D198%26epage%3D203%26doi%3D10.1021%2Facsmedchemlett.5b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomgren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dambach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaluso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Discovery of highly potent and selective Bruton’s tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">579</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.bmcl.2015.11.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=26675441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ms77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=575-579&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=C.+Eigenbrotauthor=S.+Gallionauthor=A.+R.+Johnsonauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=C.+Yuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Discovery+of+highly+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+Pyridazinone+analogs+with+improved+metabolic+stability&doi=10.1016%2Fj.bmcl.2015.11.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Eigenbrot, Charles; Gallion, Steve; Johnson, Adam R.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Yu, Christine; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">575-579</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BTK inhibitor GDC-0834 was found to be rapidly metabolized in human studies, resulting in a suspension of clin. trials.  The primary route of metab. was through cleavage of the acyclic amide bond connecting the terminal tetrahydrobenzothiophene with the central linker aryl ring.  SAR studies were focused on reducing metabolic cleavage of this amide, and resulted in the identification of several central aryl linker substituents that conferred improved stability.  The most promising substituted aryl linkers were then incorporated into an optimized pyridazinone scaffold, resulting in the identification of lead analog I, possessing improved potency, metabolic stability and preclin. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWhbh3H4N2ErVg90H21EOLACvtfcHk0lh-giHUy89BfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ms77M&md5=ff074fc16518d072ccb9b7b5d8520a03</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.076%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520Pyridazinone%2520analogs%2520with%2520improved%2520metabolic%2520stability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D575%26epage%3D579%26doi%3D10.1016%2Fj.bmcl.2015.11.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomgren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dambach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymowitz, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaluso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1337</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.bmcl.2015.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=25701252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1333-1337&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=S.+Gallionauthor=S.+G.+Hymowitzauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=B.+Maurerauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=C.+G.+Sowellauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+Discovery+of+GDC-0834&doi=10.1016%2Fj.bmcl.2015.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models.  Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as 'H3 binding pocket'.  However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics.  Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics.  In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.  This information informed the back-up program and discovery of improved inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhL04eYDiT3bVg90H21EOLACvtfcHk0lh-giHUy89BfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D&md5=fdebc0199c8222e093cfb9583244bce3</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520Discovery%2520of%2520GDC-0834%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2015.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Shi, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spergel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olini, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strnad, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muckelbauer, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tino, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Lucca, G. V.</span><span> </span><span class="NLM_article-title">Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2206</span><span class="NLM_x">–</span> <span class="NLM_lpage">2211</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.02.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.bmcl.2014.02.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=24685542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2206-2211&author=Q.+Shiauthor=A.+Tebbenauthor=A.+J.+Dyckmanauthor=H.+Liauthor=C.+Liuauthor=J.+Linauthor=S.+Spergelauthor=J.+R.+Burkeauthor=K.+W.+McIntyreauthor=G.+C.+Oliniauthor=J.+Strnadauthor=N.+Surtiauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=Y.+Anauthor=C.+Linauthor=Q.+Ruanauthor=K.+Leftherisauthor=P.+H.+Carterauthor=J.+A.+Tinoauthor=G.+V.+De+Lucca&title=Purine+derivatives+as+potent+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+for+autoimmune+diseases&doi=10.1016%2Fj.bmcl.2014.02.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases</span></div><div class="casAuthors">Shi, Qing; Tebben, Andrew; Dyckman, Alaric J.; Li, Hedy; Liu, Chunjian; Lin, James; Spergel, Steve; Burke, James R.; McIntyre, Kim W.; Olini, Gilbert C.; Strnad, Joann; Surti, Neha; Muckelbauer, Jodi K.; Chang, Chiehying; An, Yongmi; Cheng, Lin; Ruan, Qian; Leftheris, Katerina; Carter, Percy H.; Tino, Joseph; De Lucca, George V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2206-2211</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Investigation of various heterocyclic core isosteres of imidazopyrazines 1 & 2 yielded purine derivs. 3 & 8 as potent and selective BTK inhibitors.  Subsequent SAR studies of the purine series led to the discovery of 20 as a leading compd.  Compd. 20 is very selective when screened against a panel of 400 kinases and is a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited in vivo efficacy in a mouse PCA model.  Its X-ray co-crystal structure with BTK shows that the high selectivity is gained from filling a BTK specific lipophilic pocket.  However, phys. and ADME properties leading to low oral exposure hindered further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobsHsC5Hi6lbVg90H21EOLACvtfcHk0lh-giHUy89BfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D&md5=1b1649221d615d9805d5cc197a39e05a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.02.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.02.075%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DOlini%26aufirst%3DG.%2BC.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DLeftheris%26aufirst%3DK.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26atitle%3DPurine%2520derivatives%2520as%2520potent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520for%2520autoimmune%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2206%26epage%3D2211%26doi%3D10.1016%2Fj.bmcl.2014.02.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batt, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muckelbauer, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pokross, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tino, J. A.</span><span> </span><span class="NLM_article-title">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">4265</span><span class="NLM_x">–</span> <span class="NLM_lpage">4269</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.bmcl.2015.07.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=26320619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4265-4269&author=Q.+Liuauthor=D.+G.+Battauthor=J.+S.+Lippyauthor=N.+Surtiauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=L.+Chenauthor=Y.+Anauthor=C.+Changauthor=M.+Pokrossauthor=Z.+Yangauthor=H.+Wangauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Design+and+synthesis+of+carbazole+carboxamides+as+promising+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+and+Janus+kinase+2+%28JAK2%29&doi=10.1016%2Fj.bmcl.2015.07.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span></div><div class="casAuthors">Liu, Qingjie; Batt, Douglas G.; Lippy, Jonathan S.; Surti, Neha; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chen, Lin; An, Yongmi; Chang, Chiehying; Pokross, Matt; Yang, Zheng; Wang, Haiqing; Burke, James R.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4265-4269</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Four series of disubstituted carbazole-1-carboxamides, e.g. I [R = 2-F, 3-MeO, 2-Me, etc.] were designed and synthesized as inhibitors of Bruton's tyrosine kinase.  4,7- And 4,6-Disubstituted carbazole-1-carboxamides were potent and selective inhibitors of BTK, while 3,7- and 3,6-disubstituted carbazole-1-carboxamides were potent and selective inhibitors of Janus kinase 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD3SZfBfD4ZbVg90H21EOLACvtfcHk0liVDBQWg-nrag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF&md5=3558c8ca9a9c29bb38ef98936f61200a</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.102%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520carbazole%2520carboxamides%2520as%2520promising%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520and%2520Janus%2520kinase%25202%2520%2528JAK2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4265%26epage%3D4269%26doi%3D10.1016%2Fj.bmcl.2015.07.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Lucca, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batt, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rampulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discenza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obermeier, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickery, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muckelbauer, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattoli, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukral, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter-Cid, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tino, J. A.</span><span> </span><span class="NLM_article-title">Small molecule reversible inhibitors of Bruton’s tyrosine Kinase (BTK): Structure-activity relationships leading to the identification of 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7915</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7915&author=G.+B.+De+Luccaauthor=Q.+Shiauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+B.+Bertrandauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=J.+Daiauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=Y.+Zhangauthor=Z.+Yangauthor=P.+H.+Maratheauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Y.+Changauthor=H.+Zhangauthor=K.+Gilloolyauthor=T.+L.+Taylorauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=D.+W.+Kukralauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Small+molecule+reversible+inhibitors+of+Bruton%E2%80%99s+tyrosine+Kinase+%28BTK%29%3A+Structure-activity+relationships+leading+to+the+identification+of+7-%282-hydroxypropan-2-yl%29-4-%5B2-methyl-3-%284-oxo-3%2C4-dihydroquinazolin-3-yl%29phenyl%5D-9H-carbazole-1-carboxamide+%28BMS-935177%29&doi=10.1021%2Facs.jmedchem.6b00722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span></div><div class="casAuthors">De Lucca, George V.; Shi, Qing; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Rampulla, Rick; Mathur, Arvind; Discenza, Lorell; D'Arienzo, Celia; Dai, Jun; Obermeier, Mary; Vickery, Rodney; Zhang, Yingru; Yang, Zheng; Marathe, Punit; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chang, ChiehYing J.; Zhang, Huiping; Gillooly, Kathleen; Taylor, Tracy; Pattoli, Mark A.; Skala, Stacey; Kukral, Daniel W.; McIntyre, Kim W.; Salter-Cid, Luisa; Fura, Aberra; Burke, James R.; Barrish, Joel C.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7915-7935</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a crit. role in multiple cell types responsible for numerous autoimmune diseases.  This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK.  With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1HUwZaRn_w7Vg90H21EOLACvtfcHk0liVDBQWg-nrag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M&md5=7c7ec1a52121c541753c045c1cbf758b</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00722%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BB.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBertrand%26aufirst%3DM.%2BB.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DSmall%2520molecule%2520reversible%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520Kinase%2520%2528BTK%2529%253A%2520Structure-activity%2520relationships%2520leading%2520to%2520the%2520identification%2520of%25207-%25282-hydroxypropan-2-yl%2529-4-%255B2-methyl-3-%25284-oxo-3%252C4-dihydroquinazolin-3-yl%2529phenyl%255D-9H-carbazole-1-carboxamide%2520%2528BMS-935177%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7915%26doi%3D10.1021%2Facs.jmedchem.6b00722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Liu, Q.; Batt, D. G.; Delucca, G. V.; Shi, Q.; Tebben, A. J.</span><span> </span><span class="NLM_article-title">Preparation of carbazole carboxamide compounds useful as kinase inhibitors</span>. US 20100160303;  <span class="citation_source-journal">Chem. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">116044</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2010&pages=116044&author=Q.+Liu&author=D.+G.+Batt&author=G.+V.+Delucca&author=Q.+Shi&author=A.+J.+Tebben&title=Preparation+of+carbazole+carboxamide+compounds+useful+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DPreparation%2520of%2520carbazole%2520carboxamide%2520compounds%2520useful%2520as%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Abstr.%26date%3D2010%26volume%3D153%26spage%3D116044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Batt, D. G.; Bertrand, M. B.; Delucca, G. V.; Galella, M. A.; Ko, S. S.; Langevine, C. M.; Liu, Q.; Qing, S.; Srivastava, A. S.; Tino, J. A.; Watterson, S. H.</span><span> </span><span class="NLM_article-title">Substituted carbazolecarboxamide derivatives as BTK inhibitors and their preparation and use for the treatment of diseases</span>. WO 2014210085.  <span class="citation_source-journal">Chem. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">162</span><span class="NLM_x">, </span> <span class="NLM_fpage">161072</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2014&pages=161072&author=D.+G.+Batt&author=M.+B.+Bertrand&author=G.+V.+Delucca&author=M.+A.+Galella&author=S.+S.+Ko&author=C.+M.+Langevine&author=Q.+Liu&author=S.+Qing&author=A.+S.+Srivastava&author=J.+A.+Tino&author=S.+H.+Watterson&title=Substituted+carbazolecarboxamide+derivatives+as+BTK+inhibitors+and+their+preparation+and+use+for+the+treatment+of+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBatt%26aufirst%3DD.%2BG.%26atitle%3DSubstituted%2520carbazolecarboxamide%2520derivatives%2520as%2520BTK%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520for%2520the%2520treatment%2520of%2520diseases%26jtitle%3DChem.%2520Abstr.%26date%3D2014%26volume%3D162%26spage%3D161072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ko, S. S.; Batt, D. A.; Bertrand, M. B.; Delucca, G. V.; Langevine, C. M.; Liu, Q.; Srivastava, A. S.; Watterson, S. H.</span><span> </span><span class="NLM_article-title">Preparation of 4-phenylcarbazole-1-carboxamide compounds useful as Bruton’s tyrosine kinase (BTK) inhibitors</span>. WO 2014210087.  <span class="citation_source-journal">Chem. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">162</span><span class="NLM_x">, </span> <span class="NLM_fpage">150740</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2014&pages=150740&author=S.+S.+Ko&author=D.+A.+Batt&author=M.+B.+Bertrand&author=G.+V.+Delucca&author=C.+M.+Langevine&author=Q.+Liu&author=A.+S.+Srivastava&author=S.+H.+Watterson&title=Preparation+of+4-phenylcarbazole-1-carboxamide+compounds+useful+as+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DS.%2BS.%26atitle%3DPreparation%2520of%25204-phenylcarbazole-1-carboxamide%2520compounds%2520useful%2520as%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%26jtitle%3DChem.%2520Abstr.%26date%3D2014%26volume%3D162%26spage%3D150740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Miyaura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, A.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed cross-coupling reactions of organoboron compounds</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">2457</span><span class="NLM_x">–</span> <span class="NLM_lpage">2483</span><span class="refDoi"> DOI: 10.1021/cr00039a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-catalyzed+cross-coupling+reactions+of+organoboron+compounds&doi=10.1021%2Fcr00039a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0li4F6xtTBPYxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-catalyzed%2520cross-coupling%2520reactions%2520of%2520organoboron%2520compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26spage%3D2457%26epage%3D2483%26doi%3D10.1021%2Fcr00039a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Smith, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquez, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokensgard, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rheingold, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hecht, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafson, J. L.</span><span> </span><span class="NLM_article-title">Exploiting atropisomerization to increase the target selectivity of kinase inhibitors</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">11754</span><span class="refDoi"> DOI: 10.1002/anie.201506085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1002%2Fanie.201506085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=11754&author=D.+E.+Smithauthor=I.+Marquezauthor=M.+E.+Lokensgardauthor=A.+L.+Rheingoldauthor=D.+A.+Hechtauthor=J.+L.+Gustafson&title=Exploiting+atropisomerization+to+increase+the+target+selectivity+of+kinase+inhibitors&doi=10.1002%2Fanie.201506085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506085%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BE.%26aulast%3DMarquez%26aufirst%3DI.%26aulast%3DLokensgard%26aufirst%3DM.%2BE.%26aulast%3DRheingold%26aufirst%3DA.%2BL.%26aulast%3DHecht%26aufirst%3DD.%2BA.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26atitle%3DExploiting%2520atropisomerization%2520to%2520increase%2520the%2520target%2520selectivity%2520of%2520kinase%2520inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D11754%26doi%3D10.1002%2Fanie.201506085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nalbandian, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hecht, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafson, J. L.</span><span> </span><span class="NLM_article-title">The preorganizaton of atropisomers to increase target selectivity</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">983</span><span class="refDoi"> DOI: 10.1055/s-0035-1561314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1055%2Fs-0035-1561314" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=977-983&author=C.+J.+Nalbandianauthor=D.+E.+Hechtauthor=J.+L.+Gustafson&title=The+preorganizaton+of+atropisomers+to+increase+target+selectivity&doi=10.1055%2Fs-0035-1561314"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1055%2Fs-0035-1561314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0035-1561314%26sid%3Dliteratum%253Aachs%26aulast%3DNalbandian%26aufirst%3DC.%2BJ.%26aulast%3DHecht%26aufirst%3DD.%2BE.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520preorganizaton%2520of%2520atropisomers%2520to%2520increase%2520target%2520selectivity%26jtitle%3DSynlett%26date%3D2016%26volume%3D27%26spage%3D977%26epage%3D983%26doi%3D10.1055%2Fs-0035-1561314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fader, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandrick, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandrick, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hucke, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemper, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, S. P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P. J.</span><span> </span><span class="NLM_article-title">Assessing atropisomer axial chirality in drug discovery and development</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7005</span><span class="NLM_x">–</span> <span class="NLM_lpage">7022</span><span class="refDoi"> DOI: 10.1021/jm200584g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200584g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7005-7022&author=S.+R.+LaPlanteauthor=L.+D.+Faderauthor=K.+R.+Fandrickauthor=D.+R.+Fandrickauthor=O.+Huckeauthor=R.+Kemperauthor=S.+P.+F.+Millerauthor=P.+J.+Edwards&title=Assessing+atropisomer+axial+chirality+in+drug+discovery+and+development&doi=10.1021%2Fjm200584g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18c</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing Atropisomer Axial Chirality in Drug Discovery and Development</span></div><div class="casAuthors">LaPlante, Steven R.; Fader, Lee D.; Fandrick, Keith R.; Fandrick, Daniel R.; Hucke, Oliver; Kemper, Ray; Miller, Stephen P. F.; Edwards, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7005-7022</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ8uS-SDx68bVg90H21EOLACvtfcHk0li4F6xtTBPYxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFygu7zN&md5=6b44135b3871d2460fba4b3246b899e3</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1021%2Fjm200584g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200584g%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DFader%26aufirst%3DL.%2BD.%26aulast%3DFandrick%26aufirst%3DK.%2BR.%26aulast%3DFandrick%26aufirst%3DD.%2BR.%26aulast%3DHucke%26aufirst%3DO.%26aulast%3DKemper%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DS.%2BP.%2BF.%26aulast%3DEdwards%26aufirst%3DP.%2BJ.%26atitle%3DAssessing%2520atropisomer%2520axial%2520chirality%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7005%26epage%3D7022%26doi%3D10.1021%2Fjm200584g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Clayden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span> </span><span class="NLM_article-title">The challenge of atropisomerism in drug discovery</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6398</span><span class="NLM_x">–</span> <span class="NLM_lpage">6401</span><span class="refDoi"> DOI: 10.1002/anie.200901719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1002%2Fanie.200901719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=19637174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=6398-6401&author=J.+Claydenauthor=W.+J.+Moranauthor=P.+J.+Edwardsauthor=S.+R.+LaPlante&title=The+challenge+of+atropisomerism+in+drug+discovery&doi=10.1002%2Fanie.200901719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18dR"><div class="casContent"><span class="casTitleNuber">18d</span><div class="casTitle"><span class="NLM_cas:atitle">The Challenge of Atropisomerism in Drug Discovery</span></div><div class="casAuthors">Clayden, Jonathan; Moran, Wesley J.; Edwards, Paul J.; LaPlante, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">6398-6401</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Herein, we address the pharmaceutical implications of a hitherto largely overlooked alternative source of drug chirality: atropisomerism.  Atropisomers are conformers which, owing to steric or electronic constraints, interconvert slowly enough (by definition, with a half life of > 1000 s) that they can be isolated.'781 The stereochem. consequences of hindered rotation about a single bond can be such that an apparent single compd. can actually be a mixt. of two, or an apparently achiral compd. can actually be racemic.  If such pairs of stereoisomers are separable, then the implications for drug discovery may be similar to those of compds. with classical chiral centers.  In the context of a lack of std. procedures for dealing with atropisomerism, and the absence of specific regulatory policies governing conformationally based stereochem., we explore some recent examples of atropisomeric compds. that have been or are in drug development.  We also draw conclusions relating to potential strategies for design and development where atropisomerism is an issue.  We expose and propose options for the management of atropisomerism, which, many view as a lurking menace with the potential to significantly increase the cost of pharmaceutical research and development if ignored.  Atropisomerism may give rise to geometrical isomers, diastereoisomers, or enantiomers, all with the distinctive feature that they can in principle be equilibrated thermally.  In the absence of specific regulatory policies, atropisomeric stereoisomers are best dealt with in the same way as stereoisomers with classical chiral centers, but with isomerization rates and where necessary, differential conformer populations taken into account.  For racemic drug candidates, the FDA policy statement from 1992 emphasizes the importance of understanding the main therapeutic activities of the isomers through in vitro or in vivo studies.  Studies of the pharmacokinetic behavior of the individual enantiomers carried out early in the development of drug candidates are also valuable.  Knowledge gained from these studies can help guide the choice of development of a single enantiomer vs. a racemic mixt.  Development of a drug as a racemic mixt. may be appropriate if the mixt. is not reasonably separable (by synthetic methods, HPLC anal., etc.) or if racemization is rapid in vitro and/or in vivo (as in ibuprofen or thalidomide), thus making it futile to administer only the eutomer (more active isomer).  However, it is nonetheless highly recommended that crit. pharmacol. attributes related to the safety and efficacy of both isomers is investigated: overall, there must be an acceptable toxicol. profile and a suitable therapeutic window (in vitro, in animal models, and in humans).  FDA website provides some useful guidance to their expectations for drug development in this context.  Options for dealing with the phenomenon of atropisomerism can be implemented at the early stage of drug design.  For example, it may be possible to make related analogs that have the following features: (1) symmetry about a hindered bond, thus eliminating a chiral axis; (2) faster rotation about a hindered bond, thus pushing the half-life for conformational interconversion down to the order of seconds; (3) further encumbrance about a hindered bond to produce separable atropisomers whose interconversion is negligibly slow (for example, half-lives of the order of millennia); or (4) introduction of a stable stereogenic center to perturb the population of interconverting atropisomers such that only one desirable conformation predominates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsMjlS3iQPEbVg90H21EOLACvtfcHk0lj3YqopezYaAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWiurfN&md5=70ff6fe476e7db4653130fe74af9325e</span></div><a href="/servlet/linkout?suffix=cit18d&amp;dbid=16384&amp;doi=10.1002%2Fanie.200901719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200901719%26sid%3Dliteratum%253Aachs%26aulast%3DClayden%26aufirst%3DJ.%26aulast%3DMoran%26aufirst%3DW.%2BJ.%26aulast%3DEdwards%26aufirst%3DP.%2BJ.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26atitle%3DThe%2520challenge%2520of%2520atropisomerism%2520in%2520drug%2520discovery%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D6398%26epage%3D6401%26doi%3D10.1002%2Fanie.200901719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Smyth, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. A.</span><span> </span><span class="NLM_article-title">A twist of nature – the significance of atropisomers in biological systems</span> <span class="citation_source-journal">Nat. Prod. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1562</span><span class="NLM_x">–</span> <span class="NLM_lpage">1583</span><span class="refDoi"> DOI: 10.1039/C4NP00121D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1039%2FC4NP00121D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=26282828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlKnsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=1562-1583&author=J.+E.+Smythauthor=N.+M.+Butlerauthor=P.+A.+Keller&title=A+twist+of+nature+%E2%80%93+the+significance+of+atropisomers+in+biological+systems&doi=10.1039%2FC4NP00121D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18eR"><div class="casContent"><span class="casTitleNuber">18e</span><div class="casTitle"><span class="NLM_cas:atitle">A twist of nature - the significance of atropisomers in biological systems</span></div><div class="casAuthors">Smyth, Jamie E.; Butler, Nicholas M.; Keller, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1562-1583</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Covering: up to mid-2015Recently identified natural atropisomeric compds. with potential medicinal applications are presented.  The ability of natural receptors to possess differential binding between atropisomers is an important factor when considering active and inactive atropisomeric drugs, and has required the development of new techniques for atropselective synthesis of desired targets.  Advances in this field therefore have significant relevance to modern pharmaceutical and medicinal chem.  The atropisomeric natural products discussed include hibarimicinone, flavomannins, talaromannins, viriditoxin, rugulotrosin A, abyssomicin C, marinopyrroles, dixiamycins, streptorubin B, ustiloxins A-F, haouamine A, bisnicalaterines, and tedarene B, all of which show significant potential as leads in antibiotic, antiviral and anticancer studies.  The importance for the development of common practices regarding atropisomer recognition and classification is also emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0hzR1osyzPLVg90H21EOLACvtfcHk0lj3YqopezYaAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlKnsLfF&md5=449bdc252cc2b0206fa71c1b0a1ce418</span></div><a href="/servlet/linkout?suffix=cit18e&amp;dbid=16384&amp;doi=10.1039%2FC4NP00121D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4NP00121D%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DJ.%2BE.%26aulast%3DButler%26aufirst%3DN.%2BM.%26aulast%3DKeller%26aufirst%3DP.%2BA.%26atitle%3DA%2520twist%2520of%2520nature%2520%25E2%2580%2593%2520the%2520significance%2520of%2520atropisomers%2520in%2520biological%2520systems%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2015%26volume%3D32%26spage%3D1562%26epage%3D1583%26doi%3D10.1039%2FC4NP00121D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Agranat, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, J.</span><span> </span><span class="NLM_article-title">Putting chirality to work: The strategy of chiral switches</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span><div class="note"><p class="first last">and references cited therein.</p></div><span class="refDoi"> DOI: 10.1038/nrd915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1038%2Fnrd915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=12360254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVGru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=753-768&author=I.+Agranatauthor=H.+Canerauthor=J.+Caldwell&title=Putting+chirality+to+work%3A+The+strategy+of+chiral+switches&doi=10.1038%2Fnrd915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Putting chirality to work: the strategy of chiral switches</span></div><div class="casAuthors">Agranat, Israel; Caner, Hava; Caldwell, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">753-768</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most of the new drugs reaching the market today are single enantiomers, rather than the racemic mixts. that dominated up to ten years ago.  Many of the new single-enantiomer drugs were developed as such, but there are also important examples of new single-enantiomer drugs derived from 'chiral switches' of established racemates.  Indeed, a well-timed chiral switch can offer enhanced therapy and further profitability as a 'line extension' of a major racemic drug with patents that are expiring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok8OsLio3NMrVg90H21EOLACvtfcHk0lj3YqopezYaAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVGru7o%253D&md5=5f391aef19f496952f6a066b575b13a9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd915%26sid%3Dliteratum%253Aachs%26aulast%3DAgranat%26aufirst%3DI.%26aulast%3DCaner%26aufirst%3DH.%26aulast%3DCaldwell%26aufirst%3DJ.%26atitle%3DPutting%2520chirality%2520to%2520work%253A%2520The%2520strategy%2520of%2520chiral%2520switches%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D753%26epage%3D768%26doi%3D10.1038%2Fnrd915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: Further insights by examining carbo- and hetero-aromatic and – aliphatic ring types</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+Further+insights+by+examining+carbo-+and+hetero-aromatic+and+%E2%80%93+aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520Further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520%25E2%2580%2593%2520aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R.</span><span> </span><span class="NLM_article-title">The graphical representation of ADME-related molecule properties for medicinal chemists</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.drudis.2010.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=21074634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsVamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=65-72&author=T.+J.+Ritchieauthor=P.+Ertlauthor=R.+Lewis&title=The+graphical+representation+of+ADME-related+molecule+properties+for+medicinal+chemists&doi=10.1016%2Fj.drudis.2010.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">The graphical representation of ADME-related molecule properties for medicinal chemists</span></div><div class="casAuthors">Ritchie, Timothy J.; Ertl, Peter; Lewis, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The importance of striving for and maintaining drug-like physicochem. properties during the hit and lead optimization process is now well documented, and many published studies have suggested optimal ranges and/or limits for key mol. descriptors such as size, lipophilicity, H-bonding characteristics, rotatable bond and arom. ring counts, particularly with regard to the design of orally administered drugs.  The aim of this article is to review various approaches that have been used to represent mol. properties graphically in the context of oral drug likeness', with the goal of improving the decision making of medicinal chemists during the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbOsxzmGt7fLVg90H21EOLACvtfcHk0lh9kdMXkyG5FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsVamtg%253D%253D&md5=940f96e34caee0243a493c80ddfece20</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DLewis%26aufirst%3DR.%26atitle%3DThe%2520graphical%2520representation%2520of%2520ADME-related%2520molecule%2520properties%2520for%2520medicinal%2520chemists%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D65%26epage%3D72%26doi%3D10.1016%2Fj.drudis.2010.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span> <span class="citation_source-book">APEX2 Data collection and processing user interface: DOC-M86-EXX078 APEX2 User Manual</span>,<span class="NLM_publisher-name">Bruker AXS, Inc.</span>: <span class="NLM_publisher-loc">Madison, WI</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=APEX2+Data+collection+and+processing+user+interface%3A+DOC-M86-EXX078+APEX2+User+Manual%2CBruker+AXS%2C+Inc.%3A+Madison%2C+WI%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DAPEX2%2520Data%2520collection%2520and%2520processing%2520user%2520interface%253A%2520DOC-M86-EXX078%2520APEX2%2520User%2520Manual%26pub%3DBruker%2520AXS%252C%2520Inc%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Cosier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glazer, J.</span><span> </span><span class="NLM_article-title">A nitrogen-gas-stream cryostat for general x-ray diffraction studies</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1107/S0021889886089835</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1107%2FS0021889886089835" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaL28XhsF2qurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1986&pages=105-107&author=J.+Cosierauthor=J.+Glazer&title=A+nitrogen-gas-stream+cryostat+for+general+x-ray+diffraction+studies&doi=10.1107%2FS0021889886089835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A nitrogen-gas-stream cryostat for general x-ray diffraction studies</span></div><div class="casAuthors">Cosier, J.; Glazer, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-7</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    </div><div class="casAbstract">A continuous N-flow cooling device, general applicable to x-ray diffraction studies, is described.  The device works at 77.4-323.0 K with a precision of ±0.1 K and a liq.-N const. consumption rate of 0.5 L h-1 over the whole temp. range.  The supply vessel is unpressurized, so that refilling can be done without any observable influence on the cooling of the sample.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFePpax094i7Vg90H21EOLACvtfcHk0lh9kdMXkyG5FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhsF2qurY%253D&md5=f7f12cd55a16e769f915b4bd1894b8fa</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1107%2FS0021889886089835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889886089835%26sid%3Dliteratum%253Aachs%26aulast%3DCosier%26aufirst%3DJ.%26aulast%3DGlazer%26aufirst%3DJ.%26atitle%3DA%2520nitrogen-gas-stream%2520cryostat%2520for%2520general%2520x-ray%2520diffraction%2520studies%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1986%26volume%3D19%26spage%3D105%26epage%3D107%26doi%3D10.1107%2FS0021889886089835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c'],'ref2':['cit2a','cit2b','cit2c'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5a','cit5b'],'ref6':['cit6a','cit6b','cit6c'],'ref7':['cit7'],'ref8':['cit8a','cit8b'],'ref9':['cit9a','cit9b','cit9c'],'ref10':['cit10a','cit10b'],'ref11':['cit11a','cit11b','cit11c','cit11d'],'ref12':['cit12a','cit12b','cit12c','cit12d'],'ref13':['cit13a','cit13b','cit13c'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18a','cit18b','cit18c','cit18d','cit18e'],'ref19':['cit19'],'ref20':['cit20a','cit20b'],'ref21':['cit21'],'ref22':['cit22']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 64 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mark S. Tichenor, John J. M. Wiener, Navin L. Rao, Charlotte Pooley Deckhut, J. Kent Barbay, Kevin D. Kreutter, Genesis M. Bacani, Jianmei Wei, Leon Chang, Heather E. Murrey, Weixue Wang, Kay Ahn, Michael Huber, Elizabeth Rex, Kevin J. Coe, JieJun Wu, Mark Seierstad, Scott D. Bembenek, Kristi A. Leonard, Alec D. Lebsack, Jennifer D. Venable, <span class="NLM_string-name hlFld-ContribAuthor">James P. Edwards</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase with Oral Anti-Inflammatory Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 782-790. <a href="https://doi.org/10.1021/acsmedchemlett.1c00044" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00044%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252Band%252BSelective%252BCovalent%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bwith%252BOral%252BAnti-Inflammatory%252BActivity%26aulast%3DTichenor%26aufirst%3DMark%2BS.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D27012021%26date%3D28032021%26date%3D05042021%26volume%3D12%26issue%3D5%26spage%3D782%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Fan Teng, Ting Yu, Yan Peng, Weiming Hu, Huaanzi Hu, Yimiao He, Shuang Luo, <span class="NLM_string-name hlFld-ContribAuthor">Qiang Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Atroposelective Coupling–Cyclization of 2-Isocyanobenzamides to Construct Axially Chiral 2-Aryl- and 2,3-Diarylquinazolinones. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (7)
                                     , 2722-2728. <a href="https://doi.org/10.1021/jacs.1c00640" title="DOI URL">https://doi.org/10.1021/jacs.1c00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c00640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DPalladium-Catalyzed%252BAtroposelective%252BCoupling%2525E2%252580%252593Cyclization%252Bof%252B2-Isocyanobenzamides%252Bto%252BConstruct%252BAxially%252BChiral%252B2-Aryl-%252Band%252B2%25252C3-Diarylquinazolinones%26aulast%3DTeng%26aufirst%3DFan%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D18012021%26date%3D09022021%26volume%3D143%26issue%3D7%26spage%3D2722%26epage%3D2728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bin Ma, Tonika Bohnert, Kevin L. Otipoby, Eric Tien, Million Arefayene, Judy Bai, Bekim Bajrami, Eris Bame, Timothy R. Chan, Michael Humora, J. Michael MacPhee, Douglas Marcotte, Devangi Mehta, Claire M. Metrick, George Moniz, Evelyne Polack, Urjana Poreci, Annick Prefontaine, Sarah Sheikh, Patricia Schroeder, Karen Smirnakis, Lei Zhang, Fengmei Zheng, <span class="NLM_string-name hlFld-ContribAuthor">Brian T. Hopkins</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12526-12541. <a href="https://doi.org/10.1021/acs.jmedchem.0c00702" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00702%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBIIB068%25253A%252BA%252BSelective%25252C%252BPotent%25252C%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252Bas%252Ban%252BOrally%252BEfficacious%252BAgent%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DMa%26aufirst%3DBin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27042020%26date%3D06082020%26date%3D22072020%26volume%3D63%26issue%3D21%26spage%3D12526%26epage%3D12541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Daniela Angst, François Gessier, Philipp Janser, Anna Vulpetti, Rudolf Wälchli, Christian Beerli, Amanda Littlewood-Evans, Janet Dawson, Barbara Nuesslein-Hildesheim, Grazyna Wieczorek, Sascha Gutmann, Clemens Scheufler, Alexandra Hinniger, Alfred Zimmerlin, Enrico G. Funhoff, Robert Pulz, <span class="NLM_string-name hlFld-ContribAuthor">Bruno Cenni</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5102-5118. <a href="https://doi.org/10.1021/acs.jmedchem.9b01916" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01916</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01916%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BLOU064%252B%252528Remibrutinib%252529%25252C%252Ba%252BPotent%252Band%252BHighly%252BSelective%252BCovalent%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DAngst%26aufirst%3DDaniela%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D19112019%26date%3D04032020%26date%3D21022020%26volume%3D63%26issue%3D10%26spage%3D5102%26epage%3D5118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Debasmita Saha, Anupreet Kharbanda, Wei Yan, Naga Rajiv Lakkaniga, Brendan Frett, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">The Exploration of Chirality for Improved Druggability within the Human Kinome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 441-469. <a href="https://doi.org/10.1021/acs.jmedchem.9b00640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BExploration%252Bof%252BChirality%252Bfor%252BImproved%252BDruggability%252Bwithin%252Bthe%252BHuman%252BKinome%26aulast%3DSaha%26aufirst%3DDebasmita%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D15042019%26date%3D09102019%26date%3D24092019%26volume%3D63%26issue%3D2%26spage%3D441%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Bin    Ma    </span><span class="hlFld-ContribAuthor "> Chaomin    Li </span><span class="hlFld-ContribAuthor "> Brian T.    Hopkins </span><span class="hlFld-ContribAuthor "> Lloyd    Franklin </span><span class="hlFld-ContribAuthor "> Robbie    Chen    </span><span class="hlFld-ContribAuthor "> Tamera    Mack </span><span class="hlFld-ContribAuthor "> Daniel    Patience </span><span class="hlFld-ContribAuthor "> William F.    Kiesman </span><span class="hlFld-ContribAuthor "> Erin M.    O’Brien    </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Process Development of BIIB068: A Reversible Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 313-337. <a href="https://doi.org/10.1021/bk-2020-1369.ch010" title="DOI URL">https://doi.org/10.1021/bk-2020-1369.ch010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2020-1369.ch010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2020-1369.ch010%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BProcess%252BDevelopment%252Bof%252BBIIB068%25253A%252BA%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DMa%26aufirst%3DBin%26date%3D2020%26date%3D2020%26spage%3D313%26epage%3D337%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B3%26aulast%3DPesti%26aufirst%3DJaan%2BA.%26date%3D2020%26date%3D2020%26volume%3D1369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sean T. Toenjes, Valeria Garcia, Sean M. Maddox, Gregory A. Dawson, Maria A. Ortiz, F. Javier Piedrafita, <span class="NLM_string-name hlFld-ContribAuthor">Jeffrey L. Gustafson</span>. </span><span class="cited-content_cbyCitation_article-title">Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (9)
                                     , 1930-1939. <a href="https://doi.org/10.1021/acschembio.9b00407" title="DOI URL">https://doi.org/10.1021/acschembio.9b00407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00407%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DLeveraging%252BAtropisomerism%252Bto%252BObtain%252Ba%252BSelective%252BInhibitor%252Bof%252BRET%252BKinase%252Bwith%252BSecondary%252BActivities%252Btoward%252BEGFR%252BMutants%26aulast%3DToenjes%26aufirst%3DSean%2BT.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22052019%26date%3D19082019%26date%3D29082019%26date%3D19082019%26volume%3D14%26issue%3D9%26spage%3D1930%26epage%3D1939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xia Yao, Xiuyun Sun, Shuyu Jin, Ling Yang, Hongjiang Xu, <span class="NLM_string-name hlFld-ContribAuthor">Yu Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6561-6574. <a href="https://doi.org/10.1021/acs.jmedchem.9b00329" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00329%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-Aminoquinoline-3-carboxamide%252BDerivatives%252Bas%252BPotent%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DYao%26aufirst%3DXia%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21022019%26date%3D12072019%26date%3D01072019%26volume%3D62%26issue%3D14%26spage%3D6561%26epage%3D6574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Steven M. Mennen, Carolina Alhambra, C. Liana Allen, Mario Barberis, Simon Berritt, Thomas A. Brandt, Andrew D. Campbell, Jesús Castañón, Alan H. Cherney, Melodie Christensen, David B. Damon, J. Eugenio de Diego, Susana García-Cerrada, Pablo García-Losada, Rubén Haro, Jacob Janey, David C. Leitch, Ling Li, Fangfang Liu, Paul C. Lobben, David W. C. MacMillan, Javier Magano, Emma McInturff, Sebastien Monfette, Ronald J. Post, Danielle Schultz, Barbara J. Sitter, Jason M. Stevens, Iulia I. Strambeanu, Jack Twilton, Ke Wang, <span class="NLM_string-name hlFld-ContribAuthor">Matthew A. Zajac</span>. </span><span class="cited-content_cbyCitation_article-title">The Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (6)
                                     , 1213-1242. <a href="https://doi.org/10.1021/acs.oprd.9b00140" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00140%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DThe%252BEvolution%252Bof%252BHigh-Throughput%252BExperimentation%252Bin%252BPharmaceutical%252BDevelopment%252Band%252BPerspectives%252Bon%252Bthe%252BFuture%26aulast%3DMennen%26aufirst%3DSteven%2BM.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27032019%26date%3D31052019%26date%3D07052019%26volume%3D23%26issue%3D6%26spage%3D1213%26epage%3D1242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Scott H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand, Douglas G. Batt, Ling Li, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Robin Moore, Zheng Yang, Rodney Vickery, Paul A. Elzinga, Lorell Discenza, Celia D’Arienzo, Kathleen M. Gillooly, Tracy L. Taylor, Claudine Pulicicchio, Yifan Zhang, Elizabeth Heimrich, Kim W. McIntyre, Qian Ruan, Richard A. Westhouse, Ian M. Catlett, Naiyu Zheng, Charu Chaudhry, Jun Dai, Michael A. Galella, Andrew J. Tebben, Matt Pokross, Jianqing Li, Rulin Zhao, Daniel Smith, Richard Rampulla, Alban Allentoff, Michael A. Wallace, Arvind Mathur, Luisa Salter-Cid, John E. Macor, Percy H. Carter, Aberra Fura, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">Joseph A. Tino</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (7)
                                     , 3228-3250. <a href="https://doi.org/10.1021/acs.jmedchem.9b00167" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBranebrutinib%252B%252528BMS-986195%252529%25253A%252BA%252BStrategy%252Bfor%252BIdentifying%252Ba%252BHighly%252BPotent%252Band%252BSelective%252BCovalent%252BInhibitor%252BProviding%252BRapid%252Bin%252BVivo%252BInactivation%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%26aulast%3DWatterson%26aufirst%3DScott%2BH.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27012019%26date%3D29032019%26date%3D20032019%26volume%3D62%26issue%3D7%26spage%3D3228%26epage%3D3250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">John R. Coombs, Rebecca A. Green, Frederick Roberts, Eric M. Simmons, Jason M. Stevens, <span class="NLM_string-name hlFld-ContribAuthor">Steven R. Wisniewski</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in Base-Metal Catalysis: Development of a Screening Platform for Nickel-Catalyzed Borylations of Aryl (Pseudo)halides with B2(OH)4. </span><span class="cited-content_cbyCitation_journal-name">Organometallics</span><span> <strong>2019,</strong> <em>38 </em>
                                    (1)
                                     , 157-166. <a href="https://doi.org/10.1021/acs.organomet.8b00307" title="DOI URL">https://doi.org/10.1021/acs.organomet.8b00307</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.organomet.8b00307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.organomet.8b00307%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganometallics%26atitle%3DAdvances%252Bin%252BBase-Metal%252BCatalysis%25253A%252BDevelopment%252Bof%252Ba%252BScreening%252BPlatform%252Bfor%252BNickel-Catalyzed%252BBorylations%252Bof%252BAryl%252B%252528Pseudo%252529halides%252Bwith%252BB2%252528OH%2525294%26aulast%3DCoombs%26aufirst%3DJohn%2BR.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D11052018%26date%3D14082018%26volume%3D38%26issue%3D1%26spage%3D157%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mark E. Schnute, Stephen E. Benoit, Ingrid P. Buchler, Nicole Caspers, Margaret L. Grapperhaus, Seungil Han, Rajeev Hotchandani, Nelson Huang, Robert O. Hughes, Brian M. Juba, Kyung-Hee Kim, Erica Liu, Erin McCarthy, Dean Messing, Joy S. Miyashiro, Shashi Mohan, Thomas N. O’Connell, Jeffrey F. Ohren, Mihir D. Parikh, Michelle Schmidt, Shaun R. Selness, John R. Springer, Venkataraman Thanabal, John I. Trujillo, Daniel P. Walker, Zhao-Kui Wan, Jane M. Withka, Arthur J. Wittwer, Nancy L. Wood, Li Xing, Christoph W. Zapf, <span class="NLM_string-name hlFld-ContribAuthor">John Douhan, III</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrazole Carboxamide Bruton’s Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     , 80-85. <a href="https://doi.org/10.1021/acsmedchemlett.8b00461" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00461</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00461%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAminopyrazole%252BCarboxamide%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors.%252BIrreversible%252Bto%252BReversible%252BCovalent%252BReactive%252BGroup%252BTuning%26aulast%3DSchnute%26aufirst%3DMark%2BE.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03102018%26date%3D03122018%26date%3D05122018%26date%3D03122018%26volume%3D10%26issue%3D1%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marian C. Bryan, <span class="NLM_string-name hlFld-ContribAuthor">Naomi S. Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9030-9058. <a href="https://doi.org/10.1021/acs.jmedchem.8b00667" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BImmunological%252BDisorders%25253A%252BRecent%252BAdvances%26aulast%3DBryan%26aufirst%3DMarian%2BC.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D26042018%26date%3D15062018%26date%3D05062018%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Steven R. Wisniewski, Ronald Carrasquillo-Flores, Federico Lora Gonzalez, Antonio Ramirez, Matthew Casey, Maxime Soumeillant, Thomas M. Razler, <span class="NLM_string-name hlFld-ContribAuthor">Brendan Mack</span>. </span><span class="cited-content_cbyCitation_article-title">Adventures in Atropisomerism: Development of a Robust, Diastereoselective, Lithium-Catalyzed Atropisomer-Forming Active Pharmaceutical Ingredient Step. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2018,</strong> <em>22 </em>
                                    (10)
                                     , 1426-1431. <a href="https://doi.org/10.1021/acs.oprd.8b00246" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00246</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00246%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DAdventures%252Bin%252BAtropisomerism%25253A%252BDevelopment%252Bof%252Ba%252BRobust%25252C%252BDiastereoselective%25252C%252BLithium-Catalyzed%252BAtropisomer-Forming%252BActive%252BPharmaceutical%252BIngredient%252BStep%26aulast%3DWisniewski%26aufirst%3DSteven%2BR.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D01082018%26date%3D03102018%26date%3D11092018%26volume%3D22%26issue%3D10%26spage%3D1426%26epage%3D1431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jayaraman Chandrasekhar, Ryan Dick, Joshua Van Veldhuizen, David Koditek, Eve-Irene Lepist, Mary E. McGrath, Leena Patel, Gary Phillips, Kassandra Sedillo, John R. Somoza, Joseph Therrien, Nicholas A. Till, Jennifer Treiberg, Armando G. Villaseñor, Yelena Zherebina, <span class="NLM_string-name hlFld-ContribAuthor">Stephane Perreault</span>. </span><span class="cited-content_cbyCitation_article-title">Atropisomerism by Design: Discovery of a Selective and Stable Phosphoinositide 3-Kinase (PI3K) β Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6858-6868. <a href="https://doi.org/10.1021/acs.jmedchem.8b00797" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00797</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00797%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAtropisomerism%252Bby%252BDesign%25253A%252BDiscovery%252Bof%252Ba%252BSelective%252Band%252BStable%252BPhosphoinositide%252B3-Kinase%252B%252528PI3K%252529%252B%2525CE%2525B2%252BInhibitor%26aulast%3DChandrasekhar%26aufirst%3DJayaraman%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D18052018%26date%3D30072018%26date%3D17072018%26volume%3D61%26issue%3D15%26spage%3D6858%26epage%3D6868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gregory Beutner, Ronald Carrasquillo, Peng Geng, Yi Hsiao, Eric C. Huang, Jacob Janey, Kishta Katipally, Sergei Kolotuchin, Thomas La Porte, Andrew Lee, Paul Lobben, Federico Lora-Gonzalez, Brendan Mack, Boguslaw Mudryk, Yuping Qiu, Xinhua Qian, Antonio Ramirez, Thomas M. Razler, Thorsten Rosner, Zhongping Shi, Eric Simmons, Jason Stevens, Jianji Wang, Carolyn Wei, Steven R. Wisniewski, <span class="NLM_string-name hlFld-ContribAuthor">Ye Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Adventures in Atropisomerism: Total Synthesis of a Complex Active Pharmaceutical Ingredient with Two Chirality Axes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (13)
                                     , 3736-3740. <a href="https://doi.org/10.1021/acs.orglett.8b01218" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b01218</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b01218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b01218%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DAdventures%252Bin%252BAtropisomerism%25253A%252BTotal%252BSynthesis%252Bof%252Ba%252BComplex%252BActive%252BPharmaceutical%252BIngredient%252Bwith%252BTwo%252BChirality%252BAxes%26aulast%3DBeutner%26aufirst%3DGregory%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D17042018%26date%3D17062018%26volume%3D20%26issue%3D13%26spage%3D3736%26epage%3D3740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yu Xue, Peiran Song, Zilan Song, Aoli Wang, Linjiang Tong, Meiyu Geng, Jian Ding, Qingsong Liu, Liping Sun, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Ao Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (10)
                                     , 4608-4627. <a href="https://doi.org/10.1021/acs.jmedchem.8b00441" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00441</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00441%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4%25252C7-Diamino-5-%2525284-phenoxyphenyl%252529-6-methylene-pyrimido%25255B5%25252C4-b%25255Dpyrrolizines%252Bas%252BNovel%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DXue%26aufirst%3DYu%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19032018%26date%3D09052018%26date%3D01052018%26volume%3D61%26issue%3D10%26spage%3D4608%26epage%3D4627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mariel
M. Cardenas, Sean T. Toenjes, Christopher J. Nalbandian, <span class="NLM_string-name hlFld-ContribAuthor">Jeffrey L. Gustafson</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Synthesis of Pyrrolopyrimidine Scaffolds through Cation-Directed Nucleophilic Aromatic Substitution. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (7)
                                     , 2037-2041. <a href="https://doi.org/10.1021/acs.orglett.8b00579" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b00579</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b00579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b00579%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DEnantioselective%252BSynthesis%252Bof%252BPyrrolopyrimidine%252BScaffolds%252Bthrough%252BCation-Directed%252BNucleophilic%252BAromatic%252BSubstitution%26aulast%3DCardenas%26aufirst%3DMariel%2BM.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16022018%26date%3D21032018%26volume%3D20%26issue%3D7%26spage%3D2037%26epage%3D2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James J. Crawford, Adam R. Johnson, Dinah L. Misner, Lisa D. Belmont, Georgette Castanedo, Regina Choy, Melis Coraggio, Liming Dong, Charles Eigenbrot, Rebecca Erickson, Nico Ghilardi, Jonathan Hau, Arna Katewa, Pawan Bir Kohli, Wendy Lee, Joseph W. Lubach, Brent S. McKenzie, Daniel F. Ortwine, Leah Schutt, Suzanne Tay, BinQing Wei, Karin Reif, Lichuan Liu, Harvey Wong, <span class="NLM_string-name hlFld-ContribAuthor">Wendy B. Young</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (6)
                                     , 2227-2245. <a href="https://doi.org/10.1021/acs.jmedchem.7b01712" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01712</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BGDC-0853%25253A%252BA%252BPotent%25252C%252BSelective%25252C%252Band%252BNoncovalent%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252Bin%252BEarly%252BClinical%252BDevelopment%26aulast%3DCrawford%26aufirst%3DJames%2BJ.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D20112017%26date%3D23022018%26date%3D19022018%26volume%3D61%26issue%3D6%26spage%3D2227%26epage%3D2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marion  Schuller</span>, <span class="hlFld-ContribAuthor ">Kerstin  Riedel</span>, <span class="hlFld-ContribAuthor ">Ian  Gibbs-Seymour</span>, <span class="hlFld-ContribAuthor ">Kristin  Uth</span>, <span class="hlFld-ContribAuthor ">Christian  Sieg</span>, <span class="hlFld-ContribAuthor ">André P.  Gehring</span>, <span class="hlFld-ContribAuthor ">Ivan  Ahel</span>, <span class="hlFld-ContribAuthor ">Franz  Bracher</span>, <span class="hlFld-ContribAuthor ">Benedikt M.  Kessler</span>, <span class="hlFld-ContribAuthor ">Jonathan M.  Elkins</span>, and <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Selective Allosteric Inhibitor Targeting Macrodomain 2 of Polyadenosine-Diphosphate-Ribose Polymerase 14. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2017,</strong> <em>12 </em>
                                    (11)
                                     , 2866-2874. <a href="https://doi.org/10.1021/acschembio.7b00445" title="DOI URL">https://doi.org/10.1021/acschembio.7b00445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.7b00445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.7b00445%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDiscovery%252Bof%252Ba%252BSelective%252BAllosteric%252BInhibitor%252BTargeting%252BMacrodomain%252B2%252Bof%252BPolyadenosine-Diphosphate-Ribose%252BPolymerase%252B14%26aulast%3DSchuller%26aufirst%3DMarion%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D29052017%26date%3D29092017%26date%3D19102017%26date%3D17112017%26date%3D09102017%26volume%3D12%26issue%3D11%26spage%3D2866%26epage%3D2874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojing  Wang</span>, <span class="hlFld-ContribAuthor ">James  Barbosa</span>, <span class="hlFld-ContribAuthor ">Peter  Blomgren</span>, <span class="hlFld-ContribAuthor ">Meire C.  Bremer</span>, <span class="hlFld-ContribAuthor ">Jacob  Chen</span>, <span class="hlFld-ContribAuthor ">James J.  Crawford</span>, <span class="hlFld-ContribAuthor ">Wei  Deng</span>, <span class="hlFld-ContribAuthor ">Liming  Dong</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Steve  Gallion</span>, <span class="hlFld-ContribAuthor ">Jonathon  Hau</span>, <span class="hlFld-ContribAuthor ">Huiyong  Hu</span>, <span class="hlFld-ContribAuthor ">Adam R.  Johnson</span>, <span class="hlFld-ContribAuthor ">Arna  Katewa</span>, <span class="hlFld-ContribAuthor ">Jeffrey E.  Kropf</span>, <span class="hlFld-ContribAuthor ">Seung H.  Lee</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">Joseph W.  Lubach</span>, <span class="hlFld-ContribAuthor ">Jen  Macaluso</span>, <span class="hlFld-ContribAuthor ">Pat  Maciejewski</span>, <span class="hlFld-ContribAuthor ">Scott A.  Mitchell</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Ortwine</span>, <span class="hlFld-ContribAuthor ">Julie  DiPaolo</span>, <span class="hlFld-ContribAuthor ">Karin  Reif</span>, <span class="hlFld-ContribAuthor ">Heleen  Scheerens</span>, <span class="hlFld-ContribAuthor ">Aaron  Schmitt</span>, <span class="hlFld-ContribAuthor ">Harvey  Wong</span>, <span class="hlFld-ContribAuthor ">Jin-Ming  Xiong</span>, <span class="hlFld-ContribAuthor ">Jianjun  Xu</span>, <span class="hlFld-ContribAuthor ">Zhongdong  Zhao</span>, <span class="hlFld-ContribAuthor ">Fusheng  Zhou</span>, <span class="hlFld-ContribAuthor ">Kevin S.  Currie</span>, and <span class="hlFld-ContribAuthor ">Wendy B.  Young</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (6)
                                     , 608-613. <a href="https://doi.org/10.1021/acsmedchemlett.7b00103" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00103%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BSelective%252BTricyclic%252BInhibitors%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bwith%252BImproved%252BDruglike%252BProperties%26aulast%3DWang%26aufirst%3DXiaojing%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D08032017%26date%3D03052017%26date%3D16052017%26date%3D08062017%26date%3D03052017%26volume%3D8%26issue%3D6%26spage%3D608%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregory L.  Beutner</span>, <span class="hlFld-ContribAuthor ">Yi  Hsiao</span>, <span class="hlFld-ContribAuthor ">Thomas  Razler</span>, <span class="hlFld-ContribAuthor ">Eric M.  Simmons</span>, and <span class="hlFld-ContribAuthor ">William  Wertjes</span>  . </span><span class="cited-content_cbyCitation_article-title">Nickel-Catalyzed Synthesis of Quinazolinediones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (5)
                                     , 1052-1055. <a href="https://doi.org/10.1021/acs.orglett.7b00052" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b00052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b00052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b00052%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DNickel-Catalyzed%252BSynthesis%252Bof%252BQuinazolinediones%26aulast%3DBeutner%26aufirst%3DGregory%2BL.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D06012017%26date%3D13022017%26date%3D03032017%26volume%3D19%26issue%3D5%26spage%3D1052%26epage%3D1055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian T.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Eris  Bame</span>, <span class="hlFld-ContribAuthor ">Noah  Bell</span>, <span class="hlFld-ContribAuthor ">Tonika  Bohnert</span>, <span class="hlFld-ContribAuthor ">Jon K.  Bowden-Verhoek</span>, <span class="hlFld-ContribAuthor ">Minna  Bui</span>, <span class="hlFld-ContribAuthor ">Mark T.  Cancilla</span>, <span class="hlFld-ContribAuthor ">Patrick  Conlon</span>, <span class="hlFld-ContribAuthor ">Patrick  Cullen</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>, <span class="hlFld-ContribAuthor ">Junfa  Fan</span>, <span class="hlFld-ContribAuthor ">Tarra  Fuchs-Knotts</span>, <span class="hlFld-ContribAuthor ">Stig  Hansen</span>, <span class="hlFld-ContribAuthor ">Stacey  Heumann</span>, <span class="hlFld-ContribAuthor ">Tracy J.  Jenkins</span>, <span class="hlFld-ContribAuthor ">Chuck  Gua</span>, <span class="hlFld-ContribAuthor ">Ying  Yiu</span>, <span class="hlFld-ContribAuthor ">YuTing  Liu</span>, <span class="hlFld-ContribAuthor ">Mukush  Lulla</span>, <span class="hlFld-ContribAuthor ">Douglas  Marcotte</span>, <span class="hlFld-ContribAuthor ">Isaac  Marx</span>, <span class="hlFld-ContribAuthor ">Bob  McDowell</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Mertsching</span>, <span class="hlFld-ContribAuthor ">Ella  Negrou</span>, <span class="hlFld-ContribAuthor ">Michael J.  Romanowski</span>, <span class="hlFld-ContribAuthor ">Daniel  Scott</span>, <span class="hlFld-ContribAuthor ">Laura  Silvian</span>, <span class="hlFld-ContribAuthor ">Wenjin  Yang</span>, <span class="hlFld-ContribAuthor ">Min  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Utilizing Structure Based Drug Design and Metabolic Soft Spot Identification to optimize the in vitro potency and in vivo Pharmacokinetic Properties Leading to the Discovery of Novel Reversible Bruton’s Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>23 </em>, 116275. <a href="https://doi.org/10.1016/j.bmc.2021.116275" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116275%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DUtilizing%252BStructure%252BBased%252BDrug%252BDesign%252Band%252BMetabolic%252BSoft%252BSpot%252BIdentification%252Bto%252Boptimize%252Bthe%252Bin%252Bvitro%252Bpotency%252Band%252Bin%252Bvivo%252BPharmacokinetic%252BProperties%252BLeading%252Bto%252Bthe%252BDiscovery%252Bof%252BNovel%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DHopkins%26aufirst%3DBrian%2BT.%26date%3D2021%26volume%3D23%26spage%3D116275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charu  Chaudhry</span>, <span class="hlFld-ContribAuthor ">Andrew  Tebben</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Robert  Borzilleri</span>, <span class="hlFld-ContribAuthor ">William J.  Pitts</span>, <span class="hlFld-ContribAuthor ">Jonathan  Lippy</span>, <span class="hlFld-ContribAuthor ">Litao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (5)
                                     , 1115-1125. <a href="https://doi.org/10.1016/j.drudis.2021.01.018" title="DOI URL">https://doi.org/10.1016/j.drudis.2021.01.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2021.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2021.01.018%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DAn%252Binnovative%252Bkinome%252Bplatform%252Bto%252Baccelerate%252Bsmall-molecule%252Binhibitor%252Bdiscovery%252Band%252Boptimization%252Bfrom%252Bhits%252Bto%252Bleads%26aulast%3DChaudhry%26aufirst%3DCharu%26date%3D2021%26volume%3D26%26issue%3D5%26spage%3D1115%26epage%3D1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy J.  Hagen</span>, <span class="hlFld-ContribAuthor ">Travis R.  Helgren</span>. </span><span class="cited-content_cbyCitation_article-title">Chirality and Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-45. <a href="https://doi.org/10.1002/0471266949.bmc016.pub3" title="DOI URL">https://doi.org/10.1002/0471266949.bmc016.pub3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc016.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc016.pub3%26sid%3Dliteratum%253Aachs%26atitle%3DChirality%252Band%252BDrug%252BDiscovery%26aulast%3DHagen%26aufirst%3DTimothy%2BJ.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D45%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philipp  von Hundelshausen</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Siess</span>. </span><span class="cited-content_cbyCitation_article-title">Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 1103. <a href="https://doi.org/10.3390/cancers13051103" title="DOI URL">https://doi.org/10.3390/cancers13051103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13051103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13051103%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DBleeding%252Bby%252BBruton%252BTyrosine%252BKinase-Inhibitors%25253A%252BDependency%252Bon%252BDrug%252BType%252Band%252BDisease%26aulast%3Dvon%2BHundelshausen%26aufirst%3DPhilipp%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qinggang  Wang</span>, <span class="hlFld-ContribAuthor ">Brian Lingfeng  He</span>, <span class="hlFld-ContribAuthor ">Jonathan G.  Shackman</span>. </span><span class="cited-content_cbyCitation_article-title">Measuring atropisomers of BMS-986142 using 2DLC as an enabling technology. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2021,</strong> <em>193 </em>, 113730. <a href="https://doi.org/10.1016/j.jpba.2020.113730" title="DOI URL">https://doi.org/10.1016/j.jpba.2020.113730</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2020.113730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2020.113730%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DMeasuring%252Batropisomers%252Bof%252BBMS-986142%252Busing%252B2DLC%252Bas%252Ban%252Benabling%252Btechnology%26aulast%3DWang%26aufirst%3DQinggang%26date%3D2021%26volume%3D193%26spage%3D113730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonard  Sung</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent drugs in development for immune-mediated diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/bs.armc.2021.03.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2021.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2021.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2021.03.001%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bdrugs%252Bin%252Bdevelopment%252Bfor%252Bimmune-mediated%252Bdiseases%26aulast%3DSung%26aufirst%3DLeonard%26date%3D2021%26pub%3DElsevier%26date%3D2021%26volume%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingming  Sun</span>, <span class="hlFld-ContribAuthor ">Wuhong  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhenjun  Liu</span>, <span class="hlFld-ContribAuthor ">Junchao  Wei</span>, <span class="hlFld-ContribAuthor ">Ning  Xi</span>. </span><span class="cited-content_cbyCitation_article-title">19F NMR spectroscopy as a tool to detect rotations in fluorine substituted phenyl compounds. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>76 </em>
                                    (48)
                                     , 131679. <a href="https://doi.org/10.1016/j.tet.2020.131679" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131679</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131679%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3D19F%252BNMR%252Bspectroscopy%252Bas%252Ba%252Btool%252Bto%252Bdetect%252Brotations%252Bin%252Bfluorine%252Bsubstituted%252Bphenyl%252Bcompounds%26aulast%3DSun%26aufirst%3DMingming%26date%3D2020%26volume%3D76%26issue%3D48%26spage%3D131679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Deodial  Guiadeen</span>, <span class="hlFld-ContribAuthor ">Arto  Krikorian</span>, <span class="hlFld-ContribAuthor ">Xiaolei  Gao</span>, <span class="hlFld-ContribAuthor ">James  Wang</span>, <span class="hlFld-ContribAuthor ">Sobhana  Babu Boga</span>, <span class="hlFld-ContribAuthor ">Abdul-Basit  Alhassan</span>, <span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Younong  Yu</span>, <span class="hlFld-ContribAuthor ">Rajan  Anand</span>, <span class="hlFld-ContribAuthor ">Jiayi  Xu</span>, <span class="hlFld-ContribAuthor ">Joseph  Kelly</span>, <span class="hlFld-ContribAuthor ">Joseph L.  Duffy</span>, <span class="hlFld-ContribAuthor ">Shilan  Liu</span>, <span class="hlFld-ContribAuthor ">Chundao  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Wu</span>, <span class="hlFld-ContribAuthor ">Jiaqiang  Cai</span>, <span class="hlFld-ContribAuthor ">Chad  Bennett</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Maloney</span>, <span class="hlFld-ContribAuthor ">Sriram  Tyagarajan</span>, <span class="hlFld-ContribAuthor ">Ying-Duo  Gao</span>, <span class="hlFld-ContribAuthor ">Thierry O.  Fischmann</span>, <span class="hlFld-ContribAuthor ">Jeremy  Presland</span>, <span class="hlFld-ContribAuthor ">My  Mansueto</span>, <span class="hlFld-ContribAuthor ">Zangwei  Xu</span>, <span class="hlFld-ContribAuthor ">Erica  Leccese</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang-Hoover</span>, <span class="hlFld-ContribAuthor ">Ian  Knemeyer</span>, <span class="hlFld-ContribAuthor ">Charles G.  Garlisi</span>, <span class="hlFld-ContribAuthor ">Peter  Stivers</span>, <span class="hlFld-ContribAuthor ">Philip E.  Brandish</span>, <span class="hlFld-ContribAuthor ">Alexandra  Hicks</span>, <span class="hlFld-ContribAuthor ">Ronald  Kim</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (17)
                                     , 127390. <a href="https://doi.org/10.1016/j.bmcl.2020.127390" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127390%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPotent%25252C%252Bnon-covalent%252Breversible%252BBTK%252Binhibitors%252Bwith%252B8-amino-imidazo%25255B1%25252C5-a%25255Dpyrazine%252Bcore%252Bfeaturing%252B3-position%252Bbicyclic%252Bring%252Bsubstitutes%26aulast%3DLiu%26aufirst%3DJian%26date%3D2020%26volume%3D30%26issue%3D17%26spage%3D127390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian Lingfeng  He</span>, <span class="hlFld-ContribAuthor ">Nicole G.  Kleinsorge</span>, <span class="hlFld-ContribAuthor ">Ling  Zhang</span>, <span class="hlFld-ContribAuthor ">Brent  Kleintop</span>. </span><span class="cited-content_cbyCitation_article-title">Advancing stereoisomeric separation of an atropisomeric Bruton's tyrosine kinase inhibitor by using sub-2 µm immobilized polysaccharide-based chiral columns in supercritical fluid chromatography. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chromatography A</span><span> <strong>2020,</strong> <em>1626 </em>, 461320. <a href="https://doi.org/10.1016/j.chroma.2020.461320" title="DOI URL">https://doi.org/10.1016/j.chroma.2020.461320</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chroma.2020.461320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chroma.2020.461320%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chromatography%2520A%26atitle%3DAdvancing%252Bstereoisomeric%252Bseparation%252Bof%252Ban%252Batropisomeric%252BBruton%252527s%252Btyrosine%252Bkinase%252Binhibitor%252Bby%252Busing%252Bsub-2%2525C2%2525A0%2525C2%2525B5m%252Bimmobilized%252Bpolysaccharide-based%252Bchiral%252Bcolumns%252Bin%252Bsupercritical%252Bfluid%252Bchromatography%26aulast%3DHe%26aufirst%3DBrian%2BLingfeng%26date%3D2020%26volume%3D1626%26spage%3D461320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoze  Bao</span>, <span class="hlFld-ContribAuthor ">Jean  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Damien  Bonne</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Synthesis of Atropisomers with Multiple Stereogenic Axes. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (31)
                                     , 12723-12734. <a href="https://doi.org/10.1002/ange.202002518" title="DOI URL">https://doi.org/10.1002/ange.202002518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202002518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202002518%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DEnantioselective%252BSynthesis%252Bof%252BAtropisomers%252Bwith%252BMultiple%252BStereogenic%252BAxes%26aulast%3DBao%26aufirst%3DXiaoze%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D31%26spage%3D12723%26epage%3D12734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoze  Bao</span>, <span class="hlFld-ContribAuthor ">Jean  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Damien  Bonne</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Synthesis of Atropisomers with Multiple Stereogenic Axes. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (31)
                                     , 12623-12634. <a href="https://doi.org/10.1002/anie.202002518" title="DOI URL">https://doi.org/10.1002/anie.202002518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202002518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202002518%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DEnantioselective%252BSynthesis%252Bof%252BAtropisomers%252Bwith%252BMultiple%252BStereogenic%252BAxes%26aulast%3DBao%26aufirst%3DXiaoze%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D31%26spage%3D12623%26epage%3D12634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michele  Mancinelli</span>, <span class="hlFld-ContribAuthor ">Giorgio  Bencivenni</span>, <span class="hlFld-ContribAuthor ">Daniel  Pecorari</span>, <span class="hlFld-ContribAuthor ">Andrea  Mazzanti</span>. </span><span class="cited-content_cbyCitation_article-title">Stereochemistry and Recent Applications of Axially Chiral Organic Molecules. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (27)
                                     , 4070-4086. <a href="https://doi.org/10.1002/ejoc.201901918" title="DOI URL">https://doi.org/10.1002/ejoc.201901918</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201901918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201901918%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DStereochemistry%252Band%252BRecent%252BApplications%252Bof%252BAxially%252BChiral%252BOrganic%252BMolecules%26aulast%3DMancinelli%26aufirst%3DMichele%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D27%26spage%3D4070%26epage%3D4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. R.  Gataullina</span>, <span class="hlFld-ContribAuthor ">R. R.  Gataullin</span>. </span><span class="cited-content_cbyCitation_article-title">Axial Chiral Metal Complexes, Carbo- and Heterocycles: Modern
Synthesis Strategies and Examples of the Effect of Atropoisomerism on the Structure of
Reaction Products. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of General Chemistry</span><span> <strong>2020,</strong> <em>90 </em>
                                    (7)
                                     , 1255-1284. <a href="https://doi.org/10.1134/S1070363220070130" title="DOI URL">https://doi.org/10.1134/S1070363220070130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070363220070130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070363220070130%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520General%2520Chemistry%26atitle%3DAxial%252BChiral%252BMetal%252BComplexes%25252C%252BCarbo-%252Band%252BHeterocycles%25253A%252BModern%252BSynthesis%252BStrategies%252Band%252BExamples%252Bof%252Bthe%252BEffect%252Bof%252BAtropoisomerism%252Bon%252Bthe%252BStructure%252Bof%252BReaction%252BProducts%26aulast%3DGataullina%26aufirst%3DA.%2BR.%26date%3D2020%26date%3D2020%26volume%3D90%26issue%3D7%26spage%3D1255%26epage%3D1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Johanna  Frey</span>, <span class="hlFld-ContribAuthor ">Alaleh  Malekafzali</span>, <span class="hlFld-ContribAuthor ">Isabel  Delso</span>, <span class="hlFld-ContribAuthor ">Sabine  Choppin</span>, <span class="hlFld-ContribAuthor ">Françoise  Colobert</span>, <span class="hlFld-ContribAuthor ">Joanna  Wencel‐Delord</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Synthesis of N–C Axially Chiral Compounds by Cu‐Catalyzed Atroposelective Aryl Amination. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (23)
                                     , 8929-8933. <a href="https://doi.org/10.1002/ange.201914876" title="DOI URL">https://doi.org/10.1002/ange.201914876</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201914876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201914876%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DEnantioselective%252BSynthesis%252Bof%252BN%2525E2%252580%252593C%252BAxially%252BChiral%252BCompounds%252Bby%252BCu%2525E2%252580%252590Catalyzed%252BAtroposelective%252BAryl%252BAmination%26aulast%3DFrey%26aufirst%3DJohanna%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D23%26spage%3D8929%26epage%3D8933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Johanna  Frey</span>, <span class="hlFld-ContribAuthor ">Alaleh  Malekafzali</span>, <span class="hlFld-ContribAuthor ">Isabel  Delso</span>, <span class="hlFld-ContribAuthor ">Sabine  Choppin</span>, <span class="hlFld-ContribAuthor ">Françoise  Colobert</span>, <span class="hlFld-ContribAuthor ">Joanna  Wencel‐Delord</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Synthesis of N–C Axially Chiral Compounds by Cu‐Catalyzed Atroposelective Aryl Amination. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (23)
                                     , 8844-8848. <a href="https://doi.org/10.1002/anie.201914876" title="DOI URL">https://doi.org/10.1002/anie.201914876</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201914876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201914876%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DEnantioselective%252BSynthesis%252Bof%252BN%2525E2%252580%252593C%252BAxially%252BChiral%252BCompounds%252Bby%252BCu%2525E2%252580%252590Catalyzed%252BAtroposelective%252BAryl%252BAmination%26aulast%3DFrey%26aufirst%3DJohanna%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D23%26spage%3D8844%26epage%3D8848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. L.  Ong</span>, <span class="hlFld-ContribAuthor ">J. D.  Vasta</span>, <span class="hlFld-ContribAuthor ">L.  Monereau</span>, <span class="hlFld-ContribAuthor ">G.  Locke</span>, <span class="hlFld-ContribAuthor ">H.  Ribeiro</span>, <span class="hlFld-ContribAuthor ">M. A.  Pattoli</span>, <span class="hlFld-ContribAuthor ">S.  Skala</span>, <span class="hlFld-ContribAuthor ">J. R.  Burke</span>, <span class="hlFld-ContribAuthor ">S. H.  Watterson</span>, <span class="hlFld-ContribAuthor ">J. A.  Tino</span>, <span class="hlFld-ContribAuthor ">P. L.  Meisenheimer</span>, <span class="hlFld-ContribAuthor ">B.  Arey</span>, <span class="hlFld-ContribAuthor ">J.  Lippy</span>, <span class="hlFld-ContribAuthor ">L.  Zhang</span>, <span class="hlFld-ContribAuthor ">M. B.  Robers</span>, <span class="hlFld-ContribAuthor ">A.  Tebben</span>, <span class="hlFld-ContribAuthor ">C.  Chaudhry</span>. </span><span class="cited-content_cbyCitation_article-title">A High-Throughput BRET Cellular Target Engagement Assay Links Biochemical to Cellular Activity for Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2020,</strong> <em>25 </em>
                                    (2)
                                     , 176-185. <a href="https://doi.org/10.1177/2472555219884881" title="DOI URL">https://doi.org/10.1177/2472555219884881</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555219884881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555219884881%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DA%252BHigh-Throughput%252BBRET%252BCellular%252BTarget%252BEngagement%252BAssay%252BLinks%252BBiochemical%252Bto%252BCellular%252BActivity%252Bfor%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DOng%26aufirst%3DL.%2BL.%26date%3D2020%26date%3D2019%26volume%3D25%26issue%3D2%26spage%3D176%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amandeep  Thakur</span>, <span class="hlFld-ContribAuthor ">Arshdeep  Singh</span>, <span class="hlFld-ContribAuthor ">Navdeep  Kaur</span>, <span class="hlFld-ContribAuthor ">Ritu  Ojha</span>, <span class="hlFld-ContribAuthor ">Kunal  Nepali</span>. </span><span class="cited-content_cbyCitation_article-title">Steering the antitumor drug discovery campaign towards structurally diverse indolines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>94 </em>, 103436. <a href="https://doi.org/10.1016/j.bioorg.2019.103436" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103436</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103436%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSteering%252Bthe%252Bantitumor%252Bdrug%252Bdiscovery%252Bcampaign%252Btowards%252Bstructurally%252Bdiverse%252Bindolines%26aulast%3DThakur%26aufirst%3DAmandeep%26date%3D2020%26volume%3D94%26spage%3D103436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keriann M.  Backus</span>, <span class="hlFld-ContribAuthor ">Jian  Cao</span>, <span class="hlFld-ContribAuthor ">Sean M.  Maddox</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities and challenges for the development of covalent chemical immunomodulators. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (15)
                                     , 3421-3439. <a href="https://doi.org/10.1016/j.bmc.2019.05.050" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.05.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.05.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.05.050%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DOpportunities%252Band%252Bchallenges%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bcovalent%252Bchemical%252Bimmunomodulators%26aulast%3DBackus%26aufirst%3DKeriann%2BM.%26date%3D2019%26volume%3D27%26issue%3D15%26spage%3D3421%26epage%3D3439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanyan  Diao</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Fang</span>, <span class="hlFld-ContribAuthor ">Peiran  Song</span>, <span class="hlFld-ContribAuthor ">Mengzhen  Lai</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Yongjia  Hao</span>, <span class="hlFld-ContribAuthor ">Dou  Dou</span>, <span class="hlFld-ContribAuthor ">Yingqiang  Liu</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (15)
                                     , 3390-3395. <a href="https://doi.org/10.1016/j.bmc.2019.06.023" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.06.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.06.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BBiological%252Bevaluation%252Bof%252Bpyrimido%25255B4%25252C5-d%25255Dpyrimidine-2%25252C4%2525281H%25252C3H%252529-dione%252Bderivatives%252Bas%252Bpotent%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DDiao%26aufirst%3DYanyan%26date%3D2019%26volume%3D27%26issue%3D15%26spage%3D3390%26epage%3D3395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian T.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Eris  Bame</span>, <span class="hlFld-ContribAuthor ">Noah  Bell</span>, <span class="hlFld-ContribAuthor ">Tonika  Bohnert</span>, <span class="hlFld-ContribAuthor ">Jon K.  Bowden-Verhoek</span>, <span class="hlFld-ContribAuthor ">Minna  Bui</span>, <span class="hlFld-ContribAuthor ">Mark T.  Cancilla</span>, <span class="hlFld-ContribAuthor ">Patrick  Conlon</span>, <span class="hlFld-ContribAuthor ">Patrick  Cullen</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>, <span class="hlFld-ContribAuthor ">Junfa  Fan</span>, <span class="hlFld-ContribAuthor ">Tarra  Fuchs-Knotts</span>, <span class="hlFld-ContribAuthor ">Stig  Hansen</span>, <span class="hlFld-ContribAuthor ">Stacey  Heumann</span>, <span class="hlFld-ContribAuthor ">Tracy J.  Jenkins</span>, <span class="hlFld-ContribAuthor ">Douglas  Marcotte</span>, <span class="hlFld-ContribAuthor ">Bob  McDowell</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Mertsching</span>, <span class="hlFld-ContribAuthor ">Ella  Negrou</span>, <span class="hlFld-ContribAuthor ">Kevin L.  Otipoby</span>, <span class="hlFld-ContribAuthor ">Urjana  Poreci</span>, <span class="hlFld-ContribAuthor ">Michael J.  Romanowski</span>, <span class="hlFld-ContribAuthor ">Daniel  Scott</span>, <span class="hlFld-ContribAuthor ">Laura  Silvian</span>, <span class="hlFld-ContribAuthor ">Wenjin  Yang</span>, <span class="hlFld-ContribAuthor ">Min  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of novel reversible Bruton’s tyrosine kinase inhibitors identified using Tethering-fragment-based screens. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (13)
                                     , 2905-2913. <a href="https://doi.org/10.1016/j.bmc.2019.05.021" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.05.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.05.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252Bnovel%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%252Bidentified%252Busing%252BTethering-fragment-based%252Bscreens%26aulast%3DHopkins%26aufirst%3DBrian%2BT.%26date%3D2019%26volume%3D27%26issue%3D13%26spage%3D2905%26epage%3D2913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Goess</span>, <span class="hlFld-ContribAuthor ">Christopher M.  Harris</span>, <span class="hlFld-ContribAuthor ">Sara  Murdock</span>, <span class="hlFld-ContribAuthor ">Richard W.  McCarthy</span>, <span class="hlFld-ContribAuthor ">Erik  Sampson</span>, <span class="hlFld-ContribAuthor ">Rachel  Twomey</span>, <span class="hlFld-ContribAuthor ">Suzanne  Mathieu</span>, <span class="hlFld-ContribAuthor ">Regina  Mario</span>, <span class="hlFld-ContribAuthor ">Matthew  Perham</span>, <span class="hlFld-ContribAuthor ">Eric R.  Goedken</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Long</span>. </span><span class="cited-content_cbyCitation_article-title">ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation. </span><span class="cited-content_cbyCitation_journal-name">Modern Rheumatology</span><span> <strong>2019,</strong> <em>29 </em>
                                    (3)
                                     , 510-522. <a href="https://doi.org/10.1080/14397595.2018.1484269" title="DOI URL">https://doi.org/10.1080/14397595.2018.1484269</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14397595.2018.1484269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14397595.2018.1484269%26sid%3Dliteratum%253Aachs%26jtitle%3DModern%2520Rheumatology%26atitle%3DABBV-105%25252C%252Ba%252Bselective%252Band%252Birreversible%252Binhibitor%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%25252C%252Bis%252Befficacious%252Bin%252Bmultiple%252Bpreclinical%252Bmodels%252Bof%252Binflammation%26aulast%3DGoess%26aufirst%3DChristian%26date%3D2019%26date%3D2018%26volume%3D29%26issue%3D3%26spage%3D510%26epage%3D522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chufeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Jun  He</span>, <span class="hlFld-ContribAuthor ">Jiali  Zhu</span>, <span class="hlFld-ContribAuthor ">Weimin  Li</span>, <span class="hlFld-ContribAuthor ">Ting  Niu</span>, <span class="hlFld-ContribAuthor ">Mingli  Xiang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>169 </em>, 121-143. <a href="https://doi.org/10.1016/j.ejmech.2019.02.077" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.02.077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.02.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.02.077%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252B7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-amine%252Bderivatives%252Bas%252Bpotent%25252C%252Bselective%252Band%252Breversible%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DZhang%26aufirst%3DChufeng%26date%3D2019%26volume%3D169%26spage%3D121%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanni  Chen</span>, <span class="hlFld-ContribAuthor ">Shili  Wan</span>, <span class="hlFld-ContribAuthor ">Yunxiang  Wu</span>, <span class="hlFld-ContribAuthor ">Yaxi  Yang</span>, <span class="hlFld-ContribAuthor ">Bing  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Ru(II)-catalyzed regioselective C-7 hydroxymethylation of indolines with formaldehyde. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2019,</strong> <em>60 </em>
                                    (22)
                                     , 1481-1486. <a href="https://doi.org/10.1016/j.tetlet.2019.04.052" title="DOI URL">https://doi.org/10.1016/j.tetlet.2019.04.052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2019.04.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2019.04.052%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DRu%252528II%252529-catalyzed%252Bregioselective%252BC-7%252Bhydroxymethylation%252Bof%252Bindolines%252Bwith%252Bformaldehyde%26aulast%3DChen%26aufirst%3DYanni%26date%3D2019%26volume%3D60%26issue%3D22%26spage%3D1481%26epage%3D1486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shiuhang Henry  Yip</span>, <span class="hlFld-ContribAuthor ">Dauh-Rurng  Wu</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Dawn  Sun</span>, <span class="hlFld-ContribAuthor ">Scott H.  Watterson</span>, <span class="hlFld-ContribAuthor ">Rulin  Zhao</span>, <span class="hlFld-ContribAuthor ">Joseph  Tino</span>, <span class="hlFld-ContribAuthor ">Arvind  Mathur</span>. </span><span class="cited-content_cbyCitation_article-title">Separation of Bruton’s tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chromatography A</span><span> <strong>2019,</strong> <em>1586 </em>, 106-115. <a href="https://doi.org/10.1016/j.chroma.2018.12.006" title="DOI URL">https://doi.org/10.1016/j.chroma.2018.12.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chroma.2018.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chroma.2018.12.006%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chromatography%2520A%26atitle%3DSeparation%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitor%252Batropisomers%252Bby%252Bsupercritical%252Bfluid%252Bchromatography%26aulast%3DYip%26aufirst%3DShiuhang%2BHenry%26date%3D2019%26volume%3D1586%26spage%3D106%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun  Yang</span>, <span class="hlFld-ContribAuthor ">Dongmei  Zhou</span>, <span class="hlFld-ContribAuthor ">Zancong  Shen</span>, <span class="hlFld-ContribAuthor ">David M.  Wilson</span>, <span class="hlFld-ContribAuthor ">Matthew  Renner</span>, <span class="hlFld-ContribAuthor ">Jeffrey N.  Miner</span>, <span class="hlFld-ContribAuthor ">Jean-Luc  Girardet</span>, <span class="hlFld-ContribAuthor ">Caroline A.  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2019,</strong> <em>47 </em>
                                    (2)
                                     , 104-113. <a href="https://doi.org/10.1124/dmd.118.080549" title="DOI URL">https://doi.org/10.1124/dmd.118.080549</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.118.080549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.118.080549%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DCharacterization%252Bof%252BStereoselective%252BMetabolism%25252C%252BInhibitory%252BEffect%252Bon%252BUric%252BAcid%252BUptake%252BTransporters%25252C%252Band%252BPharmacokinetics%252Bof%252BLesinurad%252BAtropisomers%26aulast%3DYang%26aufirst%3DChun%26date%3D2019%26date%3D2018%26volume%3D47%26issue%3D2%26spage%3D104%26epage%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingjie  Liu</span>, <span class="hlFld-ContribAuthor ">Douglas G.  Batt</span>, <span class="hlFld-ContribAuthor ">Charu  Chaudhry</span>, <span class="hlFld-ContribAuthor ">Jonathan S.  Lippy</span>, <span class="hlFld-ContribAuthor ">Mark A.  Pattoli</span>, <span class="hlFld-ContribAuthor ">Neha  Surti</span>, <span class="hlFld-ContribAuthor ">Songmei  Xu</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">James R.  Burke</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Tino</span>. </span><span class="cited-content_cbyCitation_article-title">Conversion of carbazole carboxamide based reversible inhibitors of Bruton’s tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (18)
                                     , 3080-3084. <a href="https://doi.org/10.1016/j.bmcl.2018.07.041" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.07.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.07.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.07.041%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DConversion%252Bof%252Bcarbazole%252Bcarboxamide%252Bbased%252Breversible%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binto%252Bpotent%25252C%252Bselective%252Birreversible%252Binhibitors%252Bin%252Bthe%252Bcarbazole%25252C%252Btetrahydrocarbazole%25252C%252Band%252Ba%252Bnew%252B2%25252C3-dimethylindole%252Bseries%26aulast%3DLiu%26aufirst%3DQingjie%26date%3D2018%26volume%3D28%26issue%3D18%26spage%3D3080%26epage%3D3084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Achim  Link</span>, <span class="hlFld-ContribAuthor ">Christof  Sparr</span>. </span><span class="cited-content_cbyCitation_article-title">Remote Central-to-Axial Chirality Conversion: Direct Atroposelective Ester to Biaryl Transformation. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2018,</strong> <em>130 </em>
                                    (24)
                                     , 7254-7257. <a href="https://doi.org/10.1002/ange.201803472" title="DOI URL">https://doi.org/10.1002/ange.201803472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201803472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201803472%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DRemote%252BCentral-to-Axial%252BChirality%252BConversion%25253A%252BDirect%252BAtroposelective%252BEster%252Bto%252BBiaryl%252BTransformation%26aulast%3DLink%26aufirst%3DAchim%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D24%26spage%3D7254%26epage%3D7257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Achim  Link</span>, <span class="hlFld-ContribAuthor ">Christof  Sparr</span>. </span><span class="cited-content_cbyCitation_article-title">Remote Central-to-Axial Chirality Conversion: Direct Atroposelective Ester to Biaryl Transformation. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2018,</strong> <em>57 </em>
                                    (24)
                                     , 7136-7139. <a href="https://doi.org/10.1002/anie.201803472" title="DOI URL">https://doi.org/10.1002/anie.201803472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201803472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201803472%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DRemote%252BCentral-to-Axial%252BChirality%252BConversion%25253A%252BDirect%252BAtroposelective%252BEster%252Bto%252BBiaryl%252BTransformation%26aulast%3DLink%26aufirst%3DAchim%26date%3D2018%26date%3D2018%26volume%3D57%26issue%3D24%26spage%3D7136%26epage%3D7139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Li</span>, <span class="hlFld-ContribAuthor ">Yongli  Du</span>, <span class="hlFld-ContribAuthor ">Zhipei  Gao</span>, <span class="hlFld-ContribAuthor ">Jingkang  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2018,</strong> <em>19 </em>
                                    (4)
                                     , 1244. <a href="https://doi.org/10.3390/ijms19041244" title="DOI URL">https://doi.org/10.3390/ijms19041244</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms19041244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms19041244%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMolecular%252BModeling%252BStudies%252Bon%252BCarbazole%252BCarboxamide%252BBased%252BBTK%252BInhibitors%252BUsing%252BDocking%252Band%252BStructure-Based%252B3D-QSAR%26aulast%3DLi%26aufirst%3DRui%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D4%26spage%3D1244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuowen  Yu</span>, <span class="hlFld-ContribAuthor ">Hui  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoying  Xu</span>, <span class="hlFld-ContribAuthor ">Weicheng  Yuan</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Enatioselective Synthesis of Tetrahydrocarbazoles
              via
              Chiral Phosphoric Acid Promoted Domino Friedel-Crafts-type Reaction of Indole-3-butanal with Indoles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2018,</strong> <em>55 </em>
                                    (3)
                                     , 619-631. <a href="https://doi.org/10.1002/jhet.3079" title="DOI URL">https://doi.org/10.1002/jhet.3079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.3079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.3079%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DEnatioselective%252BSynthesis%252Bof%252BTetrahydrocarbazoles%252Bvia%252BChiral%252BPhosphoric%252BAcid%252BPromoted%252BDomino%252BFriedel-Crafts-type%252BReaction%252Bof%252BIndole-3-butanal%252Bwith%252BIndoles%26aulast%3DYu%26aufirst%3DShuowen%26date%3D2018%26date%3D2018%26volume%3D55%26issue%3D3%26spage%3D619%26epage%3D631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linhong  He</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Chufeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Shao</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Mingli  Tang</span>, <span class="hlFld-ContribAuthor ">Taijing  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoxin  Chen</span>, <span class="hlFld-ContribAuthor ">Mingli  Xiang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 7 H -pyrrolo[2,3- d ]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>145 </em>, 96-112. <a href="https://doi.org/10.1016/j.ejmech.2017.12.079" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.12.079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.12.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.12.079%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B7%252BH%252B-pyrrolo%25255B2%25252C3-%252Bd%252B%25255Dpyrimidin-4-amine%252Bderivatives%252Bas%252Bselective%252BBtk%252Binhibitors%252Bwith%252Bimproved%252Bpharmacokinetic%252Bproperties%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DHe%26aufirst%3DLinhong%26date%3D2018%26volume%3D145%26spage%3D96%26epage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linyi  Liu</span>, <span class="hlFld-ContribAuthor ">Bingyu  Shi</span>, <span class="hlFld-ContribAuthor ">Xiangqian  Wang</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (3)
                                     , 343-356. <a href="https://doi.org/10.4155/fmc-2017-0145" title="DOI URL">https://doi.org/10.4155/fmc-2017-0145</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2017-0145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2017-0145%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DStrategies%252Bto%252Bovercome%252Bresistance%252Bmutations%252Bof%252BBruton%252527s%252Btyrosine%252Bkinase%252Binhibitor%252Bibrutinib%26aulast%3DLiu%26aufirst%3DLinyi%26date%3D2018%26volume%3D10%26issue%3D3%26spage%3D343%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean T  Toenjes</span>, <span class="hlFld-ContribAuthor ">Jeffrey L  Gustafson</span>. </span><span class="cited-content_cbyCitation_article-title">Atropisomerism in medicinal chemistry: challenges and opportunities. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (4)
                                     , 409-422. <a href="https://doi.org/10.4155/fmc-2017-0152" title="DOI URL">https://doi.org/10.4155/fmc-2017-0152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2017-0152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2017-0152%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DAtropisomerism%252Bin%252Bmedicinal%252Bchemistry%25253A%252Bchallenges%252Band%252Bopportunities%26aulast%3DToenjes%26aufirst%3DSean%2BT%26date%3D2018%26volume%3D10%26issue%3D4%26spage%3D409%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter W.  Glunz</span>. </span><span class="cited-content_cbyCitation_article-title">Recent encounters with atropisomerism in drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (2)
                                     , 53-60. <a href="https://doi.org/10.1016/j.bmcl.2017.11.050" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.11.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.11.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.11.050%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRecent%252Bencounters%252Bwith%252Batropisomerism%252Bin%252Bdrug%252Bdiscovery%26aulast%3DGlunz%26aufirst%3DPeter%2BW.%26date%3D2018%26volume%3D28%26issue%3D2%26spage%3D53%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shijie  Song</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Huang</span>, <span class="hlFld-ContribAuthor ">Zhihao  Liu</span>, <span class="hlFld-ContribAuthor ">Yongming  Li</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jihong  Yao</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1847-1857. <a href="https://doi.org/10.1016/j.ejmech.2017.10.080" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.080%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bhighly%252Bpotent%252BBTK%252Band%252BJAK3%252Bdual%252Binhibitors%252Bwith%252Bimproved%252Bactivity%252Bfor%252Bthe%252Btreatment%252Bof%252BB-cell%252Blymphoma%26aulast%3DGe%26aufirst%3DYang%26date%3D2018%26volume%3D143%26spage%3D1847%26epage%3D1857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Musumeci</span>, <span class="hlFld-ContribAuthor ">Monica  Sanna</span>, <span class="hlFld-ContribAuthor ">Chiara  Greco</span>, <span class="hlFld-ContribAuthor ">Ilaria  Giacchello</span>, <span class="hlFld-ContribAuthor ">Anna Lucia  Fallacara</span>, <span class="hlFld-ContribAuthor ">Rosario  Amato</span>, <span class="hlFld-ContribAuthor ">Silvia  Schenone</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrrolo[2,3-
              d
              ]pyrimidines active as Btk inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2017,</strong> <em>27 </em>
                                    (12)
                                     , 1305-1318. <a href="https://doi.org/10.1080/13543776.2017.1355908" title="DOI URL">https://doi.org/10.1080/13543776.2017.1355908</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2017.1355908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2017.1355908%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DPyrrolo%25255B2%25252C3-%252Bd%252B%25255Dpyrimidines%252Bactive%252Bas%252BBtk%252Binhibitors%26aulast%3DMusumeci%26aufirst%3DFrancesca%26date%3D2017%26date%3D2017%26volume%3D27%26issue%3D12%26spage%3D1305%26epage%3D1318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahesh R.  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Madhav S.  Mane</span>, <span class="hlFld-ContribAuthor ">Usha  Ghosh</span>, <span class="hlFld-ContribAuthor ">Rajiv  Sharma</span>, <span class="hlFld-ContribAuthor ">Nitin P.  Lad</span>, <span class="hlFld-ContribAuthor ">Ankita  Srivastava</span>, <span class="hlFld-ContribAuthor ">Asha  Kulkarni-Almeida</span>, <span class="hlFld-ContribAuthor ">Prashant S.  Kharkar</span>, <span class="hlFld-ContribAuthor ">Vijay M.  Khedkar</span>, <span class="hlFld-ContribAuthor ">Shivaji S.  Pandit</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of tetrahydrocarbazoles as dual pERK and pRb inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>134 </em>, 366-378. <a href="https://doi.org/10.1016/j.ejmech.2017.02.062" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.02.062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.02.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.02.062%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Btetrahydrocarbazoles%252Bas%252Bdual%252BpERK%252Band%252BpRb%252Binhibitors%26aulast%3DKulkarni%26aufirst%3DMahesh%2BR.%26date%3D2017%26volume%3D134%26spage%3D366%26epage%3D378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sun Ku  Lee</span>, <span class="hlFld-ContribAuthor ">Jun  Xing</span>, <span class="hlFld-ContribAuthor ">Ian M.  Catlett</span>, <span class="hlFld-ContribAuthor ">Robert  Adamczyk</span>, <span class="hlFld-ContribAuthor ">Amber  Griffies</span>, <span class="hlFld-ContribAuthor ">Ang  Liu</span>, <span class="hlFld-ContribAuthor ">Bindu  Murthy</span>, <span class="hlFld-ContribAuthor ">Miroslawa  Nowak</span>. </span><span class="cited-content_cbyCitation_article-title">Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Clinical Pharmacology</span><span> <strong>2017,</strong> <em>73 </em>
                                    (6)
                                     , 689-698. <a href="https://doi.org/10.1007/s00228-017-2226-2" title="DOI URL">https://doi.org/10.1007/s00228-017-2226-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00228-017-2226-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00228-017-2226-2%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DSafety%25252C%252Bpharmacokinetics%25252C%252Band%252Bpharmacodynamics%252Bof%252BBMS-986142%25252C%252Ba%252Bnovel%252Breversible%252BBTK%252Binhibitor%25252C%252Bin%252Bhealthy%252Bparticipants%26aulast%3DLee%26aufirst%3DSun%2BKu%26date%3D2017%26date%3D2017%26volume%3D73%26issue%3D6%26spage%3D689%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahesh  Thakkar</span>, <span class="hlFld-ContribAuthor ">Debnath  Bhuniya</span>, <span class="hlFld-ContribAuthor ">Rahul  Kaduskar</span>, <span class="hlFld-ContribAuthor ">Tanaji  Mengawade</span>, <span class="hlFld-ContribAuthor ">Keshav  Naik</span>, <span class="hlFld-ContribAuthor ">Videsh  Salunkhe</span>, <span class="hlFld-ContribAuthor ">Amit  Bhalerao</span>, <span class="hlFld-ContribAuthor ">Santosh  Kurhade</span>, <span class="hlFld-ContribAuthor ">Jagadeesh  Mavinahalli</span>, <span class="hlFld-ContribAuthor ">Vaibhav  Jain</span>, <span class="hlFld-ContribAuthor ">Rajkanth  Petla</span>, <span class="hlFld-ContribAuthor ">Satheesh  Avaragolla</span>, <span class="hlFld-ContribAuthor ">Swagatam  Ray</span>, <span class="hlFld-ContribAuthor ">Sreekanth  Rouduri</span>, <span class="hlFld-ContribAuthor ">Avinash  Dhanave</span>, <span class="hlFld-ContribAuthor ">Siddhartha  De</span>, <span class="hlFld-ContribAuthor ">Vishal  Pathade</span>, <span class="hlFld-ContribAuthor ">Ashwini  Tambe</span>, <span class="hlFld-ContribAuthor ">Amol A.  Raje</span>, <span class="hlFld-ContribAuthor ">Vamsi  Madgula</span>, <span class="hlFld-ContribAuthor ">Sachin  Joshi</span>, <span class="hlFld-ContribAuthor ">Ahmed  Nadeem</span>, <span class="hlFld-ContribAuthor ">Madhu  bala</span>, <span class="hlFld-ContribAuthor ">Dhananjay  Umrani</span>, <span class="hlFld-ContribAuthor ">Narayanan  Hariharan</span>, <span class="hlFld-ContribAuthor ">Bheemashankar  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Kasim A.  Mookhtiar</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and evaluation of 1 H -pyrrolo[2,3- b ]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (8)
                                     , 1867-1873. <a href="https://doi.org/10.1016/j.bmcl.2017.02.026" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.02.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.02.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.02.026%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252Bevaluation%252Bof%252B1%252BH%252B-pyrrolo%25255B2%25252C3-%252Bb%252B%25255Dpyridine%252Bbased%252Bselective%252Band%252Breversible%252Bsmall%252Bmolecule%252BBTK%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DThakkar%26aufirst%3DMahesh%26date%3D2017%26volume%3D27%26issue%3D8%26spage%3D1867%26epage%3D1873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Dai</span>, <span class="hlFld-ContribAuthor ">Chunlei  Wang</span>, <span class="hlFld-ContribAuthor ">Sarah C.  Traeger</span>, <span class="hlFld-ContribAuthor ">Lorell  Discenza</span>, <span class="hlFld-ContribAuthor ">Mary T.  Obermeier</span>, <span class="hlFld-ContribAuthor ">Adrienne A.  Tymiak</span>, <span class="hlFld-ContribAuthor ">Yingru  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">The role of chromatographic and chiroptical spectroscopic techniques and methodologies in support of drug discovery for atropisomeric drug inhibitors of Bruton’s tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chromatography A</span><span> <strong>2017,</strong> <em>1487 </em>, 116-128. <a href="https://doi.org/10.1016/j.chroma.2017.01.016" title="DOI URL">https://doi.org/10.1016/j.chroma.2017.01.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chroma.2017.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chroma.2017.01.016%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chromatography%2520A%26atitle%3DThe%252Brole%252Bof%252Bchromatographic%252Band%252Bchiroptical%252Bspectroscopic%252Btechniques%252Band%252Bmethodologies%252Bin%252Bsupport%252Bof%252Bdrug%252Bdiscovery%252Bfor%252Batropisomeric%252Bdrug%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%26aulast%3DDai%26aufirst%3DJun%26date%3D2017%26volume%3D1487%26spage%3D116%26epage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0002.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Identification of lead BMS-935177 (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0003.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>2</b> has four interconverting atropisomers which were separated by chiral SFC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0004.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>14f</b> as a single, stable atropisomer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0016.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Carbazoles <b>6</b> and <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (PPh<sub>3</sub>)<sub>4</sub>Pd, 2 M aqueous K<sub>3</sub>PO<sub>4</sub>, toluene, EtOH, 74%; (b) SFC chiral separation.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0017.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Carbazoles <b>8</b>, <b>9</b>, and <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Dichloro 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)–CH<sub>2</sub>Cl<sub>2</sub> adduct, Cs<sub>2</sub>CO<sub>3</sub>, THF, water, 50–60 °C, 32–84%; (b) 1,1′-bis(di<i>tert</i>-butylphosphino)ferrocene palladium dichloride, 2 M aqueous K<sub>3</sub>PO<sub>4</sub>, THF, RT, 55–60%. (c) SFC chiral separation at carbazole C4.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0018.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Tetrahydrocarbazoles <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) a) Dichloro 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)–CH<sub>2</sub>Cl<sub>2</sub> adduct, Cs<sub>2</sub>CO<sub>3</sub>, THF, water, 50 °C, 50%; (b) 1,1′-bis(di<i>tert</i>-butylphosphino)ferrocene palladium dichloride, 2 M aqueous K<sub>3</sub>PO<sub>4</sub>, THF, RT, 93%. (c) SFC chiral separation at carbazole C5.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0019.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Optimized Preparation of <b>14f</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0020.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of the Carbazole C3 Cl Core<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NCS, NMP, CCl<sub>4</sub>, 45 °C, 92%.</p></p></figure><figure data-id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0021.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Preparation of the Carbazole C3 CN Core<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NIS, pyridine, DMF, 60 °C, 23%; (b) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 90 °C, 83%.</p></p></figure><figure data-id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0022.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Preparation of the Carbazole C3 Me, Cl, and F Cores<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaNO<sub>2</sub>, SnCl<sub>2</sub>, HCl, H<sub>2</sub>O, 50–61%%; (b) ethyl 3-oxocyclohexanecarboxylate, AcOH, toluene, 55–62%; (c) DDQ, THF, 85–90%; (d) NH<sub>4</sub>OH, EDCI, HOBt, THF, CH<sub>2</sub>Cl<sub>2</sub>, 91–95%; (e) MeLi, THF, 50–85%.</p></p></figure><figure data-id="sch8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0023.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Preparation of the Tetrahydrocarbazole Cores <b>20</b> and <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeLi, THF, 95%; (b) SFC chiral separation.</p></p></figure><figure data-id="sch9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0024.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Preparation of Boronic Ester Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Δ, xylene, 90%; (b) CDI, THF, 90%; (c) bis(pinacolato)diboron, dichloro 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)–CH<sub>2</sub>Cl<sub>2</sub> adduct, KOAc, toluene, 90%; (d) SFC chiral separation; (e) MeI, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90%.</p></p></figure><figure data-id="sch10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0025.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Preparation of Aniline <b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) pyr<sub>2</sub>IBF<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 63%; (b) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 83%; (c) NaOH, EtOH/H<sub>2</sub>O, 91%.</p></p></figure><figure data-id="fig4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0005.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Co-crystal structure (1.9 Å) of compound <b>4</b> bound to the kinase domain of BTK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS">5JRS</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0006.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Quinazoline-diones <b>5</b> and <b>6</b>, a route to locking one of the atropisomeric centers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0007.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray crystal structures of <b>7a</b> with the locked (<i>S</i>)-quinazolinedione atropisomer revealing a mixture of two interconverting C4 atropisomers (CCDC # 1501158).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0008.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Distribution of carbazole C4 atropisomers (<b>7a</b>) in multispecies plasma studies at 37 °C over 4 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0009.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Medicinal chemistry strategy: Lock the C4 atropisomer into the preferred conformation for optimal binding to BTK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0010.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>9a</b>, a single, stable atropisomer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0011.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Computational model of atropisomer <b>9a</b> and (B) computational model of atropisomer <b>9b</b>, based on the X-ray cocrystal structure of <b>4</b> bound to the kinase domain of BTK (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS">5JRS</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0012.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Metabolite formation in PK studies with <b>9a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0013.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. X-ray crystal structure of <b>14f</b> bound to the kinase domain of BTK (1.5 Å structure) (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18">5T18</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0014.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Overlay of the single crystal X-ray structure (pink) with the X-ray crystal structure of <b>14f</b> bound to the active site of BTK (gold).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/medium/jm-2016-01088m_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0015.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Efficacy of <b>14f</b> in a NZB/W lupus-prone mice model vs prednisolone and vehicle. Mice dosed daily starting at 24 weeks of age (<i>n</i> = 12 per group). (A) Percentage of mice with severe proteinuria (≥300 mg/dL) over the 14 week course of treatment. (B) Anti-dsDNA titers in serum at the end of the study, mean ± SEM. (C) Total nephritis histology scores (tubulointerstitial and glomerular nephritis) of kidneys at the end of the study, mean ± SEM. (D) Mononuclear infiltration in kidneys at the end of the study, mean ± SEM. (E) Representative sections from each group. *<i>P</i> < 0.05, **<i>P</i> < 0.01 versus the vehicle control group. Vehicle: 80:20 PEG400/water.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b01088/20161007/images/large/jm-2016-01088m_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01088&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i65">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60032" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60032" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 22 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bäckesjö, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faryal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aints, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglöf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I. E.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00741.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1111%2Fj.1600-065X.2008.00741.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=19290921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=58-73&author=A.+J.+Mohamedauthor=L.+Yuauthor=C.-M.+B%C3%A4ckesj%C3%B6author=L.+Vargasauthor=R.+Faryalauthor=A.+Aintsauthor=B.+Christenssonauthor=A.+Bergl%C3%B6fauthor=M.+Vihinenauthor=B.+F.+Noreauthor=C.+I.+E.+Smith&title=Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29%3A+function%2C+regulation%2C+and+transformation+with+special+emphasis+on+the+PH+domain&doi=10.1111%2Fj.1600-065X.2008.00741.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span></div><div class="casAuthors">Mohamed, Abdalla J.; Yu, Liang; Backesjo, Carl-Magnus; Vargas, Leonardo; Faryal, Rani; Aints, Alar; Christensson, Birger; Berglof, Anna; Vihinen, Mauno; Nore, Beston F.; Smith, C. I. Edvard</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-73</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase important in B-lymphocyte development, differentiation, and signaling.  Btk is a member of the Tec family of kinases.  Mutations in the Elk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice.  Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT).  In B cells, NF-κB was shown to bind to the Btk promoter and induce transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional Btk.  Moreover, Btk activation is tightly regulated by a plethora of other signaling proteins including protein kinase C (PKC), Sab/SH3BP5, and caveolin-1.  For example, the prolyl isomerase Pin1 neg. regulates Btk by decreasing tyrosine phosphorylation and steady state levels of Btk.  It is intriguing that PKC and Pin1, both of which are neg. regulators, bind to the pleckstrin homol. domain of Btk.  To this end, we describe here novel mutations in the pleckstrin homol. domain investigated for their transforming capacity.  In particular, we show that the mutant D43R behaves similar to E41K, already known to possess such activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1L-Ch4HjNLVg90H21EOLACvtfcHk0li9x66veHqsKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO&md5=7a84f2b3604d67bcc1490fadcbfea234</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00741.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00741.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DB%25C3%25A4ckesj%25C3%25B6%26aufirst%3DC.-M.%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DFaryal%26aufirst%3DR.%26aulast%3DAints%26aufirst%3DA.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DBergl%25C3%25B6f%26aufirst%3DA.%26aulast%3DVihinen%26aufirst%3DM.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%253A%2520function%252C%2520regulation%252C%2520and%2520transformation%2520with%2520special%2520emphasis%2520on%2520the%2520PH%2520domain%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D58%26epage%3D73%26doi%3D10.1111%2Fj.1600-065X.2008.00741.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I. E.</span><span> </span><span class="NLM_article-title">Signaling of Bruton’s tyrosine kinase, Btk</span> <span class="citation_source-journal">Scand. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1046/j.1365-3083.1999.00504.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1046%2Fj.1365-3083.1999.00504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10075013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1999&pages=113-118&author=A.+J.+Mohamedauthor=B.+F.+Noreauthor=B.+Christenssonauthor=C.+I.+E.+Smith&title=Signaling+of+Bruton%E2%80%99s+tyrosine+kinase%2C+Btk&doi=10.1046%2Fj.1365-3083.1999.00504.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling of Bruton's tyrosine kinase, Btk</span></div><div class="casAuthors">Mohamed, A. J.; Nore, B. F.; Christensson, B.; Smith, C. I. E.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-118</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review with 63 refs.  Bruton's tyrosine kinase, which is encoded by the BTK gene, is a cytoplasmic protein tyrosine kinase (PTK) crucial for B-cell development and differentiation.  It belongs to the Tec family of PTKs contg. several domains that are characteristic of signalling mols.  In humans, mutations that disrupt the function of this gene lead to the classical XLA syndrome (X-linked agammaglobulinemia), a primary immunodeficiency mainly characterized by lack of mature B cells as well as low levels of Igs.  In contrast, animal models of this disease such as the xid mice display profoundly milder XLA phenotype.  BTK phosphorylation and activation in response to engagement of the B-cell receptor (BCR) by antigen is a dynamic process whereby a variety of proteins interact with each other and recruit signalling mols. resulting in a physiol. response such as B-cell proliferation and antibody prodn.  The main players, however, that participate in the intracellular downstream cascade have not yet been identified and are therefore under intense scrutiny in several labs.  This review discusses certain aspects of BTK activation following receptor stimulation by agonists and how this event is translated into the biochem. signals within the cell that eventually lead to nuclear responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphmZBDkpS1ubVg90H21EOLACvtfcHk0li9x66veHqsKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D&md5=a3842c00d3cd4e45458c050941026476</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-3083.1999.00504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-3083.1999.00504.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DSignaling%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520Btk%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D1999%26volume%3D49%26spage%3D113%26epage%3D118%26doi%3D10.1046%2Fj.1365-3083.1999.00504.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Takata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurosaki, T.</span><span> </span><span class="NLM_article-title">A role for Bruton’s tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-γ2</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1084/jem.184.1.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1084%2Fjem.184.1.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=8691147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1ajs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=1996&pages=31-40&author=M.+Takataauthor=T.+Kurosaki&title=A+role+for+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+antigen+receptor-mediated+activation+of+phospholipase+C-%CE%B32&doi=10.1084%2Fjem.184.1.31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-γ2</span></div><div class="casAuthors">Takata, Minoru; Kurosaki, Tomohiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Defects in the gene encoding Bruton's tyrosine kinase (Btk) result in a disease called X-linked agammaglobulinemia, in which there is a profound decrease of mature B cells due to a block in B cell development.  Recent studies have shown that Btk is tyrosine phosphorylated and activated upon B cell antigen receptor (BCR) stimulation.  To elucidate the functions of this kinase, we examd. BCR signaling of DT40 B cells deficient in Btk.  Tyrosine phosphorylation of phospholipase C (PLC)-γ2 upon receptor stimulation was significantly reduced in the mutant cells, leading to the loss of both BCR-coupled phosphatidylinositol hydrolysis and calcium mobilization.  Pleckstrin homol. and Src-homol. 2 domains of Btk were required for PLC-γ2 activation.  Since Syk is also required for the BCR-induced PLC-γ2 activation, our findings indicate that PLC-γ2 activation is regulated by Btk and Syk through their concerted actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrvJR6GCfI7rVg90H21EOLACvtfcHk0li9x66veHqsKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1ajs74%253D&md5=7244a36ac8298ccde274e05016ec68ba</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1084%2Fjem.184.1.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.184.1.31%26sid%3Dliteratum%253Aachs%26aulast%3DTakata%26aufirst%3DM.%26aulast%3DKurosaki%26aufirst%3DT.%26atitle%3DA%2520role%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520antigen%2520receptor-mediated%2520activation%2520of%2520phospholipase%2520C-%25CE%25B32%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1996%26volume%3D184%26spage%3D31%26epage%3D40%26doi%3D10.1084%2Fjem.184.1.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jongstra-Bilen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puig Cano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasija, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cybulsky, M. I.</span><span> </span><span class="NLM_article-title">Dual functions of Bruton’s tyrosine kinase and Tec kinase during Fcγ receptor-induced signaling and phagocytosis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span><span class="refDoi"> DOI: 10.4049/jimmunol.181.1.288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.4049%2Fjimmunol.181.1.288" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2008&pages=288-298&author=J.+Jongstra-Bilenauthor=A.+Puig+Canoauthor=M.+Hasijaauthor=H.+Xiaoauthor=C.+I.+Smithauthor=M.+I.+Cybulsky&title=Dual+functions+of+Bruton%E2%80%99s+tyrosine+kinase+and+Tec+kinase+during+Fc%CE%B3+receptor-induced+signaling+and+phagocytosis&doi=10.4049%2Fjimmunol.181.1.288"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.181.1.288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.181.1.288%26sid%3Dliteratum%253Aachs%26aulast%3DJongstra-Bilen%26aufirst%3DJ.%26aulast%3DPuig%2BCano%26aufirst%3DA.%26aulast%3DHasija%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DCybulsky%26aufirst%3DM.%2BI.%26atitle%3DDual%2520functions%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520and%2520Tec%2520kinase%2520during%2520Fc%25CE%25B3%2520receptor-induced%2520signaling%2520and%2520phagocytosis%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D181%26spage%3D288%26epage%3D298%26doi%3D10.4049%2Fjimmunol.181.1.288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kuehn, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaven, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilfillan, A. M.</span><span> </span><span class="NLM_article-title">Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">2576</span><span class="NLM_x">–</span> <span class="NLM_lpage">2585</span><span class="refDoi"> DOI: 10.1242/jcs.071043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1242%2Fjcs.071043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=20587594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2mtL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2010&pages=2576-2585&author=H.+S.+Kuehnauthor=M.+Radingerauthor=J.+M.+Brownauthor=K.+Aliauthor=B.+Vanhaesebroeckauthor=M.+A.+Beavenauthor=D.+D.+Metcalfeauthor=A.+M.+Gilfillan&title=Btk-dependent+Rac+activation+and+actin+rearrangement+following+Fc%CE%B5RI+aggregation+promotes+enhanced+chemotactic+responses+of+mast+cells&doi=10.1242%2Fjcs.071043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells</span></div><div class="casAuthors">Kuehn, Hye Sun; Radinger, Madeleine; Brown, Jared M.; Ali, Khaled; Vanhaesebroeck, Bart; Beaven, Michael A.; Metcalfe, Dean D.; Gilfillan, Alasdair M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2576-2585</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Mast cells infiltrate the sites of inflammation assocd. with chronic atopic disease and during helminth and bacterial infection.  This process requires receptor-mediated cell chemotaxis across a concn. gradient of their chemotactic ligands.  In vivo, mast cells are likely to be exposed to several such agents, which can cooperate in a synergistic manner to regulate mast cell homing.  Here, we report that chemotaxis of mouse bone-marrow-derived mast cells (BMMCs) in response to the chemoattractants stem-cell factor (SCF) and prostaglandin (PG)E2, is substantially enhanced following antigen-dependent ligation of the high-affinity receptor for IgE (FcεRI).  These responses were assocd. with enhanced activation of phosphoinositide 3-kinase (PI3K), and downstream activation of the tyrosine protein kinase Btk, with subsequent enhanced phospholipase (PL)Cγ-mediated Ca2+ mobilization, Rac activation and F-actin rearrangement.  Antigen-induced chemotaxis, and the ability of antigen to amplify responses mediated by SCF, adenosine and PGE2 were suppressed following inhibition of PI3K, and were impaired in BMMCs derived from Btk-/- mice.  There were corresponding decreases in the PLCγ-mediated Ca2+ signal, Rac activation and F-actin rearrangement, which, as they are essential for BMMC chemotaxis, accounts for the impaired migration of Btk-deficient cells.  Taken together, these data demonstrate that, by regulating signaling pathways that control F-actin rearrangement, Btk is crucial for the ability of antigen to amplify mast-cell chemotactic responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx05z-3Sv-D7Vg90H21EOLACvtfcHk0lhiYqPOJnEFlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2mtL7O&md5=2a02fc66a2b3994eb6c983a8c3b91f63</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1242%2Fjcs.071043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.071043%26sid%3Dliteratum%253Aachs%26aulast%3DKuehn%26aufirst%3DH.%2BS.%26aulast%3DRadinger%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DAli%26aufirst%3DK.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DBeaven%26aufirst%3DM.%2BA.%26aulast%3DMetcalfe%26aufirst%3DD.%2BD.%26aulast%3DGilfillan%26aufirst%3DA.%2BM.%26atitle%3DBtk-dependent%2520Rac%2520activation%2520and%2520actin%2520rearrangement%2520following%2520Fc%25CE%25B5RI%2520aggregation%2520promotes%2520enhanced%2520chemotactic%2520responses%2520of%2520mast%2520cells%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2010%26volume%3D123%26spage%3D2576%26epage%3D2585%26doi%3D10.1242%2Fjcs.071043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tsukada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlings, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span> </span><span class="NLM_article-title">Role of Bruton’s tyrosine kinase in immunodeficiency</span> <span class="citation_source-journal">Curr. Opin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">623</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span><span class="refDoi"> DOI: 10.1016/0952-7915(94)90151-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2F0952-7915%2894%2990151-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=7946052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1994&pages=623-630&author=S.+Tsukadaauthor=D.+J.+Rawlingsauthor=O.+N.+Witte&title=Role+of+Bruton%E2%80%99s+tyrosine+kinase+in+immunodeficiency&doi=10.1016%2F0952-7915%2894%2990151-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in immunodeficiency</span></div><div class="casAuthors">Tsukada, Satoshi; Rawlings, David J.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-30</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    </div><div class="casAbstract">A review, with 71 refs.  The genetic defect assocd. with human X-linked agammaglobulinemia and murine X-linked immunodeficiency was recently shown to result from lack of function of a new cytoplasmic tyrosine kinase, called Bruton's tyrosine kinase (Btk).  The phenotypes assocd. with these immunodeficiencies indicate that Btk plays a crit. role in B lymphocyte development.  The distinctive protein structure of Btk and preliminary functional studies suggest that Btk may act in a novel manner in a variety of signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAyW0bZjSS3rVg90H21EOLACvtfcHk0lhiYqPOJnEFlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D&md5=d9932cf5d56f7a77723a46cae519cbeb</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1016%2F0952-7915%2894%2990151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0952-7915%252894%252990151-1%26sid%3Dliteratum%253Aachs%26aulast%3DTsukada%26aufirst%3DS.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520immunodeficiency%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D1994%26volume%3D6%26spage%3D623%26epage%3D630%26doi%3D10.1016%2F0952-7915%2894%2990151-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y.</span><span> </span><span class="NLM_article-title">The Tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">11526</span><span class="NLM_x">–</span> <span class="NLM_lpage">11534</span><span class="refDoi"> DOI: 10.1074/jbc.M708935200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1074%2Fjbc.M708935200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11526-11534&author=S.+H.+Leeauthor=T.+Kimauthor=D.+Jeongauthor=N.+Kimauthor=Y.+Choi&title=The+Tec+family+tyrosine+kinase+Btk+regulates+RANKL-induced+osteoclast+maturation&doi=10.1074%2Fjbc.M708935200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708935200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708935200%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DJeong%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DChoi%26aufirst%3DY.%26atitle%3DThe%2520Tec%2520family%2520tyrosine%2520kinase%2520Btk%2520regulates%2520RANKL-induced%2520osteoclast%2520maturation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D11526%26epage%3D11534%26doi%3D10.1074%2Fjbc.M708935200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Mease, P. J.</span><span> </span><span class="NLM_article-title">B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1245</span><span class="NLM_x">–</span> <span class="NLM_lpage">1255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=18609733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslajtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2008&pages=1245-1255&author=P.+J.+Mease&title=B+cell-targeted+therapy+in+autoimmune+disease%3A+rationale%2C+mechanisms%2C+and+clinical+application"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application</span></div><div class="casAuthors">Mease, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1245-1255</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">A review.  B cells play a crit. role in the pathogenesis of rheumatoid arthritis (RA) and other autoimmune diseases.  Recently, a no. of biol. agents that target B cells have been tested as therapies for these conditions.  These agents either deplete B cells, by targeting cell-surface antigens such as CD20, or block B cell function, for example by inhibiting the activity of B cell survival factors such as BLyS.  Of this group of agents, the first in clin. use has been rituximab, a chimeric monoclonal antibody that depletes B cells by binding to the CD20 cell-surface antigen.  Initially introduced as a treatment for non-Hodgkin's lymphoma, rituximab is now approved for the treatment of RA.  In this review we explore the rationale behind B cell-targeted therapy, highlight the results of clin. trials with rituximab in RA and other autoimmune diseases, and describe other emerging therapies directed at B cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpprn0Fq_lLVg90H21EOLACvtfcHk0lhiYqPOJnEFlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslajtro%253D&md5=1e31bd50b6afae7e8273a1da7a06f828</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DP.%2BJ.%26atitle%3DB%2520cell-targeted%2520therapy%2520in%2520autoimmune%2520disease%253A%2520rationale%252C%2520mechanisms%252C%2520and%2520clinical%2520application%26jtitle%3DJ.%2520Rheumatol.%26date%3D2008%26volume%3D35%26spage%3D1245%26epage%3D1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Middendorp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingjan, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlenborg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendriks, R. W.</span><span> </span><span class="NLM_article-title">Function of Bruton’s tyrosine kinase during B cell development is partially independent of its catalytic activity</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">5988</span><span class="NLM_x">–</span> <span class="NLM_lpage">5996</span><span class="refDoi"> DOI: 10.4049/jimmunol.171.11.5988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.4049%2Fjimmunol.171.11.5988" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2003&pages=5988-5996&author=S.+Middendorpauthor=G.+M.+Dingjanauthor=A.+Maasauthor=K.+Dahlenborgauthor=R.+W.+Hendriks&title=Function+of+Bruton%E2%80%99s+tyrosine+kinase+during+B+cell+development+is+partially+independent+of+its+catalytic+activity&doi=10.4049%2Fjimmunol.171.11.5988"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.171.11.5988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.171.11.5988%26sid%3Dliteratum%253Aachs%26aulast%3DMiddendorp%26aufirst%3DS.%26aulast%3DDingjan%26aufirst%3DG.%2BM.%26aulast%3DMaas%26aufirst%3DA.%26aulast%3DDahlenborg%26aufirst%3DK.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DFunction%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520during%2520B%2520cell%2520development%2520is%2520partially%2520independent%2520of%2520its%2520catalytic%2520activity%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D171%26spage%3D5988%26epage%3D5996%26doi%3D10.4049%2Fjimmunol.171.11.5988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Petro, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, S. M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, W. N.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">1745</span><span class="NLM_x">–</span> <span class="NLM_lpage">1753</span><span class="refDoi"> DOI: 10.1084/jem.191.10.1745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1084%2Fjem.191.10.1745" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2000&pages=1745-1753&author=J.+B.+Petroauthor=S.+M.+J.+Rahmanauthor=D.+W.+Ballardauthor=W.+N.+Khan&title=Bruton%E2%80%99s+tyrosine+kinase+is+required+for+activation+of+I%CE%BAB+kinase+and+nuclear+factor+%CE%BAB+in+response+to+B+cell+receptor+engagement&doi=10.1084%2Fjem.191.10.1745"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1084%2Fjem.191.10.1745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.191.10.1745%26sid%3Dliteratum%253Aachs%26aulast%3DPetro%26aufirst%3DJ.%2BB.%26aulast%3DRahman%26aufirst%3DS.%2BM.%2BJ.%26aulast%3DBallard%26aufirst%3DD.%2BW.%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520is%2520required%2520for%2520activation%2520of%2520I%25CE%25BAB%2520kinase%2520and%2520nuclear%2520factor%2520%25CE%25BAB%2520in%2520response%2520to%2520B%2520cell%2520receptor%2520engagement%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D191%26spage%3D1745%26epage%3D1753%26doi%3D10.1084%2Fjem.191.10.1745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Puck, J. M.</span><span> </span><span class="NLM_article-title">Molecular and genetic basis of X-linked immunodeficiency disorders</span> <span class="citation_source-journal">J. Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span><span class="refDoi"> DOI: 10.1007/BF01541340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1007%2FBF01541340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=8195317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaK2cXksFGht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1994&pages=81-89&author=J.+M.+Puck&title=Molecular+and+genetic+basis+of+X-linked+immunodeficiency+disorders&doi=10.1007%2FBF01541340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and genetic basis of X-linked immunodeficiency disorders</span></div><div class="casAuthors">Puck, Jennifer M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-9</span>CODEN:
                <span class="NLM_cas:coden">JCIMDO</span>;
        ISSN:<span class="NLM_cas:issn">0271-9142</span>.
    </div><div class="casAbstract">A review with 51 refs.  Topics discussed include X-linked hyper-IgM syndrome, X-linked agammaglobulinemia, X-linked severe combined immunodeficiency, and immunodeficiency genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0dSBJ76uLHLVg90H21EOLACvtfcHk0lhEyjnVj8xaew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksFGht7s%253D&md5=c9c2d448576c949acc62b4926389b46b</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1007%2FBF01541340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01541340%26sid%3Dliteratum%253Aachs%26aulast%3DPuck%26aufirst%3DJ.%2BM.%26atitle%3DMolecular%2520and%2520genetic%2520basis%2520of%2520X-linked%2520immunodeficiency%2520disorders%26jtitle%3DJ.%2520Clin.%2520Immunol.%26date%3D1994%26volume%3D14%26spage%3D81%26epage%3D89%26doi%3D10.1007%2FBF01541340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hendriks, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredius, R. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike-Overzet, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staal, F. J. T.</span><span> </span><span class="NLM_article-title">Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1003</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1517/14728222.2011.585971</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1517%2F14728222.2011.585971" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=21635151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Gkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=1003-1021&author=R.+W.+Hendriksauthor=R.+G.+M.+Brediusauthor=K.+Pike-Overzetauthor=F.+J.+T.+Staal&title=Biology+and+novel+treatment+options+for+XLA%2C+the+most+common+monogenetic+immunodeficiency+in+man&doi=10.1517%2F14728222.2011.585971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man</span></div><div class="casAuthors">Hendriks, Rudi W.; Bredius, Robbert G. M.; Pike-Overzet, Karin; Staal, Frank J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1003-1021</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: X-linked agammaglobulinemia (XLA) is the most common primary immunodeficiency in man, and is caused by a single genetic defect.  Inactivating mutations in the Bruton's tyrosine kinase (BTK) gene are invariably the cause of XLA,.  XLA is characterized by a differentiation arrest at the pre-B cell stage, the absence of Igs and recurrent bacterial infections, making it an insidious disease that gradually disables the patient, and can result in death due to chronic lung disease.  Current treatment involves prophylactic antibiotics and Ig infusions, which are non-curative.  This disease is a good candidate for curative hematopoietic stem cell (HSC)-based gene therapy, which could correct the B cell and myeloid deficiencies.  Areas covered: This paper reviews the basic biol. of BTK in B cell development, the clin. features of XLA, and the possibilities of gene therapy for XLA, covering the literature from 1995 to 2010.  Expert opinion: Work from various labs. demonstrates the feasibility of using gene-cor. HSCs to complement the immune defects of Btk-deficiency in mice.  We propose that it is timely to start clin. programs to develop stem cell based therapy for XLA, using gene-cor. autologous HSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeANh_LlclL7Vg90H21EOLACvtfcHk0lhEyjnVj8xaew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Gkt74%253D&md5=24f073dee412df4b5ec3beb5dc982b0e</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.585971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.585971%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26aulast%3DBredius%26aufirst%3DR.%2BG.%2BM.%26aulast%3DPike-Overzet%26aufirst%3DK.%26aulast%3DStaal%26aufirst%3DF.%2BJ.%2BT.%26atitle%3DBiology%2520and%2520novel%2520treatment%2520options%2520for%2520XLA%252C%2520the%2520most%2520common%2520monogenetic%2520immunodeficiency%2520in%2520man%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2011%26volume%3D15%26spage%3D1003%26epage%3D1021%26doi%3D10.1517%2F14728222.2011.585971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lederman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkelstein, J. A.</span><span> </span><span class="NLM_article-title">X-linked agammaglobulinemia: an analysis of 96 patients</span> <span class="citation_source-journal">Medicine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1097/00005792-198505000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1097%2F00005792-198505000-00001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1985&pages=145-156&author=H.+M.+Ledermanauthor=J.+A.+Winkelstein&title=X-linked+agammaglobulinemia%3A+an+analysis+of+96+patients&doi=10.1097%2F00005792-198505000-00001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1097%2F00005792-198505000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005792-198505000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DLederman%26aufirst%3DH.%2BM.%26aulast%3DWinkelstein%26aufirst%3DJ.%2BA.%26atitle%3DX-linked%2520agammaglobulinemia%253A%2520an%2520analysis%2520of%252096%2520patients%26jtitle%3DMedicine%26date%3D1985%26volume%3D64%26spage%3D145%26epage%3D156%26doi%3D10.1097%2F00005792-198505000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Whyburn, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halcomb, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contreras, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satterthwaite, A. B.</span><span> </span><span class="NLM_article-title">Haploinsufficiency of B cell linker protein enhanced B cell signaling defects in mice expressing a limiting dosage of Bruton’s tyrosine kinase</span> <span class="citation_source-journal">Int. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span><span class="refDoi"> DOI: 10.1093/intimm/dxg034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1093%2Fintimm%2Fdxg034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=12618482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFKlsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2003&pages=383-392&author=L.+R.+Whyburnauthor=K.+E.+Halcombauthor=C.+M.+Contrerasauthor=R.+Pappuauthor=O.+N.+Witteauthor=A.+C.+Chanauthor=A.+B.+Satterthwaite&title=Haploinsufficiency+of+B+cell+linker+protein+enhanced+B+cell+signaling+defects+in+mice+expressing+a+limiting+dosage+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1093%2Fintimm%2Fdxg034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Haploinsufficiency of B cell linker protein enhances B cell signaling defects in mice expressing a limiting dosage of Bruton's tyrosine kinase</span></div><div class="casAuthors">Whyburn, Lindsey R.; Halcomb, Kristina E.; Contreras, Cristina M.; Pappu, Rajita; Witte, Owen N.; Chan, Andrew C.; Satterthwaite, Anne B.</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-392</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Current models of lymphocyte activation suggest that formation of a signaling complex, or signalosome', composed of Syk, Bruton's tyrosine kinase (Btk), phospholipase γ2 and the adaptor protein B cell linker protein (BLNK) is crit. for transmission of signals from the BCR.  However, impaired B cell development in mice lacking each individual signalosome component has made it difficult to study the functional consequences of the formation of this complex in mature B cells.  Sensitized genetic systems, commonly used in Drosophila, define signaling pathways by combining partial loss of function mutations in the components of interest.  This allows genetic interactions to be obsd. in the absence of pleiotropic or lethal effects of complete deficiency of either gene.  We used this approach to demonstrate that Btk and BLNK are limiting components of a common signaling pathway that mediates the mitogenic response of mature B cells to antigen.  B cells from transgenic mice expressing a limiting dosage of Btk (Btklo) have normal nos. of mature B cells that have reduced, but measurable, responses to BCR crosslinking.  Haploinsufficiency of BLNK did not affect the development of Btklo B cells.  However, it exacerbated their defects in BCR-induced Ca2+ flux, IκB degrdn., and up-regulation of cyclin D2, bcl-xL and A1 leading to dramatic impairment of B cell mitogenic responses.  In contrast, no effect of reduced Btk and BLNK dosage was obsd. on extracellular signal-regulated kinase activation.  These results suggest that the signals regulating the maintenance and activation of mature B cells are differentially sensitive to the strength of the signal emanating from the signalosome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrowqlQ3xDitLVg90H21EOLACvtfcHk0lhMy-u83CzhTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFKlsL4%253D&md5=8d56f66c8b68159d61a86322e174c81f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxg034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxg034%26sid%3Dliteratum%253Aachs%26aulast%3DWhyburn%26aufirst%3DL.%2BR.%26aulast%3DHalcomb%26aufirst%3DK.%2BE.%26aulast%3DContreras%26aufirst%3DC.%2BM.%26aulast%3DPappu%26aufirst%3DR.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DChan%26aufirst%3DA.%2BC.%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26atitle%3DHaploinsufficiency%2520of%2520B%2520cell%2520linker%2520protein%2520enhanced%2520B%2520cell%2520signaling%2520defects%2520in%2520mice%2520expressing%2520a%2520limiting%2520dosage%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DInt.%2520Immunol.%26date%3D2003%26volume%3D15%26spage%3D383%26epage%3D392%26doi%3D10.1093%2Fintimm%2Fdxg034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jansson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmdahl, R.</span><span> </span><span class="NLM_article-title">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span> <span class="citation_source-journal">Clin. Exp. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span><span class="refDoi"> DOI: 10.1111/j.1365-2249.1993.tb08218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1111%2Fj.1365-2249.1993.tb08218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=8252807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1993&pages=459-465&author=L.+Janssonauthor=R.+Holmdahl&title=Genes+on+the+X+chromosome+affect+development+of+collagen-induced+arthritis+in+mice&doi=10.1111%2Fj.1365-2249.1993.tb08218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span></div><div class="casAuthors">Jansson, Liselotte; Holmdahl, R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-65</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">Susceptibility to collagen-induced arthritis (CIA) in mice is assocd. with a class II gene in MHC (Aq) but also with unknown genes outside MHC.  Investigated here is the influence of genes on the X chromosome as well as the role of the X-linked immunodeficiency (xid) mutation.  Reciprocal male F1 hybrids, bred to be heterozygous or homozygous for Aq, showed a genetic influence in their susceptibility to develop CIA.  Crosses were made between B10.G, B10.Q, DBA/1, SWR/J, C3H.Q and CBA/Ca, and all F1 mice were castrated to avoid sex hormone modulation of the susceptibility.  A differential timing of arthritis onset and severity were seen in the reciprocal F1 males.  An exception was the reciprocal F1 male offspring from SWR/J and DBA/1 crosses which differed only in disease severity late in the course of the disease.  The female F1 crosses did not show the same pattern of differential susceptibility to CIA as the F1 males.  To exclude the possible influence of the Y chromosome, F1 males of reciprocal crosses were back-crossed to the parental strains creating offspring with equal X chromosomes but divergent Y chromosomes.  No difference in development of arthritis was obsd. in these.  The influence of the xid mutation was investigated next.  The xid loci from the CBA/N mouse was bred into DBA/1 strain which is highly susceptible to CIA.  The resulting congenic DBA/1-xid strain was resistant to induction of CIA and did not develop an antibody response to type II collagen.  The authors concluded that polymorphic genes on the X chromosome modulate susceptibility to CIA.  The results from the expts. with mice carrying xid mutations confirm that such immune modulating genes exist on the sex chromosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuu6ocKN6h7Vg90H21EOLACvtfcHk0lhMy-u83CzhTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D&md5=77777b6215fb6c1e839b5a68d555df3c</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.1993.tb08218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.1993.tb08218.x%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DL.%26aulast%3DHolmdahl%26aufirst%3DR.%26atitle%3DGenes%2520on%2520the%2520X%2520chromosome%2520affect%2520development%2520of%2520collagen-induced%2520arthritis%2520in%2520mice%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1993%26volume%3D94%26spage%3D459%26epage%3D465%26doi%3D10.1111%2Fj.1365-2249.1993.tb08218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Steinberg, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smathers, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederiksen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, A. D.</span><span> </span><span class="NLM_article-title">Ability of the <i>xid</i> gene to prevent autoimmunity in (NZBXNZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">597</span><span class="refDoi"> DOI: 10.1172/JCI110651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1172%2FJCI110651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=6980900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1982&pages=587-597&author=B.+J.+Steinbergauthor=P.+A.+Smathersauthor=K.+Frederiksenauthor=A.+D.+Steinberg&title=Ability+of+the+xid+gene+to+prevent+autoimmunity+in+%28NZBXNZW%29F1+mice+during+the+course+of+their+natural+history%2C+after+polyclonal+stimulation%2C+or+following+immunization+with+DNA&doi=10.1172%2FJCI110651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span></div><div class="casAuthors">Steinberg B J; Smathers P A; Frederiksen K; Steinberg A D</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-97</span>
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">F1 hybrid offspring of New Zealand Black mothers and New Zealand White fathers [(NZB X NZW)F1] female mice develop antibodies to single-stranded (ss) and native DNA, immune complex glomerulonephritis, massive proteinuria, and premature death with renal failure.  By a series of matings, congenic (NZB X NZW)F1 . xid/xid mice were prepared.  These mice were different from (NZB X NZW)F1 mice in having the X chromosome-linked immune deficiency gene, xid, in homozygous form.  Such congenic (NZB X NZW)F1 . xid/xid females failed to develop antibodies to single-stranded or native DNA.  They also failed to develop fatal renal disease as measured by proteinuria, glomerular histology, glomerular immunofluorescence, and survival.  To control for unknown genetic factors, studies were performed with littermates that were derived by mating NZB . xid/+ females with NZW . xid/Y males such that the resulting offspring were either (NZB X NZW)F1 . xid/xid (and therefore "defective") or (NZB X NZW)F1 . xid/+ [phenotypically like (NZB X NZW)F1].  In these and in additional studies, mice were housed in the same cages and identified by ear tagging so as to avoid possible environmental variations from cage to cage.  In these studies, xid/xid mice failed to develop the characteristic signs of autoimmunity, whereas the controls did.  Similar results were also obtained with (NZW X NZB)F1 xid/xid mice compared with (NZW X NZB)F1 xid/+ mice.  The effect of xid/xid upon (NZB X NZW)F1 mice was further investigated by assessing responses to immunization and polyclonal B cell activation in vivo.  The xid/xid mice failed to produce anti-ssDNA following immunization with ssDNA complexed to a protein carrier in fluid form or even emulsified in adjuvant.  Finally, the xid/xid mice failed to produce antiDNA in response to multiple injections of the polyclonal activator, bacterial lipopolysaccharide (LPS), or the polyclonal activator, polyribose inosinic acid . polyribose cytidylic acid.  However, the xid/xid mice were neither generally hyporesponsive nor unable to recognize LPS because they made normal antibody responses following immunization with LPS to which multiple trinitrophenyl groups were chemically attached.  We conclude from these studies that xid/xid, which is known to cause the deletion of a B cell subset, has a profound affect upon (NZB X NZW)F1 mice, rendering them insusceptible to the naturally occurring autoimmune disease characteristic of (NZB X NZW)F1 mice, and preventing them from producing antibodies to DNA despite purposeful immunization and polyclonal B cell activation.  These results force a reevaluation of previous concepts regarding the mechanisms by which xid/xid might interfere with the development of autoimmunity, and a consideration of therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThDLn7032pYRBrI9DTGjC0fW6udTcc2eaGj4n6k7kyGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D&md5=8608a4617f65a1c46ef46a6e5388f7a6</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1172%2FJCI110651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI110651%26sid%3Dliteratum%253Aachs%26aulast%3DSteinberg%26aufirst%3DB.%2BJ.%26aulast%3DSmathers%26aufirst%3DP.%2BA.%26aulast%3DFrederiksen%26aufirst%3DK.%26aulast%3DSteinberg%26aufirst%3DA.%2BD.%26atitle%3DAbility%2520of%2520the%2520xid%2520gene%2520to%2520prevent%2520autoimmunity%2520in%2520%2528NZBXNZW%2529F1%2520mice%2520during%2520the%2520course%2520of%2520their%2520natural%2520history%252C%2520after%2520polyclonal%2520stimulation%252C%2520or%2520following%2520immunization%2520with%2520DNA%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1982%26volume%3D70%26spage%3D587%26epage%3D597%26doi%3D10.1172%2FJCI110651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postelnek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, D.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pashine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivassan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J. S.</span><span> </span><span class="NLM_article-title">RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1124/jpet.111.187740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.-Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivassanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+abrogates+immune+hypersensitivity+responses+and+arthritis+in+rodents&doi=10.1124%2Fjpet.111.187740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span></div><div class="casAuthors">Xu, Daigen; Kim, Yong; Postelnek, Jennifer; Vu, Minh Diem; Hu, Dong-Qing; Liao, Cheng; Bradshaw, Mike; Hsu, Jonathan; Zhang, Jun; Pashine, Achal; Srinivasan, Dinesh; Woods, John; Levin, Anita; O'Mahony, Alison; Owens, Timothy D.; Lou, Yan; Hill, Ronald J.; Narula, Satwant; DeMartino, Julie; Fine, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic mutation and pharmacol. inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor crosslinking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α prodn. in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-mol. disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBTQENfl5RbVg90H21EOLACvtfcHk0lhMy-u83CzhTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D&md5=06be56a47afd2eb09e0871710c1d2b47</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivassan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520abrogates%2520immune%2520hypersensitivity%2520responses%2520and%2520arthritis%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103%26doi%3D10.1124%2Fjpet.111.187740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Di Paolo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barck, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carano, R. A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeForge, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrando, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannetti, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymowitz, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staker, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell and myeloid cell-mediated arthritis</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span><span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lhCjmTx61zP4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%2BP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rankin, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreyeva, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmonds, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathialagan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benoit, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeva, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homer, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunussi-Joannopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.,  III.</span><span> </span><span class="NLM_article-title">Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">4540</span><span class="NLM_x">–</span> <span class="NLM_lpage">4550</span><span class="refDoi"> DOI: 10.4049/jimmunol.1301553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.4049%2Fjimmunol.1301553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=24068666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=4540-4550&author=A.+L.+Rankinauthor=N.+Sethauthor=S.+Keeganauthor=T.+Andreyevaauthor=T.+A.+Cookauthor=J.+Edmondsauthor=N.+Mathialaganauthor=M.+J.+Bensonauthor=J.+Syedauthor=Y.+Zhanauthor=S.+E.+Benoitauthor=J.+S.+Miyashiroauthor=N.+Woodauthor=S.+Mohanauthor=E.+Peevaauthor=S.+K.+Ramaiahauthor=D.+Messingauthor=B.+L.+Homerauthor=K.+Dunussi-Joannopoulosauthor=C.+L.+Nickerson-Nutterauthor=M.+E.+Schnuteauthor=J.+Douhan&title=Selective+inhibition+of+BTK+prevents+murine+lupus+and+antibody-mediated+glomerulonephritis&doi=10.4049%2Fjimmunol.1301553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span></div><div class="casAuthors">Rankin, Andrew L.; Seth, Nilufer; Keegan, Sean; Andreyeva, Tatyana; Cook, Tim A.; Edmonds, Jason; Mathialagan, Nagappan; Benson, Micah J.; Syed, Jameel; Zhan, Yutian; Benoit, Stephen E.; Miyashiro, Joy S.; Wood, Nancy; Mohan, Shashi; Peeva, Elena; Ramaiah, Shashi K.; Messing, Dean; Homer, Bruce L.; Dunussi-Joannopoulos, Kyri; Nickerson-Nutter, Cheryl L.; Schnute, Mark E.; Douhan, John, III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4540-4550</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Autoantibody prodn. and immune complex deposition within the kidney promote renal disease in patients with lupus nephritis.  Thus, therapeutics that inhibit these pathways may be efficacious in the treatment of systemic lupus erythematosus.  Bruton's tyrosine kinase (BTK) is a crit. signaling component of both BCR and FcR signaling.  We sought to assess the efficacy of inhibiting BTK in the development of lupus-like disease, and in this article describe (R)-5-amino-1-(1-cyanopiperidin-3-yl)-3-(4-[2,4-difluorophenoxy]phenyl)-1H-pyrazole-4-carboxamide (PF-06250112), a novel highly selective and potent BTK inhibitor.  We demonstrate in vitro that PF-06250112 inhibits both BCR-mediated signaling and proliferation, as well as FcR-mediated activation.  To assess the therapeutic impact of BTK inhibition, we treated aged NZBxWF1 mice with PF-06250112 and demonstrate that PF-06250112 significantly limits the spontaneous accumulation of splenic germinal center B cells and plasma cells.  Correspondingly, anti-dsDNA and autoantibody levels were reduced in a dose-dependent manner.  Moreover, administration of PF-06250112 prevented the development of proteinuria and improved glomerular pathol. scores in all treatment groups.  Strikingly, this therapeutic effect could occur with only a modest redn. obsd. in anti-dsDNA titers, implying a crit. role for BTK signaling in disease pathogenesis beyond inhibition of autoantibody prodn.  We subsequently demonstrate that PF-06250112 prevents proteinuria in an FcR-dependent, Ab-mediated model of glomerulonephritis.  Importantly, these results highlight that BTK inhibition potently limits the development of glomerulonephritis by impacting both cell- and effector mol.-mediated pathways.  These data provide support for evaluating the efficacy of BTK inhibition in systemic lupus erythematosus patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBldekay4INLVg90H21EOLACvtfcHk0lhCjmTx61zP4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE&md5=7abfb074bf422aa3fb63aa0bc3d8cf58</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301553%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DA.%2BL.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DAndreyeva%26aufirst%3DT.%26aulast%3DCook%26aufirst%3DT.%2BA.%26aulast%3DEdmonds%26aufirst%3DJ.%26aulast%3DMathialagan%26aufirst%3DN.%26aulast%3DBenson%26aufirst%3DM.%2BJ.%26aulast%3DSyed%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBenoit%26aufirst%3DS.%2BE.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BS.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPeeva%26aufirst%3DE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DHomer%26aufirst%3DB.%2BL.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DDouhan%26aufirst%3DJ.%26atitle%3DSelective%2520inhibition%2520of%2520BTK%2520prevents%2520murine%2520lupus%2520and%2520antibody-mediated%2520glomerulonephritis%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D4540%26epage%3D4550%26doi%3D10.4049%2Fjimmunol.1301553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Structural bioinformatics-based design of selective, irreversible kinase inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">1318</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span><span class="refDoi"> DOI: 10.1126/science1108367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1126%2Fscience1108367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=15919995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=1318-1321&author=M.+S.+Cohenauthor=C.+Zhangauthor=K.+M.+Shokatauthor=J.+Taunton&title=Structural+bioinformatics-based+design+of+selective%2C+irreversible+kinase+inhibitors&doi=10.1126%2Fscience1108367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Cohen, Michael S.; Zhang, Chao; Shokat, Kevan M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5726</span>),
    <span class="NLM_cas:pages">1318-1321</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge.  We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK).  A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells.  Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter.  Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovfUrzVFth_bVg90H21EOLACvtfcHk0ljr7tWGPY05pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D&md5=1364444dada4d1d46510aa0212428952</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1126%2Fscience1108367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience1108367%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DStructural%2520bioinformatics-based%2520design%2520of%2520selective%252C%2520irreversible%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D1318%26epage%3D1321%26doi%3D10.1126%2Fscience1108367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Leproult, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moras, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurtz, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span><span class="refDoi"> DOI: 10.1021/jm101396q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.-M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformationally+distinct+kinase+nucleotide+binding+sites%3A+application+to+the+design+of+selective+covalent+inhibitors&doi=10.1021%2Fjm101396q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span></div><div class="casAuthors">Leproult, Emeline; Barluenga, Sofia; Moras, Dino; Wurtz, Jean-Marie; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1347-1355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases have emerged as one of the most prolific therapeutic targets.  An important criterion in the therapeutic success of inhibitors targeting the nucleotide binding pocket of kinases is the inhibitor residence time.  Recently, covalent kinase inhibitors have attracted attention since they confer terminal inhibition and should thus be more effective than reversible inhibitors with transient inhibition.  The most robust approach to design irreversible inhibitors is to capitalize on the nucleophilicity of a cysteine thiol group present in the target protein.  Herein, the authors report a systematic anal. of cysteine residues present in the nucleotide binding site of kinases, which could be harnessed for irreversible inhibition, taking into consideration the different kinase conformations.  The authors demonstrate the predictive power of this anal. with the design and validation of an irreversible inhibitor of KIT/PDGFR kinases.  This is the first example of a covalent kinase inhibitor that combines a pharmacophore addressing the DFG-out conformation with a covalent trap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzqt0gMrz3rVg90H21EOLACvtfcHk0ljr7tWGPY05pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D&md5=329ae5eaa6102b6dd34a0d1274631247</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.-M.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformationally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1347%26epage%3D1355%26doi%3D10.1021%2Fjm101396q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Burger, J. A.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (BTK) inhibitors in clinical trials</span> <span class="citation_source-journal">Curr. Hematol. Malig. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">49</span><span class="refDoi"> DOI: 10.1007/s11899-013-0188-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1007%2Fs11899-013-0188-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=24357428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A280%3ADC%252BC2c3nvV2rsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=44-49&author=J.+A.+Burger&title=Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+in+clinical+trials&doi=10.1007%2Fs11899-013-0188-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (BTK) inhibitors in clinical trials</span></div><div class="casAuthors">Burger Jan A</div><div class="citationInfo"><span class="NLM_cas:title">Current hematologic malignancy reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the B-cell receptor (BCR) and tissue homing receptors.  Genetic BTK deletion causes B-cell immunodeficiency in humans and mice, making this kinase an attractive therapeutic target for B-cell disorders.  The BTK inhibitor ibrutinib (PCI-32765, brand name: Imbruvica) demonstrated high clinical activity in B-cell malignancies, especially in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom's macroglobulinemia (WM).  Therefore, ibrutinib was granted a 'breakthrough therapy' designation for these indications and was recently approved for the treatment of relapsed MCL by the U.S.  Food and Drug Administration.  Other BTK inhibitors in earlier clinical development include CC-292 (AVL-292), and ONO-4059.  In CLL and MCL, ibrutinib characteristically induces redistribution of malignant B cells from tissue sites into the peripheral blood, along with rapid resolution of enlarged lymph nodes and a surge in lymphocytosis.  With continuous ibrutinib therapy, growth- and survival-inhibitory activities of ibrutinib result in the normalization of lymphocyte counts and remissions in a majority of patients.  This review discusses the clinical advances with BTK inhibitor therapy, as well as its pathophysiological basis, and outlines perspectives for future use of BTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqhvp3dQ4UIub6AVA-44PTfW6udTcc2ebodxfK8Wcecrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3nvV2rsg%253D%253D&md5=2e6e9639a96e00f2669027ab74f8c7c4</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1007%2Fs11899-013-0188-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11899-013-0188-8%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520in%2520clinical%2520trials%26jtitle%3DCurr.%2520Hematol.%2520Malig.%2520Rep.%26date%3D2014%26volume%3D9%26spage%3D44%26epage%3D49%26doi%3D10.1007%2Fs11899-013-0188-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Akinleye, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span> </span><span class="NLM_article-title">Ibrutinib and novel BTK inhibitors in clinical development</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1186/1756-8722-6-59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1186%2F1756-8722-6-59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=23958373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=59-67&author=A.+Akinleyeauthor=Y.+Chenauthor=N.+Mukhiauthor=Y.+Songauthor=D.+Liu&title=Ibrutinib+and+novel+BTK+inhibitors+in+clinical+development&doi=10.1186%2F1756-8722-6-59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib and novel BTK inhibitors in clinical development</span></div><div class="casAuthors">Akinleye, Akintunde; Chen, Yamei; Mukhi, Nikhil; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Small mol. inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clin. outcomes in cancer patients.  Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders.  Ibrutinib, a novel first-in-human BTK inhibitor, has demonstrated clin. effectiveness and tolerability in early clin. trials and has progressed into phase III trials.  However, addnl. research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition.  This review summarizes preclin. and clin. development of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292 and ONO-4059, CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-fz7_rhCHvbVg90H21EOLACvtfcHk0ljr7tWGPY05pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI&md5=e5067b998c61818e2efbb62da935b490</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-6-59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-6-59%26sid%3Dliteratum%253Aachs%26aulast%3DAkinleye%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMukhi%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DIbrutinib%2520and%2520novel%2520BTK%2520inhibitors%2520in%2520clinical%2520development%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D6%26spage%3D59%26epage%3D67%26doi%3D10.1186%2F1756-8722-6-59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Whang, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B. Y.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1200</span><span class="NLM_x">–</span> <span class="NLM_lpage">1204</span><span class="refDoi"> DOI: 10.1016/j.drudis.2014.03.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.drudis.2014.03.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=24721226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvV2ntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1200-1204&author=J.+A.+Whangauthor=B.+Y.+Chang&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1016%2Fj.drudis.2014.03.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Whang, Jennifer A.; Chang, Betty Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1200-1204</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The function and role of Bruton's tyrosine kinase (BTK) in human B cell development was demonstrated by its assocn. with X-linked agammaglobulinemia (XLA) manifested by a substantial redn. in Igs and B cells.  BTK has a crucial role in pre-B cell receptor (BCR) and BCR signaling during normal B cell development and activation.  Aberrant BCR signaling is assocd. with autoimmune diseases, such as rheumatoid arthritis (RA).  In addn., BTK is also expressed in myeloid cell populations, including monocytes, macrophages, neutrophils and mast cells.  These innate cells infiltrate the synovial cavity and produce inflammatory cytokines, aggravating arthritic symptoms.  In myeloid cell populations, BTK functions downstream of the Fcγ receptors (FcγR) and Fcε receptors (FcεR) [1,2].  In the absence of BTK, FcR-mediated functions, such as cytokine prodn., are impaired.  In addn., Xid mice, which have a mutation in BTK, have decreased susceptibility to developing collagen-induced arthritis (CIA) [3].  Given that BTK is involved in multiple signaling pathways downstream of the BCR and FcR, it is an attractive therapeutic target for RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrfM0cjYRpt7Vg90H21EOLACvtfcHk0lgw0JuznZewww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvV2ntLw%253D&md5=59de1ccd677bb64001719daf5e83952e</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.03.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.03.028%26sid%3Dliteratum%253Aachs%26aulast%3DWhang%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DB.%2BY.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1200%26epage%3D1204%26doi%3D10.1016%2Fj.drudis.2014.03.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thamm, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">13075</span><span class="NLM_x">–</span> <span class="NLM_lpage">13080</span><span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11dR"><div class="casContent"><span class="casTitleNuber">11d</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0lgw0JuznZewww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit11d&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bradshaw, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paavilainen, V. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisconte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romanov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loughhead, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunn, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karr, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerritsen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">525</span><span class="NLM_x">–</span> <span class="NLM_lpage">531</span><span class="refDoi"> DOI: 10.1038/nchembio.1817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1038%2Fnchembio.1817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=26006010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=525-531&author=J.+M.+Bradshawauthor=J.+M.+McFarlandauthor=V.+O.+Paavilainenauthor=A.+Bisconteauthor=D.+Tamauthor=V.+T.+Phanauthor=S.+Romanovauthor=D.+Finkleauthor=J.+Shuauthor=V.+Patelauthor=T.+Tonauthor=X.+Liauthor=D.+G.+Loughheadauthor=P.+A.+Nunnauthor=D.+E.+Karrauthor=M.+E.+Gerritsenauthor=J.+O.+Funkauthor=T.+D.+Owensauthor=E.+Vernerauthor=K.+A.+Brameldauthor=R.+J.+Hillauthor=D.+M.+Goldsteinauthor=J.+Taunton&title=Prolonged+and+tunable+residence+time+using+reversible+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged and tunable residence time using reversible covalent kinase inhibitors</span></div><div class="casAuthors">Bradshaw, J. Michael; McFarland, Jesse M.; Paavilainen, Ville O.; Bisconte, Angelina; Tam, Danny; Phan, Vernon T.; Romanov, Sergei; Finkle, David; Shu, Jin; Patel, Vaishali; Ton, Tony; Li, Xiaoyan; Loughhead, David G.; Nunn, Philip A.; Karr, Dane E.; Gerritsen, Mary E.; Funk, Jens Oliver; Owens, Timothy D.; Verner, Erik; Brameld, Ken A.; Hill, Ronald J.; Goldstein, David M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">525-531</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking.  Here the authors made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors.  Using an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, the authors identified potent and selective BTK inhibitors that demonstrated biochem. residence times spanning from minutes to 7 d.  An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK for more than 18 h after clearance from the circulation.  The inverted cyanoacrylamide strategy was further used to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating the generalizability of the approach.  Targeting of noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates 'residence time by design', the ability to modulate and improve the duration of target engagement in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXCpNprhn6kLVg90H21EOLACvtfcHk0ljcHexWUzkFcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7%252FE&md5=85a73d9ecd62695d03166f7009c68dd8</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1817%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DPaavilainen%26aufirst%3DV.%2BO.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DPhan%26aufirst%3DV.%2BT.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DFinkle%26aufirst%3DD.%26aulast%3DShu%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DTon%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLoughhead%26aufirst%3DD.%2BG.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DKarr%26aufirst%3DD.%2BE.%26aulast%3DGerritsen%26aufirst%3DM.%2BE.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DProlonged%2520and%2520tunable%2520residence%2520time%2520using%2520reversible%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fnchembio.1817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Park, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byun, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suh, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span> </span><span class="NLM_article-title">HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: A potential drug for rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.1186/s13075-016-0988-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1186%2Fs13075-016-0988-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=26732314" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=1-9&author=J.+K.+Parkauthor=J.-Y.+Byunauthor=J.+A.+Parkauthor=Y.-Y.+Kimauthor=Y.+J.+Leeauthor=J.+I.+Ohauthor=S.+Y.+Jangauthor=Y.+H.+Kimauthor=Y.+W.+Songauthor=J.+Sonauthor=K.+H.+Suhauthor=Y.-M.+Leeauthor=E.+B.+Lee&title=HM71224%2C+a+novel+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+suppresses+B+cell+and+monocyte+activation+and+ameliorates+arthritis+in+a+mouse+model%3A+A+potential+drug+for+rheumatoid+arthritis&doi=10.1186%2Fs13075-016-0988-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1186%2Fs13075-016-0988-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-016-0988-z%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DByun%26aufirst%3DJ.-Y.%26aulast%3DPark%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DY.-Y.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DOh%26aufirst%3DJ.%2BI.%26aulast%3DJang%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DSong%26aufirst%3DY.%2BW.%26aulast%3DSon%26aufirst%3DJ.%26aulast%3DSuh%26aufirst%3DK.%2BH.%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DLee%26aufirst%3DE.%2BB.%26atitle%3DHM71224%252C%2520a%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520suppresses%2520B%2520cell%2520and%2520monocyte%2520activation%2520and%2520ameliorates%2520arthritis%2520in%2520a%2520mouse%2520model%253A%2520A%2520potential%2520drug%2520for%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2016%26volume%3D18%26spage%3D1%26epage%3D9%26doi%3D10.1186%2Fs13075-016-0988-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Park, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suh, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span> </span><span class="NLM_article-title">HM71224, a novel oral BTK inhibitor, inhibits human immune cell activation: New drug candidate to treat B-cell associated autoimmune diseases</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span><span class="refDoi"> DOI: 10.1136/annrheumdis-2014-eular.2783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1136%2Fannrheumdis-2014-eular.2783" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=355-356&author=J.+K.+Parkauthor=J.+A.+Parkauthor=Y.+J.+Leeauthor=J.+Songauthor=J.+I.+Ohauthor=Y.-M.+Leeauthor=K.+H.+Suhauthor=J.+Sonauthor=E.+B.+Lee&title=HM71224%2C+a+novel+oral+BTK+inhibitor%2C+inhibits+human+immune+cell+activation%3A+New+drug+candidate+to+treat+B-cell+associated+autoimmune+diseases&doi=10.1136%2Fannrheumdis-2014-eular.2783"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2014-eular.2783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2014-eular.2783%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DOh%26aufirst%3DJ.%2BI.%26aulast%3DLee%26aufirst%3DY.-M.%26aulast%3DSuh%26aufirst%3DK.%2BH.%26aulast%3DSon%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26atitle%3DHM71224%252C%2520a%2520novel%2520oral%2520BTK%2520inhibitor%252C%2520inhibits%2520human%2520immune%2520cell%2520activation%253A%2520New%2520drug%2520candidate%2520to%2520treat%2520B-cell%2520associated%2520autoimmune%2520diseases%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2014%26volume%3D73%26spage%3D355%26epage%3D356%26doi%3D10.1136%2Fannrheumdis-2014-eular.2783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Evans, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aslanian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witowski, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lounsbury, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazdiyasni, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freed, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span> </span><span class="NLM_article-title">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">228</span><span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+Btk+with+CC-292+provides+early+pharmacodynamic+assessment+of+activity+in+mice+and+humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12dR"><div class="casContent"><span class="casTitleNuber">12d</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0ljcHexWUzkFcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520Btk%2520with%2520CC-292%2520provides%2520early%2520pharmacodynamic%2520assessment%2520of%2520activity%2520in%2520mice%2520and%2520humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiadeen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krikorian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boga, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alhassan, A.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaccaro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Man, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischmann, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raaijmakers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu-Pham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Presland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manusueto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leccese, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang-Hoover, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knemeyer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garlisi, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bays, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stivers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandish, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, J. A.</span><span> </span><span class="NLM_article-title">Discovery of 8-amino-imidazo[1,5-a]pyrazines as reversible selective BTK inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=198-203&author=J.+Liuauthor=D.+Guiadeenauthor=A.+Krikorianauthor=X.+Gaoauthor=J.+Wangauthor=S.+B.+Bogaauthor=A.-B.+Alhassanauthor=Y.+Yuauthor=H.+Vaccaroauthor=S.+Liuauthor=C.+Yangauthor=H.+Wuauthor=A.+Cooperauthor=A.+De+Manauthor=A.+Kapteinauthor=K.+Maloneyauthor=V.+Hornakauthor=Y.-D.+Gaoauthor=T.+O.+Fischmannauthor=H.+Raaijmakersauthor=D.+Vu-Phamauthor=J.+Preslandauthor=M.+Manusuetoauthor=Z.+Xuauthor=E.+Lecceseauthor=J.+Zhang-Hooverauthor=I.+Knemeyerauthor=C.+G.+Garlisiauthor=N.+Baysauthor=P.+Stiversauthor=P.+E.+Brandishauthor=A.+Hicksauthor=R.+Kimauthor=J.+A.+Kozlowski&title=Discovery+of+8-amino-imidazo%5B1%2C5-a%5Dpyrazines+as+reversible+selective+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Facsmedchemlett.5b00463"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00463%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGuiadeen%26aufirst%3DD.%26aulast%3DKrikorian%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBoga%26aufirst%3DS.%2BB.%26aulast%3DAlhassan%26aufirst%3DA.-B.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DVaccaro%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DDe%2BMan%26aufirst%3DA.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DMaloney%26aufirst%3DK.%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DGao%26aufirst%3DY.-D.%26aulast%3DFischmann%26aufirst%3DT.%2BO.%26aulast%3DRaaijmakers%26aufirst%3DH.%26aulast%3DVu-Pham%26aufirst%3DD.%26aulast%3DPresland%26aufirst%3DJ.%26aulast%3DManusueto%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLeccese%26aufirst%3DE.%26aulast%3DZhang-Hoover%26aufirst%3DJ.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DGarlisi%26aufirst%3DC.%2BG.%26aulast%3DBays%26aufirst%3DN.%26aulast%3DStivers%26aufirst%3DP.%26aulast%3DBrandish%26aufirst%3DP.%2BE.%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DR.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25208-amino-imidazo%255B1%252C5-a%255Dpyrazines%2520as%2520reversible%2520selective%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D198%26epage%3D203%26doi%3D10.1021%2Facsmedchemlett.5b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomgren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dambach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaluso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Discovery of highly potent and selective Bruton’s tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">579</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.bmcl.2015.11.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=26675441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ms77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=575-579&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=C.+Eigenbrotauthor=S.+Gallionauthor=A.+R.+Johnsonauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=C.+Yuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Discovery+of+highly+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+Pyridazinone+analogs+with+improved+metabolic+stability&doi=10.1016%2Fj.bmcl.2015.11.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Eigenbrot, Charles; Gallion, Steve; Johnson, Adam R.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Yu, Christine; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">575-579</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BTK inhibitor GDC-0834 was found to be rapidly metabolized in human studies, resulting in a suspension of clin. trials.  The primary route of metab. was through cleavage of the acyclic amide bond connecting the terminal tetrahydrobenzothiophene with the central linker aryl ring.  SAR studies were focused on reducing metabolic cleavage of this amide, and resulted in the identification of several central aryl linker substituents that conferred improved stability.  The most promising substituted aryl linkers were then incorporated into an optimized pyridazinone scaffold, resulting in the identification of lead analog I, possessing improved potency, metabolic stability and preclin. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWhbh3H4N2ErVg90H21EOLACvtfcHk0ljkI2V5j3-Oww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ms77M&md5=ff074fc16518d072ccb9b7b5d8520a03</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.076%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520Pyridazinone%2520analogs%2520with%2520improved%2520metabolic%2520stability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D575%26epage%3D579%26doi%3D10.1016%2Fj.bmcl.2015.11.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blomgren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dambach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymowitz, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaluso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1337</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.bmcl.2015.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=25701252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1333-1337&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=S.+Gallionauthor=S.+G.+Hymowitzauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=B.+Maurerauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=C.+G.+Sowellauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+Discovery+of+GDC-0834&doi=10.1016%2Fj.bmcl.2015.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models.  Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as 'H3 binding pocket'.  However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics.  Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics.  In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.  This information informed the back-up program and discovery of improved inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhL04eYDiT3bVg90H21EOLACvtfcHk0ljkI2V5j3-Oww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D&md5=fdebc0199c8222e093cfb9583244bce3</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520Discovery%2520of%2520GDC-0834%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2015.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Shi, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spergel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olini, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strnad, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muckelbauer, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tino, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Lucca, G. V.</span><span> </span><span class="NLM_article-title">Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2206</span><span class="NLM_x">–</span> <span class="NLM_lpage">2211</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.02.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.bmcl.2014.02.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=24685542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2206-2211&author=Q.+Shiauthor=A.+Tebbenauthor=A.+J.+Dyckmanauthor=H.+Liauthor=C.+Liuauthor=J.+Linauthor=S.+Spergelauthor=J.+R.+Burkeauthor=K.+W.+McIntyreauthor=G.+C.+Oliniauthor=J.+Strnadauthor=N.+Surtiauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=Y.+Anauthor=C.+Linauthor=Q.+Ruanauthor=K.+Leftherisauthor=P.+H.+Carterauthor=J.+A.+Tinoauthor=G.+V.+De+Lucca&title=Purine+derivatives+as+potent+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+for+autoimmune+diseases&doi=10.1016%2Fj.bmcl.2014.02.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases</span></div><div class="casAuthors">Shi, Qing; Tebben, Andrew; Dyckman, Alaric J.; Li, Hedy; Liu, Chunjian; Lin, James; Spergel, Steve; Burke, James R.; McIntyre, Kim W.; Olini, Gilbert C.; Strnad, Joann; Surti, Neha; Muckelbauer, Jodi K.; Chang, Chiehying; An, Yongmi; Cheng, Lin; Ruan, Qian; Leftheris, Katerina; Carter, Percy H.; Tino, Joseph; De Lucca, George V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2206-2211</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Investigation of various heterocyclic core isosteres of imidazopyrazines 1 & 2 yielded purine derivs. 3 & 8 as potent and selective BTK inhibitors.  Subsequent SAR studies of the purine series led to the discovery of 20 as a leading compd.  Compd. 20 is very selective when screened against a panel of 400 kinases and is a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited in vivo efficacy in a mouse PCA model.  Its X-ray co-crystal structure with BTK shows that the high selectivity is gained from filling a BTK specific lipophilic pocket.  However, phys. and ADME properties leading to low oral exposure hindered further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobsHsC5Hi6lbVg90H21EOLACvtfcHk0liGmthJeAIrdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D&md5=1b1649221d615d9805d5cc197a39e05a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.02.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.02.075%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DOlini%26aufirst%3DG.%2BC.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DLeftheris%26aufirst%3DK.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26atitle%3DPurine%2520derivatives%2520as%2520potent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520for%2520autoimmune%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2206%26epage%3D2211%26doi%3D10.1016%2Fj.bmcl.2014.02.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batt, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muckelbauer, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pokross, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tino, J. A.</span><span> </span><span class="NLM_article-title">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">4265</span><span class="NLM_x">–</span> <span class="NLM_lpage">4269</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.bmcl.2015.07.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=26320619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4265-4269&author=Q.+Liuauthor=D.+G.+Battauthor=J.+S.+Lippyauthor=N.+Surtiauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=L.+Chenauthor=Y.+Anauthor=C.+Changauthor=M.+Pokrossauthor=Z.+Yangauthor=H.+Wangauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Design+and+synthesis+of+carbazole+carboxamides+as+promising+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+and+Janus+kinase+2+%28JAK2%29&doi=10.1016%2Fj.bmcl.2015.07.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span></div><div class="casAuthors">Liu, Qingjie; Batt, Douglas G.; Lippy, Jonathan S.; Surti, Neha; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chen, Lin; An, Yongmi; Chang, Chiehying; Pokross, Matt; Yang, Zheng; Wang, Haiqing; Burke, James R.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4265-4269</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Four series of disubstituted carbazole-1-carboxamides, e.g. I [R = 2-F, 3-MeO, 2-Me, etc.] were designed and synthesized as inhibitors of Bruton's tyrosine kinase.  4,7- And 4,6-Disubstituted carbazole-1-carboxamides were potent and selective inhibitors of BTK, while 3,7- and 3,6-disubstituted carbazole-1-carboxamides were potent and selective inhibitors of Janus kinase 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD3SZfBfD4ZbVg90H21EOLACvtfcHk0liGmthJeAIrdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF&md5=3558c8ca9a9c29bb38ef98936f61200a</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.102%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520carbazole%2520carboxamides%2520as%2520promising%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520and%2520Janus%2520kinase%25202%2520%2528JAK2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4265%26epage%3D4269%26doi%3D10.1016%2Fj.bmcl.2015.07.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Lucca, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batt, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rampulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discenza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obermeier, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickery, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebben, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muckelbauer, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattoli, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukral, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter-Cid, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tino, J. A.</span><span> </span><span class="NLM_article-title">Small molecule reversible inhibitors of Bruton’s tyrosine Kinase (BTK): Structure-activity relationships leading to the identification of 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7915</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7915&author=G.+B.+De+Luccaauthor=Q.+Shiauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+B.+Bertrandauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=J.+Daiauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=Y.+Zhangauthor=Z.+Yangauthor=P.+H.+Maratheauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Y.+Changauthor=H.+Zhangauthor=K.+Gilloolyauthor=T.+L.+Taylorauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=D.+W.+Kukralauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Small+molecule+reversible+inhibitors+of+Bruton%E2%80%99s+tyrosine+Kinase+%28BTK%29%3A+Structure-activity+relationships+leading+to+the+identification+of+7-%282-hydroxypropan-2-yl%29-4-%5B2-methyl-3-%284-oxo-3%2C4-dihydroquinazolin-3-yl%29phenyl%5D-9H-carbazole-1-carboxamide+%28BMS-935177%29&doi=10.1021%2Facs.jmedchem.6b00722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span></div><div class="casAuthors">De Lucca, George V.; Shi, Qing; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Rampulla, Rick; Mathur, Arvind; Discenza, Lorell; D'Arienzo, Celia; Dai, Jun; Obermeier, Mary; Vickery, Rodney; Zhang, Yingru; Yang, Zheng; Marathe, Punit; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chang, ChiehYing J.; Zhang, Huiping; Gillooly, Kathleen; Taylor, Tracy; Pattoli, Mark A.; Skala, Stacey; Kukral, Daniel W.; McIntyre, Kim W.; Salter-Cid, Luisa; Fura, Aberra; Burke, James R.; Barrish, Joel C.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7915-7935</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a crit. role in multiple cell types responsible for numerous autoimmune diseases.  This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK.  With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1HUwZaRn_w7Vg90H21EOLACvtfcHk0lgeX3jaA9jU4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M&md5=7c7ec1a52121c541753c045c1cbf758b</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00722%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BB.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBertrand%26aufirst%3DM.%2BB.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DSmall%2520molecule%2520reversible%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520Kinase%2520%2528BTK%2529%253A%2520Structure-activity%2520relationships%2520leading%2520to%2520the%2520identification%2520of%25207-%25282-hydroxypropan-2-yl%2529-4-%255B2-methyl-3-%25284-oxo-3%252C4-dihydroquinazolin-3-yl%2529phenyl%255D-9H-carbazole-1-carboxamide%2520%2528BMS-935177%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7915%26doi%3D10.1021%2Facs.jmedchem.6b00722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Liu, Q.; Batt, D. G.; Delucca, G. V.; Shi, Q.; Tebben, A. J.</span><span> </span><span class="NLM_article-title">Preparation of carbazole carboxamide compounds useful as kinase inhibitors</span>. US 20100160303;  <span class="citation_source-journal">Chem. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">116044</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2010&pages=116044&author=Q.+Liu&author=D.+G.+Batt&author=G.+V.+Delucca&author=Q.+Shi&author=A.+J.+Tebben&title=Preparation+of+carbazole+carboxamide+compounds+useful+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DPreparation%2520of%2520carbazole%2520carboxamide%2520compounds%2520useful%2520as%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Abstr.%26date%3D2010%26volume%3D153%26spage%3D116044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Batt, D. G.; Bertrand, M. B.; Delucca, G. V.; Galella, M. A.; Ko, S. S.; Langevine, C. M.; Liu, Q.; Qing, S.; Srivastava, A. S.; Tino, J. A.; Watterson, S. H.</span><span> </span><span class="NLM_article-title">Substituted carbazolecarboxamide derivatives as BTK inhibitors and their preparation and use for the treatment of diseases</span>. WO 2014210085.  <span class="citation_source-journal">Chem. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">162</span><span class="NLM_x">, </span> <span class="NLM_fpage">161072</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2014&pages=161072&author=D.+G.+Batt&author=M.+B.+Bertrand&author=G.+V.+Delucca&author=M.+A.+Galella&author=S.+S.+Ko&author=C.+M.+Langevine&author=Q.+Liu&author=S.+Qing&author=A.+S.+Srivastava&author=J.+A.+Tino&author=S.+H.+Watterson&title=Substituted+carbazolecarboxamide+derivatives+as+BTK+inhibitors+and+their+preparation+and+use+for+the+treatment+of+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBatt%26aufirst%3DD.%2BG.%26atitle%3DSubstituted%2520carbazolecarboxamide%2520derivatives%2520as%2520BTK%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520for%2520the%2520treatment%2520of%2520diseases%26jtitle%3DChem.%2520Abstr.%26date%3D2014%26volume%3D162%26spage%3D161072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ko, S. S.; Batt, D. A.; Bertrand, M. B.; Delucca, G. V.; Langevine, C. M.; Liu, Q.; Srivastava, A. S.; Watterson, S. H.</span><span> </span><span class="NLM_article-title">Preparation of 4-phenylcarbazole-1-carboxamide compounds useful as Bruton’s tyrosine kinase (BTK) inhibitors</span>. WO 2014210087.  <span class="citation_source-journal">Chem. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">162</span><span class="NLM_x">, </span> <span class="NLM_fpage">150740</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2014&pages=150740&author=S.+S.+Ko&author=D.+A.+Batt&author=M.+B.+Bertrand&author=G.+V.+Delucca&author=C.+M.+Langevine&author=Q.+Liu&author=A.+S.+Srivastava&author=S.+H.+Watterson&title=Preparation+of+4-phenylcarbazole-1-carboxamide+compounds+useful+as+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DS.%2BS.%26atitle%3DPreparation%2520of%25204-phenylcarbazole-1-carboxamide%2520compounds%2520useful%2520as%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%26jtitle%3DChem.%2520Abstr.%26date%3D2014%26volume%3D162%26spage%3D150740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Miyaura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, A.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed cross-coupling reactions of organoboron compounds</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">2457</span><span class="NLM_x">–</span> <span class="NLM_lpage">2483</span><span class="refDoi"> DOI: 10.1021/cr00039a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-catalyzed+cross-coupling+reactions+of+organoboron+compounds&doi=10.1021%2Fcr00039a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0lgeX3jaA9jU4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-catalyzed%2520cross-coupling%2520reactions%2520of%2520organoboron%2520compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26spage%3D2457%26epage%3D2483%26doi%3D10.1021%2Fcr00039a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Smith, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquez, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokensgard, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rheingold, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hecht, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafson, J. L.</span><span> </span><span class="NLM_article-title">Exploiting atropisomerization to increase the target selectivity of kinase inhibitors</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">11754</span><span class="refDoi"> DOI: 10.1002/anie.201506085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1002%2Fanie.201506085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=11754&author=D.+E.+Smithauthor=I.+Marquezauthor=M.+E.+Lokensgardauthor=A.+L.+Rheingoldauthor=D.+A.+Hechtauthor=J.+L.+Gustafson&title=Exploiting+atropisomerization+to+increase+the+target+selectivity+of+kinase+inhibitors&doi=10.1002%2Fanie.201506085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506085%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BE.%26aulast%3DMarquez%26aufirst%3DI.%26aulast%3DLokensgard%26aufirst%3DM.%2BE.%26aulast%3DRheingold%26aufirst%3DA.%2BL.%26aulast%3DHecht%26aufirst%3DD.%2BA.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26atitle%3DExploiting%2520atropisomerization%2520to%2520increase%2520the%2520target%2520selectivity%2520of%2520kinase%2520inhibitors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D11754%26doi%3D10.1002%2Fanie.201506085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nalbandian, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hecht, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafson, J. L.</span><span> </span><span class="NLM_article-title">The preorganizaton of atropisomers to increase target selectivity</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">983</span><span class="refDoi"> DOI: 10.1055/s-0035-1561314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1055%2Fs-0035-1561314" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=977-983&author=C.+J.+Nalbandianauthor=D.+E.+Hechtauthor=J.+L.+Gustafson&title=The+preorganizaton+of+atropisomers+to+increase+target+selectivity&doi=10.1055%2Fs-0035-1561314"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1055%2Fs-0035-1561314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0035-1561314%26sid%3Dliteratum%253Aachs%26aulast%3DNalbandian%26aufirst%3DC.%2BJ.%26aulast%3DHecht%26aufirst%3DD.%2BE.%26aulast%3DGustafson%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520preorganizaton%2520of%2520atropisomers%2520to%2520increase%2520target%2520selectivity%26jtitle%3DSynlett%26date%3D2016%26volume%3D27%26spage%3D977%26epage%3D983%26doi%3D10.1055%2Fs-0035-1561314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fader, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandrick, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandrick, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hucke, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemper, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, S. P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P. J.</span><span> </span><span class="NLM_article-title">Assessing atropisomer axial chirality in drug discovery and development</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7005</span><span class="NLM_x">–</span> <span class="NLM_lpage">7022</span><span class="refDoi"> DOI: 10.1021/jm200584g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200584g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7005-7022&author=S.+R.+LaPlanteauthor=L.+D.+Faderauthor=K.+R.+Fandrickauthor=D.+R.+Fandrickauthor=O.+Huckeauthor=R.+Kemperauthor=S.+P.+F.+Millerauthor=P.+J.+Edwards&title=Assessing+atropisomer+axial+chirality+in+drug+discovery+and+development&doi=10.1021%2Fjm200584g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18c</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing Atropisomer Axial Chirality in Drug Discovery and Development</span></div><div class="casAuthors">LaPlante, Steven R.; Fader, Lee D.; Fandrick, Keith R.; Fandrick, Daniel R.; Hucke, Oliver; Kemper, Ray; Miller, Stephen P. F.; Edwards, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7005-7022</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ8uS-SDx68bVg90H21EOLACvtfcHk0ljr7sot0jUSSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFygu7zN&md5=6b44135b3871d2460fba4b3246b899e3</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1021%2Fjm200584g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200584g%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DFader%26aufirst%3DL.%2BD.%26aulast%3DFandrick%26aufirst%3DK.%2BR.%26aulast%3DFandrick%26aufirst%3DD.%2BR.%26aulast%3DHucke%26aufirst%3DO.%26aulast%3DKemper%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DS.%2BP.%2BF.%26aulast%3DEdwards%26aufirst%3DP.%2BJ.%26atitle%3DAssessing%2520atropisomer%2520axial%2520chirality%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7005%26epage%3D7022%26doi%3D10.1021%2Fjm200584g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Clayden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span> </span><span class="NLM_article-title">The challenge of atropisomerism in drug discovery</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6398</span><span class="NLM_x">–</span> <span class="NLM_lpage">6401</span><span class="refDoi"> DOI: 10.1002/anie.200901719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1002%2Fanie.200901719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=19637174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=6398-6401&author=J.+Claydenauthor=W.+J.+Moranauthor=P.+J.+Edwardsauthor=S.+R.+LaPlante&title=The+challenge+of+atropisomerism+in+drug+discovery&doi=10.1002%2Fanie.200901719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18dR"><div class="casContent"><span class="casTitleNuber">18d</span><div class="casTitle"><span class="NLM_cas:atitle">The Challenge of Atropisomerism in Drug Discovery</span></div><div class="casAuthors">Clayden, Jonathan; Moran, Wesley J.; Edwards, Paul J.; LaPlante, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">6398-6401</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Herein, we address the pharmaceutical implications of a hitherto largely overlooked alternative source of drug chirality: atropisomerism.  Atropisomers are conformers which, owing to steric or electronic constraints, interconvert slowly enough (by definition, with a half life of > 1000 s) that they can be isolated.'781 The stereochem. consequences of hindered rotation about a single bond can be such that an apparent single compd. can actually be a mixt. of two, or an apparently achiral compd. can actually be racemic.  If such pairs of stereoisomers are separable, then the implications for drug discovery may be similar to those of compds. with classical chiral centers.  In the context of a lack of std. procedures for dealing with atropisomerism, and the absence of specific regulatory policies governing conformationally based stereochem., we explore some recent examples of atropisomeric compds. that have been or are in drug development.  We also draw conclusions relating to potential strategies for design and development where atropisomerism is an issue.  We expose and propose options for the management of atropisomerism, which, many view as a lurking menace with the potential to significantly increase the cost of pharmaceutical research and development if ignored.  Atropisomerism may give rise to geometrical isomers, diastereoisomers, or enantiomers, all with the distinctive feature that they can in principle be equilibrated thermally.  In the absence of specific regulatory policies, atropisomeric stereoisomers are best dealt with in the same way as stereoisomers with classical chiral centers, but with isomerization rates and where necessary, differential conformer populations taken into account.  For racemic drug candidates, the FDA policy statement from 1992 emphasizes the importance of understanding the main therapeutic activities of the isomers through in vitro or in vivo studies.  Studies of the pharmacokinetic behavior of the individual enantiomers carried out early in the development of drug candidates are also valuable.  Knowledge gained from these studies can help guide the choice of development of a single enantiomer vs. a racemic mixt.  Development of a drug as a racemic mixt. may be appropriate if the mixt. is not reasonably separable (by synthetic methods, HPLC anal., etc.) or if racemization is rapid in vitro and/or in vivo (as in ibuprofen or thalidomide), thus making it futile to administer only the eutomer (more active isomer).  However, it is nonetheless highly recommended that crit. pharmacol. attributes related to the safety and efficacy of both isomers is investigated: overall, there must be an acceptable toxicol. profile and a suitable therapeutic window (in vitro, in animal models, and in humans).  FDA website provides some useful guidance to their expectations for drug development in this context.  Options for dealing with the phenomenon of atropisomerism can be implemented at the early stage of drug design.  For example, it may be possible to make related analogs that have the following features: (1) symmetry about a hindered bond, thus eliminating a chiral axis; (2) faster rotation about a hindered bond, thus pushing the half-life for conformational interconversion down to the order of seconds; (3) further encumbrance about a hindered bond to produce separable atropisomers whose interconversion is negligibly slow (for example, half-lives of the order of millennia); or (4) introduction of a stable stereogenic center to perturb the population of interconverting atropisomers such that only one desirable conformation predominates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsMjlS3iQPEbVg90H21EOLACvtfcHk0ljr7sot0jUSSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWiurfN&md5=70ff6fe476e7db4653130fe74af9325e</span></div><a href="/servlet/linkout?suffix=cit18d&amp;dbid=16384&amp;doi=10.1002%2Fanie.200901719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200901719%26sid%3Dliteratum%253Aachs%26aulast%3DClayden%26aufirst%3DJ.%26aulast%3DMoran%26aufirst%3DW.%2BJ.%26aulast%3DEdwards%26aufirst%3DP.%2BJ.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26atitle%3DThe%2520challenge%2520of%2520atropisomerism%2520in%2520drug%2520discovery%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D6398%26epage%3D6401%26doi%3D10.1002%2Fanie.200901719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Smyth, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. A.</span><span> </span><span class="NLM_article-title">A twist of nature – the significance of atropisomers in biological systems</span> <span class="citation_source-journal">Nat. Prod. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1562</span><span class="NLM_x">–</span> <span class="NLM_lpage">1583</span><span class="refDoi"> DOI: 10.1039/C4NP00121D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1039%2FC4NP00121D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=26282828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlKnsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=1562-1583&author=J.+E.+Smythauthor=N.+M.+Butlerauthor=P.+A.+Keller&title=A+twist+of+nature+%E2%80%93+the+significance+of+atropisomers+in+biological+systems&doi=10.1039%2FC4NP00121D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18eR"><div class="casContent"><span class="casTitleNuber">18e</span><div class="casTitle"><span class="NLM_cas:atitle">A twist of nature - the significance of atropisomers in biological systems</span></div><div class="casAuthors">Smyth, Jamie E.; Butler, Nicholas M.; Keller, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1562-1583</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Covering: up to mid-2015Recently identified natural atropisomeric compds. with potential medicinal applications are presented.  The ability of natural receptors to possess differential binding between atropisomers is an important factor when considering active and inactive atropisomeric drugs, and has required the development of new techniques for atropselective synthesis of desired targets.  Advances in this field therefore have significant relevance to modern pharmaceutical and medicinal chem.  The atropisomeric natural products discussed include hibarimicinone, flavomannins, talaromannins, viriditoxin, rugulotrosin A, abyssomicin C, marinopyrroles, dixiamycins, streptorubin B, ustiloxins A-F, haouamine A, bisnicalaterines, and tedarene B, all of which show significant potential as leads in antibiotic, antiviral and anticancer studies.  The importance for the development of common practices regarding atropisomer recognition and classification is also emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0hzR1osyzPLVg90H21EOLACvtfcHk0ljr7sot0jUSSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlKnsLfF&md5=449bdc252cc2b0206fa71c1b0a1ce418</span></div><a href="/servlet/linkout?suffix=cit18e&amp;dbid=16384&amp;doi=10.1039%2FC4NP00121D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4NP00121D%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DJ.%2BE.%26aulast%3DButler%26aufirst%3DN.%2BM.%26aulast%3DKeller%26aufirst%3DP.%2BA.%26atitle%3DA%2520twist%2520of%2520nature%2520%25E2%2580%2593%2520the%2520significance%2520of%2520atropisomers%2520in%2520biological%2520systems%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2015%26volume%3D32%26spage%3D1562%26epage%3D1583%26doi%3D10.1039%2FC4NP00121D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Agranat, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, J.</span><span> </span><span class="NLM_article-title">Putting chirality to work: The strategy of chiral switches</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span><div class="note"><p class="first last">and references cited therein.</p></div><span class="refDoi"> DOI: 10.1038/nrd915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1038%2Fnrd915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=12360254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVGru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=753-768&author=I.+Agranatauthor=H.+Canerauthor=J.+Caldwell&title=Putting+chirality+to+work%3A+The+strategy+of+chiral+switches&doi=10.1038%2Fnrd915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Putting chirality to work: the strategy of chiral switches</span></div><div class="casAuthors">Agranat, Israel; Caner, Hava; Caldwell, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">753-768</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most of the new drugs reaching the market today are single enantiomers, rather than the racemic mixts. that dominated up to ten years ago.  Many of the new single-enantiomer drugs were developed as such, but there are also important examples of new single-enantiomer drugs derived from 'chiral switches' of established racemates.  Indeed, a well-timed chiral switch can offer enhanced therapy and further profitability as a 'line extension' of a major racemic drug with patents that are expiring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok8OsLio3NMrVg90H21EOLACvtfcHk0lgkiGJ9P3GbsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVGru7o%253D&md5=5f391aef19f496952f6a066b575b13a9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd915%26sid%3Dliteratum%253Aachs%26aulast%3DAgranat%26aufirst%3DI.%26aulast%3DCaner%26aufirst%3DH.%26aulast%3DCaldwell%26aufirst%3DJ.%26atitle%3DPutting%2520chirality%2520to%2520work%253A%2520The%2520strategy%2520of%2520chiral%2520switches%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D753%26epage%3D768%26doi%3D10.1038%2Fnrd915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: Further insights by examining carbo- and hetero-aromatic and – aliphatic ring types</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+Further+insights+by+examining+carbo-+and+hetero-aromatic+and+%E2%80%93+aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520Further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520%25E2%2580%2593%2520aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, R.</span><span> </span><span class="NLM_article-title">The graphical representation of ADME-related molecule properties for medicinal chemists</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1016%2Fj.drudis.2010.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=21074634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsVamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=65-72&author=T.+J.+Ritchieauthor=P.+Ertlauthor=R.+Lewis&title=The+graphical+representation+of+ADME-related+molecule+properties+for+medicinal+chemists&doi=10.1016%2Fj.drudis.2010.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">The graphical representation of ADME-related molecule properties for medicinal chemists</span></div><div class="casAuthors">Ritchie, Timothy J.; Ertl, Peter; Lewis, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The importance of striving for and maintaining drug-like physicochem. properties during the hit and lead optimization process is now well documented, and many published studies have suggested optimal ranges and/or limits for key mol. descriptors such as size, lipophilicity, H-bonding characteristics, rotatable bond and arom. ring counts, particularly with regard to the design of orally administered drugs.  The aim of this article is to review various approaches that have been used to represent mol. properties graphically in the context of oral drug likeness', with the goal of improving the decision making of medicinal chemists during the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbOsxzmGt7fLVg90H21EOLACvtfcHk0lgkiGJ9P3GbsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsVamtg%253D%253D&md5=940f96e34caee0243a493c80ddfece20</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DLewis%26aufirst%3DR.%26atitle%3DThe%2520graphical%2520representation%2520of%2520ADME-related%2520molecule%2520properties%2520for%2520medicinal%2520chemists%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D65%26epage%3D72%26doi%3D10.1016%2Fj.drudis.2010.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span> <span class="citation_source-book">APEX2 Data collection and processing user interface: DOC-M86-EXX078 APEX2 User Manual</span>,<span class="NLM_publisher-name">Bruker AXS, Inc.</span>: <span class="NLM_publisher-loc">Madison, WI</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=APEX2+Data+collection+and+processing+user+interface%3A+DOC-M86-EXX078+APEX2+User+Manual%2CBruker+AXS%2C+Inc.%3A+Madison%2C+WI%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DAPEX2%2520Data%2520collection%2520and%2520processing%2520user%2520interface%253A%2520DOC-M86-EXX078%2520APEX2%2520User%2520Manual%26pub%3DBruker%2520AXS%252C%2520Inc%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Cosier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glazer, J.</span><span> </span><span class="NLM_article-title">A nitrogen-gas-stream cryostat for general x-ray diffraction studies</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1107/S0021889886089835</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=10.1107%2FS0021889886089835" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;key=1%3ACAS%3A528%3ADyaL28XhsF2qurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1986&pages=105-107&author=J.+Cosierauthor=J.+Glazer&title=A+nitrogen-gas-stream+cryostat+for+general+x-ray+diffraction+studies&doi=10.1107%2FS0021889886089835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A nitrogen-gas-stream cryostat for general x-ray diffraction studies</span></div><div class="casAuthors">Cosier, J.; Glazer, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-7</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    </div><div class="casAbstract">A continuous N-flow cooling device, general applicable to x-ray diffraction studies, is described.  The device works at 77.4-323.0 K with a precision of ±0.1 K and a liq.-N const. consumption rate of 0.5 L h-1 over the whole temp. range.  The supply vessel is unpressurized, so that refilling can be done without any observable influence on the cooling of the sample.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFePpax094i7Vg90H21EOLACvtfcHk0lgkiGJ9P3GbsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhsF2qurY%253D&md5=f7f12cd55a16e769f915b4bd1894b8fa</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1107%2FS0021889886089835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889886089835%26sid%3Dliteratum%253Aachs%26aulast%3DCosier%26aufirst%3DJ.%26aulast%3DGlazer%26aufirst%3DJ.%26atitle%3DA%2520nitrogen-gas-stream%2520cryostat%2520for%2520general%2520x-ray%2520diffraction%2520studies%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D1986%26volume%3D19%26spage%3D105%26epage%3D107%26doi%3D10.1107%2FS0021889886089835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JRS','PDB','5JRS'); return false;">PDB: 5JRS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18','PDB','5T18'); return false;">PDB: 5T18</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i61"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01088">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_85767"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01088">10.1021/acs.jmedchem.6b01088</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Single crystal X-ray experimental details for <b>7a</b>, <b>9a</b>, <b>14b</b>, <b>14d</b>, and <b>14f</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01088/suppl_file/jm6b01088_si_001.pdf">PDF</a>)</p></li><li><p class="inline">PDB coordinates for the computational models of <b>9a</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01088/suppl_file/jm6b01088_si_002.pdb">PDB</a>)</p></li><li><p class="inline">PDB coordinates for the computational models of <b>9b</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01088/suppl_file/jm6b01088_si_003.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01088/suppl_file/jm6b01088_si_001.pdf">jm6b01088_si_001.pdf (343.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01088/suppl_file/jm6b01088_si_002.pdb">jm6b01088_si_002.pdb (170.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01088/suppl_file/jm6b01088_si_003.pdb">jm6b01088_si_003.pdb (172.03 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID code for <b>14f</b>: 5T18.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-19%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01088" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01088" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797edec8ca2428","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
